Multivariate methods for genetic association testing for immune traits in maternal pig breeds

Dissertation

zur Erlangung des Grades

Doktorin der Agrarwissenschaften (Dr. agr.)

der Landwirtschaftlichen Fakultät

der Rheinischen Friedrich-Wilhelms-Universität Bonn

von

Katharina Roth

aus

Stschutschinsk, Kasachstan

Bonn 2023

Referent: Dr. Ernst Tholen

Korreferent: Prof. Dr. Karl Schellander

Tag der mündlichen Prüfung: 15.09.2023

Angefertigt mit Genehmigung der Landwirtschaftlichen Fakultät der Universität Bonn

"All Models are wrong, but some are useful."

George E. P. Box

Dedicated to my grandmother Nina

Meiner Großmutter Nina

Abstract

In pig breeding immune traits are considered to serve as potential biomarkers for pig's healthcompetence. A limited number of published studies indicate medium to high heritabilities (h²) for several immune traits. Genetic variance and covariance components of immune traits were estimated in chapter 3 to examine the quantitative genetic background of these traits. For this purpose, blood samples were collected for Landrace (LR) (n=611) and Large White (LW) (n=544) piglets and their biological dams (n=298, 272, respectively) in a short period around birth. Immune profile was covered by 22 traits including immune cells, red blood cell characteristics, and cytokines. Maternal impacts on piglet's immune profile were investigated as well as close phenotypic and genetic-based relationships in a multivariate approach. Immune traits showed low to high breed-specific h². Strong positive genetic correlations (r_g) were estimated among red blood cell characteristics (0.77 to 0.99) as well as among cytokines (0.48 to 0.99). The litter impact on piglet's immunity was examined and strengthened already observed breed differences. In LR h² (0.22 to 0.15) and litter effect (c²) (0.52 to 0.44) for IFN- γ decreased after statistical consideration of maternal impact. In LW a decrease in h² (0.32 to 0.18) for IFN- γ and an increase in c² (0.54 to 0.56) was observed.

The development of selection strategies requires deep investigations with appropriate statistical genome-wide association study approaches to explore the joint genetic foundation for health biomarkers. Consideration of previously established r_g between immune traits were used to identify pleiotropic genetic markers. For this reason, several univariate (uv) and multivariate (mv) genetic association testing methods were applied on immune traits in chapter 4. Mv GWAS approaches detected 647 associations for different mv immune trait combinations that were summarized to 133 quantitative trait loci (QTL). SNPs for different trait combinations (n=66) were detected with more than one mv method. Most of these SNPs are associated with red blood cell related immune trait combinations. With uv methods shared markers were not observed between the breeds, whereas mv approaches were able to detect two conjoint SNPs for LR and LW.

Most immune traits are heritable and are promising to cover global breed-specific immunocompetence in animals. With uv and mv approaches, the joint genetic background of immune traits was demonstrated by revealing immune relevant potential candidate genes. Investigated traits can be used to gain a breeding-based health improvement in piglets whereby special attention has to be laid on the relationship between immunocompetence and further performance characteristics.

Zusammenfassung

In der Schweinezucht werden Immunmerkmale als potenzielle Bioindikatoren der Gesundheitskompetenz betrachtet. In einer begrenzten Anzahl von Veröffentlichungen wurden für eine Reihe von Immunmerkmalen mittlere bis hohe Heritabilitäten (h²) geschätzt. Im Rahmen dieser Arbeit wurden, wie in Kapitel 3 beschrieben, genetische Varianz- und Kovarianzkomponenten geschätzt. Dazu wurden in einem kurzen Zeitraum um die Geburt Blutproben von Landrasse (n=611) und Large White (n=544) Ferkeln und ihren biologischen Müttern (n=298 bzw. 272) entnommen. Das Immunprofil wurde durch 22 Merkmale einschließlich Immunzellen, Erythrozyten-Charakteristika und Zytokinen abgedeckt. Die Auswirkungen der Mutter auf das Immunprofil des Ferkels sowie vorherrschende, enge, phänotypische und genetische Beziehungen wurden in einem multivariaten (mv) Ansatz untersucht. Immunmerkmale zeigten niedriges bis hohes rassespezifische h^2 . Es wurden starke positive genetische Korrelationen (rg) zwischen den Merkmalen der roten Blutkörperchen (0,77 bis 0,99) sowie zwischen den Zytokinen (0,48 bis 0,99) geschätzt. Der Wurfumwelteffekt (c²) auf die Immunität der Ferkel wurde untersucht und verstärkte bereits beobachtete Rassenunterschiede. In LR betrugen die h² (0,22 bis 0,15) und c² (0,52 bis 0,44) für IFN- γ nach statistischer Berücksichtigung des maternalen Effekts. Bei LW wurde eine Abnahme von h² (0,32 bis 0,18) und eine Zunahme von c² (0,54 bis 0,56) beobachtet.

Die in Kapitel 3 festgestellten r_g wurden zur Identifikation von pleiotropen, genetischen Markern genutzt. Aus diesem Grund wurden verschiedene univariate (uv) und mv genetische Ansätze angewendet. Deren Anwendbarkeit und Aussagefähigkeit wurden in Kapitel 4 untereinander empirisch verglichen. Mv Ansätze detektierten 647 Assoziationen für verschiedene Immunmerkmalskombinationen, wovon 66 SNPs mit mehr als einer mv Methode nachgewiesen werden konnten. Mit uv Methoden wurden keine gemeinsamen Marker zwischen den Rassen beobachtet, während mv Ansätze zwei gemeinsame SNPs zwischen LR und LW aufweisen konnten.

Für die meisten Immunmerkmale wurde eine moderate bis hohe, rassespezifische h² festgestellt. Mit uv und mv Ansätzen konnte der gemeinsame genetische Hintergrund von Immunmerkmalen untersucht und potenzielle, immunrelevante Kandidatengene aufgedeckt werden. Immunmerkmale können zu einer züchterischen Verbesserung der Gesundheit von Ferkeln beitragen. Hierbei sollten allerdings die Beziehungen der Immunmerkmale zu weiteren Leistungsmerkmalen in Betracht gezogen werden.

Table of contents

| List o | f figu | res | Ι |
|--------|---------|-------------------------------------------------------------------------|-----|
| List o | f table | 2S | II |
| List o | f abbı | reviations | IV |
| Chap | ter 1. | General introduction | 1 |
| 1.1. | Cha | llenges in sustainable pig breeding | 2 |
| 1.2. | Sco | pe of this thesis | 3 |
| Chap | ter 2.] | Literature review | 6 |
| 2.1. | Imr | nunocompetence | 7 |
| 2.2. | The | innate and adaptive immune systems | 7 |
| 2.3. | Opp | portunities of breeding for immunocompetence | 10 |
| 2.4. | Feta | al immunity in pigs and maternal genetic potential for immunocompetence | 12 |
| 2.5. | Ger | netic foundation of immune traits | 13 |
| 2.6. | Det | ection of immune-relevant QTL and genetic markers | 17 |
| 2.7. | Mu | ltivariate approaches for QTL detection | 22 |
| 2. | 7.1. | Principal component analysis | 24 |
| 2. | 7.2. | Canonical correlation analysis | 25 |
| 2. | 7.3. | Meta-analysis | 25 |
| 2. | 7.4. | Bayesian multivariate approaches | 25 |
| 2. | 7.5. | Trait networks and structural equation models | 26 |
| 2.8. | Acc | essing genetic pleiotropy | 26 |
| Chap | ter 3. | Genetic parameters of immune traits for Landrace and Large White | pig |
| | l | breeds | 28 |
| 3.1. | Abs | stract | 29 |
| 3.2. | Intr | oduction | 30 |
| 3.3. | Ma | terial and Methods | 32 |
| 3. | 3.1. | Animals and phenotypic measurements | 32 |
| 3. | 3.2. | Statistical analysis | 33 |
| 3.4. | Res | ults | 36 |
| 3. | 4.1. | Immune trait values and influencing factors | 36 |
| 3. | 4.2. | Genetic parameters for immune traits | 37 |

| 3.4.3. | Genetic correlations between immune traits | 39 |
|------------|--------------------------------------------------------------------------------|----------|
| 3.4.4. | Maternal influences on piglet's immunity | 41 |
| 3.4.5. | Accessing highly correlated immune networks in piglets | 41 |
| 3.4.6. | Genetic parameters for condensed immune traits | 44 |
| 3.4.7. | Genetic correlation between PCs of biological functional networks | 46 |
| 3.5. Dis | scussion | 48 |
| 3.5.1. | Environmental effects affecting the immune traits | 48 |
| 3.5.2. | Genetic foundation of immune traits for piglets | 49 |
| 3.5.3. | Maternal impacts on piglet's immune traits | 50 |
| 3.5.4. | Close relationships between immune traits imply complexity of piglet's immunit | y 51 |
| 3.5.5. | The multivariate analysis emphasizes compound relationships between immune | traits53 |
| 3.6. Co | nclusion | 54 |
| Chapter 4. | Multivariate genome-wide associations for immune traits in two materr | ıal pig |
| | lines | 55 |
| 4.1. Ab | stract | 56 |
| 4.1.1. | Background | 56 |
| 4.1.2. | Results | 56 |
| 4.1.3. | Conclusions | 56 |
| 4.2. Ba | ckground | 57 |
| 4.3. Re | sults | 58 |
| 4.3.1. | Genetic markers identified with uv GWAS approaches | 58 |
| 4.3.2. | Principal component analysis of the immune traits | 59 |
| 4.3.3. | Structural multivariate trait combinations | 59 |
| 4.3.4. | Genetic markers identified with mv GWAS approaches | 63 |
| 4.3.5. | Comparison across mv GWAS results | 63 |
| 4.3.6. | Comparison between uv and mv GWAS results | 68 |
| 4.4. Dis | scussion | 70 |
| 4.4.1. | Conditional dependencies of immune networks | 70 |
| 4.4.2. | Comparison between uv and mv GWAS results and method performance | 71 |
| 4.4.3. | Comparison of genetic markers between LR and LW | 73 |
| 4.4.4. | Identification of pleiotropic genetic variants | 74 |
| 4.4.5. | Functional annotation and identification of potential candidate genes | 74 |
| 4.5. Co | nclusion | 76 |
| 4.6. Me | thods | 76 |
| 4.6.1. | Statistical analysis of immune traits | 76 |

| 4.6.2. | Genotyping and quality control of genomic markers | 77 |
|-------------|------------------------------------------------------------------|-----|
| 4.6.3. | 78 | |
| 4.6.4. | Univariate GWAS | 78 |
| 4.6.5. | Principal component analysis | 79 |
| 4.6.6. | Learning structures using Bayesian network | 79 |
| 4.6.7. | Multivariate GWAS | 80 |
| 4.6.8. | Canonical Correlation Analysis | 80 |
| 4.6.9. | Meta-analysis | 81 |
| 4.6.10. | Bayesian multivariate regression | 82 |
| 4.6.11. | Controlling population stratification and false-positive results | 82 |
| Chapter 5. | General discussion | 84 |
| 5.1. Mu | ltivariate association testing | 85 |
| 5.2. Gei | netic foundation of immune traits | 89 |
| 5.3. Tov | wards a breeding-based improvement of health traits | 91 |
| Chapter 6. | Conclusion of the thesis | 94 |
| Chapter 7. | Summary | 97 |
| Chapter 8. | References | 99 |
| Chapter 9. | Appendix | 115 |
| Funding an | d Acknowledgements | 189 |
| Funding | 5 | 190 |
| Funding | g – chapter 3 and 4 | 190 |
| Acknow | vledgments chapter 3 and 4 | 190 |
| Acknowled | gement - Danksagung | 191 |
| Publication | s and presentations | 194 |

List of figures

| Figure 1: Workflow of the studies included in this thesis | 5 |
|--------------------------------------------------------------------------------------------------|----------|
| Figure 2: Mobilization of the innate and adaptive immune response (Zimmerman et al. 2012) | 9 |
| Figure 3:Presumed network of immunity and piglet survival (modified according to Roehe et al. | (2010) |
| and Heuß (2019) | 11 |
| Figure 4: Cytogenetic map of the pig with all QTLs influencing mean corpuscular volume (| (MCV) |
| adapted from Pig QTL Database (animalgenome.org 2019) | 18 |
| Figure 5: Manhattan plot of whole-genome association analysis for hemoglobin in Large White me | odified |
| according to Dauben et al. (2021) | 19 |
| Figure 6: Conceptual classifications for multivariate methods were modified according to Gales | sloot et |
| al. (2014) | 23 |
| Figure 7: Graphical display of genetic parameters for immune variables in the piglet data set | 40 |
| Figure 8: Loading composition for first principal components within piglet's functional bio | logical |
| networks | 43 |
| Figure 9: Graphical display of genetic parameters for condensed variables in the piglet data set | 47 |
| Figure 10: Bayesian network for immune trait residuals | 61 |
| Figure 11: Venn diagram of different methods used to detect significant multivariate association | ons for |
| both breeds and significance types | 64 |
| Figure 12: Manhattan plot of SSC5 for multivariate trait combinations a RBC HMG: HMT:MCV | ':MCH |
| in Landrace with CCA, b HMG MCHC:IL10 in Landrace with CCA, and c WBC RBC:HAP:I | L1b in |
| Large White with mvBIMBAM | 67 |
| Figure 13: Genetic markers identified with GWAS approaches: Comparison of different asso | ciation |
| methods for both investigated breeds | 69 |

List of tables

| Table 1: Heritability estimates for immune-related traits found in different studies | 15 |
|---------------------------------------------------------------------------------------------------------------------------------------|---------------|
| Table 2: Overview of published porcine GWAS studies performed for hematological traits and cy | tokines |
| Table 3: Direct genetic and litter effects for immune variables of Landrace and Large White pig | lets 38 |
| Table 4: Direct genetic and litter effects for principal components of Landrace and Large White within biological functional networks | piglets 45 |
| Table 5: Resulting structural model learned from a causal network | 62 |
| Table 6: Selected significant associated genetic markers identified with multivariate methods | 65 |

Appendix

| Table S 1: ANOVA p-values for fixed effects in piglet data set | 116 |
|-------------------------------------------------------------------------------------------|-------------|
| Table S 2: Immune variables and their correspondent summary statistics for Landrace and L | arge White |
| piglets and dams. | 117 |
| Table S 3: Pairwise genetic correlations for immune variables in Landrace piglets | 118 |
| Table S 4: Pairwise genetic correlations for immune variables in Large White piglets | 120 |
| Table S 5: Principal components and their composition based on loading values of Landrace | and Large |
| White dams. | 122 |
| Table S 6: Genetic effects for Landrace and Large White piglets after consideration for | or maternal |
| environmental effects | 124 |
| Table S 7: Principal components and their composition based on loading values of Landrace | and Large |
| White piglets | 125 |
| Table S 8: Genetic parameters of principal components as new dependent immune va | riables for |
| Landrace and Large White piglets | 127 |
| Table S 9: Significant associated genetic markers identified with univariate methods | 129 |
| Table S 10: Significant associated genetic markers identified with multivariate methods | 143 |
| | |

List of abbreviations

| AAMP | Angio associated migratory cell protein |
|----------------|------------------------------------------------------------------------------------------|
| AGT | Aangiotensinogen |
| APP | Acute-Phase-Protein |
| BAS | Basophils |
| BFN | Biological functional network |
| BIMBAM | Bayesian linear regression uv approach |
| BLUP | Best linear unbiased prediction |
| BN | Bayesian network |
| c ² | Common litter effect |
| CCA | Canonical correlation analysis |
| CRISPR/Cas9 | Clustered regularly interspaced short palindromic Repeats/CRISPR-associated protein 9 |
| DNA | Desoxyribonucleic acid |
| DTH | Hypersensitivity |
| EOS | Eosinophils |
| FDR | False discovery rate |
| GV | Genetic variant |
| GWAS | Genome-wide association study |
| h^2 | Direct genetic effects/heritability |
| НАР | Haptoglobin |
| HEWL | Hen egg white lysozyme |
| HIR | High immune response |
| HMG | Hemoglobin |
| HMT | Hematocrit |

| HWE | Hardy-Weinberg equilibrium |
|----------------|---------------------------------------------------------------------------------------------|
| HYSS | Herd-year-season-sex effect |
| IBS | Identity-by-state |
| IFN | Interferone |
| IgG | Immunoglobulin G |
| IL | Interleukin |
| LIR | Low immune response |
| LR | Landrace |
| LW | Large White |
| LYM | Lymphocytes |
| m ² | Maternal genetic effect |
| MAF | Minor allele frequency |
| МСН | Mean corpuscular hemoglobin |
| MCHC | Mean corpuscular hemoglobin concentration |
| MCV | Mean corpuscular volume |
| МНС | Histocompatibility complex |
| MON | Monocytes |
| mv | Multivariate |
| mvBIMBAM | Mv Bayesian linear regression approach/ mv Bayesian imputation-based association mapping |
| NEU | Neutrophils |
| NK | Natural killer cells |
| PC | Principal component |
| PCA | Principal component analysis |
| PLT | Platelets |
| PMN | Polymorphonuclear neutrophils |
| | V |

| PNDK | Paroxysmal nonkinesiogenic dyskinesia domain containing |
|----------------|-----------------------------------------------------------------------------------|
| PRRSV | Porcine reproductive and respiratory syndrome virus |
| PRRSV | Porcine respiratory syndrome virus |
| QTL | Quantitative trait loci |
| RBC | Red blood cells |
| r _g | Genetic correlation |
| r _p | Phenotypic correlation |
| SLA | Swine leucocytes antigen |
| SNPs | Single nucleotide polymorphisms |
| TATES | Meta analysis/ Trait-based association test that uses extended Simes procedure |
| TLL1 | Tolloid like 1 |
| TLR | Toll-like receptors# |
| TMBIM1 | Transmembrane BAX inhibitor motif containing 1 |
| TNF | Tumor necrosis factor-α |
| uv | Univariate |
| WBC | White blood cells |

Chapter 1. General introduction

1.1. Challenges in sustainable pig breeding

The requirements for the management of animal products are complex and challenging. This includes the economic point of view, legal constraints, demands of the consumer and understanding of the stock farmers. One important challenge for animal scientists is to reconcile the interests of various actors from today's perspective. The systems of livestock production are currently being massively criticized. In 2015, 83% of Europeans believed the welfare of farmed animals should be better protected than it is now (European Commission, 2017). Animal breeding research can provide a sustainable contribution to improve the livestock production systems regarding profitability, human nutrition, environmental load, resource management, and animal welfare. This results in a need to design genetic strategies that support the balance between the single factors. Genetic improvement of production traits is desirable, but possible genetic antagonisms between production traits and any other characteristics require specific attention.

Since improved data recording and processing (Best Linear Unbiased Prediction (BLUP), computing power, biotechnological approaches) become more effective, strong and sufficient focus was set on production traits in pig's selection. Initially, major progress was seen in carcass traits, growth rate, and meat quality while reproductive characteristics had little attention (Merks 2000). As pig production increased, improvements in litter size were achieved through better management, nutrition and implementation of genetic selection for litter size. This course of action led to a lack of balance between fitness, animal welfare and production traits (Prunier et al. 2010). The selection for high leanness, feed efficiency, and litter size may have resulted in correlated responses in the abilities of pigs to overcome immune challenges (Rauw et al. 1998; Knap and Rauw 2008). The reproductive endocrine system is directly impaired as a result of resource-demanding, adverse environmental conditions that compromise immune response traits. As a consequence, the adaptive ability to deal with intense stress is significantly (Knap and Rauw 2008). Therefore, nowadays breeding progress is emphasized on increase in performance, improving the quality of the animal product, health status, as well as environment and resource compatibility (Merks et al. 2012).

Until now, the mechanisms involved in porcine immunity have not been fully understood. Quantitative information on the genetic variation of immune related health traits within genotypes is needed. Literature information for unchallenged pigs is scarce because immune traits are difficult to measure and to quantify on a large number of animals with various genetic backgrounds. Besides, immune traits are quantitative traits where the expression is influenced by the genome and environmental effects. Additionally, many gene locations are involved in the expression of quantitative traits. Usually, such complex traits are characterized by a low heritability (Mangino et al. 2017). Maintaining balanced homeostasis requires a high level of interaction between the distinct immune traits. The genetic relationship between the traits and to performance characteristics needs to be assessed continuously in order to reveal the genetic mechanism. The uncovered common genetic basis can help to understand the system governing the balance of immune cells in peripheral blood of protective immunity. As a consequence, it is important to develop suitable statistical analysis methods to explore such complex relationships.

Multivariate models are commonly used to estimate phenotypic, genetic and environmental variances, covariances, and correlations for multiple traits in animal breeding programs. In cases where traits are correlated, a multivariate model can gain more accuracy than a univariate model benefiting from connections in the data due to residual covariance between the traits. Furthermore, traits with low heritabilities benefit more when analyzed together with traits with high heritabilities in a multivariate analysis (Isik et al. 2017). Whereas multivariate methods are common in estimating genetic parameters or breeding values these methods are rarely used in genome-wide association studies (GWAS). Against this background it should be particular worthwhile to investigate the applicability and meaningfulness of multivariate methods for the statistical analysis of immune traits.

1.2. Scope of this thesis

The objective of this thesis was to analyze and discuss the prospects of application of multivariate methods paying special attention to the presumed low heritable and complex porcine immune traits. To achieve this goal, genetic parameters of immune traits were estimated. In order to examine the impacts of the maternal effects on the offspring's immunity genetic and environmental influences are taken into consideration during the statistical analysis. As a way to identify pleiotropic genetic markers associated with immune traits, multivariate approaches for genome-wide association tests were applied.

Chapter 2 introduces the genetic foundation of porcine immune traits. The benefit of the immunocompetence of the piglet and the dam are discussed. The application of univariate and multivariate genome-wide association methods to analyze the genetic foundation of desired traits is introduced.

This thesis includes two studies: Figure 1 gives an overview of all performed analysis steps in the studies.

In the first study, in chapter 3 the quantitative genetic background of immune traits was conducted. Data sets of purebred LR and LW subset pig populations from 2010 to 2017 were

provided by the German breeding organization Bundeshybridzuchtprogramm (BHZP) GmbH. From each litter, one male and one female piglet, as well as, their biological dam were chosen for blood sample collection. Blood samples of piglets were collected on average around 45 days after birth. From the biological dams of all phenotyped piglet's blood was sampled in a short period *postpartum* (7 days). Complete blood count, haptoglobin and cytokines were examined as immune traits to characterize immunocompetence. In order to elaborate on the genetic potential for the dam's immunocompetence, genetic and environmental influences are taken into consideration during the analysis. The genetically correlated immune traits and networks are accessed through the application of principal component analysis.

In the second study, in chapter 4, different genome-wide association approaches were used to identify genes and genetic markers for immune traits. The detection of pleiotropic single nucleotide polymorphisms in immune traits of piglets from two maternal lines was carried out using multivariate approaches besides a univariate frequentist and Bayesian approach. We empirically compared the results obtained using principal component analysis, canonical correlation analysis, meta-analysis, and a multivariate Bayesian linear regression approach with those obtained using univariate tests.

The general discussion included in chapter 5 aims to debate the gain of knowledge and further challenges due to the application of multivariate approaches on immune traits. Moreover, a possible way to implement immune traits into selection strategies is presented.



Figure 1: Workflow of the studies included in this thesis

 $GWAS = Genome-wide \ association \ study, \ SNP = Single \ nucleotide \ polymorphism$

Chapter 2. Literature review

2.1. Immunocompetence

The animal production sector is actively searching for appropriate solutions to the issue that new phenotypes are needed due to the requirements of pork value chain partners and consumer expectations. Sometimes there seems to be a disconnect between selection for efficiency of production and animal welfare. Selection for high production efficiency may result in undesired correlated responses in other traits for example litter size and piglet survival (Rauw et al., 1998). The motivation is to avoid such adverse effects with different strategies. Moreover, the emergence of antibiotic resistance and society's demands for healthier, sustainable livestock production systems require specific solutions for various disciplines including animal breeding. Health-related traits can be incorporated into pig breeding programs in order to produce healthier, resilient, and disease-resistant pigs.

Direct and indirect breeding approaches can be used to improve animal robustness and disease resistance (Colditz & Hine, 2016; Knap, 2005; Viney et al., 2005; A. H. Visscher et al., 2002). Direct methods require exposure to pathogens and can therefore intend the genetic susceptibility to specific disease incidences. However, this type of method is information-intensive, timeconsuming, expensive, and is considered critical against the background of animal welfare legislation. The alternative and indirect approach focuses on global animal immunocompetence. However, in this case, detailed knowledge of the different elements of immunocompetence and components of the immune system is required. Immunocompetence has been defined by Wilkie and Mallard (1999) as "the ability of the body to produce an appropriate and effective immune response when exposed to a variety of pathogens". A more detailed definition is used by Knap and Bishop (2000) as a broad sense to indicate the capability of the host to launch an immune response of sufficient specificity and magnitude, roughly indicating the effective quality of the host's immune system. The immune system can be assessed immunologically by measuring the immune traits. Humoral and cellular components of the immune system are considered biologically relevant parameters to value immunocompetence (Viney et al., 2005; A. H. Visscher et al., 2002). It is possible to categorize these traits into innate and adaptive immunity, although there are also traits considered bridges between the two types (Tizard, 2013; Zimmerman et al., 2012).

2.2. The innate and adaptive immune systems

The immune system has two functional divisions: innate and adaptive. The innate immune response contains phagocytic cells (macrophages, neutrophils) and the production of various cytokines, chemokines, and proteins. Besides providing antimicrobial protection, they recruit cells through inflammatory processes and activate the adaptive immune system. The adaptive

immune system includes B and T cells, cytokines, and antibodies providing a pathogen-specific memory (Calder, 2007). Immune responses to infection include both innate and adaptive actions involving different cell types, mediators, and chemical agents (Figure 2) (Zimmerman et al., 2012). The immediate defensive response to the rapid destruction of invaders is the task of innate immunity. More slowly process, adaptive immunity develops when foreign antigens bind to B or T cell antigen receptors and trigger strong defensive responses. Communication within one of the immune systems as well as between the innate and adaptive immune systems is brought about by direct cell-to-cell contacts involving cell surface proteins and the production of chemical messengers (e.g. cytokines) which send signals from one cell to another. Each cytokine can have multiple activities on different cell types (Tizard, 2013). Way of example, tumor necrosis factor α (TNF- α), interleukin (IL) 1, and IL-6 are among the most important cytokines produced by monocytes and macrophages. These cytokines activate neutrophils and monocytes to initiate bacterial and tumor cell killing, increase adhesion molecule expression on the surface of neutrophils, stimulate T- and B-lymphocyte proliferation, initiate the production of other proinflammatory cytokines and acute phase protein synthesis in the liver (Calder, 2007) (Figure 2).



Figure 2: Mobilization of the innate and adaptive immune response (Zimmerman et al., 2012) PMN= Polymorphonuclear neutrophils, TLR= Toll-like receptors, TNF- α = Tumor necrosis factor α , IL= Interleukin, IFN= Interferon, NK= Natural killer cells

2.3. Opportunities of breeding for immunocompetence

The most important element of animal breeding is to determine the breeding goal. Breeding goals and selection indexes determine how genetic improvement should be achieved. For all species, the breeding goal has shifted from being primarily production-driven to being more balanced on a equivalent improvement of production, efficiency, health, and functional traits (Berghof et al., 2018). Piglet production is primarily determined by the number of weaned piglets per sow. In response, breeding organizations have focused on improving litter size, leading to an increase in the number of piglets born alive. This course of action resulted in higher amounts of piglet losses (Alonso Spilsbury, 2007; Baxter et al., 2013; Edwards, 2002; Grandinson et al., 2010; Hellbrügge et al., 2008; Heuß et al., 2019; Rutherford et al., 2013). Previous studies have stressed the multifaceted causes of piglet survivability is particularly important in the period between conception and weaning. Genetically, the complex relationship between direct genetic (h^2), maternal genetic (m^2), and common litter (c^2) effects are presumed to determine individual immune system and piglet survival (





The selection of traits directly related to production performance has greatly improved over the past few decades in commercial pig breeds, while health-related traits have traditionally played a minor role (Ernst & Steibel, 2013). New challenges face the pig production industry due to the emergence of antibiotic resistance and society's demands for healthier livestock products (Berghof et al., 2018). As one of the most important factors contributing to productivity,

profitability, and welfare, animal health is influenced by several factors, including the coinfection of pathogens such as viruses or bacteria, environmental stressors, and management practices. To produce pig populations with more resilient, well-being and disease-resistant, health-related traits have become an emerging and challenging development in pig breeding programs (Cheng et al., 2014). To enhance animal robustness and disease resistance, breeding approaches have mainly focused on direct and indirect methods (A. H. Visscher et al., 2002; P. M. Visscher et al., 2012). To target the genetic resistance/susceptibility to specific diseases, direct methods usually require exposure to the infectious agents (Knap & Bishop, 2000).

There are several challenges associated with this approach, including cost, time, animal welfare, and information requirements. It is possible to determine the global immunocompetence of animals without signs of infection using an indirect approach, but comprehensive knowledge of the different components of the immune system is required (Knap & Bishop, 2000; A. H. Visscher et al., 2002). The immunocompetence of an individual can be measured based on immune traits as these traits are considered biologically relevant (A. H. Visscher et al., 2002). Hence, genetic markers that link health-related traits to disease resistance and robustness may contribute to a proper breeding of pigs.



Figure 3: Presumed network of immunity and piglet survival (modified according to Roehe et al. (2010) and Heuß (2019)

The genetic potential of piglet survival at the piglet's level can be described as h^2 for this trait (Roehe et al., 2010). The genetic capability of the dam to rear vital piglets and contribute to piglet survival is represented as m² (Knol, Leenhouwers, & van der Lende, 2002; Roehe et al., 2010). It refers to an inheritance pattern for certain genes in which the genotype of the mother directly determines the phenotype of her offspring (Brooker, 2012). Furthermore, genetic effects can simultaneously influence the immune system and therefore, would have an indirect impact on piglet survival. Quantitative genetic studies of piglet survival traits at the sow or piglet level showed mostly low h^2 and considerable environmental influence (Heuß, 2019). Immune-related traits can be used as further biomarkers for general immunocompetence and piglet survival. To reach that goal, relationships within individual components of the immune system and the contribution of the immune system to piglet survival as well as further performance characteristics have to be well examined.

2.4. Fetal immunity in pigs and maternal genetic potential for immunocompetence

All components of the innate and adaptive immune systems of the pig develop in utero and are functional at birth. However, they are less efficient than in an adult pigs (Hammerberg et al., 1989). Since the newborn piglet has not yet been exposed to an antigen, humoral and cellmediated immune responses to infectious agents and stressors have to be developed after exposure to antigens. After exposure, it will take seven to ten days for a primary antibody or cell-mediated immune response to develop (Zimmerman et al., 2012). During this critical period of susceptibility, resistance to infection depends on passive-mediated immunity transferred from the sow to the piglet via colostrum. Neonatal pigs have been shown to absorb colostral lymphocytes from their intestinal tract into the bloodstream (Tuboly et al., 1988; Williams, 1993). After 24 hours absorbed cells derived from colostrum were found in the liver, lungs, lymph nodes, spleen, and gastrointestinal tissue. Their direct functional impact on the piglet's immune system is not fully understood, yet. However, piglets that had absorbed the colostral lymphocytes had higher lymphocyte blastogenic responses to mitogens than control piglets (Williams, 1993). The mechanism of how the passively transferred lymphocytes transmit clinically significant cell-mediated or antigen-specific immunity from the sow to the piglet is not well examined, yet.

The epitheliochorial placenta in the sow prevents the transfer of maternal antibodies to the fetuses before birth, so piglets receive antibodies only postnatally through colostrum and milk (Matías et al., 2017). Additionally, neonates have limited ability to synthesize antibodies endogenously (Brambell, 1970). Therefore, maternal immunoglobulins, immune cells, and modulators provide a primary form of immune defense for offspring early in life. Maternal effects occur when offspring phenotype is determined not only by its genotype and environment but also determined by maternal genotype and phenotype (Kirkpatrick & Lande, 1989). Colostrum components protect neonates from disease, support immune system development, induce tolerance, immune priming, antigen neutralization, and the development of immune memory (Bandrick et al., 2008). Contrariwise, maternal-derived antibody-mediated immunity has been shown to downregulate endogenous immunoglobulin synthesis (Klobasa et al., 1981). The role of maternal cellular mediated immunity in the development of the newborn's animal immune status has remained unclear. Maternal colostral labeled cells cross the neonatal intestinal epithelium and migrate to several immune tissues (Tuboly et al., 1988). By practicing a protective effect in the digestive tract and leading to partial tolerance, they may stimulate the immune system of the newborn piglet. Although m² effects only influence the performance of growing pigs shortly and indirectly, they may offer opportunities for genetic improvement. Therefore, in chapter 3 the evaluation of the genetic potential of the sow for piglets' immunocompetence by estimating c^2 and consideration of the environmental impact of the dam's immune profile is further described.

2.5. Genetic foundation of immune traits

Previous genetic studies have provided knowledge about genetic differences in immune-related traits which are presented in Table 1 (Clapperton et al., 2009; Edfors-Lilja et al., 1998; Flori, Gao, Laloë, et al., 2011; Hermesch & Luxford, 2018). Heritability, as h² for white blood cells (WBC) (e.g. neutrophiles, lymphocytes, monocytes, eosinophils, basophils) can be characterized as moderate to high (0.40 to 0.80). Hereby, obvious breed differences should be noticed. Red blood cells (RBC) and their characteristics (mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC)) demonstrate a moderate h² (0.41-0.62). Haptoglobin, as an acute phase protein, has scattered values of h² from 0.14 to 0.55. Flori, Gao, Laloë, et al. (2011) estimated low h² for cytokines (0.00-0.11), except IL-10 (0.35) and IL-12 (0.51). In general, innate immunity shows a slightly greater genetic variance (0.14-0.72) than adaptive immunity (0.22-0.61). Estimations of h² are very diverging between previous studies. Discrepancies among the described results can be caused by the number of analyzed animals or investigated breeds. Furthermore, research

designs differ in sampling periods, immune challenges, and statistical methods for variance component estimation. The genetic variability of immune traits is further described in chapter 3.

| Immune traits | Edfors-Lilja | Henryon et | Clapperton | Clapperton | Flori, Gao, | Mpetile et al. | Ponsuksili et | Bovo et al. |
|---------------|---------------|-------------|---------------|---------------|-------------|----------------|---------------|---------------|
| | et al. (1994) | al. (2006) | et al. (2008) | et al. (2009) | Oswald, et | (2015) | al. (2016) | (2019) |
| | | | | | al. (2011) | | | |
| n | 220 | 4204 | 500 | 606 | 443 | 518 | 591 | 843 |
| Breed | Swedish | Duroc, | Large White | Large White, | Large White | Yorkshire | Landrace | Italian Large |
| | Yorkshire | Landrace, | | Landrace | | | | White |
| | | Yorkshire | | | | | | |
| WBC | 0.44 (0.29) | 0.25 (0.05) | 0.24 (0.15) | 0.28 (0.11) | 0.73 (0.20) | 0.23 (0.19) | 0.23 | 0.31 (0.07) |
| Neutrophils | | 0.22 (0.04) | | | 0.61 (0.20) | 0.31 (0.21) | | 0.24 (0.07) |
| Lymphocytes | 0.24 (0.21) | 0.24 (0.05) | | | 0.72 (0.21) | 0.15 (0.19) | 0.49 | 0.31 (0.06) |
| Monocytes | | 0.22 (0.04) | 0.52 (0.17) | 0.26 (0.13) | 0.38 (0.20) | 0.36 (0.20) | | 0.15 (0.04) |
| Eosinophils | | 0.30 (0.05) | | | 0.80 (0.21) | 0.58 (0.12) | | 0.14 (0.06) |
| Basophils | | | | | | 0.12 (0.19) | | 0.19 (0.06) |
| Platelets | | | | | 0.56 (0.19) | 0.11 (0.23) | 0.39 | 0.31 (0.06) |
| RBC | | | | | 0.43 (0.20) | 0.62 (0.25) | 0.41 | 0.36 (0.07) |
| Hemoglobin | | | | | | 0.56 (0.13) | 0.40 | 0.36 (0.06) |
| Hematocrit | | | | | 0.57 (0.03) | 0.06 (0.14) | 0.34 | 0.27 (0.06) |
| MCV | | | | | | 0.47 (0.24) | 0.69 | 0.39 (0.07) |
| МСН | | | | | | 0.37 (0.24) | 0.67 | 0.40 (0.06) |
| MCHC | | | | | | 0.04 (0.16) | 0.67 | 0.24 (0.06) |

| Table 1: Heritabili | y estimates | for immu | ne-related traits | s found in | different studies | (continued) |
|---------------------|-------------|----------|-------------------|------------|-------------------|-------------|
|---------------------|-------------|----------|-------------------|------------|-------------------|-------------|

| Immune traits | Edfors-Lilja | Henryon et | Clapperton | Clapperton | Flori, Gao, | Mpetile et al. | Ponsuksili et | Bovo et al. |
|---------------|---------------|-------------|---------------|---------------|-------------|----------------|---------------|---------------|
| | et al. (1994) | al. (2006) | et al. (2008) | et al. (2009) | Oswald, et | (2015) | al. (2016) | (2019) |
| | | | | | al. (2011) | | | |
| n | 220 | 4204 | 500 | 606 | 443 | 518 | 591 | 843 |
| Breed | Swedish | Duroc, | Large White | Large White, | Large White | Yorkshire | Landrace | Italian Large |
| | Yorkshire | Landrace, | | Landrace | | | | White |
| | | Yorkshire | | | | | | |
| IFN-γ | | | | | 0.00 (0.17) | | | |
| IL10 | | | | | 0.35 (0.19) | | | |
| IL12 | | | | | 0.51 (0.20) | | | |
| IL1-β | | | | | 0.12 (0.19) | | | |
| IL4 | | | | | 0.15 (0.18) | | | |
| IL6 | | | | | 0.11 (0.19) | | | |
| IL8 | | | | | 0.00 (0.17) | | | |
| TNF-α | | | | | 0.00 (0.19) | | | |
| Haptoglobin | | 0.14 (0.07) | | 0.20 (0.11) | 0.55 (0.21) | | | |

WBC=white blood cells, RBC=red blood cells, MCV= mean corpuscular volume, MCH= mean corpuscular hemoglobin, MCHC= mean corpuscular hemoglobin concentration, IFN- γ = interferon- γ , IL= interleukin, TNF- α = tumor necrosis factor- α . The standard error is presented in parentheses

Correlations between the various players within the immune system show a complex network of associations following biological relationships. Clapperton et al. (2008) investigated the relationships between immune parameters and growth performance. Negative correlations between some of the investigated leucocyte blood cells and daily gain were found under lower health status on farms, whereas, monocytes and an acute phase protein showed a negative correlation with the average daily gain under high health conditions on farms. Genetic correlations (r_g) from Flori, Gao, Laloë, et al. (2011) are mostly weak, except between subtypes of WBC like monocytes, neutrophils, and lymphocytes (0.4). Furthermore, a positive relationship between haptoglobin and pro-inflammatory cytokines such as IL-8 and TNF- α is described by a r_g above 0.4. Moreover, genetic markers for a share of neutrophils and lymphocytes in swine are found in the same regions as quantitative trait loci (QTLs) for cytokines interferon (IFN) and IL-10 (Lu et al., 2011), indicating close genetic-based relationships between immune cells and mediators. Such interrelations provide indications for a pleiotropic genetic structure that can be further analyzed with multivariate statistical approaches as described in chapters 3 and 4.

2.6. Detection of immune-relevant QTL and genetic markers

To explore the additive genetic background of immune-related phenotypes genome-wide association studies (GWAS) and QTL mapping can be used. The basis of QTL mapping is the association between genetically determined phenotypes for quantitative traits and molecular genetic markers such as single nucleotide polymorphisms (SNPs). In this approach, the identification of QTLs at the sites of already known markers is realized (Gondro et al., 2013). Several QTL studies revealed markers for red and white blood cells (Cho et al., 2011; Edfors-Lilja et al., 1998; Gong et al., 2010; Reiner et al., 2007, 2008; S. Yang et al., 2009; Zou et al., 2008) as well as cytokine (Uddin et al., 2011) across all chromosomes.

Pig QTL Database (Hu et al., 2019) supplies information about 3236 QTLs for traits related to immune capacity and 2900 QTLs for blood parameters. These subcategories are combined into a superset of QTLs about health, which comprises 6761 QTLs. For example, MCV is placed in an overall top 17 QTL associations in the whole Pig QTL Database with 558 observed QTLs for this blood parameter. The Figure 4 demonstrates an example of a cytogenetic map for all the pig chromosomes with detected QTLs influencing the health trait and blood parameter mean corpuscular Vvlume (MCV). distribution of QTLs across all of the *Sus Scrofa C*hromosomes (SSC) illustrates the polygenic structure of immune and health-related traits.



Figure 4: Cytogenetic map of the pig with all QTLs influencing mean corpuscular volume (MCV) adapted from Pig QTL Database (animalgenome.org, 2019)

Red QTL lines represent significant and light blue lines for suggestive statistical evidence

GWAS studies serve to detect variants, in particular, SNPs, at genomic loci that are associated with a complex trait in a population. GWAS are based upon the principle of linkage disequilibrium (LD) at the population level, whereby LD represents the nonrandom association between alleles at different loci. In general, loci that are placed closer together have stronger LD than loci that are far apart on a chromosome. The strength of the statistical association between alleles at two genome loci depends e.g. on their allele frequency (P. M. Visscher et al., 2012). Usually, GWAS studies are realized in three steps: (1) find study objects with sufficient variation for the phenotype of interest, (2) utilize desoxyribonucleic acid (DNA)-chip to identify alleles at adequate SNP genome positions, and (3) identify statistical difference with the SNPs are visualized by a Manhattan plot. An example of such a conception is given in Figure 5, where each dot represents a genetic marker. The x-axis illustrates all porcine chromosomes and the y-axis quantifies the significance value for the detected associations.



Figure 5: Manhattan plot of whole-genome association analysis for hemoglobin in Large White modified according to Dauben et al. (2021)

Manhattan plot is focusing on a putative pleiotropic region SSC5 illustrated in a red box. This region can be found between 65.8 to 65.9 Mega base pairs and include SNPs like ASGA0025952 and H3GA0016570. Genome-wide significance is computed with a Bonferroni correction with an adjusted p-value < 0.05 and is indicated by a blue line (Dauben et al., 2021)

Since 2007 the detection of loci associated within a GWAS has resulted in new biological knowledge about common diseases and other complex traits. The proportion of genetic variation explained by significant SNPs is usually very low (< 10%). However, for many diseases like type 2 diabetes, multiple sclerosis and Crohn's disease the proportion of explained genetic variance is substantial, reaching from 10 to 20%. In addition, GWAS discoveries for common diseases and complex quantitative traits have given important biological insights with direct clinical relevance. The combination of large sample sizes and stringent significance testing has led to a large number of robust and replicable associations across populations and species (P. M. Visscher et al., 2012).

Methodology development to increase the statistical power of GWAS is important for heterogeneous traits, especially in studies with small sample sizes. Previous GWAS successfully identified genetic markers as SNPs associated with different phenotypes such as RBC- and WBC-related traits (Ballester et al., 2020; Bovo et al., 2020; Bovo et al., 2019; Luo et al., 2012; Ponsuksili et al., 2016; Wang et al., 2013; F. Zhang et al., 2014; Z. Zhang et al., 2013) and cytokines like IFN and IL-10 (Dauben et al., 2021; Lu et al., 2013) (Table 2). Results of detected SNPs and candidate genes helped to clarify, verify and reveal several QTLs for immune related traits. GWAS application with univariate approaches and detected SNPs as well as candidate genes for immune traits is further described in chapter 4.

Normally, detected SNPs are distributed over the whole porcine genome and explain only a small amount of the variation for the trait of interest. In addition, immune traits are difficult to measure and quantify in a large number of animals with various genetic backgrounds. Therefore, it is crucial to develop methods where immune traits can be analyzed jointly to increase statistical power to detect genetic variants and explore the presumed biological-genetical structure.
| Table 2: Overview of published porcine GWAS | studies performed for hematological | traits and |
|---------------------------------------------|-------------------------------------|------------|
| cytokines | | |

| Reference | Inter alia traits* | Pig population | Ν | | | | |
|--------------------------------------------------------------|---------------------------------------|-----------------------|------|--|--|--|--|
| univariate GWAS | | | | | | | |
| Luo et al. (2012) | RBC, HMG, HMT, MCV, MCH, | LW x Minzhu | 430 | | | | |
| | MCHC | F2 | | | | | |
| Wang et al. (2013) | RBC, HMG, HMT, MCV, MCH, | Large White, | 421, | | | | |
| | MCHC, PLT, WBC, NEU, LYM, MON | Landrace, | 68, | | | | |
| | | Songliao Black | 79 | | | | |
| Lu et al. (2013) | IFN-γ, IL-10 | Landrace, | 68, | | | | |
| | | Yorkshire, | 415, | | | | |
| | | Songliao Black | 79 | | | | |
| Z. Zhang et al. (2013) | RBC, HMG, HMT, MCV, MCH, | White Duroc x | 1912 | | | | |
| | MCHC, WBC, PLT, LYM, MON | Erhualian F2 | | | | | |
| F. Zhang et al. (2014) | ERY, HMG, HMT, MCV, MCH, | Sutai | 436 | | | | |
| | MCHC, PLT, WBC, LYM | | | | | | |
| Ballester et al. (2020) | RBC, HMG, HMT, MCV, MCH, | Duroc | 432 | | | | |
| | MCHC, PLT, WBC, NEU, LYM, | | | | | | |
| | MON, EOS, HAP | | | | | | |
| Dauben et al. (2021) | RBC, HMG, HMT, MCV, MCH, | Landrace, | 534, | | | | |
| | MCHC, PLT, WBC, NEU, LYM, | Large White | 461 | | | | |
| | MON, EOS, BAS, HAP, IFN-γ, IL-10, | | | | | | |
| | IL-12, IL-1β, IL-4, IL-6, IL-8, TNF-α | | | | | | |
| Univariate GWAS, Bayesian univariate GWAS | | | | | | | |
| Ponsuksili et al. | RBC, HMG, HMT, MCV, MCH, | Landrace | 591 | | | | |
| (2016) | MCHC, PLT, WBC, LYM | | | | | | |
| Univariate GWAS, Bayesian univariate GWAS, multivariate GWAS | | | | | | | |
| Bovo et al. (2019) | RBC, HMG, HMT, MCV, MCH, | Large White | 843 | | | | |
| | MCHC, PLT, WBC, NEU, LYM, EOS, | | | | | | |
| | BAS, MON | | | | | | |
| | | 1 | | | | | |

GWAS= genome-wide association study, RBC=red blood cells, HMG= hemoglobin, HMT= hematocrit, MCV= mean corpuscular volume, MCH= mean corpuscular hemoglobin, MCHC= mean corpuscular hemoglobin concentration, PLT=platelets, WBC=white blood cells, NEU= neutrophils, LYM= lymphocytes, EOS= eosinophils, BAS= basophils, MON= monocytes,

IFN- γ = Interferon- γ , IL= Interleukin, N=Number of animals, *overlapping traits with own studies in chapters 3 and 4

2.7. Multivariate approaches for QTL detection

Generally, GWAS are performed on a single phenotype of interest, in an univariate (uv) trait manner. In recent years, a variety of multivariate (mv) methods have been proposed to analyze multiple phenotypes simultaneously to investigate their joint association with an SNP (Galesloot et al., 2014; Porter & O'Reilly, 2017; Salinas et al., 2018; Vroom et al., 2019b). Since mv information is increasingly available and pleiotropy is a common phenomenon within and between traits, the development of powerful mv analysis procedures is needed to detect an associated SNP.

The association between complex traits and genome-wide SNP markers is typically analyzed in a uv manner for each trait. Mv analyses, on the other hand, could provide several advantages if multiple, correlated traits are analyzed together. In uv analyses, the additional information provided by the covariance between traits is ignored; in a mv analysis, however, it increases the power in the presence of genetic correlation between the traits. An additional advantage of mv procedures is that many of them can test a single trait for association with a set of variables. In comparison to analyzing all traits separately, this reduces the number of tests performed (Zhu & Zhang, 2009). Furthermore, when pleiotropy is present, where a single genetic variant affects multiple traits, a mv GWAS is more appropriate than a cross-trait comparison using uv analyses (Galesloot et al., 2014).

Considering different conceptual classifications for mv methods (Galesloot et al., 2014; Vroom et al., 2019b; Q. Yang & Wang, 2012) the methods can be distinguished by their statistical properties in regression-based (direct), transformation-based (indirect), and composition test (uv-based). According to this classification, regression-based methods model the effects of the genetic variant directly on the traits without changing the general format and nature of the trait data. On the contrary, transformation-based methods are based on the reduction of the trait dimension. In the first step, initial traits are modified than in the second step transformed traits are regressed on the genetic variant. Uv-based composition tests combine the p-values or test statistics obtained from uv analyses to test a mv hypothesis for example in a meta-analysis (Figure 6).

Combination tests have the challenge of interpreting phenotypic correlations between p-values or test statistics resulting from associated traits in the phenotypical context within which they are conducted.



Figure 6: Conceptual classifications for multivariate methods were modified according to Galesloot et al. (2014)

T1, ...Tn= trait, GV=genetic variant. Statistical properties of multivariate methods can be distinguished in regression-based (direct), transformation-based (indirect), and composition-based (univariate-based)

Mv genetic association methods, regardless of their statistical foundation, need to deal with a significant correlation between the simultaneously modeled traits dependent on the tested GV. Different methods are used to accomplish this. Combination tests use a correction factor or permutation. Regression-based tests implement two solutions: either traits are treated as predictors (e.g. MultiPhen) or residual trait correlations are accommodated in a background covariance matrix (e.g. MANOVA, GEE, LMM). Transformation-based tests explicitly incorporate the covariance between the traits into the new variates. Thus, for the selection of a suitable mv method to apply to immune traits, several types of mv GWAS approaches were available: uv-based, indirect, and direct mv methods. Representative approaches of each type were selected subjectively in the study included in chapter 4. In the following sections, the

subjective selected mv methods are introduced briefly. Details about the statistical background of the methods are given in the original literature (Everitt & Hothorn, 2011; Ferreira & Purcell, 2009; Scutari, 2010; Servin & Stephens, 2007; Stephens, 2013; van der Sluis et al., 2013; Weller et al., 1996).

Beyond the described methods in this section, there are also further software extensions, packages, and approaches which perform mv GWAS e.g. GEMMA (Zhou & Stephens, 2014b), WOMBAT (Meyer, 2007), aSPUset (Kim et al., 2016), GUESS (Bottolo et al., 2013), BMTME (Montesinos-Lopez et al., 2016). Multi-SNP GWAS methods aim to increase power by reducing the residual variance by including other genetic variants as predictors in the model (Galesloot et al., 2014). However, reviews and studies of mv GWAS approaches state that there is no one most powerful method and that the different existing methods should be viewed as complementary (Galesloot et al., 2014; Porter & O'Reilly, 2017; Zhou & Stephens, 2014b). Except for the recent study from Bovo et al. (2019), mv GWAS methods have not been applied to porcine immune traits, yet. In the study from Bovo et al. (2019), in addition to an uv GWAS, a Bayesian method and a mv GWAS have been applied to hematological traits for slaughtered Italian LW pigs. Thus, the importance of gaining a deeper understanding of the performance of mv methods to identify strategies of analysis to maximize discovery potential and pleiotropic genetic structure is highlighted. It is important to mention that in the comparison studies the predictor of interest is the genetic variant, i.e. SNP. However, in practice, even more, complex factors and additional covariates such as sex, age, and genetic principal components are standardly included in the statistical model to consider all biological influences and to correct for population stratification.

2.7.1. Principal component analysis

A commonly used indirect method is the principal components analysis (PCA). PCA, as a mv technique, analyzes a large amount of data and aims to reduce its dimensionality while preserving as much of its original variation as possible. To achieve this, the original variables are transformed into linear combinations, called the principal components (PCs). The PCs are uncorrelated and are ordered so that the first few of them account for most of the variation in the original variables (Everitt & Hothorn, 2011). PCs derived from the components of the eigenvectors of the phenotypic covariance matrix which explain the largest proportion of the original phenotype are then used in place of the original phenotypes (Weller et al., 1996). PCA is among the oldest forms of mv analysis, having been introduced originally by Pearson (1901) and independently by Hotelling (1933). It remains a popular method for displaying mv data in

a lower dimensional space and for simplifying other analyses of the data because it provides a convenient way to display mv data.

2.7.2. Canonical correlation analysis

Canonical correlation analysis (CCA) is applied to two sets of variables (phenotypic measurements and the genetic variant) to extract a number of independent pairs of variables that explain as much covariance between the two sets (Ferreira & Purcell, 2009). Whenever there are multiple variables in each set, the objective of CCA is to find the linear functions of the variables in one set that are maximally correlated with the linear functions of the variables in the other set. The process of finding coefficients that define the required linear functions is similar to the PCA. Nevertheless, this technique isn't as widely used as other mv techniques, perhaps because the results of such an analysis are frequently difficult to interpret. As with PCs, the coefficients of each original variable in each canonical variates to interpret the original variables may provide insight into how the two sets are related to each other. The variances and covariances of the original variables in the two sets may differ considerably, which affects the sizes of the coefficients in canonical variates.

2.7.3. Meta-analysis

Meta-analytical approaches compute a single summary statistic across study populations or phenotypes. For example, TATES (trait-based association test that uses the extended Simes procedure) requires the phenotype correlation matrix and the P-values obtained from uv GWAS analyses to calculate associations across the traits. By combining the uv phenotype-specific GWAS results as p-values, TATES generates one trait-based p-value. Using a method described by Li et al. (2011), an eigenvalue decomposition of the correlation matrix between the p-values associated with phenotypes is used to estimate the effective number of p-values. After transforming this trait correlation matrix to the eigen-decomposition of this p-value correlation matrix, the uv p-values are weighted according to this matrix. A minimum of these weighted p-values is chosen as the corrected p-value for the joint association (van der Sluis et al., 2013).

2.7.4. Bayesian multivariate approaches

Direct methods, for example, Bayesian multivariate approaches with the software SNPTEST or mvBIMBAM can be applied for multi-trait analyses. MvBIMBAM (mv Bayesian imputationbased association mapping) performs Bayesian mv regression to test for association and to partition the phenotypes according to the SNP-effect in the same step (Servin & Stephens, 2007; Stephens, 2013). Bayes Factors were employed to assess the association between each phenotype group and the genetic variant. Analyses are based on mv regression models, with inputs (n x d) matrices of d phenotypes for each individual. According to the mvBIMBAM approach, response variables are grouped into three categories based on their statistical association with genetic variants: undirect, direct, and indirect. A set of models runs through partitions of the coordinates.

2.7.5. Trait networks and structural equation models

It is computationally intensive to realize all possible mv combinations for all immune phenotypes. Interaction between variables can be modeled with networks, paths, and graphs. The Bayesian network (BN) provides conditions for determining dependencies and independencies among variables (Scutari et al., 2014). Therefore, with a BN it is also possible to uncover conditional dependencies among immune traits.

BNs are graphical representations of probability distributions over a set of variables. Pearl (1988) has extended conditional independence (of random variables) to disjoint node subsets by assuming the different random variables are independent. Accordingly, in the BN approach, the graphical structure of the network was learned using model selection algorithms, and then the local distribution function parameters were estimated based on the learned structure. Different types of algorithms can be used to obtain the model from the network structure (Scutari, 2010). A score-based structure learning algorithm is a general heuristic optimization technique for solving the problem of learning the structure of a BN. An output of this algorithm is a graphical structure that shows how well the BN fits the data set, measured by a score.

Using structural modeling such as a BN, a mv modeling strategy is developed that accounts for recursive effects (effects from one phenotype are passed onto another) and simultaneous (reciprocal) structures among its variables, unlike standard mv statistical methods (Goldberger, 1972). Using SEM-GWAS, Momen et al. (2019) were also able to partition the source of the SNP effects into direct and indirect effects, allowing a better understanding of the relevant biological mechanisms. However, mv GWAS without structural equation modeling does not take into account network structure between phenotypes, estimating overall SNP effects across phenotypes, rather than combining direct and indirect SNP effects.

2.8. Accessing genetic pleiotropy

According to the literature contributing to Pig QTL Database (Hu et al., 2019), most of the detected genetic markers for health-related traits explain small amounts of phenotypic variance, are distributed across the porcine genome, and show polygenic genetic structure by being linked

to further genomic areas. Sharing the same genetic foundation between hematological traits, showed that pleiotropic QTLs are common in hematological traits like hematocrit, RBC, and MCV (F. Zhang et al., 2014). Pleiotropy refers to a single gene or genetic variant that affects multiple, different, phenotypic traits (Solovieff et al., 2013). In the context of complex traits, which are influenced by many small genetic effects across the genome (P. M. Visscher et al., 2012), pleiotropy can be considered at the SNP level. Identifying pleiotropic SNPs can lead to a greater understanding of the underlying biological network between complex traits, and identify biological pathways enriched for effects on clusters of traits for further investigation. Pleiotropy can arise in different forms, and distinguishing between them is important for understanding the biological implications. Several types of pleiotropy are distinguished further in biological, mediated, and spurious pleiotropy. Biological pleiotropy occurs when one gene has a direct effect on at least two different traits. Spurious pleiotropy is defined as a genetic variant falsely identified to be associated with more than one phenotype, whereas mediated pleiotropy exists if one phenotype is causally related to another phenotype (Solovieff et al., 2013). In chapter 3 moderate to high r_g (0.4-0.8) between immune traits like hematological parameters and cytokines, which were measured in LR and LW piglets and their biological dams, are described. Consideration of close relationships between multiple immune traits can be used to boost statistical power to detect joint SNPs, which was applied in chapter 4. Most mv GWAS methods are not optimized for the detection of pleiotropic genetic variants. Furthermore, these approaches do not require a pleiotropic effect to gain power over the uv approach. However, my GWAS methods have the potential to further describe the pleiotropic effect of a genetic variant on multiple complex traits, which was done in chapter 4.

Chapter 3. Genetic parameters of immune traits for Landrace and Large White pig breeds

Katharina Roth¹, Maren Julia Pröll-Cornelissen¹, Esther Maren Heuß¹, Christina Mechthilde Dauben¹, Hubert Henne², Anne Kathrin Appel², Karl Schellander¹, Ernst Tholen¹, Christine Große-Brinkhaus^{1*}

¹Institute of Animal Science, University of Bonn, Endenicher Allee 15, 53115 Bonn, Germany ²BHZP GmbH, An der Wassermühle 8, 21368 Dahlenburg-Ellringen, Germany

*Corresponding author: Christine Große-Brinkhaus, E-mail: cgro@itw.uni-bonn.de

Published in: Journal of Animal Breeding and Genetics published by John Wiley & Sons Ltd.; DOI: https://doi.org/10.1111/jbg.12735; Published online: 29 July 2022

3.1. Abstract

Improving the immunocompetence towards pathogens represents a desirable objective of breeding strategies to increase resilience. However, the immune system is complex and the genetic foundation of the underlying components is not yet clarified. In the present study, we focused on 22 blood parameters of 1144 Landrace (LR) and Large White (LW) piglets at the age of six to seven weeks. The immune profiles covered immune cells, red blood cell characteristics, and cytokines. Genetic parameters based on pedigree information along with possible environmental effects were estimated. Litter effects play an important role in the expression of immune parameters of their young progenies. Hence, litter impacts on the piglet's immune profile including the immune parameters of the dam itself were investigated by different models. To incorporate the complexity of the immune network, the data were further investigated with a principal component analysis.

Immune traits showed low to high breed-specific heritabilities (h²). Strong positive genetic correlations (r_g) were estimated among red blood cell characteristics (0.77 to 0.99) as well as among cytokines (0.48 to 0.99). Neutrophils and lymphocytes illustrated a high negative r_g (-0.96 to -0.98). The litter impact on piglet's immunity was examined and strengthened already observed breed differences. In LR h² (0.22 to 0.15) and litter effect (c²) (0.52 to 0.44) for IFN- γ decreased after statistical consideration of maternal impact. In LW a decrease in h² (0.32 to 0.18) for IFN- γ and an increase in c² (0.54 to 0.56) was observed. Here, sufficient correlations were detected within various immune traits and functional biological networks of principal components. Most immune traits are heritable and are promising to cover global breed-specific immunocompetence in pigs. The analysis of immune traits has to be extended in order to find an optimal range and to characterize relationships between immunity as well as performance to gain an improved immune system without accidental losses in productivity.

Keywords: Variance components, immune traits, maternal impacts, principal component analysis, pig.

3.2. Introduction

In pig breeding programs the development of breeding strategies to increase resilience represents a desirable objective. Improving immunocompetence towards pathogens could contribute to achieving this challenging goal. However, the immune system is very complex, and little is known about the genetic foundation of its parameters. Some genetic studies provide insights into the genetic variability of the immune parameters in pigs (Ballester et al., 2020; Bovo et al., 2019; Clapperton et al., 2009; Clapperton et al., 2008; Edfors-Lilja et al., 1998; Flori, Gao, Laloë, et al., 2011; Henryon et al., 2006; Hermesch & Luxford, 2018; Mpetile et al., 2015; Ponsuksili et al., 2016). From this can be concluded that immune responsiveness and disease resistance are quantitative traits regulated by the effects of numerous genes influenced by a variety of environmental factors (Mallard et al., 1992). However, the number of observations, the underlying breeds as well as non-genetic effects like the time of blood sampling, housing conditions including the hygienic farm concept, and infection pressure are very divergent. As a result, heterogeneous and non-consistent environmental as well as genetic parameters have been reported. Moreover, various studies (Flori, Gao, Laloë, et al., 2011; Mallard et al., 1992) have postulated, that animals bred for high production output could be more susceptible to pathogens.

Against this background, we focused on the immunocompetence of purebred Landrace (LR) and Large White (LW) piglets, raised under the definable condition of two nucleus farms with high hygienic status. Within these herds, piglets were born under comparable conditions with low infection pressure. Authors of already published variance component studies for health-related traits (Clapperton et al., 2005; Hermesch & Luxford, 2018; Ponsuksili et al., 2016) pointed out that traits which tend to represent the immunocompetence should be effortless to measure and to reproduce without any impairment, disease symptoms, or inflammatory and pathological signs. Therefore, for the purpose of this study pigs were not treated in any way. Our evaluation represents the first step towards a deeper insight into the genetic foundation of immune traits of breeding animals.

Many influences on a piglet's immune system have been described in the literature (Zimmerman et al., 2012). During the first days of life, maternal effects have a strong impact on the piglet's innate and adaptive immunity and thus, have an influence on the piglet's survival (Heuß et al., 2019). Passive maternal-derived humoral and cellular immunity provide additional essential protection for newborn piglets, who receive antibodies only postnatal through the colostrum (Bouma et al., 1998). Colostrum and milk serve primarily to transfer systemic and local protection due to maternal-derived humoral and cellular immunity and to influence the

development of systemic and mucosal immunity through provided hormones, antimicrobial proteins, and growth factors (Bandrick et al., 2008; Salmon et al., 2009; Zimmerman et al., 2012). Moreover, maternal genetic effects influence piglet survival directly (Knol, Ducro, et al., 2002; Roehe et al., 2010). Therefore, research on the maternal and litter impact requires an emphasis on neonatal immunity development. Since piglet mortality mostly occurs during early development, even maternal and litter effects of short duration may have important consequences (Grindstaff et al., 2003). Furthermore, a low genetic correlation between the transfer of maternal antibodies and the offspring's adult reproductive rate and some components of the immune response has been observed e.g., in chickens (Biozzi et al., 1982; Martin et al., 1990). In pigs, maternal influences have been shown to modulate offspring's birthweight, farrowing, pre-weaning, and total piglet survival (Knol, Ducro, et al., 2002; Roehe et al., 2010). It is well known that the immune system is a high-dimensional complex network with key nodes along with highly expressed relationships between the participating components. To incorporate these expected dependencies, multivariate (mv) approaches seem to be a promising analysis option. Principal components analysis (PCA) allows reducing correlated traits into a set of uncorrelated variables called principal components (PCs). This statistical method detects patterns in the data by their similarities and differences and compresses the data information (i.e., by reducing the number of dimensions) without much loss of information (Hair, 2009; Weller et al., 1996).

The objectives of this study were to estimate the genetic parameters of immune traits, to investigate the genetic associations between these traits by PCA, and to examine the impacts of the dam's immune profile on their offspring's immunity.

3.3. Material and Methods

3.3.1. Animals and phenotypic measurements

Data sets of purebred LR and LW subset pig populations were recorded from 2010 to 2017 and were provided by the German breeding organization Bundeshybridzuchtprogramm (BHZP) GmbH as been already described in Dauben et al. (2021). The animals within the nucleus populations were kept under high hygienic conditions and reflect the genetic diversity of both populations concerning their different breeding objectives. From each litter, one male and one female piglet, as well as, their biological dam were chosen for blood sample collection. Animals were apparently healthy and average in physical development. Blood samples of piglets (LR: n=611 and LW: n=533) were collected on average around 45 days (32-60) after birth by puncturing the Vena jugularis and were collected in three 7.5ml monovette containing Ethylenediaminetetraacetic acid. As an additional trait, piglets were weighed individually after blood sample collection. From the biological dams (LR: n=298 and LW: n=272) of all phenotyped piglet's blood was sampled in a short period *postpartum* (7 days). The blood sample collection period for piglets (45 days after birth) was chosen because at this age piglet's immunity is still under development (Tizard, 2013) and the importance of maternal antibodies decreases. For dams, the recorded immune profile should characterize the postnatal passive immune transmission from sow to the progeny.

Complete blood count (red blood cells (RBC), hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets, white blood cells (WBC), neutrophils, lymphocytes, monocytes, eosinophils, basophils, band and other remaining cells) was performed with an ADVIA[®] 2120 hematology system, a flow cytometry-based system, and a pig-specific setting, as described by Harris et al. (2005). Besides, serum haptoglobin was measured in 0.5 ml serum. Peroxidase activity of the haptoglobin-hemoglobin complex was carried out by a spectrophotometric method. Hematology analysis and haptoglobin were measured in an external laboratory of synlab.vet GmbH immediately after blood samples arrived on the same day.

Cytokine levels (interferon- γ , interleukin-10, interleukin-12, interleukin-1 β , interleukin-4, interleukin-6, interleukin-8, tumor necrosis factor- α) in serum samples were analyzed with a Porcine Cytokine/Chemokine Multiplex Magnetic Bead Panel (Merck KGaA) enabling the simultaneous measurement of multiple cytokines. Immunoassay of serum samples was performed using 22 plates according to the manufacturer's protocol. These fluorescence intensity measurements were performed using Luminex® 200 with xPONENT 3.1 software in

the external laboratory of the Flow Cytometry Core Facility, Medical Faculty, University of Bonn. A general overview of all investigated immune traits in piglets and dams as well as their summary statistics are presented in the results section 3.1. Cytokines were measured in the detectable concentration ranges with the chosen assay quantification method. High standard errors for the mean values are caused by a high reported variation range of the cytokines. To consider low values and the resulting left-skewed distribution of the raw cytokine and haptoglobin measurements, observations were log-transformed. Records of piglet's and dam's immune traits were excluded when they met at least one of the following criteria: Haptoglobin ≤ 0.01 mg/ml, Neutrophils =0%, Lymphocytes $\leq 10\%$, Band cells $\geq 20\%$, Cytokine's bead count < 50. In total, measurements from at least 522 LR piglets and 456 LW piglets as well as 261 LR dams and 231 LW dams were used for further analysis.

3.3.2. Statistical analysis

Variance component analysis of immune traits

Variance components of immune traits were estimated by using an animal model 1 as follows:

$$y_{ijk} = fix_i + a_{ij} + c_{ik} + e_{ijk}$$
(1)

The estimation of the genetic parameters was performed within a breed for immune traits (y_{iik}) of the complete blood count, haptoglobin, and cytokines. Model 1 includes all relevant fixed effects (fix_i), given as the class effects parity (PAR_i :1-4), herd-year-season-sex ($HYSS_i$: 1-12). Moreover, age (age_{iikl}) and weight (wt_{iikl}) and interaction between age and weight $(age \times wt)_{ijkl}$ at the time of sample collection were included in the model as covariates. Porcine Cytokine/Chemokine Multiplex Magnetic Bead Panel method requires the quantification of samples distributed among 22 analytical plates. Therefore, pl_k was included as a random term for cytokine immune traits.. The effects breed (LR or LW) or sex (boar or sow) were not included as main factors in the model because of the hierarchical classification of these effects within HYSS classes. To quantify differences between breeds or sexes, linear contrasts between relevant HYSS classes were constructed and tested via a series of Tukey-Tests. We used the fixed part of model (1) (fix_i) to analyze the impact of fixed effects within and between the two breeds. In the combined data set, linear contrasts were used to present potential effects of breed and farm. Because in the investigated combined data set most herds kept only one breed and one sex, the interpretation of linear contrasts between breeds and sex is impaired because of possible uncorrected environmental effects. The significance levels of fixed effects included in the statistical model as well as relevant linear contrasts were obtained by a generalized linear model using R (R Core Team, 2019).

In addition, this model was extended by the random, uncorrelated additive genetic (a_{ij}) and litter (c_{ik}) effects. The estimation of the additive genetic effects incorporated the relationship matrix of all piglets (a_{ij}) , which could be traced back almost completely up to the 8th generation. Litter effects (c_{ik}) include the litter information of each dam, and it was assumed that, (c_{ik}) -effects were independent and identically distributed. As usual heritability (h^2) and litter effects (c^2) were expressed as the ratios of additive genetic variance (σ_a^2) : phenotypic variance (σ_p^2) or litter variance $\sigma_c^2:\sigma_p^2$.

With a series of overlapping mv approaches (up to six traits per analysis) phenotypic (r_p) and genetic (r_g) correlations between all immune traits were established applying model 1. Based on the model (1) we have estimated the genetic parameters within a breed. This was motivated by the distinct genetic distance between the LR and LW breeds. This distance was calculated by means of available SNP information and has been published in the work of Dauben et al. (2021). Genetic parameters of each trait were estimated in combination with almost all possible sets of other traits. Identical parameters with their standard errors which were estimated in different mv runs were averaged using the median. In rare cases, the convergence criteria of the REML analysis could not be reached, so some genetic correlations were not estimable. These exceptions occur if the h^2 of one or more traits used in the mv model were close to zero. The calculations were conducted in VCE 5.1 (Kovač & Groeneveld, 2003).

Statistical consideration of maternal effects

In statistical model 1 random litter effects (c_{ik}) were included to take into account mainly the common environment of the littermates. To consider the dam's environmental influences more rigorously, immune traits of the dam were integrated as an environmental effect into the genetic analysis of the piglet data. For this purpose, the highly correlated immune traits of the dam were centered, scaled, and condensed via PCA. This analysis was performed within biological functional networks (BFN) a) immune cells (Cell), b) RBC and haptoglobin (RBC) or c) cytokines (Cyto). In the genetic analysis of the piglet data, resulting first and second dam's PCs which belong to the corresponding BFN as the piglet immune target trait were used as additional covariates in model 1. According to the statistical PCA principles (details are given in Weller et al. (1996)), PCA transformation of n traits resulted in n number of phenotypically uncorrelated variables conducted from the components of the eigenvectors of the phenotypic covariance matrix. Eigenvalue stands for the part of phenotypic variability explained by the

corresponding PC variable. The importance of each immune trait within the different PC can be quantified by their loadings. PCA was conducted in R (R Core Team, 2019).

Multivariate analysis of piglet's immune traits

Similarly, to the above section: statistical consideration of maternal effects, PCA techniques were used to condensate the highly correlated piglet's immune observations within the different BFN and breeds. An overview of PCs within the BFN together with their loading composition for the piglet data set is presented in the results section 3.5. Based on this information, it might be possible to interpret PCs in a summarizing, biological manner. The number of resulting PCs per BFN which were finally used to characterize piglet's immune system derived from eigenvalues of the correlation matrix. Applying Kaiser's criterion (Braeken & van Assen, 2017), PCs with eigenvalues above a threshold of 1.0 were used in the following analysis. Variance components of resulting PCs as new dependent variables were estimated by using the mv approach as has been described in the section above: Variance component analysis of immune traits.

3.4. Results

3.4.1. Immune trait values and influencing factors

The results from the ANOVA after formulating a generalized linear mixed model are shown in the Table S1. For most immune traits in the LR and LW piglet's data set HYSS effect had a significant influence. Age had a breed-specific effect on several phenotypes. In the LR piglet data set age influenced immune traits like MCV, MCH, platelets, WBC, and haptoglobin whereas it only had significant impacts on hemoglobin, hematocrit, MCH, and MCHC in the LW piglet data set. LR and LW immune traits like MCV, neutrophils, lymphocytes, and monocytes were influenced by the weight at the time of blood sample collection. Besides, weight also had a significant impact on RBC, hemoglobin, hematocrit, MCH, MCHC, eosinophils, IL-1 β , and IL-4 for LR piglets. The interaction of the covariates age and weight remained significant for haptoglobin, IL-1 β , IL-4 in LR and for RBC, hemoglobin, hematocrit, and MCHC in LW.

Descriptive statistics of phenotypic measurements of all piglets and dams separated by breed are given in the Table S2. The measured band and other remaining cells were excluded from further investigations because these traits showed a phenotypic variance close to zero. Breed differences were investigated by comparing the mean values of the immune traits and by linear contrasts between relevant HYSS classes that were constructed and tested. In total, 14 traits (RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, neutrophils, lymphocytes, basophils, IL-10, IL-12, IL-1 β , and IL-8) revealed significant (p < 0.05) differences between the breeds. The neutrophil value in LR piglets was 6% higher than in LW (47.64% to 41.48%), whereas the LR lymphocyte value was 7% lower in comparison to LW (45.84% to 52.89%). For the mean values of platelets, WBC, monocytes, eosinophils, haptoglobin, IFN- γ , IL-4, and TNF- α no significant differences between the breeds within the piglets' data set were found.

Within the dams' data set, similar breed contrasts regarding RBC, hemoglobin, hematocrit, platelets, and monocytes means were detected. For example, the neutrophil value in LR dams (58.58%) was 5% higher than in LW (53.85%), whereas the lymphocyte value was 6% in LR (31.43%) was lower than in LW dams (37.46%).

There are possible uncorrected environmental effects in the investigated data set since most herds kept only one breed and one sex. The interpretation of linear contrasts in the combined data set is therefore impaired.

3.4.2. Genetic parameters for immune traits

Heritabilities and c^2 effects for 22 immune traits were estimated within the LR and LW breed applying animal model 1 (Table 3). The h² and c² estimates were classified as high (h² > 0.40), moderate (0.10 < h² ≤ 0.40), and low (h² ≤ 0.10) as has been suggested by Flori, Gao, Laloë, et al. (2011). In both breeds, the h²-estimates for eight traits were categorized as high.

High h^2 were found for MCH and MCV in both breeds and RBC, hemoglobin, hematocrit, and TNF- α within LR. In contrast, h^2 close to zero were found for MCHC in the LR breed and hematocrit, platelets, WBC, eosinophils, basophils, and haptoglobin within the LW breed.

Regarding both breeds moderate to high established c^2 were only present in platelets, monocytes, and cytokines whereas for most immune cells and haptoglobin c^2 values showed almost no variability. Particular high c^2 effects were estimated for the cytokines IFN- γ , IL-10, IL-1 β , IL-4, and IL-6 in a range of 0.46 to 0.61 in both breeds.

| Trait | Landrace | | | Large White | | | |
|-------------|--------------|--------------------|--------------------|--------------|--------------------|--------------------|--|
| TTan | σ²p | h ² ±SE | c ² ±SE | σ²p | h ² ±SE | c ² ±SE | |
| RBC | 0.11 | 0.41±0.10 | 0.05 ± 0.04 | 0.17 | 0.36±0.08 | 0.03±0.03 | |
| Hemoglobin | 13476.89 | 0.41±0.11 | 0.08 ± 0.05 | 17281.73 | 0.18 ± 0.08 | 0.09±0.04 | |
| Hematocrit | 0.001 | 0.43±0.11 | 0.05 ± 0.04 | 0.001 | 0.09 ± 0.06 | 0.08 ± 0.04 | |
| MCV | 69.39 | 0.53±0.10 | 0.09±0.05 | 72.93 | 0.61±0.10 | 0.11±0.05 | |
| МСН | 1.06 | 0.41±0.08 | 0.04±0.03 | 0.79 | 0.66±0.12 | 0.08 ± 0.05 | |
| MCHC | 2.56 | 0.02 ± 0.02 | 0.02 ± 0.02 | 1.06 | 0.15±0.07 | 0.14±0.05 | |
| Platelets | 264740234.31 | 0.24±0.08 | 0.20±0.05 | 410896818.95 | 0.01±0.02 | 0.26±0.05 | |
| WBC | 472.63 | 0.18±0.06 | $0.08 {\pm} 0.04$ | 942.49 | 0.08 ± 0.07 | 0.15±0.06 | |
| Neutrophils | 7575.96 | 0.25 ± 0.08 | 0.10±0.04 | 10465.29 | 0.12 ± 0.08 | 0.16±0.05 | |
| Lymphocytes | 7823.40 | 0.30±0.08 | 0.11±0.04 | 10241.44 | 0.14 ± 0.08 | 0.16±0.05 | |
| Monocytes | 4.67 | 0.32±0.09 | 0.03 ± 0.04 | 9.24 | 0.17±0.07 | 0.33±0.06 | |
| Eosinophils | 5.24 | 0.22 ± 0.08 | 0.07 ± 0.04 | 1.30 | 0.06±0.05 | 0.04±0.03 | |
| Basophils | 0.02 | 0.22 ± 0.08 | 0.04±0.03 | 0.001 | 0.03 ± 0.04 | 0.14±0.05 | |
| Haptoglobin | 0.001 | 0.18 ± 0.07 | 0.07 ± 0.04 | 0.01 | 0.03±0.03 | 0.04±0.03 | |
| IFN-γ | 0.31 | 0.22 ± 0.08 | 0.52±0.06 | 0.42 | 0.32±0.10 | 0.54±0.06 | |
| IL-10 | 0.06 | 0.24±0.10 | 0.56±0.06 | 0.15 | 0.25±0.10 | 0.53±0.06 | |
| IL-12 | 0.001 | 0.34±0.13 | 0.36±0.07 | 0.001 | 0.18±0.09 | 0.38±0.07 | |
| IL-1β | 0.04 | 0.17±0.09 | 0.51±0.06 | 0.07 | 0.16±0.09 | 0.46±0.06 | |
| IL-4 | 0.22 | 0.19±0.09 | 0.52±0.06 | 0.40 | 0.27±0.13 | 0.45±0.07 | |
| IL-6 | 0.08 | 0.35±0.09 | 0.52±0.06 | 0.17 | 0.31±0.10 | 0.50±0.06 | |
| IL-8 | 0.01 | 0.15±0.08 | 0.23±0.06 | 0.02 | 0.36±0.11 | 0.17±0.06 | |
| TNF-α | 0.08 | 0.61±0.09 | 0.28±0.06 | 0.07 | 0.13±0.08 | 0.46±0.06 | |

Table 3: Direct genetic and litter effects for immune variables of Landrace and Large White piglets

RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC=white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , h²=heritability, c²=litter effect, σ^2_p =phenotypic variance, cytokines are log-transformed, bold font indicates high h² or c² above 0.4

3.4.3. Genetic correlations between immune traits

Pairwise r_g and r_p for all mv combinations in LR and LW can be found in Tables S3 and S4. Figure 7 provides a graphical overview of the genetic parameters, where h^2 can be found on the diagonal, r_p under the diagonal, and r_g above the diagonal for LR and LW piglets. The color key from red to blue was chosen to illustrate the classification of positive as well as negative genetic parameters in high, moderate, and low. The ellipses have their eccentricity parametrically scaled to the correlation value and are shaded to display high or low as well as positive or negative correlations. Regarding both breeds, 106 (LR) and 135 (LW) r_g among different immune traits exceeded an absolute value of 0.4. Regarding consistent across-breed correlations, RBC characteristics were highly positively correlated with each other. As expected, particular high positive r_g were found between MCH and MCV (r_g : 0.99 to 0.94, LR and LW, respectively). Furthermore, MCHC was highly positively correlated with monocytes (0.64 to 0.93) and basophils (0.94 to 0.97).

Hemoglobin and hematocrit were highly positively correlated with the cytokines IFN- γ (rg: 0.71 to 0.43, LR and LW, respectively and rg: 0.69 to 0.40, LR and LW, respectively) and TNF- α (0.65 to 0.79 and 0.61 to 0.88). In addition, RBC showed high positive correlations with cytokines like IL-1 β (0.40 to 0.75) and TNF- α (0.61 to 0.96). Between immune cells, different relationships were found. Neutrophils showed a high positive correlation with WBC (0.62 to 0.72), whereas they showed a high negative correlation with lymphocytes (-0.98 to -0.96). Furthermore, lymphocytes were highly negatively correlated with WBC (-0.71 to -0.58). Between cytokines such as IFN- γ , IL-10, IL-1 β , IL-4, IL-6, and TNF- α high positive rg were estimated. In addition, haptoglobin was highly negatively correlated with cytokines like IL-1 β (-0.89 to -0.71), IL-4 (-0.96 to -0.47), and II-6 (-0.73 to -0.84) in both breeds.

The remaining r_g revealed a contrasting relationship between the two investigated breeds. MCV was highly positively correlated with cytokines like IFN- γ , IL-10, IL-1 β , IL-4, and IL-6 in LR piglets (0.42 to 0.66) but was highly negatively correlated in LW piglets (-0.44 to -0.90). MCH showed similar relationships to cytokines IFN- γ , IL-10, and IL-1 β within the breeds LR (0.40 to 0.52) and LW (-0.47 to -0.84). A high positive relationship between monocytes, eosinophils, and TNF- α was observed for LR (0.53 to 0.40), whereas in LW high negative estimates (-0.82 to -0.85) could be observed.



Figure 7: Graphical display of genetic parameters for immune variables in the piglet data set

Heritabilities (h²) on the diagonal. Phenotypic correlations (r_p) under the diagonal and genetic correlations (r_g) above the diagonal. RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC=white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , LR=Landrace, LW=Large White

3.4.4. Maternal influences on piglet's immunity

Along with the piglet's genetic effect, we intended to investigate how a dam influences her offspring's immune system through the provided environment. To consider the dam's environmental influences in a more specific way, the first and second immune PCs of the dam were integrated as covariables into the genetic analysis of the piglet's immune traits. As has been described in section: statistical consideration of maternal effects, these PCs of the dam correspond to the BFN of the target immune trait of the piglet. These PCs reflect the specific parts of the immune system of the dam which might operate as an environmental effect for the immune traits of the piglet (Table S5).

In general, these covariables had only negligible consequences for the magnitude of maximum 0.05 for the estimated genetic parameters (Table S6). Within cytokines, the consideration of dam's PCs led to a small, breed-specific shift between h^2 and c^2 effects. For example, in LR h^2 for IL-8 decreased from 0.15 to 0.12 in favor of c^2 effects which increased from 0.23 to 0.24. The exact opposite was observed for LW piglets, where h^2 for IL-8 increased from 0.36 to 0.38 and c^2 decreased from 0.17 to 0.16. In addition, h^2 for RBC (0.41 to 0.36) and MCH (0.41 to 0.29) in LR was lowered after consideration for maternal environmental effect. For all other examined immune traits, the inclusion of immune PCs of the dam into the statistical model has changed h^2 or c^2 as well as r_g estimates only to a minor extent.

3.4.5. Accessing highly correlated immune networks in piglets

Theoretically, PCA aims for a more powerful analysis of the immune traits by reducing the dimension of information and therefore, allowing the detection of key players in immunocompetence. Variance component estimation was performed for PCs as new dependent variables of piglet's immune traits within BFN. According to the BFN and breed, three to four PCs were extracted (Table S7). The loading values for these PC-specific traits indicate how much the respective immune traits contribute to a particular PC. Moreover, the loadings can help to interpret estimated variance component results according to their biological function. Loading values for the first PC of each BFN are also presented as pie charts in Figure 8. We used a threshold of |0.3| to classify the immune trait within a BFN into the classes "contributing" or "not contributing". Within BFN RBC, PC1_{RBC} explains ~37% of the variation in both breeds (LR: 37.23%, LW: 37.49%). This PC is mainly influenced by the directly measured RBC characteristics of hemoglobin, hematocrit, and RBC (Figure 8, Table S7). On the contrary, PC2_{RBC} (LR: 22.43%, LW: 22.84%) is mainly influenced by the calculated ratio MCH and

MCV (only in LR). Within the $PC3_{RBC}$ and $PC4_{RBC}$ which also explain more than 10% of the variation, MCHC and haptoglobin are the main actors (Table S7).

Within the BFN Cells PC1_{Cell} (LW: 35.96%, LR: 35.49%) is dominated by neutrophils and lymphocytes, which were known to be negatively correlated and influenced by the time point of blood sampling (Figure 8). On the other hand, PC2_{Cell} can be characterized by the percentages of eosinophils and WBC (only in LW) (Table S7).

In BFN Cyto $PC1_{Cyto}$ explains most of the phenotypic variation (LR: 68.13%, LW: 60.13%). This PC is similarly influenced by all examined cytokines (Figure 8). Apart from that the chemokines IL-12 and Il-8 are less contributing to $PC1_{Cyto}$ but dominate in $PC2_{Cyto}$ for LW piglets (Table S7).

In general, PCs of the two breeds LW and LR can hardly be compared because their composition based on loading values is partly different. In contrast, we assumed that the variance components of the first PCs of each BFN ($PC1_{Cell}$, $PC1_{RBC}$, $PC1_{Cyto}$) are comparable between the breeds due to similarities in the contribution based on their loading values (Figure 8).



Figure 8: Loading composition for first principal components within piglet's functional biological networks

PC=principal component, LR = Landrace, LW=Large White, RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC=white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α . PCs are estimated within three distinguished biological functional networks like cells (Cell), RBC, and additional RBC characteristics including haptoglobin (RBC), and cytokines (Cyto).

3.4.6. Genetic parameters for condensed immune traits

Estimated h² and c² for relevant PCs in LR and LW piglets are presented in Table 4. Within the LR BFN Cell, PC1_{Cell} to PC3_{Cell} show moderate h² (0.18 to 0.31) and mostly low c² (0.04 to 0.06). In contrast to that, in LW only PC1_{Cell} shows a h² (0.12) > 0.1 whereas c²-values are on a slightly higher value (0.10 to 0.16).

For the BFN RBC in LR piglets, moderate (PC2_{RBC}, PC3_{RBC}) to high (PC1_{RBC}) h^2 were estimated in a range of 0.13 to 0.50, whereas c²-effects were low (0.04 to 0.07). However, for LW piglets PC1_{RBC} showed only a low h^2 (0.07), which is surprising because the composition and loadings of PC1_{RBC} in LW and LR are similar. PC2_{RBC}, PC4_{RBC}, and PC3_{RBC} had moderate to high (0.14 to 0.58) h^2 estimates in LW. Similar to the BFN Cell the estimates for c²-effects are higher than in LR in a range of 0.11 to 0.15. Within the BFN Cyto, all PC_{Cyto} were moderately heritable (0.27 to 0.32) in both breeds. Similar to the variance component estimation for single cytokines the estimated c² values were particularly high for PC1_{Cyto} in a range of 0.45 to 0.56.

| RFN | PC | Landrace | | Large White | | | |
|------|-----|----------|--------------------|--------------------|-------|--------------------|--------------------|
| DIII | IC | σ²p | h ² ±SE | c ² ±SE | σ²p | h ² ±SE | c ² ±SE |
| | PC1 | 3.87 | 0.31±0.08 | 0.06±0.03 | 3.53 | 0.12±0.07 | 0.16±0.05 |
| Cell | PC2 | 1.39 | 0.20±0.08 | $0.12{\pm}0.05$ | 1.19 | 0.05 ± 0.04 | 0.10±0.04 |
| | PC3 | 0.98 | 0.18±0.07 | 0.04±0.03 | 0.85 | 0.04±0.04 | 0.14±0.05 |
| | PC1 | 3.89 | 0.50±0.10 | 0.05±0.04 | 3.61 | $0.08{\pm}0.08$ | 0.12±0.05 |
| RBC | PC2 | 2.82 | 0.35±0.08 | $0.04{\pm}0.03$ | 3.28 | 0.58±0.11 | 0.11±0.05 |
| | PC3 | 1.04 | 0.13±0.06 | $0.07{\pm}0.04$ | 0.86 | 0.17±0.06 | 0.11±0.05 |
| | PC4 | | | | | 0.14±0.06 | 0.15±0.05 |
| Cyto | PC1 | 6.10 | 0.32±0.10 | 0.53±0.06 | 10.69 | 0.27±0.09 | 0.57±0.06 |
| | PC2 | | | | 0.88 | 0.32±0.10 | 0.30±0.06 |

Table 4: Direct genetic and litter effects for principal components of Landrace and Large White piglets within biological functional networks

BFN = Biological functional network, PC=Principal component, $\sigma^2 p$ =phenotypic variance, h²=heritability, c²=litter effect, BFN Cell=immune cells, RBC=Red blood cells, and RBC characteristics, Cyto=cytokines, bold font indicates high h² or c² over 0.4 value

3.4.7. Genetic correlation between PCs of biological functional networks

In an additional step, a mv approach provided r_p and r_g between relevant PCs of LR and LW piglets applying model 1. According to the PCA principles, the phenotypic correlation between PCs within a BFN should be close to zero (Weller et al., 1996), so only the genetic correlation of PCs among BFN was estimated. All estimates can be found in the Table S8. Graphical representation of the genetic parameters h^2 , r_p , and r_g for PCs in BFN is given in Figure 9.

As has been described in the previous section 3.4.5 breed-specific comparison of PCs is difficult because their loading composition is partly different. However, in general, many estimated genetic relationships for PCs in BFN Cell, RBC, and Cyto were characterized as high in both breeds.

In LR, high positive r_g were observed between PC3_{Cell} and PC1_{RBC}, as well as PC2_{Cell} and PC2_{RBC}. Between the BFN Cell and Cyto, all r_g were characterized as high (0.51 to 0.68), except for the relationship between PC1_{Cell} and PC1_{Cyto}, which was only moderately (0.17).

In LW, high estimated r_g were detected between PC4_{RBC} and all PCs in the BFN Cell (0.89 to - 0.84). In addition, PC2_{Cell} and PC2_{RBC}, as well as PC3_{Cell} and PC2_{RBC} show high negative r_g (- 0.89 to -0.64). Between the BFN Cell and Cyto, all r_g were characterized as moderate to high (0.36 to -0.93). Further, between PC1_{Cyto} and PC2_{RBC}, a high negative (-0.70) r_g was observed. However, the r_g was highly positive (0.89) between PC1_{Cyto} and PC3_{RBC}.

In addition, we observed that the first PCs of each BFN (PC1_{Cell}, PC1_{RBC}, PC1_{Cyto}) can be compared between the breeds due to similarities in the contribution based on their loading values (Figure 8). Therefore, breed differences were observed for high r_g between PC1_{Cyto} and PC2_{Cell}. In LR, PC1_{Cyto} and PC2_{Cell} were high positively correlated (0.51), whereas in LW they were high negatively correlated (-0.93). PC1_{Cyto} and PC1_{RBC} were high positively correlated in LR (0.68) whereas in LW this relationship was described as moderate (0.24).



Figure 9: Graphical display of genetic parameters for condensed variables in the piglet data set

Heritabilities (h^2) on the diagonal. Phenotypic correlations (r_p) under the diagonal and genetic correlations (r_g) above the diagonal. PC=Principal component, LR = Landrace, LW=Large White, PCs are estimated within three distinguished biological functional networks like cells (Cell), RBC and additional RBC characteristics including haptoglobin (RBC), and cytokines (Cyto).

3.5. Discussion

In this study, the genetic background of immune traits and their complex relationships were investigated. For this purpose, 22 immune traits were analyzed in LR and LW piglets together with their biological dams. Genetic parameters were estimated and a mv approach using a PCA was initiated. The extension of the animal mixed model for additional covariate of dam's PC allowed the investigation of environmental influences on piglet's immunity.

The comparison of phenotypic mean values between the breeds showed clear differences and was also confirmed by the neutrophil to lymphocyte ratio. Friendship et al. (1984) have reported that within the feeder, finisher pigs, and sows the number of lymphocytes exceeded the number of neutrophils, except for growing pigs. The numbers of neutrophils are expected to exceed lymphocytes in piglets because neonates were assumed to develop their adaptive immune systems (Farmer, 2015). In addition to the age, farm, physiological status (lactating or pregnant sow) of the pig can influence the hematological profile. Lactating sows had higher neutrophil and lower lymphocyte values than pregnant sows (Ježek et al., 2018). Breed differences for immune traits phenotypic values (e.g., neutrophil to lymphocyte ratio) are also reported for other breeds and will be explained further. Clapperton et al. (2005) demonstrated differences in innate immune traits between Meishan and LW pigs. Meishans had higher neutrophil and monocyte counts and lower lymphocyte counts. At the current state, it is not possible to characterize which ratio is beneficial for a stable or advantageous immune system; still, such differences in immune traits may have implications in the resistance to pathogen infection in these breeds.

3.5.1. Environmental effects affecting the immune traits

As described in the method section, the estimation of genetic parameters was realized for the LR and LW piglets separately. The selection for the suitable environmental correction was achieved by including relevant significant fixed effects into the statistical model based on ANOVA results. Published reference studies (Ježek et al., 2018; Ponsuksili et al., 2016) have described significant influences of sex, breed, farm, physiological status, and parity for hematological profiles and cytokines. Our results partly confirm already published influencing factors. Discrepancies can be explained by the chosen blood sampling period and the investigated breeds. Finally, relevant effects based on literature and our results were included in the statistical model 1. Further, the environmental impact of the biological dam was analyzed and described in detail.

3.5.2. Genetic foundation of immune traits for piglets

The inclusion of immune traits in a selection program requires these traits to be heritable across generations. Our study confirms previous findings reporting a genetic foundation for immune traits with h² estimates for several immune traits within the published range (Clapperton et al., 2009; Clapperton et al., 2008; Edfors-Lilja et al., 1998; Flori, Gao, Laloë, et al., 2011; Hermesch & Luxford, 2018; Mpetile et al., 2015; Ponsuksili et al., 2016). Moderate h² was found for RBC in LW piglets as reported by several authors (Flori, Gao, Laloë, et al., 2011; Mpetile et al., 2015; Ponsuksili et al., 2016). High h² for MCV were observed in both breeds and have been previously confirmed by Mpetile et al. (2015) in Yorkshire pigs and by Ponsuksili et al. (2016) in LR pigs. MCH showed high h^2 , which is comparable to the study of Ponsuksili et al. (2016) for LR pigs but has been in contrast to Mpetile et al. (2015) for Yorkshire pigs. Flori, Gao, Laloë, et al. (2011) have reported h² for cytokines, however, their estimates for LW swine were very low. In the current study, there were high h^2 for TNF- α in LR piglets and moderate h^2 estimates for all examined cytokines in LW piglets. Generally, there are numerous differences between these studies. Clapperton et al. (2008) estimated the h^2 of two traits in common (WBC and monocytes) in approximately 500 LW pigs at 30 and 90 kg weight under two environments. Clapperton et al. (2009) evaluated unchallenged and unvaccinated pigs that were either at a farm without major swine pathogens or at a farm where swine pathogens were documented. Flori, Gao, Laloë, et al. (2011) measured many of the same traits as investigated in this study in 443 LW pigs one week after these were vaccinated against *Mycoplasma hyopneumoniae*. However, due to fundamental differences, inter-study results should be interpreted with caution. Variations between LR and LW as well as deviations between study results and the literature can be explained by genetic diversities among the breeds but also by heterogeneous environmental conditions or different effects included in the model. Breed differences described in the present study may be related to various disease resistance traits. In the literature, pigs from Duroc and Yorkshire breeds have been shown generally to be more resistant to clinical and subclinical diseases than pigs from LR and Hampshire breeds (Henryon et al., 2001). Genetic breed variation has also been reported between LR, LW, and Duroc in delayed-type hypersensitivity (DTH) and Immunoglobulin G (IgG) (Kikuchi et al., 2002). Large White showed a significantly higher DTH area than LR and Duroc. In IgG concentration, Duroc was significantly lower than LR and LW. Between LR and LW no statistical difference in IgG concentration was detected. In a comparative study on hematological traits in LR, LW and Chinese Songliao Black pig breeds higher values of lymphocyte count, monocyte count, and hemoglobin were observed for LR piglets in comparison to LW. In contrast, MCH and MCHC were lower in LR than in LW piglets (Y. Liu et al., 2010). The authors interpret a higher immune trait value as beneficial for the immune capacity. Similar observations have been reported by Wilkie and Mallard (1999). Piglets selected for a high immune response revealed a better response to vaccination. However, for some stimuli such pigs seemed to generate some autoimmune reactions (Mallard et al., 1992; Wilkie & Mallard, 1999). Therefore, it is still necessary to identify an optima for immune traits. Incorporating resilience indicators into breeding programs seem to be promising for producing healthy and manageable livestock (Berghof et al., 2018).

A consistent result of many studies is that pigs from breeds with high levels of reproduction (Meishan, LW) are more resistant to the effects of the Porcine reproductive and respiratory syndrome virus than pigs from lines selected for lean growth rate (Duroc, Pietrain) (Halbur et al., 1998; Petry et al., 2007; Vincent et al., 2005, 2006). However, other factors also influence the outcome of an immune response, for example, environmental factors and stressors (Clapperton et al., 2009; Farmer, 2015). Our results of additive genetic effects suggest that breed-specific selective breeding for immune traits is feasible. It is necessary to note that a sufficient genetic variance is essential for a high h². Some of our investigated immune traits i.a. HMT in LR did not meet this requirement, so that it is questionable if a promising genetic response can be achieved in such cases.

3.5.3. Maternal impacts on piglet's immune traits

Besides additive genetic effects, further effects e.g. litter can additionally influence piglets' immune traits. To test this hypothesis c^2 was estimated by including the litter information as an additional random effect into the model during variance component estimation. Results for both breeds showed moderate to high c^2 in common cytokines like IFN- γ , IL-10, IL-4, and IL-6. Above mentioned immune studies consider the litter effect and report similar results.

In addition, several studies describe the maternal impacts on piglet's immunity on an environmental level such as cell and antibody transfer, development of mucosal immunity, and colostrum intake (Bandrick et al., 2008; Hermesch et al., 2017; Salmon et al., 2009). Moreover, besides a low h^2 , Rohrer et al. (2014) were even able to estimate moderate maternal genetic effect in their genetic analysis of colostrum intake measured as γ -immunoglobulins complexes bound to ammonium sulfate (immunocrit). There is limited information concerning the impact of immune factors transferred from colostrum and milk to suckling piglets on their immune development. Due to the epitheliochorial placentation of the sow, the passive transfer of antibodies from mother to offspring occurs during colostrum intake only (Farmer, 2015).

Maternal effects can also arise indirectly, whereby an immune trait of the mother would affect some part of the variation in offspring's phenotypic traits (Grindstaff et al., 2003). To consider an environmental impact, PCs of the dam's immune traits were added as an additional covariate into the model. In general, this consideration led to a decrease in h^2 while at the same time causing an increase in c^2 and r_g indicating that it is possible to adjust piglet's immune measurements. The biological dam plays a crucial role in fetal and postnatal piglet survival through the provision of vital resources and by displaying good maternal behavior. The genotype and parity of the dam, as well as the dam's physical condition during gestation and lactation influence piglet survival (Farmer, 2015) and, may have an indirect impact on the piglet's immune system. This statement implies that breeding affords immune traits in piglets that can be accessed through the biological dam.

3.5.4. Close relationships between immune traits imply complexity of piglet's immunity

The immune system is a highly interactive network where the ability to send signals from one cell to another is crucial. Communication within the adaptive immune system and between the innate and adaptive immune systems occurs directly via cell-to-cell contact or by the production of cytokines as mediators (Zimmerman et al., 2012). This leads to the presumption that immune cells and cytokines may be phenotypically or genetically correlated. Furthermore, it is expected that underlying genes may have pleiotropic effects, by influencing several immune traits at the same time (Lu et al., 2011). To investigate this close correlated relationship between examined traits, rp and rg were estimated with a mv approach. As expected, a strong positive rg was observed between cytokines IFN- γ , IL-10, IL-1 β , and IL-6 for both breeds. Pro-inflammatory cytokines (IFN- γ , IL-1 β , and IL-6) are excreted by T-lymphocytes, monocytes, or macrophages and initiate an inflammatory response to regulate the host defense against pathogens. Antiinflammatory cytokines (e.g. IL-10) are secreted by macrophages, T- and B-lymphocytes and have an immunoregulatory role by suppressing inflammatory response (Zimmerman et al., 2012). The importance of cytokines is emphasized by their function to alter metabolism. Cytokines IL-1, IL-6, and TNF-a have been found to modulate intermediary metabolism of carbohydrate, fat, protein substrates, regulate hypothalamic-pituitary outflow and act in the periphery and central nervous system (CNS) to reduce food intake (Johnson, 1997). Immune cells, but also microglial cells within the CNS can synthesize various cytokines (IL-1, IL-6, and TNF- α) at the same time (Fontana et al.). Increased mRNA and protein values of cytokines TNF- α , IL-1 α , and IFN- γ within CNS have been observed in diseased animals infected with

encephalomyelitis (Renno et al., 1995). Therefore, cytokines demonstrate local effects, but can also act systemically to change animal behavior, metabolism, and neuroendocrine secretions.

Besides cytokines, strong correlations were found between RBC and RBC characteristics. F. Zhang et al. (2014) found moderate to high r_p for several hematological traits such as RBC and RBC characteristics like hematocrit, hemoglobin, MCV, MCHC in Chinese Sutai pigs. Furthermore, genome-wide association analysis for this trait revealed single nucleotide polymorphisms (e.g., ss107842725) located in ENSSSCG00000001232 gene on *Sus Scrofa* chromosome 7 which is associated with hematocrit, RBC, and MCV. Sharing the same genetic foundation between these traits' authors express that pleiotropic quantitative trait loci are common on hematological traits.

MCH amounts to the average hemoglobin level in a RBC (Zimmerman et al., 2012). The established high r_g of MCHC to monocytes cannot be fully explained from the literature. According to a recent mouse model of deep vein thrombosis, monocytes contribute to tissue factor-driven coagulation (Rezende et al., 2014) and for this reason, may be associated with higher MCHC values.

Estimated r_g for immune factors are very rare in the literature for livestock, especially for piglets. Flori, Gao, Laloë, et al. (2011) estimated r_g for components of innate and adaptive immunity and was able to show that these two pillars of the immune system are complementary. However, no clusters of innate or adaptive immunity were revealed and estimated r_g for immune traits were mostly weak. Nevertheless, for the total number of white blood cells and different leucocyte subsets high positive r_g were estimated which is consistent with our results. Estimated relationships highlight a strong connective network within the immune system where selection for several immune traits would affect other immune components and therefore, should be carefully examined.

3.5.5. The multivariate analysis emphasizes compound relationships between immune traits

PCA was chosen as a mv approach to reduce the dimensions of phenotypic immune measurement levels. Genetic parameters for direct immune measurements and PCs as new dependent immune variables are very similar. LR and LW showed consistent moderate to high h^2 and c^2 for RBC characteristics and cytokines and PCs which are composed of these phenotypes according to their loadings. Considering the r_g results for PCs, analog relationships are found as in estimated mv r_g between immune traits. For example, a close relationship was estimated between BFN RBC and Cyto, in detail PC1_{RBC} and PC2_{Cyto} were moderate to highly correlated. According to the loadings, PC2_{RBC} is mostly composed of two immune traits: MCH and MCHC, which express mean hemoglobin and mean hemoglobin concentration. Most investigated cytokines (IFN- γ , IL-10, IL-1 β , IL-4, IL-6, TNF- α) contribute variance to the PC1_{Cyto}. As for mv direct r_g , this relationship was also observed as a high positive correlation between hemoglobin and the cytokines IFN- γ as well as TNF- α . Stimulation of human WBC with purified hemoglobin led to the release of proinflammatory cytokines IL-8 and TNF- α (McFaul et al., 2000).

The results obtained here demonstrate that PCA is a useful tool to condense information based on a phenotypic covariance matrix. The number of dependent variables can be reduced by applying this technique without losing important information (Weller et al., 1996). PCA provides from an originally large number of immune traits and variables a simpler basis for summarizing the data. A further advantage of a PCA is an appropriate weighting of immune traits within the PCs. Immunocompetence complex data was measured as immune traits in this study where a desirable directionality of an individual immune trait is unknown. PCs consider a proper weighting of these traits. Therefore, they represent an extraction of the desired and undesired direction of immune traits as the weighted sum of the original variables (Everitt & Hothorn, 2011).

3.6. Conclusion

This study investigated the genetic background of immune traits in LR and LW piglets and their corresponding dams through immune profiling. Most of the examined immune traits show moderate to high genetic parameters including h^2 , c^2 , and r_g . Condensed immune phenotypes as PCs allowed to uncover the complexity of the immune system networks. Most immune traits are heritable and are promising to cover global, but breed-specific immunocompetence in animals. The analysis of immune traits has to be extended to characterize relationships between immunity and performance to gain an improved immune system without accidental losses in productivity.

Chapter 4. Multivariate genome-wide associations for immune traits in two maternal pig lines

Katharina Roth¹, Maren Julia Pröll-Cornelissen¹, Hubert Henne², Anne Kathrin Appel², Karl Schellander¹, Ernst Tholen¹, Christine Große-Brinkhaus^{1*}

¹Institute of Animal Science, University of Bonn, Endenicher Allee 15, 53115 Bonn, Germany ²BHZP GmbH, An der Wassermühle 8, 21368 Dahlenburg-Ellringen, Germany

*Corresponding author: Christine Große-Brinkhaus, E-mail: cgro@itw.uni-bonn.de

Published in: BMC Genomics, BioMed Central Ltd, Springer Nature DOI: https://doi.org/10.1186/s12864-023-09594-w Published online: 28 August 2023

4.1. Abstract

4.1.1. Background

Immune traits are considered to serve as potential biomarkers for pig's health. Medium to high heritabilities have been observed for some of the immune traits suggesting genetic variability of these phenotypes. Consideration of previously established genetic correlations between immune traits can be used to identify pleiotropic genetic markers. Therefore, genome-wide association study (GWAS) approaches are required to explore the joint genetic foundation for health biomarkers. Usually, GWAS explores phenotypes in a univariate (uv), trait-by-trait manner. Besides two uv GWAS methods, four multivariate (mv) GWAS approaches were applied on combinations out of 22 immune traits for Landrace (LR) and Large White (LW) pig lines.

4.1.2. Results

In total 433 (LR: 351, LW: 82) associations were identified with the uv approach implemented in PLINK and a Bayesian linear regression uv approach (BIMBAM) software. Single Nucleotide Polymorphisms (SNPs) that were identified with both uv approaches (n=32) were mostly associated with immune traits such as haptoglobin, red blood cell characteristics and cytokines, and were located in protein-coding genes. Mv GWAS approaches detected 647 associations for different mv immune trait combinations which were summarized to 133 Quantitative Trait Loci (QTL). SNPs for different trait combinations (n=66) were detected with more than one mv method. Most of these SNPs are associated with red blood cell related immune trait combinations. Functional annotation of these QTL revealed 453 immune-relevant protein-coding genes. With uv methods shared markers were not observed between the breeds, whereas mv approaches were able to detect two conjoint SNPs for LR and LW. Due to unmapped positions for these markers, their functional annotation was not clarified.

4.1.3. Conclusions

This study evaluated the joint genetic background of immune traits in LR and LW piglets through the application of various uv and mv GWAS approaches. In comparison to uv methods, mv methodologies identified more significant associations, which might reflect the pleiotropic background of the immune system more accurately. In genetic research of complex traits, the SNP effects are generally small. Furthermore, one genetic variant can affect several correlated immune traits at the same time, termed pleiotropy. As mv GWAS methods consider strong dependencies among traits, the power to detect SNPs can be boosted. Both methods revealed immune-relevant potential candidate genes. Our results indicate that one single test is not able
to detect all the different types of genetic effects in the most powerful manner and therefore, the methods should be applied complementary.

Keywords: Immune traits; Pigs; Multivariate; Genome-wide Association Studies; Immunocompetence; Animal Genetics

4.2. Background

In modern swine breeding conditions, the time around birth is one main critical period for piglet survival (Heuß et al., 2019; Theil et al., 2014). Development of breeding programs to increase general immunocompetence in order to improve piglet survival are desired. Enhancing the piglet's immune capacity can result in further beneficial animal welfare and productivity of pigs. The immune system plays an essential role in the immunocompetence of piglets (Edfors-Lilja et al., 1994). For the progress of selection strategies, basic knowledge of the genetic foundation for phenotypes associated with global immunocompetence is required.

Medium to high heritabilities (h2 0.4-0.8) have been estimated for several immune traits suggesting exceeding potential of the genetic impact (Clapperton et al., 2009; Flori, Gao, Laloë, et al., 2011; Hermesch & Luxford, 2018). GWAS and QTL mapping can be used to explore the genetic background of immune phenotypes. Several QTL studies revealed markers throughout all chromosomes for immune traits related to red and white blood cells (Cho et al., 2011; Edfors-Lilja et al., 1998; Gong et al., 2010; Reiner et al., 2007, 2008; S. Yang et al., 2009; Zou et al., 2008) as well as cytokines (Uddin et al., 2011). Previous GWAS successfully identified numerous genetic markers associated with different phenotypes such as hematological, leucocyte-related traits (Ballester et al., 2020; Bovo et al., 2019; Lu et al., 2013; Luo et al., 2012; Ponsuksili et al., 2016; Wang et al., 2013; F. Zhang et al., 2014; Z. Zhang et al., 2013) and cytokines like interferone (IFN) and interleukins (IL-10) (Dauben et al., 2021; Lu et al., 2013). Usually, GWAS addresses phenotypes in a univariate (uv) trait manner. However, a variety of multivariate (mv) methods were introduced to analyze multiple traits jointly (Zelterman, 2015). The utilization of my methods is recommended to increase the statistical power to detect associations (Galesloot et al., 2014; Porter & O'Reilly, 2017; Wang et al., 2013). Previous results show moderate to high genetic correlation (rg 0.4-0.8) between immune traits (Roth et al., 2022). Consideration of rg between multiple immune traits can be used to identify pleiotropic genetic markers. So far, Bovo et al.

(Bovo et al., 2019) reported uv and mv results for the largest number of 30 hematological and clinical biochemical traits in slaughtered pigs. In these studies, pleiotropic QTL and significant tag haplotypes with effects on multiple blood parameters were detected with mv analysis e.g., a mv Bayesian approach. The aim of this study was to identify genetic markers associated with immune traits. Besides uv GWAS the following mv statistical approaches have been applied and the results have been compared: Principal component analysis (PCA), Canonical correlation analysis (CCA), Meta-analysis (TATES) and one mv Bayesian linear regression approach (mvBIMBAM). Preliminary estimated genetic correlations (Roth et al., 2022) and the construction of biological network assisted the detection of pleiotropic QTL regions. Therefore, a LR and a LW population were investigated in order to identify biologically relevant pleiotropic markers related to health and immunity.

4.3. Results

An overview of the investigated data sets, animals and immune traits can be found in Dauben et al. (2021) and Roth et al. (2022). In brief, piglets of LR and LW were phenotyped for the complete and differential blood count (15 traits), eight cytokines and haptoglobin. The experiment was conducted under mostly practical, but high hygienic conditions and without challenging the animals (Dauben et al., 2021). For the uv and mv analyses performed in this study, data sets of 522 LR and 461 LW piglets comprising 47,292 and 43,730 SNP markers, respectively, were used

4.3.1. Genetic markers identified with uv GWAS approaches

Linear and Bayesian linear regression-based approaches were applied to obtain uv GWAS results (Table S9). In total 401 significant associations were identified with PLINK (LR: 324, LW: 77; adjusted p-value < 0.05). For uv BIMBAM 32 associations were detected in total (LR: 27, LW: 5; BF > 3.02). All SNPs observed with the uv Bayesian approach were also detected by the linear regression approach as implemented in PLINK. These results were mostly associated with immune traits related to red blood cells (RBC), cytokines, and haptoglobin (HAP). The identification of pleiotropic SNPs with uv GWAS is possible when genetic markers are detected across various traits. In total, 75 SNPs (PLINK: 70, 5: BIMBAM) were detected for multiple traits like RBC (RBC, HMG, HMT) and cytokines (IL1b, IL-4, IL-6, IL-10, Tumor Necrosis Factor- α (TNF)) within uv GWAS. Aditionally, the uv GWAS results were compared

across the investigated breeds, however, no overlapping markers were observed between the breeds (Figure S1).

4.3.2. Principal component analysis of the immune traits

Details of the analysis of the PCs within the breeds can be found in the study of Roth et al. (2022). In brief, within BFN red blood cells (RBC), PC1 RBC explains ~37% of the variation in both breeds (LR: 37.23%, LW: 37.49%). This PC is mainly influenced by RBC characteristics of haemoglobin, haematocrit and RBC. On the contrary, PC2 RBC (LR: 22.43%, LW: 22.84%) is mainly influenced by the calculated ratio of mean corpuscular haemoglobin (MCH) and mean corpuscular volume (MCV) (only in LR). Within PC3 RBC and PC4 RBC which also explain more than 10% of the variation, mean corpuscular haemoglobin concentration (MCHC) and haptoglobin are the main actors. Within the BFN cells, PC1 Cell (LW: 35.96%, LR: 35.49%) is dominated by neutrophils and lymphocytes, which were known to be negatively correlated and influenced by the time point of blood sampling. On the contrary, PC2 Cell can be characterized by the percentages of eosinophils and white blood cells (WBC) (only in LW). In BFN cytokines (Cyto), PC1 Cyto explains most of the phenotypic variation (LR: 68.13%, LW: 60.13%). This PC is similarly influenced by examined cytokines. Apart from that, the chemokines IL-12 and Il-8 have less impact on PC1 Cyto but dominate PC2 Cyto in LW piglets. PCs of the two breeds cannot be compared in general because their composition based on loading values differs from breed to breed. In contrast, we assumed that the variance components of the first PCs of each BFN (PC1 Cell, PC1 RBC and PC1 Cyto) are comparable between the breeds due to similarities in the contribution based on their loading values.

4.3.3. Structural multivariate trait combinations

The identification of causal relationships among immune traits before performing mv GWAS helps to reduce extensive computation effort impaired by the realization of all possible mv combinations for all available immune phenotypes. Immune trait combinations of interest were created by performing Bayesian Network (BN) analyses based on the hill-climbing algorithm (Scutari et al., 2019) for all immune traits in LR and LW data sets.

The dependencies among the variables of the structural BN model strings are illustrated in Figure 10 and are presented in Table 5. In total 22 combinations were detected for LR and LW, respectively. In Table 1 the structure of the identified BN is displayed: a local structure is presented in square brackets [] with the first string identifying a node. There are two types of nodes: parents and children. The state input variables, or parents of the node, are listed after a vertical bar "|", separated by colons ":". Children of the node represent the interaction

determined by the conditional probability, derived from two or more parent nodes. One trait combination [HMT|HMG:Mean Corpuscular Hemoglobin Concentration (MCHC)] was identified in both breed-specific networks allowing investigations for trait combinations within as well as across the breeds.

The causal relationships among the phenotypes are also displayed in Figure 10. Each of the nodes (e.g. RBC, white blood cells (WBC), IL10) represents the measured phenotypes. A directed arrow from one node to another means a direct causal effect. For example, in LR, HAP has a direct causal effect on the variable WBC, which in turn affects neutrophils (NEU) and IL1B. To accentuate functional biological networks of phenotypes, nodes are illustrated in different colors. Node frames are highlighted in red when variables are conditionally independent (HAP in LW and LR, PLT in LR). Additionally, colors are used for arrows to indicate parental relationships of the nodes in the structured model learned from the data sets. Although BNs do not serve as biological patterns, causal relationships between immune traits mostly represent biological functional subsets. Combinations mainly based of WBC, RBC, and

cytokine-related clusters. The identified conditionally dependent traits by the network structure were used as my trait combinations for my GWAS.



Figure 10: Bayesian network for immune trait residuals

RBC=red blood cells, HMG=hemoglobin, HMT=hematocrit, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin, CHC=mean corpuscular hemoglobin, PLT=platelets, WBC=white blood cells, NEU=neutrophils, LYM=lymphocytes, MON=monocytes, EOS=eosinophils, BAS=basophils, HAP=haptoglobin, IFN=interferon-γ, IL=interleukin, TNF=tumor necrosis factor-α. Functional biological networks of phenotypes are illustrated as nodes in pale blue () for WBC, light red () for RBC, and yellow () for cytokines. Node frames are highlighted in red to highlight conditionally independent variables. Colored arrows are used to indicate parental relationships of the nodes in the structured model learned from the data sets.

| Breed | Conditional independent | Conditional dependent with one parent | Conditional dependent with two parents | Conditional dependent with multiple parents |
|-------|-------------------------|------------------------------------------|-------------------------------------------|------------------------------------------------|
| LR | [MCHC] | [BAS MON] | [HMG MCHC:IL10] | [RBC HMG:HMT:MCV:MCH] |
| | [PLT] | [EOS PLT] | [HMT HMG:MCHC] | [MCV HMG:HMT:PLT] |
| | [MON] | [IL8 TNF] | [MCH MCV:MCHC] | [WBC HMT:EOS:HAP:IL8] |
| | [HAP] | [IL12 IFN] | [IL6 IL10:IL1b] | [LYM NEU:MON:EOS:BAS: TNF] |
| | [IFN] | | [IL10 IFN:IL12] | [NEU RBC:WBC:MON:BAS] |
| | | | [TNF IFN:IL10] | [IL1b WBC:EOS:IL10:IL12] |
| | | | | [IL4 EOS:IL10:IL1b:TNF] |
| LW | [MON] | [IL12 HAP] | [MCV IL12:IL6] | [RBC HMG:HMT:MCV:MCH:MCHC] |
| | [HAP] | [HMG MCH] | [HMT HMG:MCHC] | [WBC RBC:HAP:IL1b] |
| | [IFN] | [MCHC MCV] | V] [MCH MCV:MCHC] [NEU HMT:MON:HAP:IF] | |
| | | | [PLT RBC:WBC] | [LYM NEU:MON:EOS:BAS] |
| | | | [BAS WBC:NEU] | [EOS MCV:PLT:WBC:IL8] |
| | | | [IL1b IL10:IL12] | [IL10 HAP:IFN:IL12] |
| | | | [IL8 HMT:WBC] | [IL4 IL10:IL1b:IL6] |
| | | | | [IL6 IFN:IL10:IL1b] |
| | | | | TNF/MON:IFN:IL12:IL6] |

Table 5: Resulting structural model learned from a causal network

LR=Landrace, LW=Large White, RBC=red blood cells, HMG=hemoglobin, HMT=hematocrit, MCV= mean corpuscular volume, MCH=mean corpuscular hemoglobin concentration, PLT=platelets, WBC=white blood cells, NEU=neutrophils, LYM=lymphocytes, MON=monocytes, EOS=eosinophils, BAS=basophils, HAP=haptoglobin, IFN- γ = interferon- γ , IL=interleukin, TNF- α = tumor necrosis factor- α . Conditional dependencies are indicated as straight line. Local structure is presented in square brackets [] with the first string identifying a node. Parents of the node are listed after "|" and are separated by colons ":". Children of the node represent the interaction determined by the conditional probability, derived from two or more parent nodes. These parental relationships are also indicated in different colors for arrows in Figure 10. The causal network model was assigned in three categories for more comprehensive understanding of the model structure. Conditionally dependent traits identified by the network structure given in [] were used as trait combinations for multivariate genome-wide association study

4.3.4. Genetic markers identified with mv GWAS approaches

Applying uv GWAS, the identification of pleiotropic genomic region is limited, especially in the situation of polygenic inherited traits. Therefore, the following four different mv approaches were applied on immune trait combinations for LR and LW in order to increase the detection power for pleiotropic SNP: PCA, CCA, TATES and mvBIMBAM. In total, 647 significant associated SNPs were detected with mv methods and can be found in the Additional Table S10. PCA was able to detect 98 (9 genome-wide and 89 chromosome-wide significant) and 26 (5 genome-wide and 21 chromosome-wide significant) SNPs associated with the phenotypes for LR and LW, respectively.

CCA revealed a variety of associated SNPs: 416 for LR and 151 for LW. For LR, 72 were genome-wide and 344 were chromosome-wide significant. For LW, 37 were genome-wide and 144 were chromosome-wide significant.

Twenty-eight genome-wide significant markers were determined with TATES for LR while 3 genome-wide significant genetic variants were characterized as significant for LW.

mvBIMBAM detected 8 and 23 genome-wide significant SNPs for LR and LW, respectively.

All detected SNPs with mv methods were summarized to 190 QTLs, by assuming a 1 Mbp interval around significant SNPs. Out of these QTLs, 133 were located within or close located to protein-coding genes. Functional annotation of these QTLs revealed 453 protein-coding genes (Additional Table S10).

4.3.5. Comparison across mv GWAS results

SNPs that are identified with multiple mv methods are of particular interest to characterizing pleiotropy. In total, 66 SNPs were detected for different trait combinations with more than one mv method (Figure 11). Thirty-seven of these SNPs are associated with RBC related immune trait combinations (e.g. [RBC|HMG:HMT:Mean Corpuscular Volume (MCV):Mean Corpuscular Hemoglobin (MCH), HMG|MCHC:IL10, HMT|HMG:MCHC]. Thirteen SNPs are associated with WBC subtypes and 12 with cytokines. For example, SNP ALGA0073579 (rs81442304) was identified with three mv methods CCA, TATES, as well as mvBIMBAM. CCA and TATES associated this SNP with BAS|MON in LR, whereas mvBIMBAM detected this association for cytokines IL-4|IL-10:IL-1b:IL-6 in LW. Currently, this SNP remains unmapped for Sscrofa 11.1. SNPs ALGA0086892 (rs81454413, SSC 15: 116.13 Mbp), ASGA0070586 (rs80818610, SSC15: 120.11 Mbp), and ASGA0070620 (rs80883544, SSC 15: 120.35 Mbp) were detected by all four mv methods in LR for cytokines and a five immune trait combination of WBC, HMT, eosinophils (EOS), HAP, and IL-8. With PCA these SNPs were observed for the second PC in the biological functional network of cytokines (PC2 Cyto).

According to the contribution based on loading values, this PC mainly contains cytokines IL-12 and IL-8 (Roth et al., 2022). These SNPs are located on SSC 15 within an intron region of four Mbp (116.13 to 120.35 Mbp) (Figure 11, Table 6).



Figure 11: Venn diagram of different methods used to detect significant multivariate associations for both breeds and significance types

PCA=Principal component analysis, CCA=Canonical correlation analysis, TATES=Traitbased Association Test that uses Extended Simes procedure, mvBIMBAM= multivariate Bayesian imputation-based association mapping. Multiple identical significant SNPs for different immune traits within a method are counted once.

| Breed | Trait | SSC | SNP | Pos | m/M | MAF | p-value/BF | Method | Gene |
|-----------|-----------------------------------------------------------|-----|-------------|-------|-----|---------------------|------------|---------------------------|----------------------------------------------------------------|
| LR; LW | BAS MON, NEU RBC:WBC:MON:BAS; IL-4 IL-10:IL-1b:IL-6 | | ALGA0073579 | | T/C | 0.01 and 0.21 | 0.01/3.22 | CCA, TATES, mvBIMBAM | |
| LR; LW | HMG MCHC:IL-10, PC4Cell; PLT RBC:WBC | | H3GA0016899 | | T/C | 0.04 and 0.16 | 0.04 | CCA, PCA | |
| LR | IL-8 TNF, WBC HMT:EOS:HAP:IL-8, PC2Cyto | 15 | ALGA0086892 | 120.1 | T/C | 0.50 | 0.04/3.5 | CCA, PCA, TATES, mvBIMBAM | SPAG16 |
| LR | IL-8 TNF, WBC HMT:EOS:HAP:IL-8, PC2Cyto | 15 | ASGA0070586 | 120.1 | T/C | 0.41 | 0.01/4.77 | CCA, PCA, TATES, mvBIMBAM | TNS1, RUFY4, CXCR2, ARPC2, GPBAR1, AAMP, PNKD, TMBIM6 |
| LR | IL8 TNF, WBC HMT:EOS:HAP:IL-8, PC2Cyto | 15 | ASGA0070620 | 120.3 | T/C | 0.39 | 0.03/4.04 | CCA, PCA, TATES, mvBIMBAM | , |

Table 6: Selected significant associated genetic markers identified with multivariate methods

SSC=*Sus scrofa* chromosome, SNP=single nucleotide polymorphism, Pos=position [Mbp] m/M allele=minor/major allele, MAF=minor allele frequency, p-value =adjusted p-value after correction for stratification and multiple testing, BF=Bayesian factor, Gene=selected nearest gene within a progressive number of QTL based on \pm 1Mbp distance from a significant SNP, LR=Landrace, LW=Large White, BAS=basophils, MON=monocytes, IL=interleukin, HMG=hemoglobin, HMT=hematocrit, NEU=neutrophils, RBC=red blood cells, WBC=white blood cells, PLT=platelets, IFN= interferon- γ , TNF=tumor necrosis factor- α , PC= principal component, Cell/Cyto=biological functional networks within the PCA cell/cytokines, PCA=principal component analysis, CCA=canonical correlation analysis, TATES=trait-based association test that uses extended Simes procedure, mvBIMBAM=multivariate Bayesian imputation-based association mapping. In addition, 152 markers were identified for multiple mv trait combinations (Table S10). Identical SNPs were mostly shared between immune traits related to functional biological immune trait subsets like RBC (e.g. [HMT|HMG:MCHC], MCH|MCV:MCHC], [RBC|HMG:HMT:MCV:MCH]), WBC subtypes (e.g. [NEU|RBC:WBC:Monocytes (MON):Basophils (BAS)], [Lymphocytes (LYM)|NEU:MON: EOS:BAS:TNF]) and cytokines (e.g. [IL1b|IL10:IL12], [IL4|IL10:IL1b:IL6], [IL6|IFN:IL10:IL1b]). These markers are distributed over all 18 chromosomes. Interestingly, 30% of identical markers are located on *SSC* 5 between 23.93 and 97.48 Mbp and cover 16 QTLs including 20 protein-coding genes (Figure 12).



Figure 12: Manhattan plot of SSC5 for multivariate trait combinations a RBC|HMG: HMT:MCV:MCH in Landrace with CCA, b HMG|MCHC:IL10 in Landrace with CCA, and c WBC|RBC:HAP:IL1b in Large White with mvBIMBAM

RBC=red blood cells, HMG=hemoglobin, HMT=hematocrit, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, IL=interleukin, WBC=white blood cells, HAP=haptoglobin, SNPs of interest are highlighted with green color (a DRGA0005609, ASGA0025326, ALGA0031690, MARC0021861, DRGA0005776, b ALGA0031924, MARC0001027, ALGA0032074, and c MARC0013873). Protein coding genes within annotated QTLs between 23.93 and 97.48 Mbp are stated in the box

In addition, mv results were compared across the investigated breeds. In total, 469 markers were identified for LR, whereas 180 were detected for LW applying mv GWAS. Two SNPs, ALGA0073579 (rs81442304) and H3GA0016899 (rs80959576), were repeatedly observed in both breeds (Table 6). These markers were identified by applying mv methods (CCA, TATES, mvBIMBAM) as well as with uv methods.

4.3.6. Comparison between uv and mv GWAS results

In addition, a comparison of the uv and mv results revealed that 204 markers overlap across the methods (Figure 4). All in all, these 204 markers are located near 125 protein coding genes. Filtering the overlapping SNPs for the investigated breeds revealed four interesting genetic variants (ALGA0073579 (rs81442304), H3GA0016899 (rs80959576), DRGA0006061 (rs81303269, *SSC* 5: 79.02 Mbp), ALGA0113815 (rs81342648)) that overlap between uv and mv methods (Figure 13).

CCA revealed, that ALGA0073579 (rs81442304) was significantly associated with [BAS|MON] in LR, whereas, applying mvBIMBAM, this SNPs was observed for cytokines [IL-4|IL-10:IL-1b:IL-6] in LW. Additionally, this SNP was also identified for the trait basophils in LR within uv GWAS using PLINK.

H3GA0016899 (rs80959576) was significantly associated with PC4 Cell in LR. According to the loading value, PLT and HAP mostly contributed to PC4 Cell. Applying CCA allowed to detect this SNP for [PLT|RBC:WBC] in LW. Furthermore, H3GA0016899 was also significantly associated with RBC in LW using an uv GWAS.

The genetic variant DRGA0006061 (rs81303269, *SSC* 5: 79.02 Mbp) was identified for [IL4|EOS:IL10:IL1b:TNF] with CCA in LR, whereas PLINK detected this association for RBC in LW. Currently, the SNP H3GA0016899 is unmapped for *Sscrofa* 11.1, but was previously mapped on SSC 5.

On *SSC* 12, within and intron region of the Regulator of G-protein signalling 9 (RSG9) gene (12.0 Mbp), the SNP ALGA0113815 (rs81342648) was significantly associated with a PC2 Cyto (consisting of cytokines IFN- γ , IL-12, IL-8 specified by the loading value) by applying the PCA approach in LR, whereas PLINK identified this association for IL-4 in LW (Tables S9 and S10).



Figure 13: Genetic markers identified with GWAS approaches: Comparison of different association methods for both investigated breeds

Multiple identical significant SNPs for different immune traits within a method are counted a single time. mv=multivariate, uv=univariate, LR=Landrace, LW=Large White

4.4. Discussion

The aim of this study was the detection of genetic markers associated with immune traits applying different approaches of uv and mv GWAS. In total 401 and 647 significant associations were identified with uv GWAS and mv GWAS, respectively. Of particular interest are the created immune networks using BN and PC analyses.

4.4.1. Conditional dependencies of immune networks

For my analysis 22 available immune phenotypes would result in multiple possible my combinations, which would require high computational effort. The application of a BN approach allowed to identify conditional dependencies among immune traits and to focus on relevant trait combinations. Usually, BNs do not reflect biological patterns when causal statistical relationships between variables have been detected. However, identified combinations can be classified into biological functional subsets of immune traits. For both pig lines, conditional relationships were identified within RBC-related traits, WBC subtypes, and cytokines. These networks correspond to previous estimated rg results (Roth et al., 2022). RBC were highly correlated with RBC characteristics, like HMT (LR: 0.82±0.05, LW: 0.90±0.09) and HMG (LR: 0.81±0.06, LW: 0.77±0.10). As expected, among further RBC characteristics, a high positive correlation was found between HMT and HMG (LR: 0.99±0.00, LW: 0.97±0.04), MCH, and MCV (LR: 0.99±0.02, LW: 0.94±0.03). Between cytokines such as IFN- γ , IL-10, IL-1 β , IL-4, and IL-6 high positive rg were estimated in both investigated pig lines. Immune cells such as MON and EOS were positively correlated to cytokines like TNF-a in LR but showed a high negative correlation in LW. Ballester et al. (2020) constructed a network based on phenotypic correlations for immune traits in Duroc piglets. Although only 13 immune parameters overlap between Ballester et al. (2020) and our study, similar clusters that relied on RBC and WBC subtypes were identified. The detected close relationships in the previous and current studies (Ballester et al., 2020; Bovo et al., 2020; Dauben et al., 2021; Roth et al., 2022) indicate the complexity of piglet's immunity.

As discussed by Roth et al. (2022) the PCA aims for a more powerful analysis of the immune traits by reducing the dimension of information, and therefore allowing the detection of key players in immunocompetence. In that study, PCA was shown to be an effective tool for condensing information based on a phenotypic covariance matrix. Using such a technique can reduce the number of dependent variables without compromising important information (Weller et al., 1996). Furthermore, PCAs provide an appropriate weighting of individual traits. In general, all observed phenotypic and genetic correlations as well as conditional dependencies

among immune parameters, might be helpful to create well-balanced breeding selection strategies to improve the immunocompetence of pigs.

4.4.2. Comparison between uv and mv GWAS results and method performance

Beside one uv frequentist and one uv Bayesian approach, four mv approaches (PCA, CCA, meta-analysis, mv Bayesian linear regression) were applied on two maternal pig lines. Results were empirically compared within and across the methods.

Comparing the uv approaches, identical significant associations were detected. The investigated data sets were also studied by Dauben et al. (2021) using the GenABEL-package in R (Aulchenko et al., 2007) and ASReml Software (Gilmour, 2015). In total, Dauben et al. (2021) identified 25 genome-wide and 452 chromosome-wide significant SNPs (LR: 280, LW: 197) associated with 17 immune relevant traits in both pig lines. Applying PLINK and uvBIMBAM it was possible to identify 433 (LR: 351, LW: 82) significant associations. Comparing the results of both studies, 159 and 15 associations were commonly detected for LR and LW, respectively.

One reason for the different number of significant SNP markers among the studies are caused by the requirement for the multivariate analyses. The number of phenotypes per animals have to be complete. Furthermore, the applied methods to correct for false positives and the determined threshold for genome-wide and chromosome-wide significance differ depending on the applied methodology.

Among the common associations in LR, 49 SNPs were also identified with mv methods in this study. Common results were mostly associated with immune traits related to RBC, cytokines, and HAP e. g. ASGA0070620 (rs80883544, SSC 15: 120.35 Mbp). The SNP ASGA0070620 is located near protein-coding genes such as TMBIM1 (transmembrane BAX inhibitor motif containing 1).

Generally, previous GWAS studies for immune traits focused mostly on uv statistical approaches. The application of mv methods is recommended to increase the statistical power to detect associations (Bovo et al., 2019; Galesloot et al., 2014; Porter & O'Reilly, 2017; Wang et al., 2013) even if the rg between the traits is expected to be weak (close to 0) [25, 26]. Consideration of previously published high rg ($\geq \pm 0.4$) results between multiple immune traits [27] was used to increase GWAS power to identify pleiotropic SNPs. In this study, mv methods revealed a higher number of significant associations compared to uv methods. Moreover, there was a substantial overlap of associations found by several mv methods which have different underlying statistical backgrounds. These results could be used as heuristic arguments, that mv-methods have a higher detection power. However, it should be considered that the number of

approaches differs between the applied methods. For uv analysis, two different approaches were compared, whereas for mv analysis four different mv methods were utilized.

204 SNPs were identified with uv and mv methods. When SNPs are detected with multiple approaches, they provide more certainty for the GWAS results and contribute potential candidate genes. However, 443 associations were exclusively identified with mv approaches. This underlines the importance of considering the correlation among immune traits with my methods. Common markers for comparable trait complexes were also identified between different my approaches. Nevertheless, markers match incompletely and only to a small extent. Application and comparison between multiple uv and mv approaches were addressed mostly on simulated data (Galesloot et al., 2014; Porter & O'Reilly, 2017), rather than on immune phenotypes. Recently, Bovo et al. (2020; 2019) reported uv and mv GWAS results for hematological and blood clinical-biochemical traits in LW pigs after slaughtering. Similarly, to our study, one frequentist and one Bayesian approach were applied. In general, the performance of different mv approaches is scenario-specific and sensitive to specific effects like allele frequency, the number of investigated traits, and underlying correlation structures among the traits (Galesloot et al., 2014; Porter & O'Reilly, 2017). Galesloot et al. (2014) concluded that mv methods implemented in software like PLINK, SNPTEST, MultiPhen, and mvBIMBAM performed best in terms of detection power for the majority of scenarios, which is partly consistent with our results.

Furthermore, it has to be mention, that the possibility of chromosome-wide correction for multiple testing was not applied in every approach and was limited to methodology implemented in PLINK and R. For CCA, the highest number of associated SNPs was reported in our analysis. Similar to our results, Galesloot et al. (2014) studied high power for almost all scenarios for the same approach. These authors explain higher power was observed with increasing residual correlation in case of a single QTL trait and when two or all three traits were associated with the QTL with a negative genetic correlation for methods including CCA. Due to trait correlations, test statistic distributions are likely to have longer tails, and therefore a more conservative threshold is recommended to maintain the type I error at 5% (Galesloot et al., 2014). As recommended by Galesloot et al. (2014), we lowered the threshold within the CCA approach (5 % default value to 1 % lowered threshold) and compared the association results empirically once again (results not shown). The number of detected SNPs with CCA lowered to 184 (LR: 144, LW: 40). However, the common three SNPs, which were detected with all four my approaches, remained in the results for CCA after lowering the threshold.

Zhou et al. (2014b) developed an efficient linear mixed model algorithm for GWAS which is implemented in the software GEMMA and compared this algorithm to those implemented in WOMBAT (Meyer, 2007) and GCTA (J. Yang et al., 2011). Algorithms were applied to different numbers of phenotypes in simulated data as well as human and mouse data sets. Even though the authors reported exceeded improvements in computational time and power, they recommended considering the methods as complementary rather than competing. One single test is not able to detect all the many different types of genetic effects in the most powerful manner. Salinas et al. (2018) described many of the mv methods aimed to detect genetic pleiotropy in an epidemiological context. In their study, specific method selection considering phenotype distribution type and data availability was developed. Therefore, our results contribute to a deeper understanding of the performance power and selection of suitable mv methods.

4.4.3. Comparison of genetic markers between LR and LW

A comparison of results regarding breed differences was realized since GWAS methods were applied to the investigated breeds separately. With uv methods, no overlapping markers were observed, whereas mv methods were able to identify two SNPs shared between LR and LW. These two significant SNPs were currently unmapped. Using the older assembly 10.2 H3GA0016899 (rs80959576) was located on SSC5 (80.17 Mbp) as an intergenic variant and ALGA0073579 (rs81442304) on SSC13 (203.44 Mbp) within the GRIK1 gene, which the function has not been described so far. Thirty-eight SNP listed in table 2 could not be allocated by current assembly SScrofa 11.1 but were mapped under SScrofa 10.2. Therefore, these results should be considered with caution.

Several GWAS and QTL studies for immune competence traits investigated cross-bred (White Duroc x Erthulin F2, LR x Duroc x Yorkshire, LW x Minzhu F2) and pure-bred (Chinese Sutai, LR, LW, Songliao Black, Yorkshire) pigs (Bovo et al., 2019; Cho et al., 2011; Dauben et al., 2021; Edfors-Lilja et al., 1998; Gong et al., 2010; Lu et al., 2013; Luo et al., 2012; Ponsuksili et al., 2016; Reiner et al., 2007, 2008; Uddin et al., 2011; Wang et al., 2013; S. Yang et al., 2009; F. Zhang et al., 2014; Z. Zhang et al., 2013; Zou et al., 2008). Even though the results of these studies reported a few overlapping QTL regions, most of the markers were not shared between the studies. Genetic heterogeneity of the investigated pig populations, differences in the analyzed immune traits, variety of the experimental designs, and therefore, different environmental effects considered in the statistical models during the analysis, might explain the discrepancies among the studies and between the breeds. In the current study, further options

for pre-selection of the breed-specific mv trait combinations can be applied to enable appropriate comparison between the breeds within mv methods.

4.4.4. Identification of pleiotropic genetic variants

When a locus influences several traits at the same time, pleiotropy is responsible for genetic and phenotypic correlations (Pavlicev et al., 2008). Human complex traits have been extensively reviewed and discussed under different definitions of cross-phenotype association (biological, mediated, spurious) (e.g. (Solovieff et al., 2013; van Rheenen et al., 2019)). However, in a joint analysis of complex traits, autocorrelations suggest pleiotropic effects.

The mv GWAS provides a higher level of precision and detection power in mapping pleiotropic QTL than uv analyses (Bolormaa et al., 2014; Jiang & Zeng, 1995; Knott & Haley, 2000; Korsgaard et al., 2003). In particular, this applies when studying traits that are highly correlated or when heritability is low for the trait affected by the QTL (Korsgaard et al., 2003). Nevertheless, correlated traits may lead to correlated sampling errors (Bolormaa et al., 2010). A PC method has been described as a more powerful alternative to a single trait analysis (Gilbert & Le Roy, 2003; Klei et al., 2008). This approach condenses traits of interest into a number of uncorrelated PCs that reflect the underlying (co)variance matrix. According to Mähler et al. (Mähler et al., 2002), it has been suggested to analyze only the first PC since it explains the majority of the variation. It has been demonstrated that the second PC and subsequent PCs can identify the highest phenotypic proportion that can be explained by genetic markers (Aschard et al., 2014). According to the authors, the second and following PCs may contain a substantial proportion of total genetic variation, which normally accounts for a small amount of variance in phenotypic traits. If the QTL effects oppose positively correlated traits, these PCs appear very powerful.

Using the first three PCs, this study determined that a significant portion of the total genetic association could be attributed to these PCs. However, genetic interpretation of the identified association is impossible with this approach, despite higher statistical power. Due to unclear pleiotropy or high linkage between two regions, there is not yet a clear indication of true pleiotropy [40]. This analysis is generally considered a first step in identifying pleiotropic regions, which would require further investigation with more precise models, fine-mapping or molecular experiments to confidently distinguish between the different scenarios.

4.4.5. Functional annotation and identification of potential candidate genes

Using different uv and mv GWAS approaches in this study it was possible to detect a plethora of genetic markers. SNPs were summarized into QTLs, based on their genetic distance of 1 Mbp downstream and upstream, to condense functional information. Annotation was performed

within the characterized QTLs in Sscrofa 11.1 from the Ensembl database (Hunt et al., 2018). QTLs were located within numerous protein-coding genes (uv: 354, mv: 453). 125 proteincoding genes were identified with both methods (uv and mv) and selected immune relevant genes are presented in Table 2 and Table S1 and S2. The SNP ASGA0070586 (rs80818610, SSC 15: 120.11 Mbp), located on SSC 15, was detected applying all four multivariate approaches. In the following, three out of eight candidate genes are discussed. AAMP (angio associated migratory cell protein) plays a positive role in angiogenesis, a physiological process through which new blood vessels are formed from pre-existing vessels (Beckner et al., 2002). PNDK (paroxysmal nonkinesiogenic dyskinesia domain containing) protein is involved in the regulation of neurotransmitter secretion and is associated with pancreatic, ovarian, and breast cancer in humans (Gong et al., 2014; Zhao et al., 2013). In swine, a disruption of expression and pathway of PDNK in response to infection with Actinobacillus pleuropneumoniae bacteria was observed (Reiner et al., 2014). TMBIM1 (transmembrane BAX inhibitor motif containing 1) protein binds to a TNF receptor and thus regulates the degranulation of neutrophils and the reorganization of blood vessels (Deng et al., 2018). Five additional gene were located close to ASGA0070586 (rs80818610, SSC 15: 120.11 Mbp), but a functional immune relevant relationship have not been described yet.

On SSC 14 the marker MARC0013023 (rs80797218) was significantly associated for HMG and HMT using uv PLINK and BIMBAM. In addition, this SNP was also detected applying CCA for the traits HMT, HMG and MCHC applying CCA. Within this region the protein-coding gene AGT (angiotensinogen) is located, that regulates the systemic arterial blood pressure by renin-angiotensin (Schuijt et al., 1999). According to their direct influence on immune traits these protein-coding genes represent potential candidate genes.

Some of the genetic markers detected in this study have been identified in previous association studies for hematological traits. Wang et al. (2013) detected SNPs ALGA0123028 (rs81318039, SSC 3: 71.12 Mbp) and MARC0001946 (rs81288717, SSC 3: 72.97 Mbp) located on SSC 3 for mean thrombocyte volume. These SNPs were identified for immune trait combination [WBC|HMT:EOS:HAP:IL8] in LR. In the study of Lu et al. (2013) MARC0039159 (rs81232385, SSC 5: 44.44 Mbp), located on SSC 5, was significantly associated with IL-10 , which was identified in our study with CCA and PCA for [NEU|RBC:WBC:MON:BAS] and PC3 Cell (LYM, MON, BAS contribute to this PC according to the loading value), respectively. Luo et al. (2012) identified ALGA0047813 (rs81400288, SSC 8: 43.03 Mbp) and MARC0039159 (rs81232385, SSC 5: 44.44 Mbp) on SSC 8 for MCV and MCH, which was observed in our study for the my trait combination

[RBC|HMG:HMT:MCV:MCH:MCHC] in LW with CCA. ALGA0047813 (rs81400288, SSC 8: 43.03 Mbp), is located within the intron region of the protein-coding gene TLL1 (tolloid like 1). Studies in mice suggest that TLL1 plays multiple roles in the development of the mammalian heart, and is essential for the formation of the interventricular septum. Allelic variants of this gene are associated with atrial septal defect type 6 (Sieroń & Stańczak, 2006). Further investigations of this protein function in pigs are needed, to determine the potential as a candidate gene. Dauben et al. (2021) detected associations for immune traits in the same pig population with a different uv GWAS approach. Identical markers have been identified between this and the current study (LR: 159, LW:15). Noteworthy, 49 SNPs identified in LR were observed with uv and mv methods. Therefore, in this study we were able to confirm associations with our previous results.

4.5. Conclusion

This study evaluated the joint genetic background of immune traits in LR and LW piglets through the application of various uv and mv GWAS approaches. In general, mv GWAS approaches outperformed uv methods and detected genome-wide associations for immune traits. It should be considered that the number of significant associations differs between the applied methods and the possibility of chromosome-wide correction for multiple testing was only feasible in two approaches. When associations were compared across the investigated breeds, no overlapping markers were observed with uv methods, indicating genetic breed differences. It was possible to detect two SNPs in both breeds applying mv GWAS. However, further options for pre-selection of the breed-specific mv trait combinations and cross-validation should be considered to enable appropriate breed comparison. Our results support the observation that one single test is not able to detect all the many different types of genetic effects in the most powerful manner. These analyses are initial steps to detect pleiotropic regions in general. Beside the validation of our results with other data sets, it is necessary investigate the identified associations further applying fine-mapping approaches and the analyses of candidate genes.

4.6. Methods

4.6.1. Statistical analysis of immune traits

Data sets of purebred LR and LW populations were recorded from 2010 to 2017 and were provided by the German breeding organization BHZP GmbH. Animal care, phenotypic measurements, and consideration of environmental effects were described in Roth et al. (2022).

In brief, a total of 611 piglets (3152/9307) of LR and 533 piglets (3134/9257) of LW were analysed. Animals were a subset of two nucleus populations. From each litter, one male and one female piglet, were chosen for phenotype collection. Blood samples of piglets were collected on average around 45 days (32– 60) after birth by puncturing the Vena jugularis and were collected in three 7.5 ml monovette containing ethylenediaminetetraacetic acid. Complete blood count was performed with an ADVIA® 2120 Hematology system, a flow cytometrybased system, and a pig- specific setting. Besides, serum haptoglobin was measured in 0.5 ml serum. Peroxidase activity of the haptoglobin– haemoglobin complex was carried out by a spectrophotometric method. Cytokine levels (interferon- γ , interleukin- 10, interleukin- 12, interleukin- 1 β , interleukin- 4, interleukin- 6, interleukin- 8 and tumour necrosis factor- α) in serum samples were analysed with a Porcine Cytokine/Chemokine Multiplex Magnetic Bead Panel (Merck KGaA) enabling the simultaneous measurement of multiple cytokines. Immunoassay of serum samples was performed using 22 plates according to the manufacturer's protocol.

GWAS was performed for complete blood count (RBC, haemoglobin, haematocrit, MCV, MCH, MCHC, platelets, WBC, neutrophils, lymphocytes, monocytes, eosinophils, basophils, band and other remaining cells), HAP, and cytokines (interferon- γ , interleukin-10, interleukin-12, interleukin-1 β , interleukin-4, interleukin-6, interleukin-8 and tumour necrosis factor- α) as immune traits of 1144 LR and LW piglets, corrected for environmental impacts within the breeds. A detailed description of all investigated immune traits, their summary statistics, and processing of the data set can be found in Roth et al. (2022).

4.6.2. Genotyping and quality control of genomic markers

To study genetic associations between measured phenotypes animals were genotyped with a tissue sample via an Ilumina Porcine SNP60 v2 BeadChip (Illumina, San Diego, CA, USA) in an external laboratory (GeneControl GmbH, Poing). Only autosomal markers were used in the different GWAS approaches. Regardless of the selected association method, quality control of genotype data was performed with PLINK (Shaun Purcell, 2010). Genetic markers and animals were excluded when they did not meet the following criteria: Call Rate ≥ 0.95 , Minor allele frequency (MAF) ≤ 0.01 , deviation from Hardy-Weinberg equilibrium (HWE) p-value =0.0001, acceptable Identity-by-state (IBS) threshold ≤ 0.95 . After quality control 47'292 and 43'730 markers, as well as 522 and 461 animals, remained for GWAS for LR and LW, respectively. The position in the genome and the base pair location of each SNP is based on *SScrofa* 11.1. In total, 38 markers show currently no location under this assembly. Using the assembly *SScrofa* 10.2 it was possible to report a chromosome number and a base pair position for 15 markers.

The remaining 22 markers revealed high linkage disequilibrium to other significantly associated SNP (results not shown). The observed regions correspond to the positional information given in the manifest file of the manufacturer.

4.6.3. Correction for environmental effects

The correction for environmental effects was performed within a breed and included all relevant fixed effects: the class effects parity (1-4) and herd-year-season-sex (1-12). Moreover, age and weight and interaction between age and weight at the time of sample collection were included in the model as covariates. Cytokine detection method requires the quantification of samples distributed among 22 analytical plates. Therefore, plate was included as a random term for cytokine immune traits. The effects of breed (LR or LW) or sex (boar or sow) were not included as main factors in the model because of the hierarchical classification of these effects within herd-year-season-sex classes.

4.6.4. Univariate GWAS

After quality control, one frequentist and one Bayesian method were used to analyze immune traits for uv associations with the genotype in a GWAS within each breed data set The starting point for both approaches is a mixed linear model:

$$y = \mu + Z\alpha + e \tag{1}$$

where y is a vector of phenotype measurement of animals, μ is a vector of the phenotype means of animals carrying the reference genotype, Z is a matrix of genotype covariates (coded as 0, 1, or 2) for SNP markers, α is a vector of random regression coefficients of the SNPs (marker effects), and *e* is a vector of residuals.

The frequentist association approach in PLINK (Shaun Purcell, 2010) tests each marker for association with the trait of interest since it performs a linear regression analysis with each SNP as a predictor. For Bayesian regression, prior distributions are specified for α and e. For vector of residuals e, a prior conditional on the residual variance, σ_e^2 , a normal distribution with null mean and covariance matrix $R\sigma_e^2$, is used. In this case, R is a diagonal matrix and σ_e^2 is treated as an unknown with a scaled inverse χ^2 prior (Gondro et al., 2013). Assuming that a SNP j is a Quantitative Trait Locus, then its effect is dependent on two parameters: a_j and $d_j = a_j k_j$: the additive and dominance effect, respectively. An additive effect is given by $k_j = 0$, while $k_j = 1$ and $k_j = -1$ represents a dominant effect. Bayesian linear regression carried out with BIMBAM uses two priors D₁ and D₂ to model this effects (Servin & Stephens, 2007). Bayesian Factors for observed associations were computed as posterior distributions for SNP effects using the prior D₂ averaging $a_j = 0.05, 0.1, 0.2, 0.4$ and $d_j = a_j/4$. Further detailed information about the utilized uv GWAS approaches can be found in the original literature (Gondro et al., 2013; Servin & Stephens, 2007; Shaun Purcell, 2010).

4.6.5. Principal component analysis

To condensate the estimated highly correlated immune network PCA was applied to immune observation residuals. PCA proceedings steps and results are already published and described in detail in Roth et al. (2022). Before the application of the PCA technique for each breed data set, we split the immune traits of our survey into three biological functional networks as a) Cells, b) RBC (including HAP) and c) Cytokines. This classification was motivated by the strategy to maintain the greatest possible explained variance from the original variables in the constructed PCs. The number of PCs used to characterize immune traits was based on the eigenvalues of their correlation matrix. In order to limit the number of PCs, PCs with eigenvalues lower than 1.0 were excluded (Braeken & van Assen, 2017). As far as possible, loading values of PCs were used to label them roughly and to interpret PCs according to their summarizing biological composition. BFN-specific PCs were then used as new traits during a uv GWAS which was carried out with PLINK (Shaun Purcell, 2010). The output of the association analysis generates an asymptotic significance value (p-value). Received p-values were adjusted for population stratification and multiple testing on genome and chromosome levels.

4.6.6. Learning structures using Bayesian network

The realization of all possible mv combinations for all available immune phenotypes is computationally extensive. Networks, paths, and graphs can model interactivity between variables. BN describe conditional in- and dependence relationships among variables (Scutari, 2010). Therefore, in this study, a BN approach was performed for each breed data set to reveal conditional dependencies among immune traits. Applying this approach, it was possible to set various combinations of immune traits for LR and LW regardless of the applied mv GWAS method.

Briefly, the BN is a graphical representation of a probability distribution over a set of variables (Arbib, 1998; Nagarajan et al., 2013; Scutari, 2010). The conditional independence (of the random variables) and graphical separation (of the corresponding nodes of the graph) have been stretched out to disjoint node subsets by Pearl (1988). Therefore, in the BN approach model selection algorithms were used to learn the graphical structure of the network and then estimate the parameters of the local distribution functions conditional on the learned structure. A hill-climbing algorithm (Scutari et al., 2019) was applied to the immune data set in this study. This Score-based structure learning algorithm is a general heuristic optimization technique to the

problem of learning the structure of a BN. This algorithm attempts to maximize a score that measures how well that BN describes its goodness of fit to the data set, returning a graphical structure as output (Nagarajan et al., 2013). R package bnlearn (Scutari, 2010) was used to obtain BNs for LR and LW immune trait residuals. Residuals of originally measured phenotypes were used to avoid a large number of solutions that need to be computed because of existing cross-classified effects. Resulting conditional dependencies illustrated as parents of the nodes in the network structure were used as trait combinations for mv GWAS approaches.

4.6.7. Multivariate GWAS

GWAS is generally performed on a uv (trait-by-trait) basis by testing each variant at a time. Association analyses that include multiple phenotypes may be more powerful to identify QTL for complex traits, particularly in the case of causal variants that affect multiple correlated traits (Zhou & Stephens, 2014a). In the following, principles and optional parameters of four selected mv GWAS approaches applied in this study within each breed data set are described brieflyGWAS is generally performed on a uv (trait-by-trait) basis by testing each variant at a time. Association analyses that include multiple phenotypes may be more powerful to identify QTL for complex traits, particularly in the case of causal variants that affect multiple correlated traits (Zhou & Stephens, 2014a). In the following, principles and optional parameters of four selected traits (Zhou & Stephens, 2014a). In the following, principles and optional parameters of four selected traits (Zhou & Stephens, 2014a). In the following, principles and optional parameters of four selected traits (Zhou & Stephens, 2014a). In the following, principles and optional parameters of four selected traits (Zhou & Stephens, 2014a). In the following, principles and optional parameters of four selected mv GWAS approaches applied in this study within each breed data set are described briefly.

4.6.8. Canonical Correlation Analysis

In the same way that PCA is applied to one set of possibly correlated traits to extract a number of independent variables (PCs) that explain as much variance in the original data set, CCA is applied to two sets of variables to extract a number of independent pairs of variables that explain as much covariance between the two original sets (2009). Thus, CCA represents a mv generalization of the Pearson product-moment correlation (Hotelling, 1992). CCA extracts the linear combination of traits that explain the largest possible amount of the covariation between the marker and all traits. This approach is applied to analyze the association between one SNP and multiple traits, as implemented in --mqfam --mult-pheno procedure for MV-PLINK (Ferreira & Purcell, 2009). The test implies Wilk's lambda (λ) and the corresponding F-approximation. Specifically, $\lambda = 1 - \beta^2$, where β is the canonical correlation between the marker and the traits, calculated as the square root of the eigenvalue of the product of the marker variance (S_{11}), trait covariance matrix (S_{22}), and covariance matrices between the marker and the traits (S_{12} , S_{21}); expressed as notation: $S_{11}^{-1/2} \times S_{12} \times S_{22}^{-1} \times S_{11}^{-1/2}$ (Ferreira & Purcell, 2009). Similar to PCA, an asymptotic significance mv p-value is generated in the CCA output. This p-value was subsequently adjusted for population stratification and multiple testing on the genome and chromosome levels.

In the same way that PCA is applied to one set of possibly correlated traits to extract a number of independent variables (PCs) that explain as much variance in the original data set, CCA is applied to two sets of variables to extract a number of independent pairs of variables that explain as much covariance between the two original sets (2009). Thus, CCA represents a mv generalization of the Pearson product-moment correlation (Hotelling, 1992). CCA extracts the linear combination of traits that explain the largest possible amount of the covariation between the marker and all traits. This approach is applied to analyze the association between one SNP and multiple traits, as implemented in --mqfam --mult-pheno procedure for MV-PLINK (Ferreira & Purcell, 2009). The test implies Wilk's lambda (λ) and the corresponding Fapproximation. Specifically, $\lambda = 1 - \beta^2$, where β is the canonical correlation between the marker and the traits, calculated as the square root of the eigenvalue of the product of the marker variance (S_{11}) , trait covariance matrix (S_{22}) , and covariance matrices between the marker and the traits (S_{12}, S_{21}) ; expressed as notation: $S_{11}^{-1/2} \times S_{12} \times S_{22}^{-1} \times S_{11}^{-1/2}$ (Ferreira & Purcell, 2009). Similar to PCA, an asymptotic significance mv p-value is generated in the CCA output. This p-value was subsequently adjusted for population stratification and multiple testing on the genome and chromosome levels.

4.6.9. Meta-analysis

Methodology development to increase the statistical power of GWAS is extremely important for study designs with heterogeneous traits and small sample sizes. Meta-analysis was carried out with the software TATES (Trait-based Association Test that uses Extended Simes procedure) (van der Sluis et al., 2013). TATES requires a phenotype correlation matrix of immune traits and a list of p-values in an ascending order of the phenotypes for a given SNP obtained in a corresponding uv linear regression analysis. During a meta-analysis uv GWAS was performed for each phenotype with PLINK (Shaun Purcell, 2010). Obtained p-values were adjusted to account for multiple testing and relationships between immune traits within the meta-analysis on the genome level. TATES combines the phenotype-specific p-values to obtain one overall trait-based p-value (P_T) as $P_T = Min \frac{m_e p_j}{m_{ej}}$, where m_e indicates the effective number of independent p-values of all phenotypes, and m_{ei} is the effective number of p-values among the top p-values, and p_j is the jth p-value (van der Sluis et al., 2013). Based on the procedure developed by Li et al (Li et al., 2011), the effective number of p-values (m_{ei} is estimated through a correction based on eigenvalue decomposition of the correlation matrix between the p-values associated with the phenotypes. Briefly, TATES transforms the trait correlation matrix into a corresponding SNP-p-value correlation matrix. The eigen-decomposition of this p-value

correlation matrix is used to weight uv p-values. Finally, the minimum of these weighted p-values is chosen as the corrected p-value for the joint association.

4.6.10. Bayesian multivariate regression

With the software mvBIMBAM (Stephens, 2013) a Bayesian mv regression test for association was conducted. Simultaneously the traits were subdivided according to their SNP effect and Bayes factors were used to access the association between the groups of phenotypes and a genetic variant. The analysis is based on the mv regression model like model (1), but with a Y(n x d) matrix of d phenotypes measured on each of n individuals. The mvBIMBAM approach attempts to partition the response variables Y into three groups according to their statistical association with a genetic variant: undirect (U), direct (D), and indirect (I). A set of models $\gamma = (U, D, I)$ runs through partitions of the coordinates $\{1; ..., d\}$. Under model γ an assumption is made that Y_U is independent of Z, and Y_I is conditionally independent of Z given Y_D . This gives

$$P_{\gamma} = P_{\gamma}(Y_U)P_{\gamma}(Y_D \lor Y_U, Z)P_{\gamma}(Y_I \lor Y_U, Y_D)$$

These scenarios were accessed with the option mph 2 within the mvBIMBAM software. The priors for the genetic effect were set at 0.1 and 0.2 according to the author's recommendation (Stephens, 2013). Bayes factor is computed as the support for partition γ compared with the global null hypothesis that all the phenotypes are unassociated with Z. It then summarizes the overall evidence against the null, as well as the posterior probability that each coordinate of Y is associated with Z:

$$BF_{\gamma} = \frac{P_{\gamma}(Y \lor Z)}{P_0(Y)}$$

Obtained log_{10} Bayes Factors for each genetic variant evaluated the association between the SNP and the traits averaging over all possible partitions. Log_{10} Bayes Factors value ≥ 3 was characterized as a spurious association while values ≥ 6 as a solid association between a marker and a trait on genome level.

4.6.11. Controlling population stratification and false-positive results

Genomic control (Devlin et al., 2001) was realized to correct for existing population stratification through adjustment of the significance of the test statistic in R (R Core Team, 2019). From GWAS obtained p-value was subsequently adjusted in the PCA and CCA. The inflation factor lambda was low to moderate in the LR (0.80-1.26) and LW (0.86-1.23) data sets. After stratification correction, the lambda values were acceptable in a range of < 1.05. To control the number of false-positive results false discovery rate (FDR) was applied (Benjamini & Hochberg, 1995) on genome and chromosome level for uv linear regression method, PCA, and CCA. The significance level q (p-values adjusted with FDR) for FDR was

0.05 to detect associations between marker and trait on genome and chromosome level in R (R Core Team, 2019). Bayesian approaches express significance with a log10 Bayes factor threshold. Absolute values of three and six are considered as spurious and solid significance for an association (Scutari, 2010).

For uv and mv GWAS, QTL regions were defined considering significant SNPs that mapped at least ± 1 Mbp from another significant SNP and functional annotation was performed retrieving all annotated genes within a QTL region in *Sus scrofa*11.1 from Ensembl database (Hunt et al., 2018).

Chapter 5. General discussion

5.1. Multivariate association testing

One aim of this thesis was to study the genetic background among immune traits. Therefore, to investigate joint genetic foundation mv approaches were applied to immune traits in chapters 3 and 4. By theory, mv approaches should increase the power in QTL detection, but this superiority is markedly different across multiple effects. Multiple factors determine the true genotype-phenotype model, including the strength and sign of the correlation between the traits, the sign and generality of the SNP effect, and the presence of unaffected traits (Vroom et al., 2019a). The complexity of these factors makes it difficult to formulate globally applicable recommendations.

At first, detected SNPs and their implications were compared between different approaches and investigated pig breeds, LR and LW. As a first result, we found that all established SNPs with uvBIMBAM were completely overlapping the uvPLINK results. Hence, although very different in the underlying statistical background, SNP detection in our dataset is to a large extent independent of the uv method of choice.

Initially, a PCA was chosen to reduce the dimensions of information on phenotypic immune measurement levels. The majority of variation can be explained by analyzing only the first PC (Mähler et al., 2002). It has been shown by Aschard et al. (2014) that the second and following PCs may contain a considerable proportion of total genetic variation, which normally accounts for a tiny proportion of variance in phenotypic traits. Interestingly, when QTL effects oppose positively correlated traits, these PCs appear to be very powerful. When the correlation between the traits was taken into account, genetic variants with genotypic effects on phenotypes were more likely to be detected than those with negative pleiotropic genetic effects (Korte et al., 2012). In our study, the application of a PCA has led to a successful condensation of immune trait measurements. The first three PCs were significantly associated with 124 SNPs, which SNPs cover presumably a large proportion of the total genetic variation of the immune system. In addition, genetic analysis based on PCs instead of immune traits would consider the underlying strong biological trait relationships within the immune system. However, from a statistical point of view, the derivation of PC is solely based on the variance-covariance structure of the underlying data. Hence, despite higher statistical QTL detection power, the PC approach does not allow a clear genetic interpretation of the identified association. Even though PC loadings are sometimes useful for revealing the natural variables underlying biological processes, the loadings should be interpreted with greater caution (Crawley, 2007).

Besides the PC approach, various other mv methods are used to analyze complex data with a distinct correlation structure. Until now, no generally acceptable rule has been described in the

literature which of these methods is most effective regarding QTL detection. In our study (chapter 4), we utilized various mv (and uv) GWAS approaches and presented the theoretical background of these methods. We inspected Venn diagrams, which visualize overlapping SNP results of the different approaches. This comparison is not able to quantify the reliability, but a SNP which will be detected by the majority of the applied methods would have a higher expressiveness than those which has been found solely by one approach. This is in agreement with Aschard et al. (2014), who postulated that the application of various complementary methods allows for considering all the many different types of genetic effects in the most powerful manner.

A comparison of the uv and mv results revealed that a majority of markers (204) overlap across the methods, but only three common markers were identified with all applied mv approaches. On the other hand, taking into account an overlap of at least two or three methods (e.g. TATES, mvBIMBAM & CCA, or PCA & CCA) common QTL can be found, which can be linked to four interesting genetic variants as potential candidate genes (see chapter 4 for further details). Intuitively, when SNPs are detected with multiple approaches, they (should) provide more certainty for the GWAS results and contribute potential protein-coding candidate genes. However, a large amount of non-overlapping results shows, that QTL detection in our complex data depends on the statistical method of choice to a large extent.

Regarding this question, an inspection of the significance levels might be a useful complement to the assessment criteria "QTL overlap". However, significance levels can only be estimated in an approximative manner. In addition, the possibility of chromosome-wide correction for multiple testing was not achievable for every my approach.

Based on our result we conclude that the performance of different mv approaches is scenariospecific. This assessment complies with Galesloot et al. (2014) and Porter and O'Reilly (2017). Their simulation studies demonstrate the dependency of QTL detection power of different mv approaches and specific effects like allele frequency, number of investigated traits, and underlying correlation structures among the traits.

Until now, there is no single test that can detect all the variations of genetic effects that might occur within a GWAS setting (Zhou & Stephens, 2014b). Any given test can be manufactured to be as powerful as possible by manufacturing simulations. It is therefore important to view mv and uv tests as complementary instead of competing. Thus, it is necessary to identify the circumstances under which specific mv approaches perform well or poorly, as well as which (classes of) methods are most effective. Overall, mv approaches (mvPLINK, mvSNPTEST, MultiPhen, mvBIMBAM, PCHAT, TATES) outperform uv analyses in simulation scenarios

represented in simulations studies (Galesloot et al., 2014; Porter & O'Reilly, 2017; Vroom et al., 2019a). However, uv analysis performed well when all traits were associated with the genetic variant and the genetic correlation was positive. Even when the genetic correlation between traits is expected to be weak, mv GWAS can be recommended (Galesloot et al., 2014). Usually, the reviews (given in chapter 4) focus only on frequentist-based mv approaches that do not rely on permutation or bootstrapping. Methods based on mv Bayesian modeling e. g. SNPtest (Marchini et al., 2007) and mvBIMBAM (Stephens, 2013) or bootstrapping e. g. PCHAT (Klei et al., 2008) can be applied to detect pleiotropic SNPs as in the studies by Galesloot et al. (2014) and Porter and O'Reilly (2017).

The power in QTL detection of different mv methods depends on the size and sign of genetic and residual correlations of the traits (Galesloot et al. 2014). In their simulation study, the authors constructed 30 different scenarios for the number of traits associated with the QTL (one, two, or three out of three) and a combination of different parameter values like heritability, minor allele frequency, sign and size of residual and genetic correlation. They observed a higher power for mv methods than uv methods. Methods like CCA, MultiPhen, mvSNPTEST, and mvBIMBAM showed the best and similar performance with higher power with increasing residual correlation. This was most noticeable when the correlation induced by the QTL was negative for the scenarios when two out of three or all three traits were associated with the QTL. This superiority of mentioned four mv methods remained under simulation scenarios with negative genetic correlation. In this case, their power increased with increasing residual correlation. This effect has been also described in the literature (Ferreira & Purcell, 2009; J.-F. Liu et al., 2009; O'Reilly et al., 2012).

Usually, methods are compared based on empirically derived significance levels, adjusting each method to an exact 5% type I error rate. Simulations illustrated that for mvPLINK, mvSNPTEST, MultiPhen, mvBIMBAM, TATES, and PCA these empirical significance levels were all close to the nominal level of 0.05 for p-values or \geq 3 for substantial Bayesian Factor values (Galesloot et al., 2014; Porter & O'Reilly, 2017).

In addition to power (and type I errors), other characteristics are considered when choosing the appropriate mv GWAS. The output from mv association results from mvPLINK contain trait loadings, which indicate how much each trait contributed (Ferreira & Purcell, 2009). Based on an overall association with at least one trait, mvBIMBAM calculates marginal posterior probabilities for each trait to be unaffected, directly affected, or indirectly affected by the QTL (Stephens, 2013). In addition to providing insight into the underlying biology, this additional

information can also facilitate the differentiation between pleiotropic and independent QTL effects.

Additionally, mvPLINK, MultiPhen, and TATES can be used to assess both quantitative and binary traits (case-control) (Ferreira & Purcell, 2009; O'Reilly et al., 2012; van der Sluis et al., 2013). It is possible to apply mvBIMBAM and TATES to GWAS result data without access to raw phenotype and genotype data which might be useful for meta-analyses (Stephens, 2013). The mvSNPTEST, MultiPhen, TATES, and PCA methods can also handle genotype probabilities that are obtained by imputation (Marchini et al., 2007; O'Reilly et al., 2012; van der Sluis et al., 2013). As a final point, simulation studies revealed that the methods take significantly different amounts of CPU time to run.

The study by Bray et al. (1995) showed that the power of MV approaches (e.g. MANOVA) can be improved by incorporating traits that are unaffected by the SNP if these traits are correlated with the affected traits. This knowledge can be applied to experimental studies if we possess prior or theoretical knowledge of which traits a given manipulation is expected to affect. GWAS, however, does not usually use such a theory to determine which traits to include or exclude.

Following Bray et al. (1995), adding further traits to the mv analysis is always beneficial:

- if the newly added indicators are not related to the SNP, then the power of mv methods generally increases because adding unrelated traits increases the power of mv methods
- if the newly added indicators are related to the SNP but in an opposite way to the relations that the already included indicators have to the SNP (opposite effects), then the power of mv methods to detect the SNP increases
- if the newly added indicators are also related to the SNP and in the same way (same direction of effect), then the power of mv methods will decrease, but generally no more than max. 15%.

It is often necessary to perform follow-up analyses after mv analyses to answer whether all or many traits are associated with the SNP. In preparation for the mv GWAS in chapter 4 we faced the same decision processes for the in- or exclusion of immune traits. Applying the Bayesian network approach, it was possible to set various combinations of immune traits for LR and LW regardless of the applied mv GWAS method.

In simulations, only additive codominant SNPs and normally distributed continuous traits are considered (Galesloot et al., 2014; Porter & O'Reilly, 2017; Vroom et al., 2019a). These choices fit the (distributional) assumptions underlying most mv analyses. It is important to note, that Type I error rates of various techniques (e.g., MANOVA, uv regression) may not be correct

when standard assumptions are violated in case of severely non-normal or non-continuous data (O'Reilly et al., 2012). However, Porter and O'Reilly (2017) have shown that for two of the most commonly used mv methods that may accommodate dichotomous data, the pattern of results is similar to that of continuous data.

Recently, multiple methods were developed that allow estimation of the genetic covariance between traits using GWAS e. g. GCTA (J. Yang et al., 2011), BOLT-REML (Loh et al., 2015), LD Score Regression (Bulik-Sullivan et al., 2015), MTAG (Turley et al., 2018) and genomic SEM (Grotzinger et al., 2019), which use this genetic covariance among traits to boost the statistical power to detect SNPs for sets of target traits. Applying these techniques was beyond the scope of our study and therefore, they were not included in the analyses described in chapter 4.

My methods can all be used to detect associations that may be due to pleiotropy. However, they do not answer the question of whether the detected association is truly pleiotropy, that is, whether the marker locus directly affects all my components. A detectable association can affect some phenotypes and/or mediate the effects of these phenotypes on other phenotypes (C. Yang et al., 2015). It can be expected that underlying genes for immunocompetence may have pleiotropic effects which result in a close genetic correlation between several immune traits. Against this background, the utilization of mv methods is recommended to increase the statistical power to detect associations even if the rg between the traits is expected to be weak (Wimmers et al. 2009). My methods are often used to discover pleiotropic genetic variants, that is, SNPs that are statistically associated with more than one trait, possibly pointing toward a shared biological substrate (Solovieff et al., 2013). Simulations studies show that as the degree of the phenotypic correlation between traits increases, the power to detect global variants decreases (Minica et al., 2010; Neale et al., 2010; Vroom et al., 2019a); as one would expect with an increase in genetic relatedness; thus, my approaches aren't optimized for identifying true pleiotropic genetic variants at the moment (Porter & O'Reilly, 2017). In our study in chapter 4, we focused on an empiric overlap between methods to identify pleiotropic QTL. However, it is only a rough method for the characterization of pleiotropy. Other methods, like Bayesian colocalization methods, are more suitable to detect pleiotropic SNPs and distinguish between different pleiotropic types as described by (Solovieff et al., 2013).

5.2. Genetic foundation of immune traits

In this thesis, the genetic foundation of porcine immune traits was studied with uv and mv approaches through immune profiling. The genetic potential for immunocompetence of the piglet and the dam was elaborated for two German maternal pig lines, LR and LW, in chapter

3. As a result, breed differences for immune traits phenotypic values, and genetic parameters were reported. Breed differences described also in previous studies are presumed to be related to various disease resistance traits (Henryon et al., 2001; Joling et al., 1993). Antibody response, lymphocyte proliferation, and delayed-type hypersensitivity (DTH) responsiveness were compared among purebred Dutch Landrace, Norwegian Landrace, Finnish Landrace, and Yorkshire (Joling et al., 1993). In this study, immunocompetence showed genetic involvement with h2 from 0.13 to 0.33 for antibody response and a h^2 from 0.41 to 0.44 for lymphocyte proliferation. The factors of breed, boar, and litter contributed significantly to the variation in immunocompetence. The Yorkshire breed showed a low-level response to all three immune parameters. The authors explain that within the genetic system the major histocompatibility complex (MHC), also called swine leucocytes antigen (SLA), genes are particularly important in terms of immune reactivity. The phenotype of the products of that gene complex has a considerable effect on the magnitude of the immunocompetence in the form of antibody response (Mallard et al., 1989). The distribution of SLA haplotypes is different between the breeds, which has been also investigated in specific pathogen-free Canadian Yorkshire and Landrace pigs (Gao et al., 2017). Furthermore, pigs from Duroc, LR, Hampshire, and Yorkshire breeds were shown to be genetically different in resistance to clinical and subclinical diseases (Henryon et al., 2001). However, other environmental and genetic factors may also influence the outcome of an immune response (Clapperton et al., 2009; Farmer, 2015). At the current state, a beneficial, stable, or advantageous immune system for different pig life stages and breeds is not characterized. Generally, the inclusion of immune traits in a selection program requires sufficient h² across generations. Results in chapter 3 suggest adequate genetic influence and therefore possible selective breeding for immune traits.

Besides additive genetic effects, maternal genes are presumed to influence the immunity of the piglet (Roehe et al., 2010). Previous studies on genetic indicators had not considered the dam as a source of variation for genetic variance component estimation. In the study from Rohrer et al. (2014) moderate m2 in genetic analysis of colostrum intake measured as γ -immunoglobulins complexes bound to ammonium sulfate (immunocrit) was estimated. Due to the epitheliochorial placentation of the sow, the passive transfer of antibodies from dams to piglets occurs during colostrum intake (Farmer, 2015). Therefore, several studies describe the importance of colostrum for the development of the piglet and a maternal impact on piglet's immunity in the form of antibody transfer, maturation of mucosal immunity, and colostrum intake (Bandrick et al., 2008; Hermesch et al., 2017; Rooke & Bland, 2002; Salmon et al., 2009). Considering the direct-maternal correlations between traits, the results of Knol et al. (2002) showed a positive

correlation between the direct component of piglet birth weight and the maternal component of stillbirth, indicating a negative influence on stillbirth if selection on the direct component of the individual birth weight occurs. In addition, Knol et al. (2001) reported decreased litter birth weight if selected directly for individual piglet survival. These findings show that direct-maternal correlations can be indicative when it comes to designing a model to breed for improved piglet survival. According to Bijma (2006), an estimation of (co)variances between direct and maternal effects is not feasible in populations with multiple litters and multiple offspring per litter. Heuß (2019), showed that direct-maternal correlations cause convergence problems, are not significant, and range massively between testing the models for traits like stillbirth, pre-weaning loss, and birth weight.

The impacts of maternal genetic and transferred immune factors on piglet's immunity are not completely clarified, yet. Consideration of maternal environmental effects and litter effects on piglet's immune traits in chapter 3 led to a decrease in h2 while at the same time causing an increase in m2 and rg indicating that it is possible to adjust piglet's immune measurements for maternal-derived immunity. Therefore, selection for immune traits in piglets can be accessed through the biological dam, which creates further opportunities to develop breeding strategies for immune-competent piglets.

Immune traits can send signals from one cell to another and communicate through direct cellto-cell contacts (Zimmerman et al., 2012). In chapter 3 the relationships between immune cells, haptoglobin, and cytokines were investigated by estimation of rp and rg parameters. Moreover, a shared genetic foundation as common genetic markers between hematological immune traits were revealed in Chinese Sutai pigs (F. Zhang et al., 2014). Flori, Gao, Laloë, et al. (2011) estimated rg for components of innate and adaptive immunity and showed that components of the immune system are complementary. Detected correlations between immunocompetence parameters (IgG antibody response, lymphocyte proliferation, DTH) were moderate to highly positive (0.33-0.99) indicating strong connections within the immune system (Joling et al., 1993). This demonstrates associated relationships and highlights a strong network within the immune system where selection for specific immune traits would affect other immune components. Therefore, relationships between immune traits and other performance phenotypes should be examined in detail before including specific traits in any selection strategy.

5.3. Towards a breeding-based improvement of health traits

Currently, many animal breeding research institutions as well as commercial pig breeding are focused on the improving of health and robustness traits. In our and related studies (see chapter

3) moderate to high h2 for most of the immune traits were found. This implies that the incorporation of these traits into selection indexes, along with another economically relevant trait, is feasible.

Even though immune traits are heritable across generations and are promising to cover global immunocompetence in animals, amplification of breeding goals for such traits has not been done, yet. Possible reasons for retained schemes in breeding companies can be very diverse. It is difficult to determine correlative and causal relationships between immunity and other performance and animal welfare-related traits. Therefore, modification of the immune system could lead to unintentional or unfavorable relationships between performance and animal welfare. Directed modification to optimize immune traits is not possible due to missing reference values that would classify beneficial immunity for different animal life stages and environments. Nevertheless, the improvement of the animal immune system through breeding is influential to animal welfare and the economy. Evaluation of the economic value of different immune traits at the current stage is rather imprudent. Regardless of open research questions results within this thesis provide knowledge about immune traits as corresponding factors for immunocompetence. Underlying studies contribute to the development of breeding strategies for health-related traits.

Besides index selection novel biotechnological tools might help to improve health and robustness traits efficiently. As an example, in 2017 it was possible to generate pigs in which the porcine reproductive and respiratory syndrome virus (PRRSV) protein receptor on macrophages was modified with Clustered Regularly Interspaced Short Palindromic Repeats/CRISPR-associated protein 9 (CRISPR/Cas9) gene editing. These pigs showed a full resistance to infection with the PRRSV strain which can result in a general health benefit and a decreased need for antimicrobial use (Burkard et al., 2017). However, direct biotechnological or selection strategies that target specific pathogen resistance may result in increased susceptibility to other diseases which was already shown by Mallard et al. (1992) and Wilkie and Mallard (1999). Mallard et al. (1992) challenged pigs with Hen Egg White Lysozyme (HEWL), synthetic peptide TGAL, and sheep erythrocytes, and selected according to the antibody and cell-mediated response (adaptive immunity), and monocyte function (innate immunity) of Yorkshire pigs. The h2 of these immunological traits ranged from 0 for monocyte function to 0.25 for secondary antibody response (HEWL). After eight years of selection, two distinct lines were formed: a high immune response (HIR) and a low immune response (LIR). HIR line had a higher incidence of arthritis after the Mycoplasma hyorhinis challenge (Wilkie & Mallard, 1999). This selection experiment demonstrates that selection for response against a
specific pathogen may have unpredictable consequences for other traits and unfavorable effects on the response against other pathogens. So far, most extensively studied immune response traits in pigs are those reflecting the antibody cell-mediated immunity such as antibody response to various antigens (Edfors-Lilja et al., 1994; Groves et al., 1993; Kadowaki et al., 2012; Mallard et al., 1992; Nguyen et al., 1998; Wilkie & Mallard, 1999).

In their review, Pluske et al. (2018) suggested that there are negative outcomes for animal health and productivity through both under- and over-responsiveness of the immune system. Pigs reared in conventional housing systems with high microbial loads grow 10-20% more slowly than pigs kept in 'clean' environments or pigs reared in isolation or pigs receiving antibiotics. An animal should have the capacity to mount a substantial immune response against invading pathogenic organisms, but the negative effects of pro-inflammatory cytokines should be minimized. Selecting pigs, particularly in a non-challenging environment, without including immune traits in the index is likely to lead to progeny that is less capable of dealing with demanding environments. Best results are likely to occur when pigs are selected in the same environment where the progeny will be reared and immune traits are included in the selection index. For this purpose, previous research has focused on breeding pigs for high robustness for a various range of environments (Hermesch et al., 2015; Knap, 2005; Pluske et al., 2018).

An indirect breeding approach focuses on immune traits providing a measure of immunocompetence and can predict the responses to pathogens in general (Flori, Gao, Oswald, et al., 2011). Genetic differences in the total and differential number of circulating leukocytes and the ability of mononuclear cells to produce IL-2 have earlier been indicated in swine (Edfors-Lilja et al., 1994). In addition, QTL for a cellular and humoral immune response (leucocyte counts, phagocytosis, mitogen-induced proliferation, IL-2 production, interferonalpha production antibody response) were identified by Edfors-Lilja et al. (1998) and Wimmers et al. (2009). An indirect indicator for disease incidence or animal health status of immune responsiveness. Moreover, immunological traits are associated with performance (Clapperton et al., 2009; Clapperton et al., 2008). These traits have also been found to display genetic variation within, and between breeds (Clapperton et al., 2009; Flori, Gao, Oswald, et al., 2011; Henryon et al., 2001), demonstrating the possibility of breeding for resistance, tolerance, or both, through selection for breed-specific immunocompetence. Currently, the implementation of the relationships among immune traits, as it has been detected here (chapter 4), cannot be realized. Besides missing biological causes for these relationships among the immune traits, it is necessary to determine the optimal range of these traits before breeding progress can be achieved.

Chapter 6. Conclusion of the thesis

Examined immune traits demonstrate genetic potential for immunocompetence of LR and LW piglets and their corresponding dams. Examined immune traits show moderate to high, breed-specific genetic parameters including h2, m2, and rg. With the help of mv approaches condensed immune phenotypes for example PCs can be considered to establish breeding strategies that take into account highly correlated relationships among different traits. In further, the joint genetic background of immune traits in LR and LW piglets through the application of various uv and mv GWAS approaches was determined. GWAS uv and mv methodology revealed several overlapping associations and immune-relevant potential candidate genes. The possibility of chromosome- or a genome-wide correction for multiple testing was only conducted in two approaches. In this thesis, the observation that one single test is not able to detect all the many different types of genetic effects in the most powerful manner was confirmed.

Modification of the immune system could lead to unintentional or unfavorable relationships to performance and animal welfare. Reference values are needed to evaluate and characterize the immune status. Currently, directed adjustment to optimize immune traits is not possible due to missing reference values that would classify beneficial immunity for different animal life stages and environments. A physiological reference value update is necessary due to accelerated genetic progress and changes in breeding objectives over the past few years.

Yet, it is unclear how the biological dam fully influences piglets' immune system. The results indicate consequences for immune traits in piglets depending on their biological dam's immune trait status. Nevertheless, a more defined correction for the dam's effect as a random parameter is needed.

According to our results, there is a clear difference between breeds. Furthermore, our results confirm that immunologically relevant traits and health indicators have a complex genetic background. Pleiotropic backgrounds are suggested by several genomic regions. There needs to be further investigation of the relationships between the immune system, survivability, performance characteristics, and other economically critical traits. Our results provide important insights into regions whose immune system is particularly crucial for piglets, as health and immune traits are expected to become more and more important in balanced pig breeding.

The improvement of the animal immune system through breeding is profitable and beneficial to consumers' concerns about animal welfare. Immune traits can be used to gain breeding-based health improvement. The analysis of immune traits has to be extended to characterize relationships between immunity and performance to gain an improved immune system without

accidental losses in productivity. In further research steps, the economic value of different immune traits should be classified.

Chapter 7. Summary

In pig breeding immune traits are considered to serve as potential biomarkers for pig's healthcompetence. A limited number of published studies indicate medium to high heritabilities (h²) for several immune traits. Genetic variance and covariance components of immune traits were estimated in chapter 3 to examine the quantitative genetic background of these traits. For this purpose, blood samples were collected for Landrace (LR) (n=611) and Large White (LW) (n=544) piglets and their biological dams (n=298, 272, respectively) in a short period around birth. Immune profile was covered by 22 traits including immune cells, red blood cell characteristics, and cytokines. Maternal impacts on piglet's immune profile were investigated as well as close phenotypic and genetic-based relationships in a multivariate approach. Immune traits showed low to high breed-specific h². Strong positive genetic correlations (r_g) were estimated among red blood cell characteristics (0.77 to 0.99) as well as among cytokines (0.48 to 0.99). The litter impact on piglet's immunity was examined and strengthened already observed breed differences. In LR h² (0.22 to 0.15) and litter effect (c²) (0.52 to 0.44) for IFN- γ decreased after statistical consideration of maternal impact. In LW a decrease in h² (0.32 to 0.18) for IFN- γ and an increase in c² (0.54 to 0.56) was observed.

The development of selection strategies requires deep investigations with appropriate statistical genome-wide association study approaches to explore the joint genetic foundation for health biomarkers. Consideration of previously established r_g between immune traits were used to identify pleiotropic genetic markers. For this reason, several univariate (uv) and multivariate (mv) genetic association testing methods were applied on immune traits in chapter 4. Mv GWAS approaches detected 647 associations for different mv immune trait combinations that were summarized to 133 quantitative trait loci (QTL). SNPs for different trait combinations (n=66) were detected with more than one mv method. Most of these SNPs are associated with red blood cell related immune trait combinations. With uv methods shared markers were not observed between the breeds, whereas mv approaches were able to detect two conjoint SNPs for LR and LW.

Most immune traits are heritable and are promising to cover global breed-specific immunocompetence in animals. With uv and mv approaches, the joint genetic background of immune traits was demonstrated by revealing immune relevant potential candidate genes. Investigated traits can be used to gain a breeding-based health improvement in piglets whereby special attention has to be laid on the relationship between immunocompetence and further performance characteristics.

Chapter 8. References

- Alonso Spilsbury, M. (2007). Piglet survival in early lactation: a review. Journal of Animal and Veterinary Advances, 6(1), 76.
- animalgenome.org (2019). Pig QTL Database.
- Arbib, Michael A. (1998). A Bradford book. The handbook of brain theory and neural networks. MIT Press.
- Aschard, H., Vilhjálmsson, B. J., Greliche, N., Morange, P.-E., Trégouët, D.-A., & Kraft, P. (2014). Maximizing the power of principal-component analysis of correlated phenotypes in genome-wide association studies. American Journal of Human Genetics, 94(5), 662–676. https://doi.org/10.1016/j.ajhg.2014.03.016
- Aulchenko, Y. S., Ripke, S., Isaacs, A., & van Duijn, C. M. (2007). Genabel: An R library for genome-wide association analysis. Bioinformatics, 23(10), 1294–1296. https://doi.org/10.1093/bioinformatics/btm108
- Ballester, M., Ramayo-Caldas, Y., González-Rodríguez, O., Pascual, M., Reixach, J., Díaz, M., Blanc, F., López-Serrano, S., Tibau, J., & Quintanilla, R. (2020). Genetic parameters and associated genomic regions for global immunocompetence and other health-related traits in pigs. Scientific Reports, 10(1), 18462. https://doi.org/10.1038/s41598-020-75417-7
- Bandrick, M., Pieters, M., Pijoan, C., & Molitor, T. W. (2008). Passive transfer of maternal Mycoplasma hyopneumoniae-specific cellular immunity to piglets. Clinical and Vaccine Immunology, 15(3), 540–543. https://doi.org/10.1128/CVI.00466-07
- Baxter, E. M., Rutherford, K. M., D'Eath, R. B., Arnott, G., Turner, S. P., Sandøe, P., Moustsen, V. A., Thorup, F., Edwards, S. A., & Lawrence, A. B. (2013). The welfare implications of large litter size in the domestic pig II: Management factors. Animal Welfare, 22(2), 219–238. https://doi.org/10.7120/09627286.22.2.219
- Beckner, M. E., Jagannathan, S., & Peterson, V. A. (2002). Extracellular angio-associated migratory cell protein plays a positive role in angiogenesis and is regulated by astrocytes in coculture. Microvascular Research, 63(3), 259–269. https://doi.org/10.1006/mvre.2001.2384
- Benjamini, Y., & Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society, 57(1), 289–300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x
- Berghof, T. V. L., Poppe, M., & Mulder, H. A. (2018). Opportunities to Improve Resilience in Animal Breeding Programs. Frontiers in Genetics, 9, 692. https://doi.org/10.3389/fgene.2018.00692
- Biozzi, Guido; Mouton, D.; Heumann, A.; Bouthillier, Y. (1982). Genetic regulation of immunoresponsiveness in relation to resistance against infectious diseases. : Vol. 5.
 Publicaciones del Minsterio de Agricultura, Pesca y Alimentación Madrid.
- Bolormaa, S., Pryce, J. E., Hayes, B. J., & Goddard, M. E. (2010). Multivariate analysis of a genome-wide association study in dairy cattle. Journal of Dairy Science, 93(8), 3818– 3833. https://doi.org/10.3168/jds.2009-2980
- Bolormaa, S., Pryce, J. E., Reverter, A., Zhang, Y., Barendse, W., Kemper, K., Tier, B., Savin, K., Hayes, B. J., & Goddard, M. E. (2014). A multi-trait, meta-analysis for

detecting pleiotropic polymorphisms for stature, fatness and reproduction in beef cattle. PLoS Genetics, 10(3), e1004198. https://doi.org/10.1371/journal.pgen.1004198

- Bottolo, L., Chadeau-Hyam, M., Hastie, D. I., Zeller, T., Liquet, B., Newcombe, P.,
 Yengo, L., Wild, P. S., Schillert, A., Ziegler, A., Nielsen, S. F., Butterworth, A. S.,
 Ho, W. K., Castagné, R., Munzel, T., Tregouet, D., Falchi, M., Cambien, F.,
 Nordestgaard, B. G., ... Richardson, S. (2013). Guess-ing polygenic associations with
 multiple phenotypes using a GPU-based evolutionary stochastic search algorithm.
 PLoS Genetics, 9(8), e1003657. https://doi.org/10.1371/journal.pgen.1003657
- Bouma, A., Jong, M. de, & Kimman, T. G. (1998). The influence of maternal immunity on the development of the in vitro lymphocyte proliferation response against pseudorabies virus in pigs. Research in Veterinary Science, 64(2), 167–171. https://doi.org/10.1016/S0034-5288(98)90014-5
- Bovo, S., Ballan, M., Schiavo, G., Gallo, M., Dall'Olio, S., & Fontanesi, L. (2020).
 Haplotype-based genome-wide association studies reveal new loci for haematological and clinical-biochemical parameters in Large White pigs. Animal Genetics, 51(4), 601–606. https://doi.org/10.1111/age.12959
- Bovo, S., Mazzoni, G., Bertolini, F., Schiavo, G., Galimberti, G., Gallo, M., Dall'Olio, S., & Fontanesi, L. (2019). Genome-wide association studies for 30 haematological and blood clinical-biochemical traits in Large White pigs reveal genomic regions affecting intermediate phenotypes. Scientific Reports, 9(1), 7003. https://doi.org/10.1038/s41598-019-43297-1
- Braeken, J., & van Assen, M. A. L. M. (2017). An empirical Kaiser criterion. Psychological Methods, 22(3), 450–466. https://doi.org/10.1037/met0000074
- Brambell, F. W. R. (1970). The transmission of passive immunity from mother to young. Frontiers of biology: Vol. 18. North-Holland-Publ.
- Bray, J. H., Maxwell, S. E., & Cole, D. (1995). Multivariate statistics for family psychology research. Journal of Family Psychology, 9(2), 144–160. https://doi.org/10.1037/0893-3200.9.2.144
- Brooker, R. J. (2012). Concepts of genetics. McGraw-Hill.
- Bulik-Sullivan, B. K., Loh, P.-R., Finucane, H. K., Ripke, S., Yang, J., Patterson, N., Daly, M. J., Price, A. L., & Neale, B. M. (2015). Ld Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nature Genetics, 47(3), 291–295. https://doi.org/10.1038/ng.3211
- Burkard, C., Lillico, S. G., Reid, E., Jackson, B., Mileham, A. J., Ait-Ali, T.,
 Whitelaw, C. B. A., & Archibald, A. L. (2017). Precision engineering for PRRSV resistance in pigs: Macrophages from genome edited pigs lacking CD163 SRCR5 domain are fully resistant to both PRRSV genotypes while maintaining biological function. PLoS Pathogens, 13(2), e1006206. https://doi.org/10.1371/journal.ppat.1006206
- Calder, P. C. (2007). Immunological parameters: What do they mean? The Journal of Nutrition, 137(3 Suppl 2), 773S-80S. https://doi.org/10.1093/jn/137.3.773S

- Cheng, G., Hao, H., Xie, S., Wang, X., Dai, M., Huang, L., & Yuan, Z. (2014). Antibiotic alternatives: The substitution of antibiotics in animal husbandry? Frontiers in Microbiology, 5, 217. https://doi.org/10.3389/fmicb.2014.00217
- Cho, I. C., Park, H. B., Yoo, C. K., Lee, G. J., Lim, H. T., Lee, J. B., Jung, E. J., Ko, M. S., Lee, J. H., & Jeon, J. T. (2011). Qtl analysis of white blood cell, platelet and red blood cell-related traits in an F2 intercross between Landrace and Korean native pigs. Animal Genetics, 42(6), 621–626. https://doi.org/10.1111/j.1365-2052.2011.02204.x
- Clapperton, M., Bishop, S. C., & Glass, E. J. (2005). Innate immune traits differ between Meishan and Large White pigs. Veterinary Immunology and Immunopathology, 104(3-4), 131–144. https://doi.org/10.1016/j.vetimm.2004.10.009
- Clapperton, M., Diack, A. B., Matika, O., Glass, E. J., Gladney, C. D., Mellencamp, M. A., Hoste, A., & Bishop, S. C. (2009). Traits associated with innate and adaptive immunity in pigs: Heritability and associations with performance under different health status conditions. Genetics, Selection, Evolution : GSE, 41, 54. https://doi.org/10.1186/1297-9686-41-54
- Clapperton, M., Glass, E. J., & Bishop, S. C. (2008). Pig peripheral blood mononuclear leucocyte subsets are heritable and genetically correlated with performance. Animal : An International Journal of Animal Bioscience, 2(11), 1575–1584. https://doi.org/10.1017/S1751731108002929
- Colditz, I. G., & Hine, B. C. (2016). Resilience in farm animals: Biology, management, breeding and implications for animal welfare. Animal Production Science, 56(12), 1961. https://doi.org/10.1071/AN15297
- Crawley, M. J. (2007). The R Book. John Wiley & Sons, Ltd. https://doi.org/10.1002/9780470515075
- Dauben, C. M., Pröll-Cornelissen, M. J., Heuß, E. M., Appel, A. K., Henne, H., Roth, K., Schellander, K., Tholen, E., & Große-Brinkhaus, C. (2021). Genome-wide associations for immune traits in two maternal pig lines. BMC Genomics, 22(1), 717. https://doi.org/10.1186/s12864-021-07997-1
- Deng, K.-Q., Zhao, G.-N., Wang, Z., Fang, J., Jiang, Z., Gong, J., Yan, F.-J., Zhu, X.-Y., Zhang, P., She, Z.-G., & Li, H. (2018). Targeting Transmembrane BAX Inhibitor Motif Containing 1 Alleviates Pathological Cardiac Hypertrophy. Circulation, 137(14), 1486–1504. https://doi.org/10.1161/CIRCULATIONAHA.117.031659
- Devlin, B., Roeder, K., & Wasserman, L. (2001). Genomic control, a new approach to genetic-based association studies. Theoretical Population Biology, 60(3), 155–166. https://doi.org/10.1006/tpbi.2001.1542
- Edfors-Lilja, I., Wattrang, E., Magnusson, U., & Fossum, C. (1994). Genetic variation in parameters reflecting immune competence of swine. Veterinary Immunology and Immunopathology, 40(1), 1–16. https://doi.org/10.1016/0165-2427(94)90011-6
- Edfors-Lilja, I., Wattrang, E., Marklund, L., Moller, M., Andersson-Eklund, L., Andersson, L., & Fossum, C. (1998). Mapping quantitative trait loci for immune capacity in the pig. Journal of Immunology, 161(2), 829–835.

- Edwards, S. A. (2002). Perinatal mortality in the pig: Environmental or physiological solutions? Livestock Production Science, 78(1), 3–12. https://doi.org/10.1016/S0301-6226(02)00180-X
- Ernst, C. W., & Steibel, J. P. (2013). Molecular advances in QTL discovery and application in pig breeding. Trends in Genetics, 29(4), 215–224. https://doi.org/10.1016/j.tig.2013.02.002
- European Commission (2017, June 13). Annual activity reports 2016.
- Everitt, B., & Hothorn, T. (2011). An introduction to applied multivariate analysis with R. Use R! Springer. http://www.loc.gov/catdir/enhancements/fy1304/2011926793-b.html
- Farmer, C. (2015). The gestating and lactating sow. Wageningen Academic Publishers. https://doi.org/10.3920/978-90-8686-803-2
- Ferreira, M. A. R., & Purcell, S. M. (2009). A multivariate test of association. Bioinformatics, 25(1), 132–133. https://doi.org/10.1093/bioinformatics/btn563
- Flori, L., Gao, Y., Laloë, D., Lemonnier, G., Leplat, J.-J., Teillaud, A., Cossalter, A.-M., Laffitte, J., Pinton, P., Vaureix, C. de, Bouffaud, M., Mercat, M.-J., Lefèvre, F., Oswald, I. P., Bidanel, J.-P., & Rogel-Gaillard, C. (2011). Immunity traits in pigs: Substantial genetic variation and limited covariation. PloS One, 6(7), e22717. https://doi.org/10.1371/journal.pone.0022717
- Flori, L., Gao, Y., Oswald, I. P., Lefèvre, F., Bouffaud, M., Mercat, M.-J., Bidanel, J.-P., & Rogel-Gaillard, C. (2011). Deciphering the genetic control of innate and adaptive immune responses in pig: A combined genetic and genomic study. BMC Proceedings, 5 Suppl 4, S32. https://doi.org/10.1186/1753-6561-5-S4-S32
- Fontana, A., Bodmer, S., & Frei, K. Immunoregulatory Factors Secreted by Astrocytes and Glioblastoma Cells. In Lymphokines (91–121). https://doi.org/10.1016/B978-0-12-432014-7.50008-5
- Friendship, R. M., Lumsden, J. H., McMillan, I., & Wilson, M. R. (1984). Hematology and biochemistry reference values for Ontario swine. Canadian Journal of Comparative Medicine : Revue Canadienne De Medecine Comparee, 48(4), 390–393.
- Galesloot, T. E., van Steen, K., Kiemeney, L. A. L. M., Janss, L. L., & Vermeulen, S. H. (2014). A comparison of multivariate genome-wide association methods. PloS One, 9(4), e95923. https://doi.org/10.1371/journal.pone.0095923
- Gao, C., Quan, J., Jiang, X., Li, C., Lu, X., & Chen, H. (2017). Swine Leukocyte Antigen Diversity in Canadian Specific Pathogen-Free Yorkshire and Landrace Pigs. Frontiers in Immunology, 8, 282. https://doi.org/10.3389/fimmu.2017.00282
- Gilbert, H., & Le Roy, P. (2003). Comparison of three multitrait methods for QTL detection. Genetics Selection Evolution, 35(3), 281. https://doi.org/10.1186/1297-9686-35-3-281
- Gilmour, A. R. (2015). ASReml User Guide. VSN Release 4 International Ltd, Hemel Hempstead, HP1 1ES, UK. www.vsni.co.uk
- Goldberger, A. S. (1972). Structural Equation Methods in the Social Sciences. Econometrica, 40(6), 979. https://doi.org/10.2307/1913851

- Gondro, Cedric; van der Werf, Julius; Hayes, Ben J. (2013). SpringerLink Bücher: Vol. 1019. Genome-Wide Association Studies and Genomic Prediction. Humana Press. http://dx.doi.org/10.1007/978-1-62703-447-0
- Gong, Y.-F., He, H., Liu, H., Zhang, C., Zhao, W., & Shao, R.-G. (2014). Phosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cells. FEBS Letters, 588(17), 2903–2910. https://doi.org/10.1016/j.febslet.2014.07.018
- Gong, Y.-F., Lu, X., Wang, Z., Hu, F., Luo, Y.-R., Cai, S.-Q., Qi, C.-M., Li, S., Niu, X.-Y., Qiu, X.-T., Zeng, J., & Zhang, Q. (2010). Detection of quantitative trait loci affecting haematological traits in swine via genome scanning. BMC Genetics, 11, 56. https://doi.org/10.1186/1471-2156-11-56
- Grandinson, K., Lund, M. S., Rydhmer, L., & Strandberg, E. (2010). Genetic Parameters for the Piglet Mortality Traits Crushing, Stillbirth and Total Mortality, and their Relation to Birth Weight. Acta Agriculturae Scandinavica, 52(4), 167–173. https://doi.org/10.1080/090647002762381041
- Grindstaff, J. L., Brodie, E. D., & Ketterson, E. D. (2003). Immune function across generations: Integrating mechanism and evolutionary process in maternal antibody transmission. Proceedings. Biological Sciences, 270(1531), 2309–2319. https://doi.org/10.1098/rspb.2003.2485
- Grotzinger, A. D., Rhemtulla, M., Vlaming, R. de, Ritchie, S. J., Mallard, T. T., Hill, W. D., Ip, H. F., Marioni, R. E., McIntosh, A. M., Deary, I. J., Koellinger, P. D., Harden, K. P., Nivard, M. G., & Tucker-Drob, E. M. (2019). Genomic structural equation modelling provides insights into the multivariate genetic architecture of complex traits. Nature Human Behaviour, 3(5), 513–525. https://doi.org/10.1038/s41562-019-0566-x
- Groves, T. C., Wilkie, B. N., Kennedy, R. B., & Mallard, B. A. (1993). Effect of selection of swine for high and low immune responsiveness on monocyte superoxide anion production and Class II MHC antigen expression. Veterinary Immunology and Immunopathology, 36(4), 347–358. https://doi.org/10.1016/0165-2427(93)90030-8
- Hair, J. F. (2009). Multivariate data analysis.
- Halbur, P. G., Rothschild, M. F., Thacker, B. J., Meng, X.-J., Paul, P. S., & Bruna, J. D. (1998). Differences in susceptibility of Duroc, Hampshire, and Meishan pigs to infection with a high virulence strain (VR2385) of porcine reproductive and respiratory syndrome virus (PRRSV). Journal of Animal Breeding and Genetics, 115(1-6), 181–189. https://doi.org/10.1111/j.1439-0388.1998.tb00341.x
- Hammerberg, C., Schurig, G. G., & Ochs, D. L. (1989). Immunodeficiency in young pigs. American Journal of Veterinary Research, 50(6), 868–874.
- Harris, N., Kunicka, J., & Kratz, A. (2005). The ADVIA 2120 hematology system: flow cytometry-based analysis of blood and body fluids in the routine hematology laboratory. Laboratory Hematology, 11(1), 47–61.
- Hellbrügge, B., Tölle, K.-H., Bennewitz, J., Henze, C., Presuhn, U., & Krieter, J. (2008). Genetic aspects regarding piglet losses and the maternal behaviour of sows. Part 1.

Genetic analysis of piglet mortality and fertility traits in pigs. Animal : An International Journal of Animal Bioscience, 2(9), 1273–1280. https://doi.org/10.1017/S1751731108002504

- Henryon, M., Berg, P., Jensen, J., & Andersen, S. (2001). Genetic variation for resistance to clinical and subclinical diseases exists in growing pigs. Animal Science, 73(03), 375– 387. https://doi.org/10.1017/S1357729800058343
- Henryon, M., Heegaard, P. M. H., Nielsen, J., Berg, P., & Juul-Madsen, H. R. (2006). Immunological traits have the potential to improve selection of pigs for resistance to clinical and subclinical disease. Animal Science, 82(05), 597. https://doi.org/10.1079/ASC200671
- Hermesch, S., Li, L., Doeschl-Wilson, A. B., & Gilbert, H. (2015). Selection for productivity and robustness traits in pigs. Animal Production Science, 55(12), 1437. https://doi.org/10.1071/AN15275
- Hermesch, S., & Luxford, B. G. (2018). Genetic parameters for white blood cells, haemoglobin and growth in weaner pigs for genetic improvement of disease resilience. Proceedings of the World Congress on Genetics Applied to Livestock Production, Species - Porcine 2, 384.
- Hermesch, S., McKenna, T., Bauer, M. M., & Sales, N. (2017). The effect of dam parity on growth, white blood cell count, haemoglobin and immunoglobulin levels of weaner pigs. Animal Production Science, 57(12), 2482. https://doi.org/10.1071/ANv57n12Ab134
- Heuß, E. M. (2019). Genetic analyses of piglet survival and postnatal growth [Dissertation]. Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn.
- Heuß, E. M., Pröll-Cornelissen, M. J., Neuhoff, C., Tholen, E., & Große-Brinkhaus, C. (2019). Invited review: Piglet survival: Benefits of the immunocompetence. Animal : An International Journal of Animal Bioscience, 1–11. https://doi.org/10.1017/S1751731119000430
- Hotelling, H. (1933). Analysis of a complex of statistical variables into principal components. Journal of Educational Psychology, 24(6), 417–441. https://doi.org/10.1037/h0071325
- Hotelling, H. (1992). Relations Between Two Sets of Variates. In S. Kotz & N. L. Johnson (Eds.), Springer Series in Statistics. Breakthroughs in Statistics (162–190). Springer New York. https://doi.org/10.1007/978-1-4612-4380-9_14
- Hu, Z.-L., Park, C. A., & Reecy, J. M. (2019). Building a livestock genetic and genomic information knowledgebase through integrative developments of Animal QTLdb and CorrDB. Nucleic Acids Research, 47(D1), D701–D710. https://doi.org/10.1093/nar/gky1084
- Hunt, S. E., McLaren, W., Gil, L., Thormann, A., Schuilenburg, H., Sheppard, D., Parton, A., Armean, I. M., Trevanion, S. J., Flicek, P., & Cunningham, F. (2018). Ensembl variation resources. Database : The Journal of Biological Databases and Curation, 2018. https://doi.org/10.1093/database/bay119
- Ježek, J., Starič, J., Nemec, M., Plut, J., Oven, I. G., Klinkon, M., & Štukelj, M. (2018). The influence of age, farm, and physiological status on pig hematological profiles. Journal of Swine Health and Production, 26(2), 72–78.

- Jiang, C., & Zeng, Z. B. (1995). Multiple trait analysis of genetic mapping for quantitative trait loci. Genetics, 140(3), 1111–1127. https://doi.org/10.1093/genetics/140.3.1111
- Johnson, R. W. (1997). Inhibition of growth by pro-inflammatory cytokines: An integrated view. Journal of Animal Science, 75(5), 1244. https://doi.org/10.2527/1997.7551244x
- Joling, P., Mok, K. S., Vries Reilingh, G. de, Wever, P. J., Cornelis, R. S., Oskam, J. P., & Henken, A. M. (1993). An evaluation of immune competence in different swine breeds. The Veterinary Quarterly, 15(1), 9–15. https://doi.org/10.1080/01652176.1993.9694360
- Kadowaki, H., Suzuki, E., Kojima-Shibata, C., Suzuki, K., Okamura, T., Onodera, W., Shibata, T., & Kano, H. (2012). Selection for resistance to swine mycoplasmal pneumonia over 5 generations in Landrace pigs. Livestock Science, 147(1-3), 20–26. https://doi.org/10.1016/j.livsci.2012.03.014
- Kikuchi, Y.; Ogawa, T.; Wako, K.; Suzuki, K.; Shibata, T.; Kadowaki, H.; Shinohara, H.; Otomo, Y.; Nishida, A. (2002). A prospect for genetic improvement of chronic disease resistance in swine.
- Kim, J., Zhang, Y., & Pan, W. (2016). Powerful and Adaptive Testing for Multi-trait and Multi-SNP Associations with GWAS and Sequencing Data. Genetics, 203(2), 715– 731. https://doi.org/10.1534/genetics.115.186502
- Kirkpatrick, M., & Lande, R. (1989). The Evolution of Maternal Characters. Evolution, 43(3), 485. https://doi.org/10.2307/2409054
- Klei, L., Luca, D., Devlin, B., & Roeder, K. (2008). Pleiotropy and principal components of heritability combine to increase power for association analysis. Genetic Epidemiology, 32(1), 9–19. https://doi.org/10.1002/gepi.20257
- Klobasa, F., Werhahn, E., & Butler, J. E. (1981). Regulation of humoral immunity in the piglet by immunoglobulins of maternal origin. Research in Veterinary Science, 31(2), 195–206. https://doi.org/10.1016/S0034-5288(18)32494-9
- Knap, P. W. (2005). Breeding robust pigs. Australian Journal of Experimental Agriculture, 45(8), 763. https://doi.org/10.1071/EA05041
- Knap, P. W., & Bishop, S. C. (2000). Relationships between genetic change and infectious disease in domestic livestock. BSAP Occasional Publication, 27, 65–80. https://doi.org/10.1017/S1463981500040553
- Knol, E. F., Ducro, B. J., van Arendonk, J., & van der Lende, T. (2002). Direct, maternal and nurse sow genetic effects on farrowing-, pre-weaning- and total piglet survival. Livestock Production Science, 73(2-3), 153–164. https://doi.org/10.1016/S0301-6226(01)00248-2
- Knol, E. F., Leenhouwers, J., & van der Lende, T. (2002). Genetic aspects of piglet survival. Livestock Production Science, 78(1), 47–55. https://doi.org/10.1016/S0301-6226(02)00184-7
- Knott, S. A., & Haley, C. S. (2000). Multitrait least squares for quantitative trait loci detection. Genetics, 156(2), 899–911.
- Korsgaard, I. R., Lund, M. S., Sorensen, D., Gianola, D., Madsen, P., & Jensen, J. (2003). Multivariate Bayesian analysis of Gaussian, right censored Gaussian, ordered

categorical and binary traits using Gibbs sampling. Genetics, Selection, Evolution : GSE, 35(2), 159–183. https://doi.org/10.1186/1297-9686-35-2-159

- Korte, A., Vilhjálmsson, B. J., Segura, V., Platt, A., Long, Q., & Nordborg, M. (2012). A mixed-model approach for genome-wide association studies of correlated traits in structured populations. Nature Genetics, 44, 1066 EP -.
- Kovač, M., & Groeneveld, E. (2003). VCE-5: User's guide and reference manual: version 5.1. Biotechnical Faculty, Department of Animal Science.
- Li, M.-X., Gui, H.-S., Kwan, J. S. H., & Sham, P. C. (2011). Gates: A rapid and powerful gene-based association test using extended Simes procedure. American Journal of Human Genetics, 88(3), 283–293. https://doi.org/10.1016/j.ajhg.2011.01.019
- Liu, J.-F., Pei, Y., Papasian, C. J., & Deng, H.-W. (2009). Bivariate association analyses for the mixture of continuous and binary traits with the use of extended generalized estimating equations. Genetic Epidemiology, 33(3), 217–227. https://doi.org/10.1002/gepi.20372
- Liu, Y., Luo, Y.-R., Lu, X., Qiu, X.-T., Fu, W. X., Zhou, J. P., Zhang, Q., & Yin, Z. J. (2010). Investigation and comparative study on haematological traits, lysozyme concentration and T lymphocyte subpopulation in three pig breeds. Journal of Animal and Veterinary Advances, 9(21), 2748–2751.
- Loh, P.-R., Bhatia, G., Gusev, A., Finucane, H. K., Bulik-Sullivan, B. K., Pollack, S. J., Candia, T. R. de, Lee, S. H., Wray, N. R., Kendler, K. S., O'Donovan, M. C., Neale, B. M., Patterson, N., & Price, A. L. (2015). Contrasting genetic architectures of schizophrenia and other complex diseases using fast variance-components analysis. Nature Genetics, 47(12), 1385–1392. https://doi.org/10.1038/ng.3431
- Lu, X., Gong, Y.-F., Liu, J. F., Wang, Z., Hu, F., Qiu, X.-T., Luo, Y.-R., & Zhang, Q. (2011). Mapping quantitative trait loci for cytokines in the pig. Animal Genetics, 42(1), 1–5. https://doi.org/10.1111/j.1365-2052.2010.02071.x
- Lu, X., Liu, J.-F., Fu, W., Zhou, J. P., Luo, Y.-R., Ding, X., Liu, Y., & Zhang, Q. (2013). Genome-wide association study for cytokines and immunoglobulin G in swine. PloS One, 8(10), e74846. https://doi.org/10.1371/journal.pone.0074846
- Luo, W., Chen, S., Cheng, D., Wang, L., Li, Y., Ma, X., Song, X., Liu, Y., Li, W., Liang, J., Yan, H., Zhao, K., Wang, C., & Zhang, L. (2012). Genome-wide association study of porcine hematological parameters in a Large White × Minzhu F2 resource population. International Journal of Biological Sciences, 8(6), 870–881. https://doi.org/10.7150/ijbs.4027
- Mähler, M., Most, C., Schmidtke, S., Sundberg, J. P., Li, R., Hedrich, H. J., & Churchill, G. A. (2002). Genetics of colitis susceptibility in IL-10-deficient mice: Backcross versus F2 results contrasted by principal component analysis. Genomics, 80(3), 274–282. https://doi.org/10.1006/geno.2002.6840
- Mallard, B. A., Wilkie, B. N., & Kennedy, R. B. (1989). The influence of the swine major histocompatibility genes (SLA) on variation in serum immunoglobulin (Ig) concentration. Veterinary Immunology and Immunopathology, 21(2), 139–151. https://doi.org/10.1016/0165-2427(89)90062-7

- Mallard, B. A., Wilkie, B. N., Kennedy, R. B., & Quinton, M. (1992). Use of estimated breeding values in a selection index to breed Yorkshire pigs for high and low immune and innate resistance factors. Animal Biotechnology, 3(2), 257–280. https://doi.org/10.1080/10495399209525776
- Marchini, J., Howie, B., Myers, S., McVean, G., & Donnelly, P. (2007). A new multipoint method for genome-wide association studies by imputation of genotypes. Nature Genetics, 39, 906 EP -.
- Martin, A., Dunnington, E. A., Gross, W. B., Briles, W. E., Briles, R. W., & Siegel, P. B. (1990). Production traits and alloantigen systems in lines of chickens selected for high or low antibody responses to sheep erythrocytes. Poultry Science, 69(6), 871–878. https://doi.org/10.3382/ps.0690871
- Matías, J., Berzosa, M., Pastor, Y., Irache, J. M., & Gamazo, C. (2017). Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections. Vaccines, 5(4). https://doi.org/10.3390/vaccines5040048
- McFaul, S. J., Bowman, P. D., & Villa, V. M. (2000). Hemoglobin stimulates the release of proinflammatory cytokines from leukocytes in whole blood. The Journal of Laboratory and Clinical Medicine, 135(3), 263–269. https://doi.org/10.1067/mlc.2000.105180
- Meyer, K. (2007). Wombat: A tool for mixed model analyses in quantitative genetics by restricted maximum likelihood (REML). Journal of Zhejiang University. Science. B, 8(11), 815–821. https://doi.org/10.1631/jzus.2007.B0815
- Minica, C. C., Boomsma, D. I., van der Sluis, S., & Dolan, C. V. (2010). Genetic association in multivariate phenotypic data: Power in five models. Twin Research and Human Genetics : The Official Journal of the International Society for Twin Studies, 13(6), 525–543. https://doi.org/10.1375/twin.13.6.525
- Momen, M., Campbell, M. T., Walia, H., & Morota, G. (2019). Utilizing trait networks and structural equation models as tools to interpret multi-trait genome-wide association studies. Plant Methods, 15, 107. https://doi.org/10.1186/s13007-019-0493-x
- Montesinos-Lopez, O. A., Montesinos-Lopez, A., Crossa, J., Toledo, F. H., Perez-Hernandez, O., Eskridge, K. M., & Rutkoski, J. (2016). A Genomic Bayesian Multitrait and Multi-environment Model. G3 (Bethesda, Md.), 6(9), 2725–2744. https://doi.org/10.1534/g3.116.032359
- Mpetile, Z., Young, J. M., Gabler, N. K., Dekkers, J. C. M., & Tuggle, C. K. (2015). Assessing peripheral blood cell profile of Yorkshire pigs divergently selected for residual feed intake. Journal of Animal Science, 93(3), 892–899. https://doi.org/10.2527/jas.2014-8132
- Nagarajan, R., Scutari, M., & Lèbre, S. (2013). Bayesian Networks in R: With Applications in Systems Biology. Use R! Vol. 48. Springer. http://dx.doi.org/10.1007/978-1-4614-6446-4 https://doi.org/10.1007/978-1-4614-6446-4
- Neale, B. M., Medland, S. E., Ripke, S., Asherson, P., Franke, B., Lesch, K.-P.,
 Faraone, S. V., Nguyen, T. T., Schäfer, H., Holmans, P., Daly, M., Steinhausen, H.C., Freitag, C., Reif, A., Renner, T. J., Romanos, M., Romanos, J., Walitza, S.,
 Warnke, A., . . . Nelson, S. (2010). Meta-analysis of genome-wide association studies

of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 49(9), 884–897. https://doi.org/10.1016/j.jaac.2010.06.008

- Nguyen, V. P., Wong, C. W., Hinch, G. N., Singh, D., & Colditz, I. G. (1998). Variation in the immune status of two Australian pig breeds. Australian Veterinary Journal, 76(9), 613–617. https://doi.org/10.1111/j.1751-0813.1998.tb10241.x
- O'Reilly, P. F., Hoggart, C. J., Pomyen, Y., Calboli, F. C. F., Elliott, P., Jarvelin, M.-R., & Coin, L. J. M. (2012). Multiphen: Joint model of multiple phenotypes can increase discovery in GWAS. PloS One, 7(5), e34861. https://doi.org/10.1371/journal.pone.0034861
- Pavlicev, M., Kenney-Hunt, J. P., Norgard, E. A., Roseman, C. C., Wolf, J. B., & Cheverud, J. M. (2008). Genetic variation in pleiotropy: Differential epistasis as a source of variation in the allometric relationship between long bone lengths and body weight. Evolution, 62(1), 199–213. https://doi.org/10.1111/j.1558-5646.2007.00255.x
- Pearl, J. (1988). Probabilistic Reasoning in Intelligent Systems: Networks of Plausible Inference. Elsevier Reference Monographs. http://gbv.eblib.com/patron/FullRecord.aspx?p=1876690
- Pearson, K. (1901). Principal components analysis. The London, Edinburgh, and Dublin Philosophical Magazine and Journal of Science, 6(2), 559.
- Petry, D. B., Lunney, J., Boyd, P., Kuhar, D., Blankenship, E., & Johnson, R. K. (2007). Differential immunity in pigs with high and low responses to porcine reproductive and respiratory syndrome virus infection. Journal of Animal Science, 85(9), 2075–2092. https://doi.org/10.2527/jas.2006-721
- Pluske, J. R., Kim, J. C., & Black, J. L. (2018). Manipulating the immune system for pigs to optimise performance. Animal Production Science. Advance online publication. https://doi.org/10.1071/AN17598
- Ponsuksili, S., Reyer, H., Trakooljul, N., Murani, E., & Wimmers, K. (2016). Single- and Bayesian Multi-Marker Genome-Wide Association for Haematological Parameters in Pigs. PloS One, 11(7), e0159212. https://doi.org/10.1371/journal.pone.0159212
- Porter, H. F., & O'Reilly, P. F. (2017). Multivariate simulation framework reveals performance of multi-trait GWAS methods. Scientific Reports, 7, 38837. https://doi.org/10.1038/srep38837
- R Core Team. (2019). R: A language and environment for statistical computing. http://www.R-project.org/
- Rauw, W. M., Kanis, E., Noordhuizen-Stassen, E., & Grommers, F. (1998). Undesirable side effects of selection for high production efficiency in farm animals: A review. Livestock Production Science, 56(1), 15–33. https://doi.org/10.1016/S0301-6226(98)00147-X
- Reiner, G., Dreher, F., Drungowski, M., Hoeltig, D., Bertsch, N., Selke, M., Willems, H., Gerlach, G. F., Probst, I., Tuemmler, B., Waldmann, K.-H., & Herwig, R. (2014).
 Pathway deregulation and expression QTLs in response to Actinobacillus pleuropneumoniae infection in swine. Mammalian Genome : Official Journal of the

International Mammalian Genome Society, 25(11-12), 600–617. https://doi.org/10.1007/s00335-014-9536-9

- Reiner, G., Fischer, R., Hepp, S., Berge, T., Köhler, F., & Willems, H. (2007). Quantitative trait loci for red blood cell traits in swine. Animal Genetics, 38(5), 447–452. https://doi.org/10.1111/j.1365-2052.2007.01629.x
- Reiner, G., Fischer, R., Hepp, S., Berge, T., Köhler, F., & Willems, H. (2008). Quantitative trait loci for white blood cell numbers in swine. Animal Genetics, 39(2), 163–168. https://doi.org/10.1111/j.1365-2052.2008.01700.x
- Renno, T., Krakowski, M., Piccirillo, C., Lin, J. Y., & Owens, T. (1995). Tnf-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. Journal of Immunology (Baltimore, Md. : 1950), 154(2), 944–953.
- Rezende, S. M., Lijfering, W. M., Rosendaal, F. R., & Cannegieter, S. C. (2014). Hematologic variables and venous thrombosis: Red cell distribution width and blood monocyte count are associated with an increased risk. Haematologica, 99(1), 194–200. https://doi.org/10.3324/haematol.2013.083840
- Roehe, R., Shrestha, N. P., Mekkawy, W., Baxter, E. M., Knap, P. W., Smurthwaite, K. M., Jarvis, S., Lawrence, A. B., & Edwards, S. A. (2010). Genetic parameters of piglet survival and birth weight from a two-generation crossbreeding experiment under outdoor conditions designed to disentangle direct and maternal effects. Journal of Animal Science, 88(4), 1276–1285. https://doi.org/10.2527/jas.2009-2287
- Rohrer, G. A., Rempel, L. A., Miles, J. R., Keele, J. W., Wiedmann, R. T., & Vallet, J. L. (2014). Identifying genetic loci controlling neonatal passive transfer of immunity using a hybrid genotyping strategy. Animal Genetics, 45(3), 340–349. https://doi.org/10.1111/age.12131
- Rooke, J., & Bland, I. (2002). The acquisition of passive immunity in the new-born piglet. Livestock Production Science, 78(1), 13–23. https://doi.org/10.1016/S0301-6226(02)00182-3
- Roth, K., Pröll-Cornelissen, M. J., Heuß, E. M., Dauben, C. M., Henne, H., Appel, A. K., Schellander, K., Tholen, E., & Große-Brinkhaus, C. (2022). Genetic parameters of immune traits for Landrace and Large White pig breeds. Journal of Animal Breeding and Genetics = Zeitschrift Fur Tierzuchtung Und Zuchtungsbiologie, 139(6), 695–709. https://doi.org/10.1111/jbg.12735
- Rutherford, K. M., Baxter, E. M., D'Eath, R. B., Turner, S. P., Arnott, G., Roehe, R., Ask, B., Sandøe, P., Moustsen, V. A., Thorup, F., Edwards, S. A., Berg, P., & Lawrence, A. B. (2013). The welfare implications of large litter size in the domestic pig I: Biological factors. Animal Welfare, 22(2), 199–218. https://doi.org/10.7120/09627286.22.2.199
- Salinas, Y. D., Wang, Z., & DeWan, A. T. (2018). Statistical Analysis of Multiple Phenotypes in Genetic Epidemiologic Studies: From Cross-Phenotype Associations to Pleiotropy. American Journal of Epidemiology, 187(4), 855–863. https://doi.org/10.1093/aje/kwx296

- Salmon, H., Berri, M., Gerdts, V., & Meurens, F. (2009). Humoral and cellular factors of maternal immunity in swine. Developmental and Comparative Immunology, 33(3), 384–393. https://doi.org/10.1016/j.dci.2008.07.007
- Schuijt, M. P., van Kats, J. P., Zeeuw, S. de, Duncker, D. J., Verdouw, P. D., Schalekamp, M. A., & Danser, A. H. (1999). Cardiac interstitial fluid levels of angiotensin I and II in the pig. Journal of Hypertension, 17(12 Pt 2), 1885–1891. https://doi.org/10.1097/00004872-199917121-00017
- Scutari, M. (2010). Learning Bayesian Networks with the bnlearnR Package. Journal of Statistical Software, 35(3). https://doi.org/10.18637/jss.v035.i03
- Scutari, M., Graafland, C. E., & Gutiérrez, J. M. (2019). Who learns better Bayesian network structures: Accuracy and speed of structure learning algorithms. International Journal of Approximate Reasoning, 115(3), 235–253. https://doi.org/10.1016/j.ijar.2019.10.003
- Scutari, M., Howell, P., Balding, D. J., & Mackay, I. (2014). Multiple quantitative trait analysis using bayesian networks. Genetics, 198(1), 129–137. https://doi.org/10.1534/genetics.114.165704
- Servin, B., & Stephens, M. (2007). Imputation-based analysis of association studies: Candidate regions and quantitative traits. PLoS Genetics, 3(7), e114. https://doi.org/10.1371/journal.pgen.0030114
- Shaun Purcell (2010). PLINK (1.07) Documentation.
- Sieroń, A. L., & Stańczak, P. (2006). Asd--lessons on genetic background from transgenic mice with inactive gene encoding metalloprotease, Tolloid-like 1 (TLL1). Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 12(1), RA17-22.
- Solovieff, N., Cotsapas, C., Lee, P. H., Purcell, S. M., & Smoller, J. W. (2013). Pleiotropy in complex traits: Challenges and strategies. Nature Reviews. Genetics, 14(7), 483–495. https://doi.org/10.1038/nrg3461
- Stephens, M. (2013). A unified framework for association analysis with multiple related phenotypes. PloS One, 8(7), e65245. https://doi.org/10.1371/journal.pone.0065245
- Theil, P. K., Lauridsen, C., & Quesnel, H. (2014). Neonatal piglet survival: Impact of sow nutrition around parturition on fetal glycogen deposition and production and composition of colostrum and transient milk. Animal : An International Journal of Animal Bioscience, 8(7), 1021–1030. https://doi.org/10.1017/S1751731114000950
- Tizard, I. R. (2013). Veterinary immunology (9th ed.). Elsevier/Saunders.
- Tuboly, S., Bernáth, S., Glávits, R., & Medveczky, I. (1988). Intestinal absorption of colostral lymphoid cells in newborn piglets. Veterinary Immunology and Immunopathology, 20(1), 75–85. https://doi.org/10.1016/0165-2427(88)90027-X
- Turley, P., Walters, R. K., Maghzian, O., Okbay, A., Lee, J. J., Fontana, M. A., Nguyen-Viet, T. A., Wedow, R., Zacher, M., Furlotte, N. A., Magnusson, P., Oskarsson, S., Johannesson, M., Visscher, P. M., Laibson, D., Cesarini, D., Neale, B. M., & Benjamin, D. J. (2018). Multi-trait analysis of genome-wide association summary

statistics using MTAG. Nature Genetics, 50(2), 229–237. https://doi.org/10.1038/s41588-017-0009-4

- Uddin, M. J., Cinar, M. U., Große-Brinkhaus, C., Tesfaye, D., Tholen, E., Juengst, H., Looft, C., Wimmers, K., Phatsara, C., & Schellander, K. (2011). Mapping quantitative trait loci for innate immune response in the pig. International Journal of Immunogenetics, 38(2), 121–131. https://doi.org/10.1111/j.1744-313X.2010.00985.x
- van der Sluis, S., Posthuma, D., & Dolan, C. V. (2013). Tates: Efficient multivariate genotype-phenotype analysis for genome-wide association studies. PLoS Genetics, 9(1), e1003235. https://doi.org/10.1371/journal.pgen.1003235
- van Rheenen, W., Peyrot, W. J., Schork, A. J., Lee, S. H., & Wray, N. R. (2019). Genetic correlations of polygenic disease traits: From theory to practice. Nature Reviews. Genetics, 20(10), 567–581. https://doi.org/10.1038/s41576-019-0137-z
- Vincent, A. L., Thacker, B. J., Halbur, P. G., Rothschild, M. F., & Thacker, E. L. (2005). In vitro susceptibility of macrophages to porcine reproductive and respiratory syndrome virus varies between genetically diverse lines of pigs. Viral Immunology, 18(3), 506– 512. https://doi.org/10.1089/vim.2005.18.506
- Vincent, A. L., Thacker, B. J., Halbur, P. G., Rothschild, M. F., & Thacker, E. L. (2006). An investigation of susceptibility to porcine reproductive and respiratory syndrome virus between two genetically diverse commercial lines of pigs. Journal of Animal Science, 84(1), 49–57. https://doi.org/10.2527/2006.84149x
- Viney, M. E., Riley, E. M., & Buchanan, K. L. (2005). Optimal immune responses: Immunocompetence revisited. Trends in Ecology & Evolution, 20(12), 665–669. https://doi.org/10.1016/j.tree.2005.10.003
- Visscher, A. H., Janss, L. L., Niewold, T. A., & Greef, K. H. de (2002). Disease incidence and immunological traits for the selection of healthy pigs. A review. The Veterinary Quarterly, 24(1), 29–34. https://doi.org/10.1080/01652176.2002.9695121
- Visscher, P. M., Brown, M. A., McCarthy, M. I., & Yang, J. (2012). Five years of GWAS discovery. American Journal of Human Genetics, 90(1), 7–24. https://doi.org/10.1016/j.ajhg.2011.11.029
- Vroom, C.-R., Leeuw, C. A. d., Posthuma, D., Dolan, C. V., & van der Sluis, S. (2019a). The more the merrier? Multivariate approaches to genome-wide association analysis. BioRxiv.
- Vroom, C.-R., Leeuw, C. de, Posthuma, D., Dolan, C. V., & van der Sluis, S. (2019b). The more the merrier? Multivariate approaches to genome-wide association analysis. Cold Spring Harbor Laboratory.
- Wang, J. Y., Luo, Y.-R., Fu, W. X., Lu, X., Zhou, J. P., Ding, X. D., Liu, J. F., & Zhang, Q. (2013). Genome-wide association studies for hematological traits in swine. Animal Genetics, 44(1), 34–43. https://doi.org/10.1111/j.1365-2052.2012.02366.x
- Weller, J. I., Wiggans, G. R., VanRaden, P. M., & Ron, M. (1996). Application of a canonical transformation to detection of quantitative trait loci with the aid of genetic markers in a multi-trait experiment. TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik, 92(8), 998–1002. https://doi.org/10.1007/BF00224040

- Wilkie, B. N., & Mallard, B. A. (1999). Selection for high immune response: An alternative approach to animal health maintenance? Veterinary Immunology and Immunopathology, 72(1-2), 231–235. https://doi.org/10.1016/S0165-2427(99)00136-1
- Williams, P. P. (1993). Immunomodulating effects of intestinal absorbed maternal colostral leukocytes by neonatal pigs. Canadian Journal of Veterinary Research = Revue Canadienne De Recherche Veterinaire, 57(1), 1–8.
- Wimmers, K., Murani, E., Schellander, K., & Ponsuksili, S. (2009). Qtl for traits related to humoral immune response estimated from data of a porcine F2 resource population. International Journal of Immunogenetics, 36(3), 141–151. https://doi.org/10.1111/j.1744-313X.2009.00838.x
- Yang, C., Li, C., Wang, Q., Chung, D., & Zhao, H. (2015). Implications of pleiotropy: Challenges and opportunities for mining Big Data in biomedicine. Frontiers in Genetics, 6, 229. https://doi.org/10.3389/fgene.2015.00229
- Yang, J., Lee, S. H., Goddard, M. E., & Visscher, P. M. (2011). Gcta: A tool for genome-wide complex trait analysis. American Journal of Human Genetics, 88(1), 76–82. https://doi.org/10.1016/j.ajhg.2010.11.011
- Yang, Q., & Wang, Y. (2012). Methods for Analyzing Multivariate Phenotypes in Genetic Association Studies. Journal of Probability and Statistics, 2012(358), 1–13. https://doi.org/10.1155/2012/652569
- Yang, S., Ren, J., Yan, X., Huang, X., Zou, Z., Zhang, Z., Yang, B., & Huang, L. (2009). Quantitative trait loci for porcine white blood cells and platelet-related traits in a White Duroc x Erhualian F resource population. Animal Genetics, 40(3), 273–278. https://doi.org/10.1111/j.1365-2052.2008.01830.x
- Zelterman, D. (2015). Applied multivariate statistics with R. Statistics for biology and health. Springer. http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1048 543
- Zhang, F., Zhang, Z., Yan, X., Chen, H., Zhang, W., Hong, Y., & Huang, L. (2014). Genomewide association studies for hematological traits in Chinese Sutai pigs. BMC Genetics, 15, 41. https://doi.org/10.1186/1471-2156-15-41
- Zhang, Z., Hong, Y., Gao, J., Xiao, S., Ma, J., Zhang, W., Ren, J., & Huang, L. (2013). Genome-wide association study reveals constant and specific loci for hematological traits at three time stages in a White Duroc × Erhualian F2 resource population. PloS One, 8(5), e63665. https://doi.org/10.1371/journal.pone.0063665
- Zhao, C.-Y., Guo, Z.-J., Dai, S.-M., Zhang, Y., & Zhou, J.-J. (2013). Clinicopathological and prognostic significance of myofibrillogenesis regulator-1 protein expression in pancreatic ductal adenocarcinoma. Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine, 34(5), 2983–2987. https://doi.org/10.1007/s13277-013-0862-4
- Zhou, X., & Stephens, M. (2014a). Efficient multivariate linear mixed model algorithms for genome-wide association studies. Nature Methods, 11(4), 407–409. https://doi.org/10.1038/nmeth.2848

- Zhou, X., & Stephens, M. (2014b). Efficient multivariate linear mixed model algorithms for genome-wide association studies. Nature Methods, 11, 407 EP -.
- Zhu, W., & Zhang, H. (2009). Why Do We Test Multiple Traits in Genetic Association Studies? Journal of the Korean Statistical Society, 38(1), 1–10. https://doi.org/10.1016/j.jkss.2008.10.006
- Zimmerman, J., Karriker, L., Ramirez, A., Schwartz, K., & Stevenson, G. (2012). Diseases of Swine (10th ed.). John Wiley & Sons. http://site.ebrary.com/lib/alltitles/docDetail.action?docID=10538663
- Zou, Z., Ren, J., Yan, X., Huang, X., Yang, S., Zhang, Z., Yang, B., Li, W., & Huang, L. (2008). Quantitative trait loci for porcine baseline erythroid traits at three growth ages in a White Duroc x Erhualian F(2) resource population. Mammalian Genome : Official Journal of the International Mammalian Genome Society, 19(9), 640–646. https://doi.org/10.1007/s00335-008-9142-9

Chapter 9. Appendix

| | | | Landra | ace | | | | Large | e White | | | Ι | andrace | and Large W | hite |
|-------------|-------|--------|--------|--------|--------------|-------|--------|-------|---------|--------------|-------|--------|-------------------|----------------------|------------------------------|
| Trait | HYSS | Parity | Age | Weight | Age x weight | HYSS | Parity | Age | Weight | Age x weight | HYSS | Parity | (Age x breed)* | (Weight x breed)* | ((Breed x age) x weight)* |
| RBC | 0.000 | 0.277 | 0.204 | 0.047 | 0.196 | 0.000 | 0.900 | 0.190 | 0.467 | 0.004 | 0.000 | 0.695 | 0.237 | 0.098 | 0.005 |
| Hemoglobin | 0.000 | 0.727 | 0.675 | 0.000 | 0.102 | 0.000 | 0.748 | 0.005 | 0.126 | 0.004 | 0.000 | 0.808 | 0.014 | 0.000 | 0.003 |
| Hematocrit | 0.000 | 0.729 | 0.939 | 0.001 | 0.265 | 0.000 | 0.783 | 0.048 | 0.065 | 0.001 | 0.000 | 0.723 | 0.143 | 0.001 | 0.002 |
| MCV | 0.000 | 0.074 | 0.017 | 0.004 | 0.658 | 0.000 | 0.322 | 0.088 | 0.010 | 0.179 | 0.000 | 0.143 | 0.022 | 0.001 | 0.361 |
| MCH | 0.015 | 0.032 | 0.007 | 0.000 | 0.732 | 0.285 | 0.375 | 0.002 | 0.064 | 0.934 | 0.057 | 0.088 | 0.000 | 0.000 | 0.954 |
| MCHC | 0.000 | 0.477 | 0.351 | 0.014 | 0.432 | 0.000 | 0.534 | 0.011 | 0.338 | 0.044 | 0.000 | 0.275 | 0.062 | 0.012 | 0.177 |
| Platelets | 0.000 | 0.492 | 0.006 | 0.267 | 0.982 | 0.001 | 0.224 | 0.446 | 0.776 | 0.737 | 0.000 | 0.549 | 0.049 | 0.383 | 0.895 |
| WBC | 0.000 | 0.418 | 0.000 | 0.101 | 0.194 | 0.000 | 0.104 | 0.956 | 0.774 | 0.199 | 0.000 | 0.302 | 0.007 | 0.224 | 0.178 |
| Neutrophils | 0.001 | 0.537 | 0.971 | 0.001 | 0.350 | 0.002 | 0.848 | 0.797 | 0.000 | 0.364 | 0.000 | 0.575 | 0.930 | 0.000 | 0.449 |
| Lymphocytes | 0.000 | 0.459 | 0.898 | 0.022 | 0.410 | 0.000 | 0.640 | 0.906 | 0.000 | 0.510 | 0.000 | 0.306 | 0.959 | 0.000 | 0.591 |
| Monocytes | 0.000 | 0.018 | 0.090 | 0.000 | 0.304 | 0.000 | 0.465 | 0.599 | 0.001 | 0.536 | 0.000 | 0.031 | 0.201 | 0.000 | 0.534 |
| Eosinophils | 0.021 | 0.108 | 0.601 | 0.016 | 0.514 | 0.002 | 0.018 | 0.560 | 0.463 | 0.058 | 0.012 | 0.181 | 0.785 | 0.009 | 0.225 |
| Basophils | 0.027 | 0.475 | 0.076 | 0.838 | 0.197 | 0.011 | 0.006 | 0.303 | 0.985 | 0.673 | 0.024 | 0.421 | 0.040 | 0.743 | 0.354 |
| Haptoglobin | 0.000 | 0.795 | 0.000 | 0.941 | 0.000 | 0.000 | 0.747 | 0.061 | 0.177 | 0.765 | 0.000 | 0.723 | 0.000 | 0.355 | 0.000 |
| IFN-γ | 0.000 | 0.000 | 0.668 | 0.101 | 0.106 | 0.000 | 0.367 | 0.143 | 0.730 | 0.757 | 0.000 | 0.000 | 0.186 | 0.164 | 0.187 |
| IL-10 | 0.000 | 0.001 | 0.385 | 0.150 | 0.143 | 0.000 | 0.000 | 0.653 | 0.294 | 0.267 | 0.000 | 0.000 | 0.754 | 0.158 | 0.147 |
| IL-12 | 0.000 | 0.025 | 0.648 | 0.430 | 0.423 | 0.001 | 0.195 | 0.781 | 0.749 | 0.700 | 0.000 | 0.065 | 0.904 | 0.897 | 0.874 |
| IL-1β | 0.000 | 0.063 | 0.055 | 0.010 | 0.009 | 0.000 | 0.001 | 0.449 | 0.718 | 0.634 | 0.000 | 0.000 | 0.298 | 0.050 | 0.043 |
| IL-4 | 0.000 | 0.002 | 0.163 | 0.046 | 0.045 | 0.000 | 0.000 | 0.401 | 0.675 | 0.544 | 0.000 | 0.000 | 0.426 | 0.151 | 0.131 |
| IL-6 | 0.000 | 0.016 | 0.289 | 0.139 | 0.138 | 0.000 | 0.000 | 0.300 | 0.693 | 0.666 | 0.000 | 0.000 | 0.428 | 0.285 | 0.281 |
| IL-8 | 0.057 | 0.103 | 0.801 | 0.288 | 0.232 | 0.046 | 0.178 | 0.529 | 0.084 | 0.101 | 0.005 | 0.075 | 0.939 | 0.237 | 0.239 |
| TNF-α | 0.000 | 0.036 | 0.896 | 0.171 | 0.184 | 0.000 | 0.046 | 0.581 | 0.768 | 0.688 | 0.000 | 0.023 | 0.828 | 0.316 | 0.326 |

Table S 1: ANOVA p-values for fixed effects in piglet data set

 $HYSS=herd-year-season-sex, RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN-<math>\gamma$ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , x=interaction, *=nested effect, cytokines and haptoglobin were log-transformed

| | | | | Piglet | data s | set | | | | Dam d | lata s | et | |
|------------------------|----------|-----|-------------------------|--------------|--------|---------------------------|--------------|-----|--------------------|--------------|--------|--------------------|--------------|
| Trait | Unit | | Landrac | e | | Large Wh | ite | | Landra | ce | | Large W | hite |
| | | Ν | Mean±SD | Min-Max | Ν | Mean±SD | Min-Max | Ν | Mean±SD | Min-Max | Ν | Mean±SD | Min-Max |
| Flow cytometry | | | | | | | | | | | | | |
| RBC | T/1 | 611 | $6.35{\pm}0.66^{a}$ | 3.50-8.51 | 533 | 6.07 ± 0.75^{b} | 2.30-8.10 | 298 | 5.65 ± 0.6 | 2.14-8.29 | 272 | 5.67 ± 0.80 | 1.71-7.67 |
| Hemoglobin | g/l | 611 | $119.2{\pm}13.26^{a}$ | 67.00-158.00 | 533 | 108.86±14.31 ^b | 41.00-150.00 | 298 | 115.47 ± 10.68 | 44.00-165.00 | 272 | 115.39 ± 15.27 | 34.00-152.00 |
| Hematocrit | 1/1 | 611 | $0.40{\pm}0.04^{a}$ | 0.21-0.54 | 533 | $0.36{\pm}0.05^{b}$ | 0.13-0.47 | 298 | 0.36 ± 0.03 | 0.12-0.52 | 272 | $0.36{\pm}0.05$ | 0.10-0.48 |
| MCV | fl | 611 | 62.16±3.12 ^a | 53.60-71.00 | 533 | 58.56±3.13 ^b | 50.00-68.20 | 298 | 63.68±3.18 | 56.30-75.50 | 272 | 62.79±3.54 | 54.00-76.60 |
| MCH | pg | 611 | 18.8 ± 1.16^{a} | 11.30-30.20 | 533 | 17.94 ± 0.98^{b} | 15.20-22.80 | 298 | 20.51 ± 1.05 | 18.00-23.90 | 272 | $20.40{\pm}1.08$ | 17.20-23.60 |
| MCHC | g/dl | 611 | $30.26{\pm}1.6^{a}$ | 17.80-48.60 | 533 | 30.67 ± 1.11^{b} | 27.10-36.00 | 298 | 32.22 ± 0.94 | 28.70-35.40 | 272 | 32.51 ± 0.85 | 30.00-35.30 |
| Platelets | G/l | 611 | 338.67±134.55ª | 24.00-783.00 | 533 | $346.88{\pm}146.18^{a}$ | 14.00-830.00 | 298 | 273.92 ± 92.55 | 17.00-543.00 | 272 | 270.75 ± 91.64 | 6.00-580.00 |
| WBC | G/l | 611 | $19.74{\pm}4.98^{a}$ | 5.70-49.00 | 533 | 19.13 ± 5.78^{a} | 4.50-45.70 | 298 | 14.31±3.2 | 3.40-30.50 | 272 | 12.92 ± 3.30 | 3.90-25.80 |
| Neutrophils | % | 611 | 47.64 ± 9.98^{a} | 18.00-87.00 | 533 | 41.48 ± 10.67^{b} | 3.00-74.00 | 298 | 58.58 ± 8.06 | 33.00-86.00 | 272 | $53.85{\pm}10.15$ | 8.00-86.00 |
| Lymphocytes | % | 611 | $45.84{\pm}9.98^{a}$ | 10.00-74.00 | 533 | 52.89±10.51 ^b | 22.00-93.00 | 298 | 31.43±6.96 | 10.00-55.00 | 272 | 37.46 ± 8.72 | 12.00-67.00 |
| Monocytes | % | 611 | $3.53{\pm}1.65^{a}$ | 0.00-10.00 | 533 | $3.57{\pm}1.86^{a}$ | 0.00-14.00 | 298 | 3.64 ± 1.44 | 1.00-9.00 | 272 | 3.98 ± 3.17 | 0.00-50.00 |
| Eosinophils | % | 611 | 2.78 ± 1.57^{a} | 0.00-13.00 | 533 | 1.88 ± 1.12^{a} | 0.00-8.00 | 298 | 6.01±2.91 | 1.00-21.00 | 272 | 4.43±2.09 | 0.00-18.00 |
| Basophils | % | 611 | $0.15{\pm}0.37^{a}$ | 0.00-2.00 | 533 | 0.07 ± 0.26^{b} | 0.00-2.00 | 298 | 0.21 ± 0.43 | 0.00-2.00 | 272 | 0.11 ± 0.31 | 0.00-1.00 |
| Band cells | % | 611 | $0.00{\pm}0.04^{a}$ | 0.00-1.00 | 533 | 0.01 ± 0.17^{b} | 0.00-4.00 | 298 | 0.00 ± 0.00 | 0.00-0.00 | 272 | 0.00 ± 0.06 | 0.00-1.00 |
| Other cells | % | 611 | $0.01{\pm}0.12^{a}$ | 0.00-1.00 | 533 | $0.01{\pm}0.11^{a}$ | 0.00-1.00 | 298 | 0.02 ± 0.16 | 0.00-1.00 | 272 | 0.00 ± 0.06 | 0.00-1.00 |
| Spectrophotomet | ry | | | | | | | | | | | | |
| Haptoglobin | mg/ml | 610 | $0.62{\pm}0.52^{a}$ | 0.30-2.50 | 531 | $0.72{\pm}0.64^{a}$ | 0.30-7.20 | 298 | 1.81 ± 0.5 | 0.31-2.50 | 272 | 1.92 ± 0.53 | 0.30-2.50 |
| Multiplex Magne | tic Bead | | | | | | | | | | | | |
| IFN-γ | ng/ml | 522 | $10.89{\pm}20.12^{a}$ | 0.06-109.65 | 456 | $8.88{\pm}18.86^{a}$ | 0.06-129.14 | 261 | 31.8±36.72 | 0.06-182.76 | 231 | 22.94±26.64 | 0.06-111.07 |
| IL-10 | ng/ml | 534 | 1.66 ± 3.09^{a} | 0.01-15.61 | 461 | 1.32±2.73 ^b | 0.01-25.66 | 257 | 10.57±31.68 | 0.06-388.22 | 232 | 5.50 ± 5.30 | 0.01-38.23 |
| IL-12 | ng/ml | 534 | $0.66{\pm}0.47^{a}$ | 0.08-2.82 | 461 | $0.84{\pm}0.42^{b}$ | 0.13-3.13 | 259 | 1.32 ± 1.45 | 0.08-14.07 | 234 | 1.06 ± 0.74 | 0.10-3.97 |
| IL-1β | ng/ml | 534 | $1.04{\pm}1.6^{a}$ | 0.06-9.04 | 461 | 0.83 ± 1.41^{b} | 0.06-9.56 | 256 | 4.15±5.21 | 0.06-55.87 | 231 | 2.93 ± 2.30 | 0.06-10.28 |
| IL-4 | ng/ml | 534 | 3.21 ± 7.43^{a} | 0.03-39.94 | 461 | $2.46{\pm}6.6^{a}$ | 0.03-63.22 | 260 | 19.81±32.18 | 0.03-250.00 | 232 | 11.61 ± 13.14 | 0.03-63.33 |
| IL-6 | ng/ml | 534 | 0.56 ± 1.14^{a} | 0.01-6.94 | 461 | 0.46 ± 1.15^{b} | 0.01-11.94 | 261 | 4.98±13.67 | 0.02-103.66 | 235 | 2.02±2.38 | 0.01-16.39 |
| IL-8 | ng/ml | 534 | 0.71 ± 0.75^{a} | 0.01-8.28 | 461 | $0.60{\pm}0.71^{b}$ | 0.02-7.70 | 265 | 0.54 ± 0.94 | 0.01-10.61 | 235 | 0.22 ± 0.28 | 0.01-2.15 |
| TNF-α | ng/ml | 534 | $0.35{\pm}0.88^{\rm a}$ | 0.01-5.40 | 461 | $0.20{\pm}0.58^{a}$ | 0.01-5.40 | 264 | 1.36±2.58 | 0.01-20.69 | 235 | 0.54 ± 0.88 | 0.01-4.68 |

| Table S 2: Immune variables and their correspondent summa | ry statistics for Landrace and Large White piglet | s and dams. |
|-----------------------------------------------------------|---------------------------------------------------|-------------|
|-----------------------------------------------------------|---------------------------------------------------|-------------|

RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , Means with different letters (a, b) differ significantly at the 5% level.

Appendix

| | RBC | Hemo- globin | Hema- tocrit | MCV | МСН | MCHC | Platelets | WBC | Neutro- phils | Lympho- cytes | Mono- cytes | Eosino- phils | Baso- phils | Hapto- globin | IFN-γ | IL-10 | IL-12 | IL-1β | IL-4 | IL-6 | IL-8 | TNF-α |
|------------------|-------|-----------------|-----------------|--------------------|---------------|--------------------|----------------|-----------------|------------------|------------------|----------------|------------------|----------------|------------------|-----------------|-----------------|--------------------|-----------------|-----------------|-----------------|--------------------|-----------------|
| DDC | 0.41 | 0.81 | 0.82 | -0.21 | -0.38 | -0.87 | -0.18 | 0.51 | -0.29 | 0.26 | 0.34 | 0.14 | -0.16 | -0.47 | 0.49 | 0.43 | 0.01 | 0.40 | 0.36 | 0.21 | 0.36 | 0.61 |
| квс | ±0.10 | ± 0.06 | ± 0.05 | ± 0.19 | ± 0.20 | ± 0.43 | ± 0.30 | ± 0.28 | ± 0.12 | ± 0.12 | ± 0.2 | ± 0.41 | ± 0.54 | ± 0.37 | ± 0.29 | ± 0.31 | ± 0.29 | ± 0.43 | ± 0.36 | ± 0.33 | ± 0.35 | ± 0.17 |
| Hemo- | 0.83 | 0.41 | 0.99 | 0.39 | 0.24 | -0.86 | -0.34 | 0.27 | -0.15 | 0.08 | 0.50 | 0.13 | 0.04 | -0.12 | 0.71 | 0.71 | 0.09 | 0.73 | 0.69 | 0.56 | 0.32 | 0.65 |
| globin | | ±0.11 | ± 0.00 | ±0.15 | ±0.07 | ±0.46 | ±0.33 | ±0.16 | ±0.17 | ±0.16 | ±0.21 | ±0.27 | ±0.30 | ±0.26 | ±0.23 | ±0.25 | ±0.28 | ±0.44 | ±0.28 | ±0.27 | ±0.37 | ±0.16 |
| Hema- tocrit | 1.00 | 1.00 | 0.43 ±0.11 | 0.37 ± 0.14 | 0.24 ±0.14 | -0.8 4 ± 0.44 | -0.39 ±0.35 | 0.26 ± 0.14 | -0.17 ±0.16 | 0.11 ± 0.15 | 0.46 ± 0.2 | 0.12 ± 0.27 | -0.09 ±0.22 | -0.04 ±0.26 | 0.68 ± 0.22 | 0.69 ± 0.25 | 0.07 ± 0.27 | 0.66 ± 0.32 | 0.69 ± 0.23 | 0.52 ± 0.23 | 0.37 ± 0.29 | 0.61 ± 0.17 |
| NOU | 0.16 | 0.04 | 0.25 | 0.53 | 0.99 | 0.02 | -0.30 | -0.30 | 0.18 | -0.21 | 0.14 | 0.06 | 0.12 | 0.16 | 0.47 | 0.55 | 0.14 | 0.42 | 0.66 | 0.62 | 0.03 | 0.12 |
| MCV | -0.16 | 0.24 | 0.35 | ±0.1 | ± 0.02 | ± 0.72 | ± 0.21 | ± 0.16 | ± 0.19 | ± 0.22 | ± 0.18 | ± 0.18 | ± 0.17 | ± 0.18 | ± 0.24 | ± 0.27 | ± 0.21 | ± 0.32 | ± 0.21 | ± 0.18 | ± 0.24 | ± 0.19 |
| МСН | -0.29 | 0.29 | 0.06 | 0.67 | 0.41 | 0.09 | -0.24 | -0.26 | 0.29 | -0.30 | 0.24 | 0.08 | 0.26 | 0.13 | 0.40 | 0.49 | 0.13 | 0.52 | 0.71 | 0.54 | -0.07 | 0.12 |
| | | | | | ±0.08 | ±0.57 | ± 0.16 | ± 0.20 | ±0.20 | ± 0.15 | ± 0.13 | ±0.17 | ±0.17 | ± 0.23 | ± 0.14 | ±0.22 | ±0.21 | ± 0.36 | ±0.27 | ±0.21 | ±0.26 | ± 0.2 |
| MCHC | -0.15 | 0.12 | -0.33 | -0.26 | 0.57 | 0.02 +0.02 | 0.35 + 0.40 | 0.61 + 0.38 | 0.41 + 0.54 | -0.44 +0.22 | 0.64 + 0.43 | 0.09 +0.25 | 0.97 | -0.11 +0.31 | 0.31 +0.32 | 0.21 +0.27 | 0.17 +0.42 | 0.43 +1.12 | 0.20 + 1.04 | -0.16 +1.12 | -0.54 +0.4 | 0.10 + 0.28 |
| Plate- | | | | | | _0.02 | 0.24 | -0.19 | -0.40 | 0.35 | -0.12 | -0.26 | 0.05 | -0.32 | 0.30 | 0.21 | 0.18 | 0.33 | 0.20 | 0.42 | 0.48 | 0.14 |
| lets | 0.03 | -0.04 | -0.01 | -0.05 | -0.12 | -0.1 | ±0.08 | ± 0.28 | ±0.27 | ± 0.18 | ±0.22 | ±0.19 | ± 0.19 | ± 0.28 | ± 0.28 | ±0.25 | ±0.32 | ± 0.34 | ± 0.40 | ±0.25 | ±0.33 | ±0.25 |
| WBC | 0.18 | 0.13 | 0.19 | 0.00 | -0.06 | -0.09 | 0.13 | 0.18 | 0.62 | -0.71 | -0.27 | 0.42 | -0.25 | 0.14 | 0.43 | -0.11 | 0.00 | 0.23 | 0.13 | -0.11 | 0.18 | -0.04 |
| | | | , | | | | | ±0.06 | ±0.23 | ±0.25 | ±0.14 | ±0.25 | ±0.17 | ±0.22 | ±0.26 | ±0.22 | ±0.22 | ±0.25 | ±0.31 | ±0.23 | ±0.28 | ±0.2 |
| Neutro- nhils | -0.14 | -0.11 | -0.14 | 0.03 | 0.06 | 0.05 | -0.09 | 0.28 | 0.25 +0.08 | -0.98 +0.01 | -0.28 +0.20 | 0.64 +0.16 | -0.48 +0.17 | -0.03 +0.20 | -0.03 +0.25 | +0.01 +0.43 | -0.10 +0.36 | 0.10 +0.60 | 0.00 + 0.52 | -0.26 +0.26 | -0.57 +0.27 | -0.43 +0.19 |
| Lympho- | | 0.10 | 0.10 | 0 0 - | 0.00 | . | 0.10 | | _0.00 | 0.30 | 0.12 | -0.82 | 0.36 | 0.18 | -0.18 | -0.05 | 0.20 | -0.03 | -0.08 | 0.10 | 0.28 | 0.18 |
| cytes | 0.14 | 0.10 | 0.13 | -0.05 | -0.08 | -0.05 | 0.12 | -0.23 | -0.97 | ±0.08 | ±0.18 | ±0.17 | ± 0.17 | ±0.29 | ±0.25 | ±0.31 | ±0.20 | ±0.35 | ±0.32 | ±0.16 | ±0.25 | ±0.17 |
| Mono- | 0.00 | 0.03 | 0.04 | 0.04 | 0.06 | 0.01 | 0.02 | -0.09 | -0.17 | 0.01 | 0.32 | -0.16 | 0.23 | 0.02 | 0.65 | 0.26 | -0.28 | 0.42 | 0.56 | 0.44 | 0.83 | 0.53 |
| cytes | 0100 | 0.02 | 0101 | 0.01 | 0.000 | 0101 | 0102 | 0105 | 0117 | 0101 | ±0.09 | ±0.2 | ±0.21 | ±0.22 | ±0.22 | ±0.28 | ±0.19 | ±0.30 | ±0.25 | ±0.24 | ±0.17 | ±0.15 |
| Eosino- nhils | 0.00 | 0.02 | 0.00 | 0.02 | 0.01 | 0.01 | -0.24 | -0.22 | 0.05 | -0.22 | 0.01 | 0.22 +0.08 | 0.37 +0.23 | -0.5 6+0.25 | 0.47 | 0.29 +0.29 | -0.21 +0.18 | -0.08 +0.32 | 0.04 + 0.31 | 0.19 +0.24 | 0.05 + 0.30 | 0.40 + 0.20 |
| Baso- | | | | | | | | | | | | -0.00 | 0.22 | -0.14 | 0.7 | 0.48 | 0.47 | 0.49 | 0.63 | 0.53 | 0.71 | 0.30 |
| phils | 0.03 | 0.07 | 0.09 | 0.04 | 0.06 | 0.00 | 0.03 | -0.02 | -0.17 | 0.10 | 0.18 | 0.06 | ±0.08 | ±0.21 | 3±0.18 | ±0.28 | ±0.26 | ±0.40 | ±0.36 | ±0.29 | ±0.29 | ±0.23 |
| Hapto- | 0.00 | -0.08 | -0.12 | -0.11 | -0.12 | -0.03 | 0.01 | 0.21 | 0.14 | -0.14 | 0.06 | 0.00 | 0.01 | 0.18 | -0.13 | -0.86 | -0.62 | -0.89 | -0.96 | -0.73 | 0.12 | -0.48 |
| globin | 0.00 | 0.00 | 0.12 | 0.11 | 0.12 | 0.05 | 0.01 | 0.21 | 0.11 | 0.11 | 0.00 | 0.00 | 0.01 | ±0.07 | ±0.36 | ±0.16 | ±0.29 | ±0.13 | ±0.10 | ±0.18 | ±0.33 | ±0.19 |
| IFN-γ | 0.09 | 0.12 | 0.13 | 0.08 | 0.04 | -0.04 | 0.02 | -0.01 | -0.10 | 0.08 | -0.03 | 0.05 | 0.11 | -0.05 | 0.22 +0.08 | 0.73 + 0.13 | -0.37 +0.22 | 0.61 + 0.65 | 0.63 + 0.42 | 0.88 + 0.16 | 0.87 + 0.23 | 0.78 + 0.11 |
| | | | | | | | | | | | | | | | ±0.00 | 0.15 | 0.22 | ± 0.05 | 1.00 | £0.10 | 0.72 | 0.91 |
| IL-10 | 0.11 | 0.15 | 0.16 | 0.12 | 0.08 | -0.03 | 0.03 | 0.00 | -0.14 | 0.12 | 0.00 | 0.03 | 0.15 | -0.08 | 0.64 | ±0.10 | ±0.34 | ±0.06 | ±0.01 | ±0.02 | ±0.17 | ±0.07 |
| П_12 | 0.02 | 0.04 | 0.02 | 0.02 | 0.04 | 0.04 | 0.00 | 0.04 | -0.03 | 0.03 | -0.04 | 0.01 | 0.06 | 0.00 | -0.17 | 0.18 | 0.34 | 0.35 | 0.38 | 0.34 | -0.43 | 0.12 |
| 1112 | 0.02 | 0.04 | 0.02 | 0.02 | 0.04 | 0.04 | 0.00 | 0.04 | -0.05 | 0.05 | -0.04 | 0.01 | 0.00 | 0.00 | -0.17 | 0.10 | ±0.13 | ±0.37 | ±0.32 | ±0.28 | ±0.28 | ±0.28 |
| IL-1β | 0.12 | 0.16 | 0.14 | 0.05 | 0.05 | 0.02 | 0.00 | 0.07 | -0.04 | 0.02 | -0.01 | 0.06 | 0.10 | 0.00 | 0.53 | 0.85 | 0.25 | 0.17 | 0.97 | 0.93 | 0.64 | 0.96 ± 0.06 |
| - | | | | | | | | | | | | | | | | | | ±0.09 | ±0.04 | ±0.00 | ± 0.38 0.70 | ±0.00 |
| IL-4 | 0.07 | 0.11 | 0.11 | 0.09 | 0.06 | -0.02 | 0.01 | -0.02 | -0.12 | 0.10 | 0.04 | 0.07 | 0.13 | -0.13 | 0.59 | 0.89 | 0.23 | 0.82 | ±0.09 | ±0.03 | ±0.28 | ±0.09 |

| T 11 / | α | D ' | • • | · • | 1 | C | • | • 1 | 1 . | т | 1 | • 1 | |
|----------|------------|-------|----------|---------|--------------|-----|---------|--------|---------|---------|--------|-------|------|
| I oblo ' | x 4 | · µ01 | 1111100 | anotic | correlatione | tor | immiina | Vorioh | 10C 11 | า I อท/ | draca. | 10101 | otc |
| Iauro | J.J. | . I a | 11 W 15C | genetic | conciations | IUI | mmune | variau | וו בסוי | | Juace | וצוט | ULS. |
| | | | | 0 | | | | | | | | F-0- | |

| | | | | | | | | | | Appen | ıdix | | | | | | | | | | | |
|-------|------|------|------|-------|------|-------|-------|-------|-------|-------|------|------|------|-------|------|------|------|------|------|---------------|---------------|---------------|
| | | | | | | | | | | | | | | | | | | | | | | |
| IL-6 | 0.09 | 0.14 | 0.13 | 0.10 | 0.07 | -0.02 | 0.03 | 0.03 | -0.14 | 0.12 | 0.00 | 0.05 | 0.14 | -0.08 | 0.62 | 0.92 | 0.16 | 0.81 | 0.84 | 0.35 ±0.09 | 0.73 ±0.22 | 0.80 ±0.09 |
| IL-8 | 0.10 | 0.12 | 0.10 | -0.01 | 0.02 | 0.05 | -0.05 | -0.18 | -0.16 | 0.13 | 0.02 | 0.08 | 0.09 | -0.12 | 0.15 | 0.12 | 0.02 | 0.14 | 0.11 | 0.10 | 0.15 ±0.08 | 0.65 ±0.23 |
| TNF-α | 0.10 | 0.12 | 0.12 | 0.05 | 0.03 | -0.02 | 0.00 | 0.02 | -0.08 | 0.06 | 0.07 | 0.02 | 0.04 | -0.08 | 0.56 | 0.58 | 0.11 | 0.55 | 0.57 | 0.58 | 0.14 | 0.61 ±0.09 |

Bold font indicates heritabilities ($h^2\pm SE$) on the diagonal. Phenotypic correlations (r_p) under the diagonal and genetic correlations ($r_g\pm SE$) above the diagonal RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , NA=not available.

Appendix

| | RBC | Hemo- globin | Hema- tocrit | MCV | МСН | МСНС | Platelets | WBC | Neutro- phils | Lympho- cytes | Mono- cytes | Eosino- phils | Baso- phils | Hapto- globin | IFN-γ | IL-10 | IL-12 | IL-1β | IL-4 | IL-6 | IL-8 | TNF-α |
|------------------|-------|-----------------|-----------------|------------|------------|------------|--------------------|--------------------------|------------------|------------------|---------------------|--------------------------|--------------------------|------------------|--------------------------|--------------------------|--------------------------|-----------------------|--------------------------|--------------------------|-----------------------|--------------------------|
| RBC | 0.36 | 0.77 | 0.90 | -0.99 | -0.64 | 0.43 | 0.23 | 0.33 | -0.16 | 0.29 | -0.35 | -0.70 | -0.24 | 0.17 | 0.56 | 0.46 | 0.77 | 0.75 | 0.50 | 0.74 | 0.00 | 0.96 |
| Hama | ±0.08 | ±0.10 | ±0.09 | ± 0.00 | ± 0.24 | ±0.26 | ± 0.88 0.79 | ± 0.30 | ± 0.14 | ± 0.14 | ±0.17 | ± 0.20 | ± 0.74 | ±0.59 | ± 0.24 | ±0.35 | ±0.33 | ± 0.30 | ± 0.38 | ± 0.28 | ± 0.17 | ± 0.10 |
| globin | 0.00 | ± 0.08 | ±0.04 | ±0.24 | ±0.35 | ±0.12 | ±0.55 | ±0.36 | ±0.13 | ±0.27 | ± 0.30 | ± 0.32 | ±0.67 | ± 0.62 | ± 0.32 | ±0.38 | ±0.28 | ±0.43 | ±0.48 | ±0.39 | ±0.17 | ±0.20 |
| Hema- | 1.00 | 1.00 | 0.09 | -0.55 | -0.34 | 0.87 | 0.65 | 0.04 | -0.04 | 0.07 | -0.25 | -0.82 | 0.17 | 0.01 | 0.40 | -0.02 | 0.78 | 0.10 | 0.03 | 0.69 | 0.22 | 0.88 |
| tocrit | | | ± 0.06 | ± 0.30 | ± 0.35 | ±0.21 | ± 0.70 | ± 0.42 | ± 0.27 | ± 0.3 | ± 0.35 | ± 0.37 | ± 0.71 | ± 0.60 | ± 0.34 | ± 0.47 | ± 0.32 | ± 0.42 | ± 0.32 | ± 0.81 | ± 0.25 | ± 0.16 |
| MOV | -0.23 | 0.16 | 0.25 | 0.61 | 0.94 | 0.18 | 0.67 | -0.46 | 0.19 | -0.34 | 0.49 | 0.65 | 0.19 | -0.27 | -0.58 | -0.69 | -0.44 | -0.90 | -0. | -0.80 | 0.16 | -0.87 |
| MCV | | | | ± 0.1 | ± 0.03 | ±0.23 | ± 0.88 | ± 0.36 | ±0.26 | ±0.21 | ±0.23 | ± 0.38 | ±0.47 | ±0.4 | ±0.19 | ±0.21 | ±0.25 | ±0.16 | 79 +0.15 | ±0.13 | ±0.15 | ±0.17 |
| мен | -0.26 | 0.23 | 0.09 | 0.79 | 0.66 | 0.49 | 0.79 | -0.60 | 0.20 | -0.45 | 0.62 | 0.45 | 0.45 | -0.38 | -0.47 | -0.71 | -0.12 | -0.84 | -0.66 | -0.73 | 0.19 | -0.58 |
| мсн | | | | | ± 0.12 | ± 0.20 | ± 0.50 | ± 0.30 | ± 0.22 | ± 0.20 | ± 0.21 | ± 0.24 | ± 0.44 | ± 0.42 | ± 0.20 | ± 0.24 | ± 0.25 | ± 0.17 | ± 0.17 | ± 0.20 | ± 0.17 | ± 0.17 |
| мснс | -0.16 | 0.12 | -0.20 | -0.24 | 0.40 | 0.15 | 0.57 | -0.28 | -0.03 | -0.11 | 0.93 | -0.24 | 0.94 | -0.31 | 0.17 | 0.07 | 0.72 | -0.07 | 0.25 | 0.14 | 0.08 | 0.48 |
| Dista | 0.10 | 0.14 | 0.17 | 0.05 | 0.12 | ± 0.07 | ±0.91 | ± 0.43 | ± 0.43 | ± 0.30 | ± 0.24 | ± 0.34 | ± 0.26 | ± 0.63 | ± 0.32 | ± 0.41 | ± 0.27 | ± 0.33 | ± 0.21 | ±0.21 | ± 0.26 | ± 0.22 |
| Plate- | 0.19 | 0.14 | 0.17 | -0.05 | -0.12 | -0.14 | ±0.01 | ± 0.54 ± 0.65 | ±1.03 | ± 0.65 | ±0.10 | ±0.18 | ± 0.50 ± 0.64 | ±1.13 | ± 0.81 ± 0.43 | +0.04 ±0.86 | ±1.04 | ±0.97 | -0.20 ±1.41 | ± 0.58 ± 0.63 | ±0.43 | ± 0.16 |
| ND G | 0.25 | 0.21 | 0.26 | -0.03 | -0.10 | -0.11 | 0.26 | 0.08 | 0.72 | -0.58 | -0.76 | 0.19 | -0.93 | -0.36 | 0.54 | 0.41 | -0.68 | 0.63 | 0.58 | 0.43 | -0.14 | 0.07 |
| WBC | | | | | | | | ± 0.07 | ± 0.29 | ± 0.38 | ± 0.30 | ± 0.42 | ± 0.18 | ± 0.70 | ± 0.44 | ± 0.48 | ± 0.37 | ± 0.66 | ± 0.67 | ± 0.59 | ± 0.58 | ± 0.69 |
| Neutro- | -0.11 | -0.11 | -0.15 | -0.05 | 0.01 | 0.08 | 0.04 | 0.24 | 0.12 | -0.96 | 0.15 | -0.08 | -0.61 | -0.85 | 0.43 | 0.67 | -0.14 | 0.84 | 0.67 | 0.71 | -0.65 | 0.31 |
| phils | 0.12 | 0.11 | 0.15 | 0.01 | 0.04 | 0.07 | 0.02 | 0.21 | ± 0.08 | ± 0.03 | ±0.29 | ± 0.45 | ± 0.48 | ±0.32 | ± 0.41 | ± 0.33 | ± 0.32 | ± 0.16 | ± 0.24 | ±0.29 | ± 0.25 | ± 0.36 |
| Lympho- cytes | 0.13 | 0.11 | 0.15 | 0.01 | -0.04 | -0.07 | -0.02 | -0.21 | -0.98 | 0.14 ± 0.08 | $\pm 0.46 \pm 0.28$ | ± 0.15 ± 0.48 | ± 0.00 | ± 0.88 | ± 0.22 ± 0.41 | ± 0.62 ± 0.32 | ± 0.03 ± 0.41 | ± 0.83 ± 0.26 | ± 0.70 ± 0.31 | ± 0.78 ± 0.20 | ± 0.86 ± 0.10 | ± 0.10 ± 0.32 |
| Mono- | -0.02 | 0.01 | 0.04 | 0.14 | 0.08 | -0.10 | 0.08 | -0.10 | -0.22 | 0.05 | 0.17 | 0.40 | 0.78 | -0.51 | -0.21 | 0.12 | 0.33 | 0.18 | 0.16 | 0.24 | -0.30 | -0.82 |
| cytes | | | | | | | | | | | ± 0.07 | ± 0.44 | ± 0.38 | ± 0.39 | ± 0.34 | ± 0.35 | ± 0.35 | ± 0.43 | ± 0.37 | ± 0.28 | ± 0.19 | ± 0.17 |
| Eosino- | -0.13 | -0.07 | -0.09 | 0.12 | 0.14 | 0.04 | -0.27 | -0.17 | 0.07 | -0.17 | -0.06 | 0.06 | 0.08 | -0.44 | -0.92 | -0.57 | 0.41 | -0.57 | -0.50 | -0.54 | 0.15 | -0.85 |
| phils | 0.00 | 0.07 | 0.05 | 0.01 | 0.00 | 0.02 | 0.01 | 0.12 | 0.15 | 0.12 | 0.10 | ± 0.05 | ± 0.63 | ± 0.52 | ± 0.16 | ± 0.44 | ± 0.37 | ±0.39 | ±0.52 | ±0.51 | ±0.43 | ± 0.26 |
| Baso- | 0.06 | 0.07 | 0.05 | -0.01 | 0.00 | 0.03 | 0.01 | 0.12 | -0.15 | 0.12 | 0.10 | -0.04 | +0.03 | 0.62 +0.52 | -0.24 +0.60 | -0.18 +0.53 | +0.81 | +0.13 | +0.43 | -0.16 +0.64 | +0.64 | +0.12 +0.72 |
| Hanto- | -0.01 | -0.10 | -0.08 | -0.11 | -0.09 | -0.10 | 0.16 | 0.18 | 0.10 | -0.10 | -0.02 | 0.06 | 0.00 | 0.03 | -0.15 | -0.66 | -0.48 | -0.71 | -0.47 | -0.84 | 0.64 | -0.65 |
| globin | | | | | | | | | | | | | | ± 0.03 | ± 0.70 | ± 0.50 | ±0.56 | ± 0.37 | ± 0.44 | ±0.26 | ± 0.47 | ±0.54 |
| IFN-w | 0.11 | 0.04 | 0.04 | -0.16 | -0.13 | 0.03 | 0.00 | 0.09 | 0.11 | -0.09 | -0.06 | -0.13 | -0.05 | 0.00 | 0.32 | 0.89 | -0.27 | 0.92 | 0.73 | 0.99 | -0.44 | 0.35 |
| 11/14-7 | | | | | · · - | | | | | | | | | | ±0.10 | ±0.11 | ±0.30 | ±0.11 | ±0.17 | ± 0.08 | ±0.28 | ±0.32 |
| IL-10 | 0.04 | 0.01 | -0.04 | -0.14 | -0.07 | 0.11 | -0.01 | 0.11 | 0.05 | -0.05 | 0.00 | -0.12 | 0.02 | 0.06 | 0.60 | 0.25 + 0.10 | 0.22 + 0.31 | 0.97 | 0.95 + 0.05 | 0.98 + 0.04 | -0.62 +0.48 | 0.38 + 0.40 |
| | 0.02 | 0.06 | 0.02 | 0.06 | 0.06 | 0.00 | -0.01 | -0.03 | -0.10 | 0.10 | 0.02 | -0.03 | 0.03 | -0.19 | -0.14 | 0.14 | 0.18 | 0.28 | 0.52 | 0.10 | -0.12 | ±0.40 0.51 |
| IL-12 | 0.02 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.01 | 0.05 | 0.10 | 0.10 | 0.02 | 0.05 | 0.05 | 0.19 | 0.11 | 0.11 | ±0.09 | ±0.35 | ±0.28 | ±0.44 | ±0.39 | ±0.44 |
| TT 10 | 0.06 | 0.04 | 0.00 | -0.12 | -0.06 | 0.08 | 0.02 | 0.14 | 0.03 | -0.03 | 0.05 | -0.16 | 0.06 | 0.03 | 0.52 | 0.88 | 0.18 | 0.16 | 0.95 | 0.96 | -0.67 | 0.48 |
| 117-1h | | | | | | | | | | | | | | | | | | ±0.09 | ±0.06 | ±0.06 | ±0.33 | ±0.34 |
| IL-4 | 0.07 | 0.04 | -0.01 | -0.16 | -0.10 | 0.10 | 0.05 | 0.10 | 0.00 | 0.00 | 0.02 | -0.10 | 0.00 | 0.04 | 0.53 | 0.85 | 0.18 | 0.82 | 0.27 + 0.13 | 0.85 + 0.08 | -0.45 +0.30 | 0.58 + 0.38 |
| 1 | 1 | | | | | | | | | | | | | | | | | | -0.13 | -0.00 | ± 0.50 | +0.50 |

| T 11 C 4 D | | · · | 1 | C | • | • 1 1 | • | т | XX 71 · | • 1 / |
|-------------|-----------|---------|--------------|-----|---------|----------|-------|--------|---------|---------|
| Table N 4 P | 291TW/160 | genefic | correlations | tor | immiine | Variable | z 1m | l arge | W/h1te | nialeta |
| | | genetic | conclations | 101 | mmune | variable | 5 III | Laige | | pigicio |
| | | 0 | | | | | | 0 | | 10 |

| | | | | | | | | | | Appen | ndix | | | | | | | | | | | |
|-------|------|------|------|-------|-------|-------|-------|-------|-------|-------|------|-------|-------|-------|------|-------|------|-------|-------|---------------|----------------|----------------|
| | | | | | | | | | | | | | | | | | | | | | | |
| IL-6 | 0.12 | 0.09 | 0.05 | -0.18 | -0.08 | 0.16 | 0.05 | 0.12 | 0.02 | -0.01 | 0.01 | -0.16 | -0.02 | 0.05 | 0.59 | 0.90 | 0.12 | 0.85 | 0.86 | 0.31 ±0.10 | -0.49 ±0.28 | 0.54 ±0.26 |
| IL-8 | 0.12 | 0.18 | 0.25 | 0.14 | 0.14 | 0.00 | -0.14 | -0.31 | -0.33 | 0.33 | 0.02 | -0.04 | 0.00 | -0.09 | 0.01 | -0.04 | 0.10 | -0.05 | -0.03 | -0.05 | 0.36 ±0.11 | -0.06 ±0.33 |
| TNF-α | 0.11 | 0.08 | 0.12 | -0.04 | -0.06 | -0.04 | 0.09 | 0.09 | 0.06 | -0.06 | 0.02 | -0.13 | -0.01 | 0.06 | 0.56 | 0.52 | 0.11 | 0.52 | 0.51 | 0.53 | 0.05 | 0.13 ±0.08 |

Bold font indicates heritabilities ($h^2\pm SE$) on the diagonal. Phenotypic correlations (r_p) under the diagonal and genetic correlations ($r_g\pm SE$) above the diagonal. RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , NA=not available.

| | Land | drace | Large | White |
|-----------------------|---------------|--------------|-------|-------|
| | PC1 | PC2 | PC1 | PC2 |
| Biological fun | ctional netwo | ork: RBC | | |
| RBC | 31.48 | 0.03 | 31.50 | 1.24 |
| Hemoglobin | 23.32 | 9.99 | 29.61 | 1.85 |
| Hematocrit | 25.93 | 9.85 | 30.58 | 2.96 |
| MCV | 4.51 | 38.59 | 0.30 | 48.29 |
| MCH | 9.55 | 31.41 | 1.79 | 40.94 |
| MCHC | 3.82 | 0.49 | 2.53 | 4.07 |
| Platelets | 1.25 | 9.16 | 3.26 | 0.64 |
| Haptoglobin | 0.16 | 0.47 | 0.43 | 0.02 |
| % of variance | 38.83 | 23.95 | 37.81 | 25.25 |
| Biological fun | ctional netwo | ork: Cells | | |
| WBC | 14.10 | 12.47 | 14.48 | 3.55 |
| Neutrophils | 36.72 | 3.31 | 37.82 | 2.75 |
| Lymphocytes | 27.45 | 0.04 | 29.54 | 0.26 |
| Monocytes | 13.18 | 0.93 | 7.41 | 42.00 |
| Eosinophils | 6.17 | 37.05 | 6.34 | 35.30 |
| Basophils | 2.39 | 46.21 | 4.42 | 16.15 |
| % of variance | 41.43 | 18.72 | 40.37 | 17.48 |
| Biological fun | ctional netwo | ork: Cytokin | es | |
| IFN-γ | 9.86 | | 10.12 | 2.42 |
| IL-10 | 14.90 | | 15.35 | 4.17 |
| IL-12 | 14.66 | | 14.93 | 2.17 |
| IL-1β | 14.69 | | 15.03 | 4.64 |
| IL-4 | 14.97 | | 15.53 | 3.77 |
| IL-6 | 14.85 | | 15.54 | 3.82 |
| IL-8 | 5.88 | | 5.89 | 43.89 |
| TNF-α | 10.20 | | 7.62 | 35.12 |
| % of variance | 79.28 | | 75.27 | 12.97 |

Table S 5: Principal components and their composition based on loading values of Landrace and Large White dams.

PC=Principal component, % of variance= percentage of explained variance by a PC, RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α . PCs are estimated within three distinguished biological functional frameworks like cells (Cell), RBC and additional RBC characteristics including haptoglobin (RBC), and Cytokines.

| | | Landrace | | | Large White | |
|-------------|--------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| Trait | σ^2_p | h ² ±SE | c ² ±SE | $\sigma^{2}{}_{p}$ | h ² ±SE | c ² ±SE |
| RBC | 0.10 | 0.36±0.12 | $0.06{\pm}0.04$ | 0.06 | 0.35±0.08 | 0.02±0.01 |
| Hemoglobin | 13462.96 | 0.41±0.12 | $0.08{\pm}0.05$ | 17200.32 | $0.28{\pm}0.08$ | $0.04{\pm}0.03$ |
| Hematocrit | 0.001 | 0.44±0.12 | $0.05 {\pm} 0.04$ | 0.001 | 0.14 ± 0.06 | 0.06 ± 0.04 |
| MCV | 0.001 | 0.41±0.09 | $0.10{\pm}0.05$ | 67.73 | 0.59±0.09 | 0.10 ± 0.04 |
| МСН | 0.83 | $0.29{\pm}0.07$ | $0.03{\pm}0.03$ | 0.71 | 0.66±0.09 | 0.05 ± 0.03 |
| MCHC | 2.25 | $0.02{\pm}0.03$ | $0.03{\pm}0.02$ | 1.06 | $0.16{\pm}0.08$ | 0.14 ± 0.06 |
| Platelets | 263542756.00 | $0.22{\pm}0.08$ | $0.21{\pm}0.05$ | 419554927.64 | 0.01 ± 0.02 | $0.27{\pm}0.05$ |
| WBC | 567.87 | 0.17 ± 0.06 | $0.08{\pm}0.04$ | 929.03 | $0.09{\pm}0.07$ | 0.16±0.06 |
| Neutrophils | 7508.22 | $0.22{\pm}0.08$ | 0.11 ± 0.04 | 10348.99 | 0.13 ± 0.07 | 0.17 ± 0.05 |
| Lymphocytes | 7873.01 | $0.30{\pm}0.08$ | $0.11{\pm}0.05$ | 9990.00 | 0.13 ± 0.07 | 0.17±0.05 |
| Monocytes | 4.67 | 0.31 ± 0.08 | $0.03{\pm}0.04$ | 8.58 | 0.17 ± 0.07 | 0.29 ± 0.06 |
| Eosinophils | 5.29 | 0.21 ± 0.07 | $0.08{\pm}0.04$ | 1.28 | 0.05 ± 0.05 | $0.04{\pm}0.03$ |
| Basophils | 0.02 | $0.24{\pm}0.08$ | $0.04{\pm}0.03$ | 0.001 | $0.04{\pm}0.04$ | $0.14{\pm}0.05$ |
| Haptoglobin | 0.001 | $0.18{\pm}0.07$ | $0.06 {\pm} 0.04$ | 0.01 | 0.03 ± 0.04 | $0.04{\pm}0.03$ |
| IFN-γ | 0.18 | 0.15 ± 0.08 | 0.44±0.06 | 0.29 | $0.18{\pm}0.09$ | 0.56±0.06 |
| IL-10 | 0.04 | $0.16{\pm}0.10$ | 0.53±0.06 | 0.08 | 0.23±0.12 | 0.44±0.07 |
| IL-12 | 0.001 | 0.31±0.12 | $0.36{\pm}0.07$ | 0.001 | $0.20{\pm}0.10$ | 0.35 ± 0.07 |
| IL-1β | 0.03 | $0.09{\pm}0.08$ | 0.49±0.06 | 0.05 | $0.10{\pm}0.07$ | 0.40±0.06 |
| IL-4 | 0.12 | $0.14{\pm}0.08$ | 0.47±0.06 | 0.24 | $0.16{\pm}0.09$ | 0.42±0.07 |
| IL-6 | 0.05 | $0.19{\pm}0.09$ | 0.52±0.06 | 0.11 | 0.28 ± 0.11 | 0.45±0.07 |
| IL-8 | 0.01 | $0.12{\pm}0.07$ | $0.24{\pm}0.06$ | 0.02 | $0.38{\pm}0.11$ | 0.16 ± 0.06 |
| TNF-α | 0.06 | 0.41±0.11 | $0.31{\pm}0.07$ | 0.06 | 0.08 ± 0.06 | 0.42±0.06 |

Table S 6: Genetic effects for Landrace and Large White piglets after consideration for maternal environmental effects

RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , h²=heritability, c²=litter effect, σ_p^2 =phenotypic variance, cytokines are log-transformed, bold font indicates high h² or c² above 0.4

| Table S 7: Principal components and their composition based on loading values of Landrace |
|-------------------------------------------------------------------------------------------|
| and Large White piglets |

| | Landrace | | | Large White | | | | | | | |
|--------------------------------------|------------|----------|-------|-------------|-------|-------|-------|--|--|--|--|
| | PC1 | PC2 | PC3 | PC1 | PC2 | PC3 | PC4 | | | | |
| Biological functional network: RBC | | | | | | | | | | | |
| RBC | 22.88 | 14.35 | 3.26 | 24.94 | 12.80 | 0.50 | 0.91 | | | | |
| Hemoglobin | 31.55 | 0.004 | 3.59 | 32.39 | 0.72 | 0.99 | 0.12 | | | | |
| Hematocrit | 31.20 | 2.86 | 1.02 | 31.65 | 1.34 | 1.35 | 0.60 | | | | |
| MCV | 6.76 | 14.78 | 33.89 | 4.67 | 32.13 | 20.36 | 0.12 | | | | |
| МСН | 5.24 | 44.79 | 0.37 | 5.99 | 39.14 | 0.74 | 9.30 | | | | |
| MCHC | 0.001 | 16.77 | 50.04 | 0.22 | 1.24 | 61.08 | 16.12 | | | | |
| Platelets | 2.36 | 3.28 | 0.06 | 0.02 | 7.96 | 6.60 | 29.27 | | | | |
| Haptoglobin | 0.02 | 3.17 | 7.76 | 0.11 | 4.68 | 8.37 | 43.56 | | | | |
| % of variance | 37.23 | 22.43 | 16.98 | 37.49 | 22.84 | 16.57 | 12.47 | | | | |
| Biological functional network: Cells | | | | | | | | | | | |
| WBC | 8.03 | 17.35 | 23.47 | 2.60 | 45.02 | 0.47 | | | | | |
| Neutrophils | 44.04 | 0.54 | 0.10 | 45.08 | 0.47 | 0.03 | | | | | |
| Lymphocytes | 41.17 | 6.50 | 0.87 | 43.32 | 0.30 | 0.50 | | | | | |
| Monocytes | 2.43 | 13.91 | 34.34 | 5.20 | 5.58 | 1.07 | | | | | |
| Eosinophils | 0.35 | 46.82 | 13.09 | 3.08 | 38.32 | 18.61 | | | | | |
| Basophils | 3.97 | 14.88 | 28.12 | 0.74 | 10.32 | 79.31 | | | | | |
| % of variance | 35.96 | 20.95 | 18.94 | 35.49 | 21.89 | 16.42 | | | | | |
| Biological functional | network: C | ytokines | | | | | | | | | |
| IFN-γ | 12.53 | | | 13.09 | 0.65 | | | | | | |
| IL-10 | 17.17 | | | 18.79 | 0.37 | | | | | | |
| IL-12 | 6.67 | | | 2.30 | 33.72 | | | | | | |
| IL-1β | 15.68 | | | 17.58 | 0.33 | | | | | | |
| IL-4 | 16.58 | | | 17.48 | 0.28 | | | | | | |
| IL-6 | 16.50 | | | 18.40 | 0.85 | | | | | | |
| IL-8 | 1.97 | | | 0.31 | 63.75 | | | | | | |
| TNF-α | 12.90 | | | 12.05 | 0.06 | | | | | | |
| % of variance | 68.13 | | | 60.13 | 13.45 | | | | | | |

PC=Principal component, % of variance= percentage of explained variance by a PC, RBC=red blood cells, MCV=mean corpuscular volume, MCH=mean corpuscular hemoglobin,

MCHC=mean corpuscular hemoglobin concentration, WBC= white blood cells, IFN- γ =interferon- γ , IL=interleukin, TNF- α =tumor necrosis factor- α , bold font indicates contributing immune traits within the PC. PCs are estimated within three distinguished biological functional frameworks like cells (Cell), RBC and additional RBC characteristics including haptoglobin (RBC), and Cytokines.

| BFN | РС | Cell | | | RBC | | | | Cyto | | |
|------|-----|------------------------|------------------------|------------------------|-------------------------|-------------------------|------------------------------------|------------------|-------------------------|------------------|----------|
| | | PC1 | PC2 | PC3 | PC1 | PC2 | PC3 | PC4 | PC1 | PC2 | Breed |
| Cell | PC1 | 0.31±0.08 0.12±0.07 | | | 0.16±0.16 0.00±0.39 | -0.24±0.16 0.06±0.25 | 0.07±0.30 -0.02±0.29 | NA -0.84±0.30 | 0.17±0.20 0.52±0.41 | NA 0.78±0.26 | LR LW |
| | PC2 | | 0.20±0.08 0.05±0.04 | | 0.06±0.19 -0.27±0.63 | 0.54±0.20 0.19±0.39 | -0.31±0.28 -0.64±0.28 | NA 0.89±0.26 | 0.51±0.27 -0.93±0.19 | NA -0.71±0.27 | LR LW |
| | PC3 | | | 0.18±0.07 0.04±0.04 | 0.46±0.20 0.38±0.79 | 0.00±0.25 -0.89±0.29 | $0.34{\pm}0.25$ $0.15{\pm}0.47$ | NA -0.84±0.45 | 0.68±0.25 0.36±0.44 | NA 0.77±0.42 | LR LW |
| RBC | PC1 | 0.07 -0.10 | -0.02 -0.15 | 0.10 -0.02 | 0.50±0.10 0.08±0.08 | | | | 0.68±0.16 0.24±0.54 | NA -0.70±0.34 | LR LW |
| | PC2 | -0.06 0.01 | 0.15 0.24 | -0.06 -0.09 | | 0.35±0.08 0.58±0.11 | | | 0.34±0.25 -0.70±0.20 | NA -0.02±0.15 | LR LW |
| | PC3 | -0.02 0.03 | 0.00 0.14 | 0.03 -0.04 | | | 0.13±0.06 0.17±0.06 | | -0.30±0.26 0.86±0.19 | NA -0.16±0.21 | LR LW |
| | PC4 | NA 0.13 | NA -0.14 | NA 0.03 | | | | NA 0.10±0.06 | NA -0.05±0.15 | NA -0.54±0.25 | LR LW |
| Cyto | PC1 | 0.11 0.03 | 0.04 -0.17 | 0.05 0.07 | 0.17 0.02 | 0.01 -0.13 | -0.06 0.09 | NA 0.06 | 0.32±0.10 0.27±0.09 | | LR LW |
| | PC2 | NA 0.35 | NA -0.21 | NA 0.43 | NA -0.21 | NA -0.14 | NA -0.02 | NA 0.14 | | NA 0.14±0.06 | LR LW |

Table S 8: Genetic parameters of principal components as new dependent immune variables for Landrace and Large White piglets

BFN=biological functional network, PC=principal component, PCs are estimated within three distinguished BFN like cells (Cell), RBC and additional RBC characteristics including haptoglobin (RBC), cytokines (Cyto), heritabilities ($h^2\pm SE$) are indicated in bold font on the diagonal, phenotypic correlations (r_p) under the diagonal and genetic correlations ($r_g\pm SE$) above the diagonal, LR=Landrace, LW=Large White, NA=not available



Figure S 1: Comparison of different methods used to detect significant univariate associations for Landrace and Large White

Multiple identical significant SNPs for different immune traits within a method are counted a single time. uv=univariate, LR=Landrace, LW=Large White
Appendix

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------|-----|-------------|-----------|---------------|-------|----------------|----------------------|------------------|-----|---------------------------------------------------------|
| LW | МСН | 1 | ALGA0000795 | 8724875 | A/G | 74,10 | 0,03 | CHR | PLINK | 1 | TULP4, GTF2H5, SERAC1, SYNJ2, SNX9, ZDHHC14, TMEM242 |
| LW | MCH | 1 | ASGA0000892 | 8739103 | T/C | 25,90 | 0,03 | CHR | PLINK | 1 | |
| LW | MCH | 1 | ALGA0000837 | 8810463 | T/G | 25,80 | 0,03 | CHR | PLINK | 1 | |
| LW | MCH | 1 | ASGA0000925 | 8896901 | T/C | 25,90 | 0,03 | CHR | PLINK | 1 | |
| LW | MCH | 1 | ALGA0106880 | 9725288 | A/G | 26,00 | 0,03 | CHR | PLINK | 1 | |
| LW | MCH | 1 | ASGA0000922 | 10777632 | C/T | 74,00 | 0,04 | CHR | PLINK | 2 | |
| LW | MCH | 1 | H3GA0000711 | 10830305 | A/G | 25,90 | 0,03 | CHR | PLINK | 2 | |
| LW | HMG | 2 | DRGA0002793 | 21669969 | A/G | 87,10 | 0,03 | CHR | PLINK | 3 | |
| LW | HMG | 2 | ASGA0101016 | 21751485 | C/T | 86,90 | 0,03 | CHR | PLINK | 3 | |
| LW | HMG | 2 | ALGA0012559 | 22792581 | G/A | 86,40 | 0,03 | CHR | PLINK | 4 | |
| LW | HMG | 2 | ALGA0012570 | 22989364 | T/G | 90,00 | 0.03 | CHR | PLINK | 4 | |
| LR | HAP | 2 | MARC0055904 | 37117707 | A/G | 91.50 | 0.02 | CHR | PLINK | 5 | SLC17A6, ANO5, U6, NELL1 |
| LR | НАР | 2 | ALGA0013060 | 37186143 | C/T | 4,10 | 0.001/3.5 | CHR | PLINK, BIMBAM | 5 | |
| LR | НАР | 2 | ALGA0013078 | 37762734 | A/G | 4,10 | 0.001/3.5 | CHR | PLINK, BIMBAM | 5 | |
| LR | HAP | 2 | MARC0064216 | 37514046 | A/G | 90,00 | 0,04 | CHR | PLINK | 5 | |
| LR | HAP | 2 | MARC0018628 | 37632205 | T/C | 89,60 | 0,04 | CHR | PLINK | 5 | |
| LR | НАР | 2 | ALGA0013104 | 37945462 | G/T | 4,10 | 0.001/3.5 9 | CHR | PLINK, BIMBAM | 5 | |
| LR | НАР | 2 | DRGA0002935 | 37202269 | C/T | 95,90 | 0.001/3.5 | CHR | PLINK, BIMBAM | 5 | |
| LR | HAP | 2 | ALGA0013106 | 38128487 | T/C | 90,70 | 0,01 | CHR | PLINK | 6 | NELL1 |
| LR | BAS | 3 | MARC0006534 | 112713663 | T/G | 78,90 | 0,04 | GEN | PLINK | 7 | HADHB |
| LW | MCH | 4 | MARC0084905 | 4298000 | G/A | 4,60 | 0,05 | CHR | PLINK | 8 | COL22A1 |
| LW | MCH | 4 | ASGA0017522 | 5419206 | C/T | 4,80 | 0,05 | CHR | PLINK | 9 | |
| LR | MCV | 4 | ALGA0026246 | 82530260 | T/G | 48,80 | 0,02 | CHR | PLINK | 10 | |
| LR | MCHC | 5 | ALGA0106408 | 17162699 | C/T | 68,80 | 0,00 | CHR | PLINK | 11 | SCN8A |
| LR | MCHC | 5 | H3GA0016097 | 23400843 | A/C | 37,10 | 0,03 | CHR | PLINK | 12 | LRIG3 |
| LR | HMT | 5 | ASGA0025128 | 23778757 | A/G | 46,70 | 0,05 | CHR | PLINK | 12 | |
| LR | HMT | 5 | ASGA0025132 | 23816873 | G/A | 42,50 | 0,05 | CHR | PLINK | 12 | |
| LR | HMT | 5 | ASGA0025137 | 23933098 | T/C | 79,00 | 0,01 | CHR | PLINK | 12 | |
| LR | HMT | 5 | ALGA0031314 | 24000573 | G/T | 21,00 | 0,01 | CHR | PLINK | 12 | |
| LR | HMT | 5 | ASGA0025140 | 24069910 | T/G | 79,10 | 0,01 | CHR | PLINK | 12 | |
| LR | HMT | 5 | ALGA0031321 | 24135911 | A/C | 79,30 | 0,01 | CHR | PLINK | 12 | |
| LR | MCHC | 5 | DRGA0005609 | 29991703 | T/G | 84,10 | 0,02 | CHR | PLINK | 13 | |
| LR | MCHC | 5 | DRGA0005613 | 30469491 | T/G | 84,10 | 0,02 | CHR | PLINK | 13 | HMGA2 |

Table S 9: Significant associated genetic markers identified with univariate methods (continued)

Appendix

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------|-----|-------------|----------|---------------|-------|----------------|----------------------|------------------|-----|----------------------------------------------------|
| LR | MCHC | 5 | ASGA0025326 | 31271737 | A/C | 22.10 | 0.02 | CHR | PLINK | 14 | U6. ssc-mir-9808. CAND1 |
| LR | MCHC | 5 | ALGA0034323 | 31867380 | A/G | 88.60 | 0.02 | CHR | PLINK | 14 | -,, |
| LR | MCHC | 5 | MARC0114715 | 32497165 | A/C | 0,00 | 0,04 | CHR | PLINK | 15 | IL26, IL22 |
| LR | MCHC | 5 | ALGA0031657 | 32603961 | C/T | 19,30 | 0,04 | CHR | PLINK | 15 | |
| LR | MCHC | 5 | ALGA0031690 | 33946621 | A/G | 27,10 | 0,02 | CHR | PLINK | 16 | CCT2, RAB3A, BEST3, MYRFL, CNOT2, KCNMB4, PTPRB |
| LR | HMT | 5 | H3GA0016244 | 34769398 | A/G | 70,20 | 0.01/3.17 | CHR | PLINK, BIMBAM | 16 | |
| LR | MCHC | 5 | ALGA0031731 | 36197319 | A/C | 25,50 | 0,02 | CHR | PLINK | 17 | TRHDE, U4 |
| LR | HMT | 5 | ALGA0031736 | 36314172 | A/C | 27,90 | 0,05 | CHR | PLINK | 17 | |
| LR | HMT | 5 | ASGA0025454 | 36903934 | C/T | 35,90 | 0,03 | CHR | PLINK | 17 | |
| LR | HMT | 5 | ALGA0031749 | 37261727 | T/C | 32,50 | 0,02 | CHR | PLINK | 18 | |
| LR | MCHC | 5 | INRA0019263 | 38864890 | T/C | 69,80 | 0,02 | CHR | PLINK | 19 | |
| LR | MCHC | 5 | MARC0037200 | 38880761 | T/C | 69,80 | 0,02 | CHR | PLINK | 19 | |
| LR | MCHC | 5 | rs334622443 | 42436328 | A/T | NA | 0,02 | CHR | PLINK | 20 | AMN1, ETFBKMT, DENND5B, SINHCAF, CAPRIN2, IPO8 |
| LR | MCHC | 5 | DRGA0005776 | 43220509 | C/T | 30,50 | 0,02 | CHR | PLINK | 20 | |
| LR | MCHC | 5 | DRGA0005773 | 43252599 | A/G | 75,30 | 0,02 | CHR | PLINK | 20 | |
| LR | MCHC | 5 | MARC0113545 | 43293810 | A/G | 0,00 | 0,02 | CHR | PLINK | 20 | |
| LR | MCHC | 5 | ALGA0031826 | 43320525 | C/A | 30,50 | 0,02 | CHR | PLINK | 20 | |
| LR | MCHC | 5 | ASGA0025493 | 43385239 | G/A | 30,50 | 0,02 | CHR | PLINK | 20 | |
| LR | MCHC | 5 | H3GA0016271 | 43428743 | C/A | 30,50 | 0,02 | CHR | PLINK | 20 | |
| LR | MCHC | 5 | ASGA0025490 | 43480338 | T/C | 71,40 | 0,02 | CHR | PLINK | 21 | U6, TMTC1 |
| LR | MCHC | 5 | DRGA0005767 | 43556787 | C/T | 30,50 | 0,02 | CHR | PLINK | 21 | |
| LR | MCHC | 5 | MARC0003440 | 43664480 | T/C | 69,50 | 0,02 | CHR | PLINK | 21 | |
| LR | MCHC | 5 | INRA0019288 | 43688401 | T/C | 73,50 | 0,02 | CHR | PLINK | 21 | |
| LR | MCHC | 5 | MARC0030421 | 43750584 | C/T | 28,60 | 0,02 | CHR | PLINK | 21 | |
| LR | MCHC | 5 | ALGA0031834 | 43879295 | G/A | 30,60 | 0,02 | CHR | PLINK | 21 | |
| LR | MCHC | 5 | ALGA0031838 | 43979571 | T/G | 30,50 | 0,02 | CHR | PLINK | 21 | |
| LR | MCHC | 5 | H3GA0016294 | 47424047 | A/G | 38,30 | 0,02 | CHR | PLINK | 22 | ITPR2 |
| LR | MCHC | 5 | ALGA0031924 | 48896828 | T/G | 57,00 | 0,01 | GEN | PLINK | 23 | BCAT1 |
| LR | MCHC | 5 | MARC0001027 | 50094492 | G/A | 23,70 | 0,01 | CHR | PLINK | 24 | SOX5 |
| LR | MCHC | 5 | DRGA0005841 | 50243918 | A/G | 76,30 | 0,01 | CHR | PLINK | 24 | |
| LR | MCHC | 5 | ALGA0032074 | 58601394 | A/G | 76,00 | 0,01 | GEN | PLINK | 25 | GRIN2B, EMP1 |
| LR | MCHC | 5 | H3GA0016359 | 58625915 | C/T | 25,10 | 0,00 | CHR | PLINK | 25 | |
| LR | MCHC | 5 | H3GA0016379 | 58840179 | G/A | 23,90 | 0,00 | CHR | PLINK | 25 | |
| LR | MCHC | 5 | ALGA0032146 | 59340760 | A/C | 82,80 | 0,01 | GEN | PLINK | 25 | |
| | | | | | | | | | | | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------|-----|-------------|-----------|---------------|-------|----------------|----------------------|--------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| LR | MCV | 5 | ASGA0025778 | 61783155 | A/G | 23,10 | 0,02 | CHR | PLINK | 26 | TMEM52B, OLR1, CLEC7A, CLEC1A, CLEC12B, CLEC1B, CLEC12A, CLEC12B, CLEC2B, CD69, LOC100520491, CLEC2D, KLRB1, LOC100524679, PZP, A2M, KLRG1, M6PR, PHC1, A2ML1, PIMKLB |
| LR | MCV | 5 | ASGA0025791 | 61931507 | A/G | 76 80 | 0.02 | CHR | PLINK | 26 | MOLK, THEI, AZWEI, KIWKED |
| LR | MCV | 5 | DRGA0005951 | 61966384 | G/A | 76,80 | 0.02 | CHR | PLINK | 26 | |
| LR | MCV | 5 | ASGA0025794 | 62115185 | T/G | 23.40 | 0.02 | CHR | PLINK | 26 | |
| LR | MCV | 5 | DRGA0005956 | 62134657 | T/G | 80.00 | 0.02 | CHR | PLINK | 26 | |
| LR | MCHC | 5 | MARC0100616 | 62372560 | C/T | 0.00 | 0.00 | CHR | PLINK | 26 | |
| LR | MCV | 5 | ALGA0032322 | 62455175 | G/A | 65.60 | 0.02 | CHR | PLINK | 26 | |
| LR | MCV | 5 | DIAS0000002 | 62481418 | A/G | 34,90 | 0,02 | CHR | PLINK | 26 | |
| LR | MCV | 5 | ASGA0025802 | 62601778 | T/C | 77,10 | 0,02 | CHR | PLINK | 26 | |
| LR | MCV | 5 | ALGA0032345 | 62737145 | T/C/G | 39,00 | 0,02 | CHR | PLINK | 26 | |
| LR | MCHC | 5 | ASGA0025827 | 63827447 | G/A | 84,70 | 0,03 | CHR | PLINK | 27 | ENO2 |
| LW | RBC | 5 | ALGA0033064 | 77286779 | T/C | 98,20 | 0,02 | CHR | PLINK | 28 | SLC38A4, AMIGO2, PCED1B, RPAP3 |
| LW | RBC | 5 | ASGA0093314 | 77402409 | A/G | 8,50 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | ALGA0104452 | 77541676 | A/G | 7,50 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | MARC0090729 | 77680830 | C/T | 0,00 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | MARC0098250 | 77948633 | G/A | 0,00 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | ALGA0109048 | 77962305 | T/C | 6,20 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | ALGA0101247 | 77990021 | A/G | 2,90 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | ALGA0104065 | 77997876 | C/T | 97,10 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | MARC0009241 | 78029583 | G/A | 97,10 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | ALGA0104516 | 78032160 | G/T | 97,10 | 0,02 | CHR | PLINK | 28 | |
| LW | RBC | 5 | ALGA0033127 | 79513170 | A/G | 87,80 | 0,02 | CHR | PLINK | 29 | ALDH1L2, C12orf45, SLC41A2, U6, CHST11, TXNRD1 |
| LW | RBC | 5 | H3GA0016899 | 80171271 | C/T | 90,30 | 0,02 | CHR | PLINK | 29 | |
| LW | RBC | 5 | ALGA0115368 | 80487779 | T/C | 6,20 | 0,02 | CHR | PLINK | 29 | |
| LW | RBC | 5 | ALGA0103880 | 80562374 | T/C | 94,10 | 0,02 | CHR | PLINK | 30 | |
| LW | RBC | 5 | DRGA0006061 | 82345818 | A/G | 1,60 | 0,02 | CHR | PLINK | 31 | |
| LR | IFN | 5 | MARC0080493 | 90118573 | A/G | 79,20 | 0,03 | CHR | PLINK | 32 | |
| LR | MCHC | 5 | ASGA0101924 | 97259676 | T/C | 98,90 | 0,00 | CHR | PLINK | 33 | |
| LR | MCHC | 5 | DRGA0006295 | 97412529 | A/C | 98,70 | 0,00 | CHR | PLINK | 33 | |
| LR | MCHC | 5 | H3GA0017216 | 97477241 | C/T | 1,10 | 0,00 | CHR | PLINK | 33 | |
| LR | MCHC | 5 | DRGA0006288 | 102305039 | A/G | 1,10 | 0,00 | CHR | PLINK | 34 | |
| LR | MCHC | 5 | INRA0020540 | 102513112 | A/G | 98,90 | 0,00 | CHR | PLINK | 34 | |
| LR | IL-6 | 6 | MARC0041561 | 16171435 | C/T | 80,90 | 0,05 | CHR | PLINK | 35 | |
| LR | IL-6 | 6 | MARC0075761 | 16188799 | G/A | 80,90 | 0,05 | CHR | PLINK | 35 | |
| LR | IL-4 | 6 | H3GA0055874 | 47536918 | C/T | 16,30 | 0,04 | CHR | PLINK | 36 | ACTN4, HNRNPL |
| LR | MCV | 6 | ASGA0094719 | 70404572 | A/G | 34,60 | 0,04 | CHR | PLINK | 37 | UBE4B |

| | | 1. |
|-----|------|------|
| Λ 1 | man | div |
| | JUCH | IUIA |
| | | |

| | | | | | m/M | | P- | Type of | | | |
|-------|-----------------------|-----|-------------|----------|--------|-------|----------|--------------|--------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Breed | Trait | SSC | SNP | Position | allele | MAF | value/BF | significance | Method | QTL | Nearest gene within QTL |
| LR | MCV | 6 | ALGA0111762 | 70460911 | C/T | 67,30 | 0,04 | CHR | PLINK | 37 | |
| LR | MCV | 6 | ALGA0105286 | 74623829 | C/A | 31,30 | 0,01 | CHR | PLINK | 38 | FHAD1 |
| LR | MCV | 6 | ALGA0105225 | 75820891 | C/T | 36,60 | 0,04 | CHR | PLINK | 39 | PADI1-6, RCC2, ARHGEF10L |
| LR | MCV | 6 | MARC0076222 | 75960523 | C/T | 34,50 | 0,04 | CHR | PLINK | 39 | |
| LR | MCV | 6 | ALGA0115349 | 75971546 | C/T | 32,60 | 0,04 | CHR | PLINK | 39 | |
| LR | MCV | 6 | MARC0098064 | 76038583 | C/T | 0,00 | 0,05 | CHR | PLINK | 39 | |
| LR | MCV | 6 | MARC0004865 | 76063337 | G/A | 34,60 | 0,04 | CHR | PLINK | 39 | |
| LR | MCV | 6 | ASGA0090874 | 76089914 | G/A | 53,00 | 0,04 | CHR | PLINK | 39 | |
| LR | MCV | 6 | ALGA0116768 | 76114734 | A/G | 65,40 | 0,04 | CHR | PLINK | 39 | |
| LR | MCV | 6 | ASGA0101002 | 76151935 | A/G | 64,60 | 0,05 | CHR | PLINK | 39 | |
| LR | MCV | 6 | MARC0098251 | 76210521 | T/C | 0,00 | 0,04 | CHR | PLINK | 39 | |
| LR | MCV | 6 | ALGA0035695 | 80258992 | G/A | 62,40 | 0,04 | CHR | PLINK | 40 | ZBTB40, EPHA8, C1QA, C1QC, C1QB |
| LR | MCV | 6 | MARC0026937 | 80582130 | G/A | 42,60 | 0,01 | CHR | PLINK | 40 | |
| LR | MCV | 6 | DBWU0000032 | 80596783 | T/C | 31,30 | 0,01 | CHR | PLINK | 40 | |
| LR | MCV | 6 | ALGA0114670 | 80603591 | C/A | 31,30 | 0,01 | CHR | PLINK | 40 | |
| LR | MCV | 6 | H3GA0055046 | 80642168 | C/T | 31,30 | 0,01 | CHR | PLINK | 40 | |
| LR | MCV | 6 | ASGA0099954 | 80643934 | T/C | 57,30 | 0,01 | CHR | PLINK | 40 | |
| LR | MCV | 6 | ASGA0098887 | 84046293 | A/G | 31,80 | 0,01 | CHR | PLINK | 41 | ARID1A, PIGV, ZDHHC18, GPATCH3, NR0B2, NUDC, KDF1, TRNP1, TENT5B, SLC9A1, WDTC1, TMEM222, SYTL1, MAP3K6, CD164L2, GPR3, WASF2, FGR JEI6 FAM76A STX12 |
| LR | MCV | 6 | ALGA0105183 | 84069079 | A/G | 31.80 | 0.01 | CHR | PLINK | 41 | |
| LR | MCV | 6 | ASGA0028717 | 84522894 | G/A | 47.30 | 0.04 | CHR | PLINK | 41 | |
| LR | MCV | 6 | ASGA0028724 | 84705728 | A/G | 52.90 | 0.01 | CHR | PLINK | 41 | |
| | MCV | 6 | ASGA0099240 | 84961781 | C/T | 65.90 | 0.02 | CHR | PLINK | 41 | |
| LR | MCV | 6 | ALGA0121599 | 85086986 | A/G | 37,50 | 0,04 | CHR | PLINK | 42 | XKR8, EYA3, PTAFR, U1, DNAJC8, ATP5IF1, SESN2, MED18, PHACTR4, SNORA73, RCC1, TRNAU1AP, SNORD99, SNORA61, SNORA44, SNORA16B, RAB42, TAF12, GMEB1, YTHDF2, OPRD1, EPB41, SRSF4 |
| LR | MCV | 6 | MARC0018089 | 85997279 | C/T | 49,40 | 0.05 | CHR | PLINK | 42 | |
| LR | MCV | 6 | ALGA0103867 | 86036915 | T/C | 45.40 | 0.04 | CHR | PLINK | 42 | |
| LR | MCV | 6 | ALGA0035788 | 86282384 | A/G | 47.00 | 0.04 | CHR | PLINK | 43 | |
| LR | MCV | 6 | ASGA0028727 | 86333941 | A/G | 41.00 | 0.04 | CHR | PLINK | 43 | |
| LR | MCV | 6 | ALGA0114520 | 86401903 | A/G | 40.10 | 0.04 | CHR | PLINK | 43 | |
| LR | IL-10, IL-4 | 6 | ASGA0083561 | 87364936 | T/C | 67.90 | 0.04 | CHR | PLINK | 44 | LAPTM5 |
| LR | MCV | 6 | ASGA0028790 | 88118337 | C/A | 39.10 | 0.04 | CHR | PLINK | 45 | HCRTR1, PEF1, COL16A1, ADGRB2 |
| LR | IL-10, IL- 6, IL-4 | 6 | ASGA0028956 | 88264983 | T/C | 59,30 | 0,04 | CHR | PLINK | 45 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|----------|-----------------------|--------|----------------------------|----------------------|---------------|---------------|----------------|----------------------|----------------|----------|------------------------------------------------------------------------------------------------------------------------------------------------|
| LR | IL-10, IL-6 | 6 | H3GA0053380 | 93420594 | G/T | 47,80 | 0,02 | CHR | PLINK | 46 | ZC3H12A, MEAF6, SNIP1, DNAL11, GNL2, RSPO1, C1orf109, CDCA8, EPHA10, MANEAL, YRDC, C1orf122, MTF1, INPP5B, SF3A3, FHL3, UTP11, POU3F1 |
| LR | IL-10, IL-6 | 6 | MARC0082470 | 93442952 | T/C | 47,90 | 0,04 | CHR | PLINK | 46 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0117017 | 93498560 | A/G | 92,70 | 0,02 | CHR | PLINK | 46 | |
| LR | IL-10, IL-6 | 6 | ASGA0028870 | 93958186 | A/G | 55,50 | 0,03 | CHR | PLINK | 46 | |
| LR | IL-10, IL- 4 IL-6 | 6 | DIAS0000434 | 93982653 | G/A | 22,70 | 0,02 | CHR | PLINK | 46 | |
| LR | IL-10, IL-6 | 6 | ALGA0035971 | 94051380 | C/T | 62,30 | 0,03 | CHR | PLINK | 46 | |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0019060 | 94096694 | T/C | 72,40 | 0,01 | CHR | PLINK | 46 | |
| LR LR | IL-10, IL-6 IL-10 | 6 6 | MARC0114889 ASGA0028900 | 94223271 94309034 | C/T A/G | 0,00 91,50 | 0,04 0,04 | CHR CHR | PLINK PLINK | 46 46 | PPAGE PPAGE GIAO PHPDI 2 AVIDINI |
| LR | IL-10, IL- 4, IL-6 | 6 | M1GA0008815 | 94712287 | C/T | 33,60 | 0,01 | CHR | PLINK | 47 | NAUC, NAUC, OJA, KIBDL2, AKIKINI, NDUFS5, U6, MACF1, KIAA0754, BMP8A, PABPC4, SNORA55, HEYL, NT5C1A, HPCAL4, PPIE, BMP8B, TBIT1 |
| LR | IL-10 | 6 | ASGA0028941 | 94769975 | C/T | 29,90 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4 II -6 | 6 | DIAS0002803 | 94919296 | A/G | 59,30 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | SIRI0000176 | 95054229 | C/T | 0,00 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036052 | 95081294 | G/T | 59,30 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036056 | 95114962 | T/C | 40,70 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0008963 | 95161607 | T/C | 59,30 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 6, IL-4 | 6 | ASGA0028958 | 95203496 | T/G | 40,70 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036062 | 95230387 | T/C | 59,30 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036064 | 95251820 | T/C | 59,30 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0076965 | 95275331 | A/G | 59,40 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 6, IL-4 | 6 | ASGA0028971 | 95359973 | G/T | 40,70 | 0,04 | CHR | PLINK | 47 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|---------------------------------|--------|----------------------------|----------|---------------|----------------|----------------|----------------------|------------------|----------|--------------------------------------------------------------------------------------|
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036086 | 95397864 | A/G | 40,70 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | H3GA0018528 | 95498545 | A/G | 59,20 | 0,02 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036101 | 95512565 | A/C/G | 59,20 | 0,02 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036104 | 95528500 | A/G | 59,20 | 0,02 | CHR | PLINK | 47 | |
| LR | IL-4, IL-6 | 6 | ALGA0036113 | 95648826 | C/T | 58,50 | 0,04 | CHR | PLINK | 47 | |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0033580 | 95566980 | G/A | 45,50 | 0.001/3.5 8 | CHR | PLINK, BIMBAM | 47 | |
| LR | IL-10, IL- 6, IL-4 | 6 | ASGA0029025 | 95751711 | C/T | 40,80 | 0,02 | CHR | PLINK | 48 | MFSD2A, CAP1, PPT1, RLF, TMCO2, MPSTE24, COL9A2, MC5R, RNMT, LDLRAD4, CEP192 |
| LR | IL-4, IL-6 | 6 | MARC0097281 | 95772705 | G/A | 0,00 | 0,03 | CHR | PLINK | 48 | |
| LR | IL-6 | 6 | MARC0074457 | 96121023 | T/C | 41,10 | 0,03 | CHR | PLINK | 48 | |
| LR | IL-6 | 6 | MARC0054619 | 96196142 | G/A | 41,20 | 0,03 | CHR | PLINK | 48 | |
| LR | IL-6 | 6 | MARC0015713 | 96240060 | T/C | 58,80 | 0,03 | CHR | PLINK | 48 | |
| | IL-6 | 6 | ASGA009/503 | 96306952 | C/1 | 41,10 | 0,03 | CHR | PLINK DLDW | 48 | |
| | IL-0 IL-6 | 0 6 | ASGA0106427 DIAS0001681 | 96344704 | A/G G/A | 58,90 41 20 | 0,03 | CHR | PLINK PLINK | 48 48 | |
| LR | IL-10, IL- | 6 | MARC0022542 | 96650040 | T/G | 59,80 | 0,02 | CHR | PLINK | 48 | |
| LR | 4, 1L-0 IL-6 | 6 | MARC0074986 | 96678769 | A/G | 31,90 | 0,03 | CHR | PLINK | 48 | |
| LR | IL-10, IL- 1b, IL-4, IL-6 | 6 | ALGA0036131 | 97620286 | T/C | 32,20 | 0.001/3.3 7 | CHR | PLINK, BIMBAM | 49 | |
| LR | IL-10, IL- 4, IL-6 | 6 | M1GA0026030 | 96767590 | A/G | 59,80 | 0,02 | CHR | PLINK | 49 | PTPN2, PSMG2, CEP76, SPIRE1, PRELID3A, AFG3L2, TUBB6, CIDEC, IMPA2, MPPE1_GNAL |
| LR | IL-6 | 6 | DIAS0004325 | 96880806 | C/T | 30,40 | 0,03 | CHR | PLINK | 49 | NITEL, ONAL |
| LR | IL-10, IL- 4, IL-6 | 6 | CASI0006620 | 96926928 | G/A | 31,00 | 0,03 | CHR | PLINK | 49 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ASGA0091444 | 97104675 | T/G | 8,80 | 0,01 | CHR | PLINK | 49 | |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0032131 | 97343439 | T/C | 23,50 | 0,01 | CHR | PLINK | 49 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036189 | 99931515 | G/A | 72,60 | 0,01 | CHR | PLINK | 50 | PTPRM |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036191 | 99956687 | T/C | 94,30 | 0,02 | CHR | PLINK | 50 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-----------------------|-----|-------------|-----------|---------------|-------|----------------|----------------------|--------|-----|------------------------------------------------------------------------------------------------------------|
| LR | IL-10, IL- 4, IL-6 | 6 | CASI0005798 | 100018316 | T/C | 94,30 | 0,02 | CHR | PLINK | 51 | PTPRM, LRRC30, LAMA1, ARHGAP28 |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0003203 | 100175109 | G/A | 27,90 | 0,01 | CHR | PLINK | 51 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0115176 | 100207770 | C/T | 1,40 | 0,02 | CHR | PLINK | 51 | |
| LR | IL-10, IL- 4, IL-6 | 6 | MARC0021350 | 100311040 | C/T | 5,70 | 0,02 | CHR | PLINK | 51 | |
| LR | IL-10, IL- 4, IL-6 | 6 | H3GA0054139 | 100709160 | T/C | 87,00 | 0,01 | CHR | PLINK | 51 | |
| LR | IL-10, IL- 6, IL-4 | 6 | ASGA0029105 | 102340927 | G/A | 9,80 | 0,01 | CHR | PLINK | 52 | DLGAP1 |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036219 | 102362625 | G/A | 9,40 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036233 | 102464736 | T/C | 98,60 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036235 | 102495561 | A/G | 98,40 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | H3GA0018606 | 102641493 | C/T | 10,10 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | DRGA0006658 | 102664930 | T/G | 89,90 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | H3GA0018609 | 102696604 | G/A | 10,10 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 6, IL-4 | 6 | ASGA0029117 | 102709352 | T/G | 89,90 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ALGA0036251 | 102732393 | A/G | 10,10 | 0,01 | CHR | PLINK | 52 | |
| LR | IL-10, IL- 4, IL-6 | 6 | ASGA0097110 | 108033469 | C/T | 5,90 | 0,01 | CHR | PLINK | 53 | |
| LR | MCV | 6 | ALGA0107074 | 119087839 | C/T | 62,60 | 0,04 | CHR | PLINK | 54 | ZSCAN30, ZNF397, ZNF24, ZNF396, INO80C, GALNT1, C18orf21, RPRD1A, U6, SLC39A6, ELP2, MOCOS, FHOD3 |
| LR | MCV | 6 | MARC0042822 | 120066519 | A/G | 60,10 | 0,05 | CHR | PLINK | 54 | |
| LR | MCV | 6 | ALGA0036538 | 120233587 | C/T | 18,90 | 0,04 | CHR | PLINK | 55 | FHOD3 |
| LR | MCV | 6 | MARC0087327 | 120497118 | G/A | 39,50 | 0,04 | CHR | PLINK | 55 | |
| LR | MCV | 6 | ASGA0104109 | 152485189 | C/T | 19,60 | 0,01 | CHR | PLINK | 56 | CYP2J34 |
| LR | MCV | 6 | H3GA0019217 | 164044870 | A/C/G | 44,90 | 0,04 | CHR | PLINK | 57 | FOXD2, FOXE3, CMPK1, STIL |
| LR | MCV | 6 | DIAS0002089 | 164172188 | G/A | 58,70 | 0,04 | CHR | PLINK | 57 | |
| LR | MCV | 6 | ALGA0037661 | 164267809 | A/G | 41,30 | 0,04 | CHR | PLINK | 57 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------|-----|-------------|-----------|---------------|-------|----------------|-------------------------|------------------|-----|--------------------------------------------------------------------------------------------------------|
| LR | MCV | 6 | DIAS0000412 | 165061162 | A/G | 52,60 | 0,04 | CHR | PLINK | 58 | FAAH, NSUN4, LOC100524873, LRRC41, RAD54L, LURAP1, POMGNT1, TSPAN1, P3R3URF, LOC100511937, MAST2 |
| LR | MCV | 6 | ALGA0037681 | 165115253 | A/C | 41,70 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ALGA0037677 | 165136688 | G/A | 47,50 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | CASI0007691 | 165252413 | G/A | 73,90 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ASGA0030214 | 165295895 | A/G | 23,80 | 0,04 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ALGA0037700 | 165361501 | C/T | 73,90 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ASGA0030228 | 165464833 | T/C | 73,50 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ALGA0037714 | 165590160 | A/G | 80,10 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ASGA0030235 | 165616490 | C/T | 61,20 | 0,01 | CHR | PLINK | 58 | |
| LR | MCV | 6 | ALGA0037706 | 165657661 | G/A | 70,30 | 0,01 | CHR | PLINK | 58 | |
| LR | IL-10 | 6 | CASI0008589 | 169767808 | C/T | 60,10 | 0,03 | CHR | PLINK | 59 | |
| LW | BAS | 7 | H3GA0019427 | 2568232 | C/T | 3,40 | 0,04 | CHR | PLINK | 60 | |
| LR | IFN | 7 | H3GA0019660 | 5050865 | C/T | 67,60 | 0,04 | CHR | PLINK | 61 | BMP6 |
| LR | IFN | 7 | H3GA0019664 | 5067246 | T/C | 42,00 | 0,04 | CHR | PLINK | 61 | |
| LW | IL-6 | 7 | ALGA0038559 | 10527098 | C/T | 15,10 | 0,03 | CHR | PLINK | 62 | |
| LR | MCH | 7 | ALGA0039086 | 17730613 | T/C | 78,50 | 0,03 | CHR | PLINK | 63 | |
| LR | IFN | 7 | DRGA0007705 | 61127162 | G/A | 17,50 | 0,05 | CHR | PLINK | 64 | SEC23A |
| LR | IFN | 7 | MARC0055700 | 64966359 | G/A | 69,00 | 0,01 | CHR | PLINK | 65 | BAZ1A |
| LR | IFN | 7 | DRGA0007743 | 66272613 | C/T | 72,00 | 0,05 | CHR | PLINK | 66 | NPAS3 |
| LR | IFN | 7 | ALGA0042479 | 67635211 | C/T | 21,00 | 0,01 | CHR | PLINK | 67 | NUBPL, GPR33, DTD2, HECTD1 |
| LR | IFN | 7 | ALGA0042490 | 67678462 | T/C | 58,80 | 0,02 | CHR | PLINK | 67 | |
| LR | IFN | 7 | ASGA0034445 | 68130280 | G/A | 23,50 | 0,01 | CHR | PLINK | 67 | |
| LR | IFN | 7 | ASGA0034452 | 68167119 | A/G | 76,50 | 0,01 | CHR | PLINK | 67 | |
| LR | IFN | 7 | H3GA0022038 | 68213063 | T/C | 23,50 | 0,01 | CHR | PLINK | 67 | |
| LR | IFN | 7 | ASGA0034456 | 68344394 | G/A | 72,70 | 0,01 | CHR | PLINK | 67 | |
| LR | IFN | 7 | ASGA0034457 | 68408727 | A/G | 76,50 | 0,01 | CHR | PLINK | 67 | |
| LR | IFN | 7 | INRA0026398 | 72991035 | A/G | 76,50 | 0,01 | CHR | PLINK | 68 | |
| LR | IFN | 7 | ALGA0042582 | 74264086 | C/T | 28,30 | 0,02 | CHR | PLINK | 69 | STXBP6 |
| LR | IFN | 7 | ALGA0042584 | 74302403 | A/G | 72,90 | 0,02 | CHR | PLINK | 69 | |
| LR | IFN | 7 | ALGA0042597 | 74546893 | T/C | 43,60 | 0,02 | CHR | PLINK | 69 | |
| LR | IFN | 7 | ALGA0042601 | 74580371 | A/G | 43,60 | 0,02 | CHR | PLINK | 69 | |
| LW | IL-8 | 7 | M1GA0010866 | 115793412 | C/T | 15,50 | 0,02 | CHR | PLINK | 70 | |
| LW | IL-8 | 7 | rs338367467 | 122915952 | G/A | NA | 0,02 | CHR | PLINK | 71 | |
| LW | IL-4 | 8 | MARC0111479 | 4598871 | T/G | 0,00 | 0,03 | CHR | PLINK | 72 | JAKMIP1, C8H4orf50 |
| LW | IL-4 | 8 | ALGA0107038 | 4605432 | T/C | 36,80 | 0,02 | CHR | PLINK | 72 | |
| LW | IL-4 | 8 | ASGA0092577 | 4674424 | G/A | 76,30 | 0,02 | CHR | PLINK | 72 | |
| LR | TNF | 8 | ALGA0046861 | 20647847 | C/T | 1,30 | 0.02/3.23 | GEN | PLINK, BIMBAM | 73 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|------------------|-----|----------------------------|-----------|---------------|-------|----------------|----------------------|------------------|----------|---------------------------------------------------------------------------|
| LR | IL-1b, IL-6 | 8 | ALGA0046899 | 20831553 | G/A | 26,30 | 0.03/3.16 | CHR | PLINK, BIMBAM | 73 | |
| LR | MCH | 8 | ASGA0038765 | 39341631 | T/C | 84,40 | 0.02/3.09 | CHR | PLINK, BIMBAM | 74 | |
| LW | TNF | 9 | ALGA0056053 | 138782132 | T/C | 36,50 | 0.001/3.4 | CHR | PLINK, BIMBAM | 75 | |
| LW | TNF | 9 | ASGA0097568 | 138517855 | T/C | 79,30 | 0.001/4.1 4 | CHR | PLINK, BIMBAM | 75 | |
| LW | BAS | 10 | ALGA0057018 | 10046457 | A/C | 79,60 | 0,05 | CHR | PLINK | 76 | MARK1, C1orf115, MARC2, HLX |
| LW | BAS | 10 | ASGA0046469 | 10399957 | A/C | 6,60 | 0,05 | CHR | PLINK | 76 | |
| LR | PLT | 10 | ALGA0057208 | 13092434 | C/G | 32,40 | 0,03 | CHR | PLINK | 77 | |
| LW | IFN | 10 | ALGA0057334 | 14504374 | G/A | 52,90 | 0,03 | CHR | PLINK | 78 | |
| LW | IL-10, IL- 1b | 10 | ASGA0085873 | 14348970 | T/C | 34,20 | 0.02/3.02 | CHR | PLINK, BIMBAM | 78 | |
| LW | PLT | 10 | MARC0008318 | 16846881 | C/T | 46,30 | 0,04 | CHR | PLINK | 79 | ZBTB18, ADSS, CATSPERE, DESI2, COX20, HNRNPU, EFCAB2, KIF26B |
| LW | IFN | 10 | ALGA0057529 | 17731595 | T/C | 40,50 | 0,04 | CHR | PLINK | 79 | |
| LR | BAS | 10 | ASGA0046986 | 19572163 | C/A | 22,70 | 0,03 | GEN | PLINK | 80 | CCDC185, CAPN8, CAPN2, TP53BP2, FBXO28, ASPM, ZBTB41, CRB1, DENND1B |
| LR | BAS | 10 | ALGA0057739 | 20062069 | G/A | 16,30 | 0,03 | GEN | PLINK | 80 | |
| LR | BAS | 10 | ASGA0047018 | 20134916 | G/A | 63,30 | 0,01 | CHR | PLINK | 80 | |
| LR | BAS | 10 | MARC0058358 | 20157046 | C/T | 13,70 | 0,01 | CHR | PLINK | 80 | |
| LR | BAS | 10 | MARC0050841 | 20188434 | G/A | 63,40 | 0,01 | CHR | PLINK | 80 | |
| LR | BAS | 10 | ALGA0106008 | 20444762 | A/C | 75,40 | 0,01 | CHR | PLINK | 80 | |
| LR | BAS | 10 | H3GA0053667 | 20584936 | C/T | 73,00 | 0,04 | GEN | PLINK | 81 | DENND1B, Clorf53, LHX9, NEK7 |
| LR | BAS | 10 | H3GA0052936 | 20795956 | T/C | 69,90 | 0,02 | GEN | PLINK | 81 | |
| | BAS | 10 | ASGA0098001 | 20805520 | C/T T/C | 30,10 | 0,02 | GEN | PLINK | 81 | |
| | BAS | 10 | MARC0108/93 | 21031390 | 1/C | 0,00 | 0,04 | GEN | PLINK | 81 | |
| | BAS | 10 | MARC0018828 | 21054/56 | G/A | 6,20 | 0,04 | GEN | PLINK DLDIV | 81 | DTDDC |
| | BAS | 10 | DKGA001038/ | 21/20002 | T/G | 05,40 | 0,01 | CHR | PLINK DLINK | 82 82 | PIPKC |
| | DAS | 10 | ALGA0057857 | 22018239 | | 98,00 | 0,01 | | PLINK DLINK | 0Z 82 | |
| | DAS | 10 | ASGA0047084 H3GA0020613 | 22210883 | G/A G/T | 1,40 | 0,01 | CHR | PLINK DI INK | 82 82 | |
| | BAS | 10 | ASGA0023013 | 22302388 | | 91 70 | 0,03 | GEN | PL INK | 82 | NR 5A 2 |
| LR | IFN | 10 | ALGA0059049 | 47339095 | G/A | 13.80 | 0.02 | CHR | PLINK | 84 | FRMD4A PRPF18 |
| LR | WBC | 10 | H3GA0030245 | 47362497 | C/A | 67.40 | 0.03 | CHR | PLINK | 84 | |
| LR | IFN | 10 | ALGA0059118 | 47607670 | C/T | 36.00 | 0.02 | CHR | PLINK | 84 | |
| LR | IFN | 10 | H3GA0030271 | 47676308 | G/T | 36.00 | 0.02 | CHR | PLINK | 84 | |
| LR | IFN | 10 | ALGA0103761 | 47805800 | G/A | 40,50 | 0,02 | CHR | PLINK | 84 | |

| | 1. | |
|-----|---------|---|
| Λ 1 | mondix | 7 |
| | JUCHULA | |
| | | - |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------------|-----|-------------|-----------|---------------|-------|----------------|----------------------|------------------|-----|---------------------------------------------------------|
| LR | IFN | 10 | MARC0063711 | 47808917 | G/A | 77,50 | 0,02 | CHR | PLINK | 84 | |
| LR | IFN | 10 | MARC0018399 | 47902144 | T/C | 63,70 | 0,02 | CHR | PLINK | 84 | |
| LR | IFN | 10 | ALGA0106385 | 48144674 | A/G | 69,80 | 0,05 | CHR | PLINK | 84 | |
| LR | PLT | 11 | DRGA0011044 | 29520725 | G/A | 24,60 | 0,04 | CHR | PLINK | 85 | |
| LR | PLT | 11 | ALGA0061774 | 31018065 | A/G | 24,60 | 0,04 | CHR | PLINK | 86 | |
| LR | PLT | 11 | ALGA0061941 | 37838969 | C/A | 56,20 | 0,03 | CHR | PLINK | 87 | |
| LR | PLT | 11 | MARC0063044 | 38170099 | G/A | 57,60 | 0,03 | CHR | PLINK | 87 | |
| LW | IL-4, IL-6 | 12 | MARC0051288 | 11986602 | T/C | 19,40 | 0,05 | CHR | PLINK | 88 | RGS9 |
| LW | IL-4, IL-6 | 12 | ALGA0113815 | 12017916 | G/A | 11,60 | 0,05 | CHR | PLINK | 88 | |
| LW | PLT | 12 | ASGA0105124 | 43334485 | A/G | 48,70 | 0,05 | CHR | PLINK | 89 | |
| LW | RBC | 12 | ALGA0066876 | 50111768 | T/C | 79,00 | 0,05 | CHR | PLINK | 90 | ZZEF1 |
| LW | RBC | 12 | ALGA0066881 | 50146135 | A/G | 79,00 | 0,05 | CHR | PLINK | 90 | |
| LR | MCH | 12 | H3GA0035045 | 59136124 | T/G | 63,20 | 0,04 | CHR | PLINK | 91 | TRPV2 |
| LR | PLT | 13 | CASI0007872 | 80594858 | G/A | 13,20 | 0,04 | CHR | PLINK | 92 | |
| LR | IL-4 | 13 | MARC0096953 | 159404532 | C/T | 0,00 | 0,06 | CHR | PLINK | 92 | |
| LR | BAS | 13 | ALGA0073579 | 192910051 | T/C | 10,50 | 0,02 | GEN | PLINK | 93 | GRIK1 |
| LW | IL-6 | 13 | MARC0058120 | 199890469 | T/C | 92,10 | 0,04 | CHR | PLINK | 94 | DOP1B |
| LR | HMT | 14 | ASGA0063672 | 57514155 | T/C | 89,30 | 0,04 | CHR | PLINK | 95 | |
| LR | HMG, HMT | 14 | H3GA0040407 | 57739629 | C/T | 26,80 | 0,02 | CHR | PLINK | 96 | |
| LR | HMG, HMT | 14 | ALGA0077929 | 57765084 | A/G | 26,60 | 0,02 | CHR | PLINK | 96 | |
| LR | HMT | 14 | ALGA0078039 | 59298541 | C/T | 51,40 | 0,05 | CHR | PLINK | 97 | |
| LR | HMG, HMT | 14 | ALGA0078088 | 59646142 | C/T | 30,80 | 0,01 | CHR | PLINK | 97 | |
| LR | HMG, HMT | 14 | ALGA0078075 | 59656180 | A/C | 30,90 | 0,01 | CHR | PLINK | 97 | |
| LR | HMG, HMT | 14 | ALGA0106769 | 59712299 | A/G | 11,30 | 0,04 | CHR | PLINK | 97 | |
| LR | HMG, HMT | 14 | MARC0004519 | 59803997 | G/A | 65,30 | 0,01 | CHR | PLINK | 97 | |
| LR | HMG, HMT | 14 | ALGA0078091 | 59831072 | T/C | 71,40 | 0,01 | CHR | PLINK | 97 | |
| LR | HMG, HMT | 14 | ASGA0063815 | 59277912 | C/T | 30,40 | 0.01/3.07 | CHR | PLINK, BIMBAM | 97 | |
| LR | HMG, HMT | 14 | MARC0013023 | 59263540 | C/T | 12,60 | 0.01/3.07 | CHR | PLINK, BIMBAM | 97 | TRIM67, FAM89A, ARV1, TTC13, C1orf198, CAPN9, AGT, COG2 |
| LR | IL-4, IL-10 | 14 | ASGA0066844 | 126901849 | T/C | 35,70 | 0.04/3.49 | CHR | PLINK, BIMBAM | 98 | HSPA12A |
| LR | IL-4 | 14 | M1GA0019225 | 126921868 | C/T | 33,70 | 0.04/3.09 | CHR | PLINK, BIMBAM | 98 | |

| | 1. |
|-------|---------|
| Λ 101 | non div |
| AD | ренсих |
| 1 1 P | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|---------------|-----|----------------|-----------|---------------|--------------------|----------------|----------------------|----------------|-----|----------------------------------|
| LW | RBC | 15 | ALGA0085557 | 55981133 | G/A | 94 30 | 0.03 | CHR | PLINK | 99 | |
| LR | IL-8 | 15 | INRA0049820 | 84421614 | T/C | 95.80 | 0.02 | CHR | PLINK | 100 | |
| LR | IL-8 | 15 | INRA0049822 | 93936954 | A/G | 4.30 | 0.02 | CHR | PLINK | 101 | COL5A2 |
| LR | IL-8 | 15 | DRGA0017581 | 102403412 | T/C | 63.20 | 0.03 | CHR | PLINK | 102 | U6 |
| LR | IL-8 | 15 | INRA0049968 | 102936048 | G/A | 12.70 | 0.03 | CHR | PLINK | 102 | |
| LR | IL-8 | 15 | ALGA0086618 | 107604568 | T/C | 14,50 | 0,01 | CHR | PLINK | 103 | PARD3B |
| LR | IL-8 | 15 | DRGA0015341 | 107753847 | G/A | 83,50 | 0,02 | CHR | PLINK | 103 | |
| LR | IL-8 | 15 | MARC0089453 | 107887493 | C/A | 34,30 | 0,02 | CHR | PLINK | 103 | |
| TD | по | 15 | ALC A009((2) | 100024616 | T/C | 46.70 | 0.001/3.1 | CUD | PLINK, | 104 | |
| LK | IL-8 | 15 | ALGA0080031 | 108024010 | 1/C | 40,70 | 3 | СНК | BIMBAM | 104 | PARD3B, U6 |
| ID | П 9 | 15 | ALCA0108727 | 108225252 | G/A | 10 00 | 0.01/2.20 | CUD | PLINK, | 104 | |
| LK | IL-0 | 15 | ALUA0108/37 | 108555555 | U/A | 40,00 | 0.01/5.59 | CIIK | BIMBAM | 104 | |
| LR | IL-8 | 15 | ALGA0086637 | 108446984 | G/A | 57,80 | 0,04 | CHR | PLINK | 104 | |
| LR | IL-8 | 15 | DRGA0015357 | 108505209 | A/G | 53,00 | 0,02 | CHR | PLINK | 104 | |
| LR | IL-8 | 15 | MARC0089139 | 108677884 | A/C | 65,30 | 0,01 | CHR | PLINK | 104 | |
| LR | IL-8 | 15 | ASGA0070317 | 108794926 | A/G | 32,30 | 0,01 | CHR | PLINK | 104 | |
| LR | IL-8 | 15 | H3GA0044820 | 108848114 | G/C | 39,60 | 0,02 | CHR | PLINK | 104 | |
| LR | П -8 | 15 | ASGA0102483 | 108311749 | C/T | 48 80 | 0.001/3.3 | CHR | PLINK, | 104 | |
| LIC | IL 0 | 15 | 1156/10102 105 | 100511715 | 0/1 | 10,00 | 9 | CIIIC | BIMBAM | 101 | |
| LR | IL-8 | 15 | ALGA0086678 | 109394965 | G/A | 50.70 | 0.001/3.2 | CHR | PLINK, | 105 | |
| 2.11 | | 10 | | 10,00,000 | 0/11 | 20,70 | 8 | onne | BIMBAM | 100 | |
| LR | IL-8 | 15 | ALGA0086703 | 109971469 | G/A | 60.00 | 0.001/3.0 | CHR | PLINK, | 105 | |
| | | | | | | , | 9 | | BIMBAM | | BLOOD NEWEST FEETRA CHORDS |
| I D | H O | 1.5 | 19910000000 | 100015007 | | 14.20 | 0.02 | CIID | | 105 | INO80D, NDUFSI, EEFIB2, SNORD51, |
| LR | IL-8 | 15 | ASGA0093834 | 109215027 | G/A | 14,30 | 0,02 | CHR | PLINK | 105 | SNORA41, GPR1, ZDBF2, |
| I D | но | 1.5 | DID 40050045 | 110004050 | | 15 (0 | 0.04 | CUD | | 100 | ADAM23, FAM23/A, DYIN |
| | IL-8 | 15 | INKA0050045 | 112324352 | C/A | 45,60 | 0,04 | CHR | PLINK | 106 | MAP2, UNC80 |
| LR | MON | 15 | ALGA0086800 | 112624977 | G/A | 90,10 | 0,02 | CHR | PLINK | 106 | |
| LR | IL-8 | 15 | ALGA0086892 | 116134508 | A/C | 68,80 | 0.001/3.8 | CHR | PLINK, | 107 | |
| τD | πο | 15 | ASC A0007264 | 115607024 | T/C | 79 60 | 0.02 | CUD | DI DIV | 107 | SDAC16 |
| | IL-8 П. 9 | 15 | ASGA0097504 | 115067234 | 1/C | 78,00 | 0,02 | | PLINK DLINK | 107 | SPAGIO |
| | IL-8 П. 9 | 15 | ASGA0070437 | 115900755 | C/1 T/C | 20,50 | 0,02 | | DI INIZ | 107 | |
| | IL-8 П. 9 | 15 | ASGA0070443 | 115987500 | 1/C T/C | 55, 4 0 | 0,03 | | DI INIZ | 107 | |
| | IL-8 II 8 | 15 | MARC0034808 | 116078414 | 1/C T/C | 78.60 | 0,03 | CHR | PLINK DLINK | 107 | |
| IP | IL-0 II -8 | 15 | H3GA004/287 | 116385367 | T/C | 23 00 | 0,02 | CHR | PLINK | 107 | |
| LR | П8 | 15 | MARC0109222 | 116779658 | C/A | 0.00 | 0.02 | CHR | PLINK | 107 | VWC2L |
| LR | П-8 | 15 | ASGA0100540 | 116787417 | T/C | 22.00 | 0.02 | CHR | PLINK | 108 | |
| LR | П8 | 15 | ALGA0086910 | 116823946 | G/A | 78.00 | 0.02 | CHR | PLINK | 108 | |
| | | 15 | | 110023510 | 5/11 | , 0,00 | 0.001/4.4 | | PLINK. | 100 | |
| LR | IL-8 | 15 | ALGA0087116 | 120286163 | A/G | 31,90 | 7 | CHR | BIMBAM | 109 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------|-----|-------------|-----------|---------------|-------|----------------|----------------------|------------------|-----|----------------------------------------------------------|
| LR | IL-8 | 15 | ASGA0070586 | 120106066 | T/C | 68,20 | 0.001/5.8 | CHR | PLINK, BIMBAM | 109 | |
| LR | IL-8 | 15 | ASGA0070620 | 120351434 | T/C | 41,60 | 0.001/4.2 | CHR | PLINK, BIMBAM | 109 | |
| LR | IL-8 | 15 | H3GA0044814 | 119982356 | A/G | 53,70 | 0,02 | CHR | PLINK | 109 | TNS1, RUFY4, CXCR2, ARPC2, GPBAR1, AAMP, PNKD, TMBIM1 |
| LR | IL-8 | 15 | H3GA0044951 | 119984036 | T/C | 59,10 | 0,02 | CHR | PLINK | 109 | |
| LR | IL-8 | 15 | ASGA0070560 | 119995203 | T/C | 40,00 | 0,02 | CHR | PLINK | 109 | |
| LR | IL-8 | 15 | ASGA0070582 | 120083397 | G/A | 59,80 | 0,02 | CHR | PLINK | 109 | |
| LR | IL-8 | 15 | ALGA0087090 | 120139024 | T/C | 87,80 | 0,01 | CHR | PLINK | 109 | |
| LR | IL-8 | 15 | M1GA0020457 | 121398466 | C/A | 30,00 | 0,02 | CHR | PLINK | 110 | DNPEP, ssc-mir-4334, DES, SPEGNB, GMPPA, ASIC4, CHPF, |
| | | | | | | | , i | | | | TMEM198, OBSL1 |
| LR | IL-8 | 15 | ASGA0083683 | 121570012 | G/A | 56,30 | 0,02 | CHR | PLINK | 110 | |
| LR | IL-8 | 15 | ALGA0110389 | 121570230 | A/G | 43,60 | 0,02 | CHR | PLINK | 110 | |
| LR | IL-8 | 15 | ASGA0070855 | 122524508 | T/C | 57,50 | 0,03 | CHR | PLINK | 111 | EPHA4 |
| LR | IL-8 | 15 | ALGA0087356 | 122895848 | C/A | 43,80 | 0,01 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ALGA0087350 | 122979514 | C/T | 15.40 | 0.04 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | MARC0114457 | 123052286 | T/C | 0,00 | 0,02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | DRGA0015530 | 123132577 | T/C | 60,00 | 0.03 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ALGA0087340 | 123144118 | C/T | 23.10 | 0.03 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ASGA0070822 | 123171616 | C/T | 10.90 | 0.02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ALGA0087328 | 123241971 | A/G | 68.10 | 0.02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | MARC0070811 | 123293141 | T/C | 68.10 | 0.02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | MARC0028230 | 123311817 | C/T | 10.80 | 0.02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ALGA0087324 | 123363010 | G/A | 21.40 | 0.02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ALGA0087321 | 123392506 | T/C | 59.10 | 0.02 | CHR | PLINK | 111 | |
| LR | IL-8 | 15 | ALGA0100462 | 123671193 | C/T | 32.30 | 0.02 | CHR | PLINK | 112 | PAX3, SGPP2 |
| LR | IL-8 | 15 | ALGA0087297 | 123851318 | T/G | 40.20 | 0.02 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | ASGA0070779 | 124103554 | C/T | 55.70 | 0.03 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | ASGA0070769 | 124118055 | C/T | 40.80 | 0.04 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | M1GA0020474 | 124151048 | T/C | 59.30 | 0.04 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | H3GA0045081 | 124207280 | G/A | 40.80 | 0.04 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | ALGA0087267 | 124331577 | T/C | 63.10 | 0.02 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | H3GA0045073 | 124347713 | G/T | 35.60 | 0.02 | CHR | PLINK | 112 | |
| LR | IL-8 | 15 | ASGA0071003 | 126072246 | T/C | 37,00 | 0.001/3.5 | CHR | PLINK, BIMBAM | 113 | |
| LR | IL-8 | 15 | H3GA0045046 | 124686575 | A/G | 61.30 | 0.03 | CHR | PLINK | 113 | ACSL3, KCNE4, SCG2, AP1S3, WDFY1, |
| LR | IL-8 | 15 | ASGA0101298 | 126013489 | C/T | 55,60 | 0,02 | CHR | PLINK | 113 | MRPL44, SERPINE2 |
| | | | | | | | | | | | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-----------------------|-----|-------------|----------|---------------|-------|----------------|----------------------|------------------|-----|-----------------------------------------------------------------------------------------------|
| LW | RBC | 16 | ALGA0089752 | 23580846 | T/G | 74,10 | 0,01 | CHR | PLINK | 114 | EGFLAM, LIFR, OSMR, RICTOR, U6, U4, FYB1 |
| LW | RBC | 16 | DRGA0015975 | 24344082 | T/C | 53,10 | 0,00 | CHR | PLINK | 114 | |
| LW | RBC | 16 | ALGA0089777 | 24362179 | T/C | 39,40 | 0,01 | CHR | PLINK | 114 | |
| LW | RBC | 16 | ASGA0072751 | 25032947 | C/T | 82,10 | 0,00 | CHR | PLINK | 115 | |
| LW | MCH | 16 | ALGA0090595 | 45164366 | C/A | 22,60 | 0,04 | CHR | PLINK | 116 | MAST4 |
| LW | MCH | 16 | ALGA0090596 | 45178452 | T/C | 55,30 | 0,04 | CHR | PLINK | 116 | |
| LW | MCH | 16 | DRGA0016198 | 45430274 | T/C | 30,30 | 0,04 | CHR | PLINK | 116 | |
| LW | MCH | 16 | ALGA0090558 | 48020257 | T/G | 43,30 | 0,04 | CHR | PLINK | 117 | |
| LW | МСН | 16 | ALGA0091962 | 73764474 | A/C | 42,10 | 0.001/3.0 | CHR | PLINK, BIMBAM | 118 | |
| LW | MCH | 16 | MARC0075417 | 73485704 | A/C | 44,40 | 0,04 | CHR | PLINK | 118 | U6 |
| LW | MCH PBC | 16 | ALGA0091954 | 73703925 | G/A | 61,40 | 0,04 | CHR | PLINK | 118 | |
| LW | HMG, HMT | 16 | ASGA0074790 | 78019054 | C/T | 99,10 | 0,03 | GEN | PLINK | 119 | |
| LW | RBC, HMG, HMT | 16 | M1GA0021462 | 78037702 | T/C | 7,90 | 0,00 | CHR | PLINK | 119 | |
| LW | BAS | 17 | ALGA0112929 | 106110 | G/A | 55,50 | 0,01 | GEN | PLINK | 120 | |
| LW | IL-10, TNF | 17 | DRGA0016627 | 20677871 | T/G | 8,40 | 0,03 | CHR | PLINK | 121 | |
| LW | IL-10, TNF | 17 | MARC0055684 | 20763022 | A/C | 89,70 | 0,03 | CHR | PLINK | 121 | |
| LW | IL-10 | 17 | ASGA0075780 | 22286059 | C/T | 37,00 | 0,01 | CHR | PLINK | 122 | TASP1 |
| LW | IL-10, IL- 1b, TNF | 17 | ASGA0075903 | 26077336 | C/T | 81,10 | 0.01/3.23 | CHR | PLINK, BIMBAM | 123 | |
| LW | IL-10 | 17 | MARC0069703 | 25378015 | C/T | 74,30 | 0,01 | CHR | PLINK | 123 | PCSK2, BFSP1, DSTN, RRBP1 |
| LW | IL-10 | 17 | ASGA0075884 | 25454088 | C/A | 4,40 | 0,04 | CHR | PLINK | 123 | |
| LW | IL-10 | 17 | ASGA0075887 | 25830486 | A/G | 69,60 | 0,03 | CHR | PLINK | 123 | |
| LR | PLT | 17 | ASGA0076045 | 28192131 | C/T | 8,80 | 0.001/3.1 | CHR | PLINK, BIMBAM | 124 | CFAP61 |
| LR | PLT | 17 | MARC0093077 | 28351838 | G/A | 0,00 | 0.001/3.1 | CHR | PLINK, BIMBAM | 124 | |
| LR | PLT | 17 | ASGA0076328 | 30803219 | A/C | 78,90 | 0,04 | CHR | PLINK | 125 | ACSS1 |
| LR | PLT | 17 | ASGA0076514 | 33282761 | C/T | 95,70 | 0.001/3.3 | CHR | PLINK, BIMBAM | 126 | |
| LW | TNF | 17 | M1GA0021900 | 32932811 | A/G | 51,60 | 0,03 | CHR | PLINK | 126 | EBF4, IDH3B, NOP56, SNORD57, SNORD56, SNORD86, SNORD110, TMC2, SNRPB, TGM6, STK35, PDYN |
| LW | TNF | 17 | H3GA0048609 | 33080621 | T/C | 43,70 | 0,03 | CHR | PLINK | 126 | |
| LW | TNF | 17 | MARC0018597 | 33099516 | A/G | 54,90 | 0,03 | CHR | PLINK | 126 | |
| LR | PLT | 17 | M1GA0021930 | 33651909 | A/C | 72,60 | 0,01 | CHR | PLINK | 126 | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P- value/BF | Type of significance | Method | QTL | Nearest gene within QTL |
|-------|-------|-----|-------------|----------|---------------|-------|----------------|----------------------|--------|-----|------------------------------------|
| LW | BAS | 18 | DRGA0016945 | 25162286 | G/A | 16,60 | 0,02 | CHR | PLINK | 127 | PTPRZ1 |
| LW | BAS | 18 | ALGA0097582 | 25200554 | C/T | 83,40 | 0,02 | CHR | PLINK | 127 | |
| LW | BAS | 18 | ASGA0079343 | 25373224 | C/T | 17,00 | 0,02 | CHR | PLINK | 127 | |
| LR | IL-8 | 18 | H3GA0051155 | 50710948 | T/C | 7,20 | 0,01 | CHR | PLINK | 128 | DDX56, NPC1L1, NUDCD3, GCK, CAMK2B |
| LR | IL-8 | 18 | M1GA0023403 | 50826524 | G/A | 95,50 | 0,06 | CHR | PLINK | 128 | |
| LR | IL-8 | 18 | ALGA0098768 | 50874905 | A/C | 16,00 | 0,06 | CHR | PLINK | 128 | |

SSC=Sus scrofa chromosome, SNP=single nucleotide polymorphism, m/M allele=minor/major allele, MAF=minor allele frequency, QTL nr.=quantitative trait loci progressive number based on ± 1 Mbp distance from a significant SNP, LR=Landrace, LW=Large White, RBC=red blood cells, HMG=hemoglobin, HMT=hematocrit, MCV= mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, PLT=platelets, WBC=white blood cells, NEU=neutrophils, LYM=lymphocytes, MON=monocytes, EOS=eosinophils, BAS=basophils, HAP=haptoglobin, IFN- γ = interferon- γ , IL=interleukin, TNF- α = tumor necrosis factor- α .

| Drood | Troit | SSC | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-------------------------------------|-----|---------------|----------|--------|-------|----------|--------------|--------------|-----|----------------|
| breeu | | 350 | 5111 | rosition | allele | MAF | BF | significance | Ivietnou | QIL | within QTL |
| LW | IL4 IL10 IL1b IL6, L6 IFN IL10 IL1b | 1 | MARC0070292 | 2139822 | C/A | 43,70 | 3,17 | GEN | mvBIMBA M | 1 | |
| LR | HMT HMG MCHC | 1 | MARC0008402 | 3478464 | G/T | 17,00 | 0,01 | CHR | CCA | 2 | |
| | | | | | | | | | | | IGF2R, MAS1, |
| | | | | | | | | | | | PNLDC, MRPL18, |
| | | | | | | | | | | | TCP1, SNORA29, |
| LR | HMT HMG MCHC | 1 | ALGA0000682 | 7402285 | A/G | 87,30 | 0,01 | CHR | CCA | 3 | ACAT2, |
| | | | | | | | | | | | SNORA20, SOD2, |
| | | | | | | | | | | | FNDC1, TAGAP, |
| | | | | | | | | | | | RSPH3 |
| LW | RBC HMG HMT MCV MCH MCHC | 1 | ALGA0000778 | 8362294 | G/A | 23,10 | 0,05 | CHR | CCA | 3 | |
| LW | RBC HMG HMT MCV MCH MCHC | 1 | ALGA0000795 | 8724875 | A/G | 74,10 | 0,05 | CHR | CCA | 4 | TULP4 |
| LW | RBC HMG HMT MCV MCH MCHC | 1 | ASGA0000892 | 8739103 | T/C | 25,90 | 0,05 | CHR | CCA | 4 | |
| | | | | | | | | | | | TULP4, SERAC1, |
| I W | RBC HMG HMT MCV MCH MCHC | 1 | ALGA0000837 | 8810463 | T/G | 25.80 | 0.05 | CHR | CCA | 5 | SYNJ2, SNX9, |
| L | NDC HING HIMT MCV MCH MCHC | 1 | 71LG/10000037 | 0010405 | 1/0 | 25,00 | 0,05 | CIIK | cen | 5 | ZDHHC14, |
| | | | | | | | | | | | TMEM242 |
| LW | RBC HMG HMT MCV MCH MCHC | 1 | ASGA0000925 | 8896901 | T/C | 25,90 | 0,05 | CHR | CCA | 5 | |
| | RBC HMG HMT MCV MCH MCHC | | | | | | 0.023/3 | | CCA, | | |
| LW | HMG MCHC | 1 | ALGA0106880 | 9725288 | A/G | 26,00 | 0.02575. | GEN | mvBIMBA | 5 | |
| | | | | | | | 21 | | М | | |
| LW | IFN IL12 IL8 TNF | 1 | ASGA0001122 | 12337822 | A/G | 46,30 | 0,01 | CHR | PCA | 6 | CNKSR3 |
| T W | ИАН 10 И 15 И 6 | 1 | H2CA0002125 | 78746460 | C/A | 12.20 | 2 16 | CEN | mvBIMBA | 7 | |
| | | 1 | 113UA0002155 | /0/40409 | U/A | 12,30 | 3,10 | JEN | М | / | |
| | | | | | | | | | | | |

| Table S 10: Significant | associated a | genetic markers | identified wi | ith multivariat | e methods (| (continued) | |
|-------------------------|--------------|-----------------|---------------|-----------------|-------------|-------------|--|
| - 0 | 4 | | | | | · / | |

| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P-value/ BF | Type of significance | Method | QTL | Nearest Gene within QTL |
|-------|-----------------------------------------------------------|-----|-------------|---------------|---------------|-------|----------------|-------------------------|--------|-----|--------------------------------------|
| LR | WBC NEU LYM MON | 1 | ASGA0004864 | 14801378 8 | G/A | 70,70 | 0,05 | CHR | PCA | 8 | ZNF516 |
| LR | WBC NEU LYM MON | 1 | H3GA0003011 | 14845220 3 | A/G | 87,30 | 0,05 | CHR | PCA | 8 | |
| LR | WBC NEU LYM MON | 1 | ALGA0006425 | 14926164 6 | A/G | 90,20 | 0,05 | CHR | PCA | 9 | ZNF407, CNDP1, CNDP2 |
| LR | WBC NEU LYM MON | 1 | ALGA0006427 | 14928624 8 | A/G | 90,20 | 0,05 | CHR | PCA | 9 | |
| LR | WBC NEU LYM MON | 1 | ASGA0004896 | 14957391 6 | T/C | 90,20 | 0,05 | CHR | PCA | 9 | |
| LR | WBC NEU LYM MON | 1 | ALGA0006599 | 15966030 3 | G/A | 45,70 | 0,05 | CHR | PCA | 10 | CDH20 |
| LR | WBC NEU LYM MON | 1 | ALGA0006623 | 16034718 8 | T/C | 37,60 | 0,05 | CHR | PCA | 10 | |
| LW | RBC HMG HMT MCV MCH MCHC | 1 | ASGA0006456 | 24318293 5 | T/C | 6,60 | 0,01 | GEN | CCA | 11 | TMEM246 |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | ASGA0006490 | 24518694 4 | G/A | 71,20 | 0,05 | CHR | CCA | 12 | SMC2, OR13C8, NIPSNAP3A, ABCA1 |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | DRGA0002258 | 24524335 0 | T/C | 28,80 | 0,05 | CHR | CCA | 12 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | ASGA0006492 | 24533272 4 | G/A | 71,20 | 0,05 | CHR | CCA | 12 | |
| LW | HMT HMG MCHC | 1 | DIAS0000064 | 24556498 8 | T/C | 26,20 | 0,02 | CHR | CCA | 12 | |

| Brood | Troit | SSC | SND | Position | m/M | MAE | P-value/ | Type of | Mathad | ΟΤΙ | Nearest Gene |
|-------|-----------------------------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|--------------|-----|-------------------------------------------|
| Diccu | 11 au | 350 | 5141 | 1 USITION | allele | WIAF | BF | significance | Wittiou | QIL | within QTL |
| LW | RBC HMG HMT MCV MCH MCHC | 1 | DIAS0000004 | 24618546 1 | T/C | 8,40 | 0,03 | GEN | CCA | 12 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | ALGA0008960 | 24705172 5 | T/C | 27,20 | 0,03 | GEN | CCA | 13 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | MARC0053473 | 24763079 8 | G/A | 20,30 | 0,05 | CHR | CCA | 14 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | ALGA0008971 | 24768813 9 | G/A | 14,40 | 0,05 | CHR | CCA | 14 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC, PLT RBC WBC | 1 | ALGA0008972 | 24772138 2 | T/C | 84,40 | 0,05 | CHR | CCA | 14 | |
| LW | RBC HMG HMT | 1 | ASGA0008077 | 27096882 5 | G/A | 1,20 | 0,05 | CHR | РСА | 15 | LAMC3, AIF1L, NUP214, PLPP7, FAM78A |
| LW | RBC HMG HMT | 1 | H3GA0056709 | 27123966 5 | T/C | 95,30 | 0,05 | CHR | PCA | 15 | |
| LW | RBC HMG HMT | 1 | MARC0039390 | 27125144 0 | G/A | 13,30 | 0,05 | CHR | PCA | 15 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | H3GA0053137 | 9252507 | C/T | 39,70 | 0,02 | CHR | CCA | 16 | |
| LW | IL4 IL10 IL1b IL6 | 2 | H3GA0006173 | 17462745 | T/C | 98,00 | 4,06 | GEN | mvBIMBA M | 17 | TP53I11, TSPAN18 |
| LR | HMT HMG MCHC | 2 | ALGA0122588 | 17672685 | G/A | 11,70 | 0,00 | GEN | CCA | 17 | |
| LR | HMT HMG MCHC | 2 | H3GA0006190 | 17683291 | A/G | 88,20 | 0,00 | GEN | CCA | 17 | |

| Drood | Tueit | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-------------------------------------------|-----|-------------|----------|--------|-------|----------------|--------------|----------------------|-----|-----------------|
| Бгеец | 1 ган | ssc | SINF | rosition | allele | MAF | BF | significance | Method | QIL | within QTL |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC | 2 | DRGA0002793 | 21669969 | A/G | 87,10 | 0,04 | GEN | CCA | 18 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC | 2 | ASGA0101016 | 21751485 | C/T | 86,90 | 0,01 | CHR | CCA | 18 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMG MCH | 2 | ALGA0012559 | 22792581 | G/A | 86,40 | 0,01 | CHR | CCA | 19 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0012570 | 22989364 | T/G | 90,00 | 0,01 | CHR | CCA | 19 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | H3GA0006308 | 23073900 | G/A | 7,40 | 0,02 | CHR | CCA | 19 | |
| LR | WBC HMT EOS HAP IL8 | 2 | ALGA0013060 | 37186143 | C/T | 4,10 | 0,03 | CHR | CCA, TATES | 20 | ANO5, U6, NELL1 |
| LR | WBC HMT EOS HAP IL8 | 2 | DRGA0002935 | 37202269 | A/G | 95,90 | 0,03 | CHR | CCA, TATES | 20 | |
| LR | WBC HMT EOS HAP IL8 | 2 | ALGA0013078 | 37762734 | G/T | 4,10 | 0,03 | CHR | CCA, TATES | 20 | |
| LR | WBC HMT EOS HAP IL8 | 2 | ALGA0013104 | 37945462 | C/T | 4,10 | 0,03 | CHR | CCA, TATES | 20 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0025931 | 82861588 | G/A | 28,50 | 0,02 | CHR | CCA | 21 | ARHGEF28 |
| | | | | | | | | | | | SV2C, IQGAP2, |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010629 | 84881427 | T/C | 64,10 | 0,02 | CHR | CCA | 22 | F2RL2, F2R, |
| | | | | | | | | | | | F2RL1, S100Z |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010636 | 84975794 | G/A | 47,30 | 0,05 | CHR | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | H3GA0006974 | 85003252 | T/G | 68,20 | 0,05 | CHR | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014115 | 85026066 | T/C | 52,70 | 0,05 | CHR | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010644 | 85053423 | G/A | 32,30 | 0,04 | GEN | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014120 | 85137614 | G/A | 33,40 | 0.001/3. 24 | GEN | CCA, mvBIMBA M | 22 | |

| Durad | Tueit | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|----------|-----------------------------------------------------------------------|-----|----------------------------|----------------------|------------|----------------|------------------------|--------------|-----------------------------|----------|-------------------------------------------------------------------|
| вгееа | | 350 | SINF | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | H3GA0006975 | 85151135 | T/C | 57,70 | 0,01 | GEN | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0064603 | 85463127 | C/T | 39,90 | 0,03 | GEN | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC | 2 | ASGA0105637 | 85559227 | A/G | 66,20 | 0,00 | GEN | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010665 | 85664532 | A/G | 52,00 | 0,03 | GEN | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | H3GA0006999 | 85759107 | A/G | 44,30 | 0,03 | CHR | CCA | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | DRGA0003080 | 85772887 | C/T | 41,30 | 0.001/3. 16 | GEN | CCA, mvBIMBA M | 22 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0104997 | 86320678 | T/C | 54,80 | 0,03 | GEN | ССА | 23 | WDR41, OTP, TBCA, AP3B1, SCAMP1, LHFPL2, ssc-mir-10384-2 |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014192 | 86505377 | T/C | 41,90 | 0,03 | CHR | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014189 | 86542827 | A/G | 42,70 | 0,03 | CHR | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010704 | 86556317 | C/T | 48,40 | 0,03 | GEN | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC | 2 | ASGA0101845 | 86593472 | G/A | 38,20 | 0.001/3. 27 | GEN | CCA, mvBIMBA M | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010722 | 86799398 | G/A | 32,30 | 0,05 | GEN | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014199 | 86842615 | A/C | 56,20 | 0,03 | GEN | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014200 | 86869012 | T/C | 55,80 | 0,03 | GEN | CCA | 23 | |
| LW LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014210 ALGA0014211 | 86926962 86998119 | C/T G/T | 24,80 56,00 | 0.001/3. 39 0,03 | GEN GEN | CCA, mvBIMBA M CCA | 23 23 | |
| | | | | | | | | | | | |

| Droad | Troit | SSC | SND | Desition | m/M | мае | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-------------------------------------------|-----|-------------|---------------|--------|-------|----------------|--------------|----------------------|-----|--------------------------------------------------|
| Diccu | 11 au | 350 | 5141 | 1 05101011 | allele | WIAT | BF | significance | WICHIOU | QIL | within QTL |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014214 | 87021610 | G/A | 40,40 | 0.001/3. 16 | GEN | CCA, mvBIMBA M | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010734 | 87247735 | T/C | 54,70 | 0,05 | GEN | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014235 | 87337977 | A/G | 65,10 | 0,02 | GEN | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014249 | 87434796 | T/C | 59,90 | 0,01 | CHR | CCA | 23 | |
| LW | RBC HMG HMT MCV MCH MCHC, HMT HMG MCHC | 2 | ASGA0010750 | 87530974 | C/T | 24,90 | 0.001/3. 39 | GEN | CCA, mvBIMBA M | 24 | ARSB, DMGDH, BHMT |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010766 | 87596607 | T/C | 51,80 | 0,05 | CHR | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010767 | 87610569 | G/A | 48,10 | 0,05 | CHR | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014269 | 87662401 | C/T | 41,70 | 0,05 | GEN | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0085122 | 87708844 | A/G | 62,90 | 0,03 | GEN | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010772 | 87745745 | T/C | 50,50 | 0,02 | GEN | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0055537 | 87768647 | C/T | 47,60 | 0,02 | GEN | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0010776 | 87798540 | G/T | 39,90 | 0,01 | CHR | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0014272 | 87888457 | A/G | 44,10 | 0,05 | GEN | CCA | 24 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0097255 | 11909879 8 | G/A | 48,60 | 0,05 | CHR | CCA | 25 | |
| LR | BAS MON | 2 | ALGA0102645 | 12072860 2 | G/T | 38,40 | 0,03 | GEN | CCA | 26 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0085402 | 12968498 2 | G/A | 9,40 | 0,03 | CHR | CCA | 27 | ALDH7A1, PHAX, TEX43, LMNB1, MARCH3, PRRC1 |
| LR | HMG MCHC IL10, HMT HMG MCHC | 2 | DIAS0002725 | 12969547 6 | G/A | 80,50 | 0,04 | GEN | CCA | 27 | |

| Drood | Trait | SSC | SC SNP P | Desition | m/M | мае | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|----------|-----|----------------------------------------|
| Dreeu | Trait | ssc | 5111 | rosition | allele | IVIAT | BF | significance | Ivietnou | QIL | within QTL |
| LR | HMG MCHC IL10, HMT HMG MCHC | 2 | DIAS0003483 | 12972351 6 | T/C | 10,30 | 0,02 | GEN | CCA | 27 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0015941 | 13046091 5 | T/C | 25,80 | 0,01 | CHR | CCA | 27 | |
| LW | IFN IL8 TNF | 2 | ALGA0016514 | 13858983 1 | A/G | 5,80 | 0,02 | CHR | PCA | 28 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0002516 | 14835795 9 | A/G | 70,50 | 0,05 | CHR | CCA | 29 | PPP2R2B, STK32A, DPYSL3, JAKMIP2 |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0106143 | 14844741 2 | G/A | 51,30 | 0,05 | CHR | CCA | 29 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0106373 | 14849992 4 | G/A | 48,70 | 0,05 | CHR | CCA | 29 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0115025 | 14853688 2 | T/C | 48,60 | 0,05 | CHR | CCA | 29 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | H3GA0052415 | 14855061 3 | T/C | 51,30 | 0,05 | CHR | CCA | 29 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ALGA0116650 | 14861604 4 | A/G | 20,80 | 0,05 | CHR | CCA | 29 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | ASGA0104922 | 14863140 5 | C/T | 49,60 | 0,05 | CHR | CCA | 29 | |
| LW | RBC HMG HMT MCV MCH MCHC | 2 | MARC0011897 | 14890519 8 | T/C | 59,00 | 0,03 | CHR | CCA | 29 | |
| LR | WBC NEU MON EOS BAS TNF | 3 | ASGA0093070 | 18058797 | C/T | 29,00 | 0,05 | CHR | CCA | 30 | MVP |
| LR | WBC NEU MON EOS BAS TNF | 3 | ASGA0084261 | 18059444 | G/A | 29,00 | 0,05 | CHR | CCA | 30 | |
| | | | | | | | | | | | |

| Breed | Trait S | SSC | SC SNP P | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------|-----|----------------|----------|--------|--------|----------|--------------|--------|-----|----------------|
| Breed | I rait | 350 | SINF | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| | | | | | | | | | | | COG7, SCNN1B, |
| ID | WRC NELLMON FOS BAS THE | 3 | MADC0081878 | 22701601 | A/G | 43 10 | 0.05 | GEN | CCA | 31 | SCNN1G, USP31, |
| LK | when the more easily int | 5 | WARCOUT070 | 22791091 | AU | 43,10 | 0,05 | OLN | CCA | 51 | HS3ST2, OTOA, |
| | | | | | | | | | | | METTL9, IGSF6 |
| LR | WBC NEU MON EOS BAS TNF | 3 | ASGA0099130 | 23688143 | A/G | 33,90 | 0,03 | CHR | CCA | 31 | |
| | | | | | | | | | | | SDR42E2, |
| | | | | | | | | | | | VWA3A, MOSMO, |
| LR | WBC NEU MON EOS BAS TNF | 3 | ASGA0094403 | 23968274 | T/C | 88.00 | 0.05 | CHR | CCA | 32 | PDZD9, UQCRC2, |
| | | | | | | | - , | | | | CRYM, |
| | | | | | | | | | | | ANKS4B, ZP2, |
| | | | | | | | | | | | TMEM159 |
| LR | WBC NEU MON EOS BAS TNF | 3 | ASGA0013894 | 24070234 | C/A | 51,10 | 0,05 | CHR | CCA | 32 | |
| LR | WBC NEU MON EOS BAS TNF | 3 | M1GA0004187 | 24176936 | T/G | 87,30 | 0,04 | CHR | CCA | 32 | |
| LR | WBC NEU MON EOS BAS TNF | 3 | ALGA0123859 | 24582079 | C/T | 14,50 | 0,05 | CHR | CCA | 32 | |
| LR | WBC NEU MON EOS BAS TNF, | 3 | ASGA0094325 | 24963920 | C/T | 16.40 | 0.03 | GEN | CCA | 32 | |
| | NEU RBC WBC MON BAS | | | | | - / - | - , | | | - | |
| | | | | | | | | | | | LYRM1, |
| | | | | | | | | | | | DCUN1D3, |
| | | | | | | | | | | | REXO5, ERI2, |
| LR | WBC NEU MON FOS BAS TNF | 3 | ASGA0013904 | 25072734 | A/G | 70.60 | 0.05 | CHR | CCA | 33 | ACSM3, |
| LIC | | 5 | 110 0110012501 | 20072701 | 110 | , 0,00 | 0,05 | cint | con | 55 | THUMPD1, |
| | | | | | | | | | | | ACSM4, ACSM5, |
| | | | | | | | | | | | PDILT, UMOD, |
| | | | | | | | | | | | GP2, GPR139 |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Dread | Troit | SSC | CND | Desition | m/M | мае | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|----------------------------------------------------------|-----|-------------|---------------|--------|-------|---------------|--------------|----------------------|------------|--------------------------------------------|
| Dieeu | Trait | sse | 5111 | rosition | allele | MAF | BF | significance | wiethou | VIL | within QTL |
| LR | WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 3 | ASGA0013908 | 25111534 | C/A | 20,00 | 0.001/3. 1 | GEN | CCA, mvBIMBA M | 33 | |
| LR | WBC NEU MON EOS BAS TNF | 3 | ALGA0102450 | 25723257 | C/A | 62,30 | 0,04 | GEN | CCA | 33 | |
| LW | BAS WBC NEU, LYM NEU MON EOS BAS | 3 | ASGA0014250 | 35404289 | G/T | 76,50 | 4,51 | GEN | mvBIMBA M | 34 | RBFOX1 |
| LR | WBC HMT EOS HAP IL8 | 3 | ALGA0019692 | 70967762 | G/A | 4,90 | 0,03 | CHR | CCA | 35 | |
| LR | WBC HMT EOS HAP IL8 | 3 | ALGA0123028 | 71124411 | C/T | 4,90 | 0,03 | CHR | CCA | 35 | |
| LR | WBC HMT EOS HAP IL8 | 3 | MARC0055616 | 71462992 | G/A | 4,90 | 0,03 | CHR | CCA | 35 | |
| LR | WBC HMT EOS HAP IL8 | 3 | ASGA0015118 | 72651493 | C/T | 90,60 | 0,02 | CHR | CCA | 36 | ANXA4, AAK1, NFU1, GFPT1, U6, ANTXR1 |
| LR | WBC HMT EOS HAP IL8 | 3 | MARC0001946 | 72973452 | A/G | 95,30 | 0,02 | CHR | CCA | 36 | |
| LR | WBC HMT EOS HAP IL8 | 3 | MARC0021343 | 73260048 | T/C | 95,20 | 0,02 | CHR | CCA | 36 | |
| LR | BAS MON | 3 | MARC0006534 | 11271366 3 | T/G | 78,90 | 0,05 | CHR | CCA | 37 | HADHB |
| LR | EOS PLT, WBC HMT EOS HAP IL8, WBC NEU MON EOS BAS TNF | 3 | ASGA0016494 | 12113918 1 | G/A | 30,70 | 4,63 | GEN | mvBIMBA M | 38 | |
| LR | RBC HMG HMT MCV MCH | 4 | ALGA0023253 | 12432764 | G/A | 91,60 | 0,04 | CHR | CCA | 39 | |
| LR | IFN IL12 IL8 | 4 | ALGA0023430 | 14382005 | A/G | 65,60 | 0,06 | CHR | PCA | 40 | NSMCE2, WASHC5 |
| LR | IFN IL12 IL8 | 4 | ASGA0018536 | 14601654 | G/A | 64,20 | 0,03 | CHR | PCA | 40 | |
| LW | NEU LYM | 4 | DBWU0000703 | 36228000 | C/T | 55,70 | 0,02 | CHR | PCA | 41 | |
| LR | IL6 IL10 IL1b | 4 | H3GA0012747 | 56888492 | C/T | 23,50 | 0,05 | CHR | CCA | 42 | |
| LR | IL6 IL10 IL1b | 4 | MARC0096487 | 60396561 | G/A | 0,00 | 0,01 | CHR | CCA | 43 | |
| LR | IL6 IL10 IL1b | 4 | ALGA0025441 | 63422287 | G/T | 38,60 | 0,01 | CHR | CCA | 44 | TRPA1 |
| LR | IL6 IL10 IL1b | 4 | H3GA0012835 | 63533485 | G/A/T | 36,10 | 0,01 | CHR | CCA | 44 | |

| Drood | reed Trait | SEC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-------------------------------------------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|--------------|-----|-----------------------------|
| Бгеец | 1 ran | 350 | SINF | rosition | allele | MAF | BF | significance | Methou | QIL | within QTL |
| LR | IL6 IL10 IL1b | 4 | MARC0063844 | 63563088 | G/T | 36,30 | 0,01 | CHR | CCA | 44 | |
| LR | RBC HMG HMT MCV MCH | 4 | INRA0015168 | 79694780 | T/C | 8,60 | 0,06 | GEN | CCA | 45 | PRKDC |
| LR | RBC HMG HMT MCV MCH | 4 | H3GA0013209 | 81279399 | A/G | 67,90 | 0,01 | CHR | CCA | 46 | SELL |
| LR | RBC HMG HMT MCV MCH | 4 | ASGA0020483 | 81301454 | A/C | 62,90 | 0,01 | CHR | CCA | 46 | |
| LR | RBC HMG HMT MCV MCH | 4 | ASGA0020484 | 81321340 | T/C | 62,90 | 0,01 | CHR | CCA | 46 | |
| LR | RBC HMG HMT MCV MCH | 4 | ALGA0026246 | 82530260 | T/G | 48,80 | 0,01 | CHR | CCA | 47 | |
| LR | RBC HMG HMT MCV MCH | 4 | ALGA0026434 | 86347263 | G/A | 97,10 | 0,06 | GEN | CCA | 48 | |
| LR | RBC HMG HMT MCV MCH | 4 | ALGA0026437 | 86379017 | G/A | 1,60 | 0,06 | GEN | CCA | 48 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 4 | ALGA0026453 | 87048942 | A/C | 71,00 | 0,00 | GEN | CCA | 48 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 4 | ALGA0027586 | 10387635 3 | A/G | 72,50 | 0,05 | CHR | CCA | 49 | CD2, IGSF3, CD58, ATP1A1 |
| LW | RBC HMG HMT MCV MCH MCHC, HMG MCHC, WBC RBC HAP IL1b, PLT RBC WBC | 4 | ASGA0021646 | 10437311 5 | C/T | 79,20 | 3,38 | GEN | mvBIMBA M | 49 | |
| LR | NEU RBC WBC MON BAS | 4 | H3GA0014300 | 11253490 3 | G/A | 35,50 | 0,04 | CHR | CCA | 50 | NTNG1, PRMT6 |
| LR | NEU RBC WBC MON BAS | 4 | ASGA0022296 | 11263543 0 | C/T | 40,40 | 0,04 | CHR | CCA | 50 | |
| LR | NEU RBC WBC MON BAS | 4 | ASGA0022298 | 11266712 1 | C/T | 25,80 | 0,04 | CHR | CCA | 50 | |
| LR | NEU RBC WBC MON BAS | 4 | DRGA0005123 | 11268624 5 | G/A | 20,90 | 0,05 | GEN | CCA | 50 | |
| LR | NEU RBC WBC MON BAS | 4 | DRGA0005125 | 11270819 1 | C/T | 43,60 | 0,04 | CHR | CCA | 50 | |
| LR | WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 4 | H3GA0014305 | 11285011 7 | A/G | 34,30 | 0,05 | GEN | CCA | 50 | |

| Brood | Trait | SSC | SND | Position | m/M | MAE | P-value/ | Type of | Mathad | ΟΤΙ | Nearest Gene |
|-------|---------------------|-----|-------------|---------------|--------|-------|----------|--------------|--------|-----|----------------------|
| Dreeu | Trait | sse | 5111 | rosition | allele | MAT | BF | significance | Methou | QIL | within QTL |
| LR | NEU RBC WBC MON BAS | 4 | ASGA0022330 | 11300608 0 | C/T | 51,30 | 0,04 | CHR | CCA | 50 | |
| LR | NEU RBC WBC MON BAS | 4 | ALGA0028362 | 11302462 0 | T/C | 48,70 | 0,04 | CHR | CCA | 50 | |
| LR | NEU RBC WBC MON BAS | 4 | DRGA0005145 | 11305235 9 | G/A | 48,60 | 0,04 | CHR | CCA | 50 | |
| LR | NEU RBC WBC MON BAS | 4 | ASGA0087092 | 11307123 6 | A/G | 52,00 | 0,04 | CHR | CCA | 50 | |
| LR | RBC HMG HMT MCV MCH | 4 | ALGA0028434 | 11401661 3 | T/C | 40,80 | 0,03 | CHR | CCA | 51 | |
| LR | HMT HMG MCHC | 4 | M1GA0006536 | 12203714 1 | A/C | 38,90 | 0,02 | CHR | CCA | 52 | |
| LR | HMT HMG MCHC | 4 | ASGA0090553 | 12282899 7 | T/G | 17,00 | 0,04 | CHR | CCA | 53 | F3 |
| LR | RBC HMG HMT MCV MCH | 5 | H3GA0015293 | 6978152 | C/T | 1,50 | 0,04 | CHR | CCA | 54 | CSDC2 |
| LW | HMG MCH | 5 | ALGA0030157 | 8854690 | A/G | 74,90 | 0,04 | CHR | CCA | 55 | |
| | | | | | | | | | | | CRY1, MTERF2, |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0024572 | 13266811 | T/C | 45,90 | 0,04 | CHR | CCA | 56 | TMEM263, RIC8B, |
| | | | | | | | | | | | POLR3B, POLR3B |
| LR | RBC HMG HMT MCV MCH | 5 | H3GA0015743 | 13586949 | T/C | 77,50 | 0,04 | CHR | CCA | 56 | |
| LR | RBC HMG HMT MCV MCH | 5 | MARC0091257 | 13633289 | T/C | 0,00 | 0,04 | CHR | CCA | 56 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0024585 | 13654097 | C/T | 45,70 | 0,04 | CHR | CCA | 56 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0030680 | 13697150 | C/T | 48,30 | 0,06 | CHR | CCA | 56 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0030691 | 13798075 | T/C | 48,30 | 0,06 | CHR | CCA | 56 | |
| LR | HMT HMG MCHC | 5 | ALGA0030761 | 14608518 | T/G | 35,10 | 0,04 | CHR | CCA | 57 | CCNT1, C5H12orf75 |
| LR | HMT HMG MCHC | 5 | ALGA0030794 | 14788695 | C/A | 31,10 | 0,03 | CHR | CCA | 57 | |

| Dread | Turit | SSC | CNID | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------|-----|---------------|----------|--------|-------|----------|--------------|--------|-----|-------------------|
| Breed | | 350 | SINF | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| | RECHMG HMT MCV MCH HMG | | | | | | | | | | SCN8A, ACVRL1, |
| IR | MCHC II 10 | 5 | AI GA0106408 | 17162699 | C/T | 68 80 | 0.04 | CHR | CCA, | 58 | ACVR1B, GRASP, |
| LIC | HMT HMG MCHC | | | 1/102077 | 0/1 | 00,00 | 0,04 | CIIK | TATES | 50 | NR4A1, ATG101, |
| | | | | | | | | | | | KRT80, KRT7 |
| LR | HMT HMG MCHC | 5 | MARC0095571 | 17585540 | G/A | 0,00 | 0,06 | CHR | CCA | 58 | |
| LR | HMT HMG MCHC | 5 | H3GA0016097 | 23400843 | A/C | 37,10 | 0,02 | CHR | CCA | 59 | LRIG3 |
| LR | HMT HMG MCHC | 5 | ASGA0025128 | 23778757 | A/G | 46,70 | 0,02 | CHR | CCA | 59 | |
| LR | HMT HMG MCHC | 5 | ASGA0025132 | 23816873 | G/A | 42,50 | 0,02 | CHR | CCA | 59 | |
| IR | RBC HMG HMT MCV MCH, HMT | 5 | ASGA0025137 | 23933098 | T/C | 79.00 | 0.03 | CHR | CCA | 59 | |
| LIC | HMG MCHC | | 10010023137 | 23733070 | 1/0 | 79,00 | 0,05 | CIIK | cen | 57 | |
| IR | RBC HMG HMT MCV MCH, HMT | 5 | AI GA0031314 | 24000573 | G/T | 21.00 | 0.03 | CHR | CCA | 59 | |
| LIC | HMG MCHC | 5 | 712070051514 | 24000375 | 0/1 | 21,00 | 0,05 | CIIK | cen | 57 | |
| IR | RBC HMG HMT MCV MCH, HMT | 5 | ASGA0025140 | 24069910 | T/G | 79.10 | 0.03 | CHR | CCA | 59 | |
| LIC | HMG MCHC | 5 | 1156/10025140 | 24000010 | 1/0 | 79,10 | 0,05 | CIIK | cen | 57 | |
| ID | RBC HMG HMT MCV MCH, HMT | 5 | AL GA0031321 | 24135011 | | 70.30 | 0.02 | CHD | CCA | 50 | |
| LK | HMG MCHC | 5 | ALGA0051521 | 24133911 | AC | 79,50 | 0,02 | CHK | CCA | 39 | |
| LR | HMT HMG MCHC | 5 | INRA0018998 | 24393356 | A/G | 55,80 | 0,02 | CHR | CCA | 59 | |
| LR | HMT HMG MCHC | 5 | INRA0019001 | 24702306 | T/C | 55,00 | 0,01 | CHR | CCA | 60 | |
| ID | RBC HMG HMT MCV MCH, HMT | 5 | DPGA0005600 | 20001702 | T/C | 84.10 | 0.06 | CUD | CCA | 61 | HMGA2 |
| LK | HMG MCHC | 5 | DIGA0005009 | 29991703 | 1/0 | 04,10 | 0,00 | CHK | CCA | 01 | TIMOAZ |
| ID | RBC HMG HMT MCV MCH, HMT | 5 | DBCA0005612 | 20460401 | T/C | 84.10 | 0.06 | CUD | CCA | 61 | |
| LK | HMG MCHC | 5 | DKGA0003013 | 30409491 | 1/0 | 04,10 | 0,00 | CIIK | CCA | 01 | |
| ID | RBC HMG HMT MCV MCH, HMT | 5 | ASC A0025226 | 21271727 | A/C | 22.10 | 0.06 | CUD | CCA | 62 | U6, ssc-mir-9808, |
| LK | HMG MCHC | 5 | ASGA0023320 | 512/1/5/ | A/C | 22,10 | 0,00 | СПК | CCA | 02 | CAND1 |
| TD | RBC HMG HMT MCV MCH, HMT | 5 | ALCA0024222 | 21967290 | A/G | 88 60 | 0.06 | CHD | CCA | 62 | |
| LK | HMG MCHC | 5 | ALUA0034323 | 5160/560 | A/U | 00,00 | 0,00 | UNK | CCA | 02 | |
| LR | HMT HMG MCHC | 5 | MARC0114715 | 32497165 | A/C | 0,00 | 0,01 | CHR | CCA | 63 | IL26, IL22 |

| Dread | ed Trait | 88C | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-----------------------------------------|-----|-------------|----------|--------|-------|----------|--------------|---------|-----|------------------------------------------------|
| Dreeu | Trait | ssc | 5111 | rosition | allele | WIAF | BF | significance | wiethou | QIL | within QTL |
| LR | HMT HMG MCHC | 5 | ALGA0031657 | 32603961 | C/T | 19,30 | 0,01 | CHR | CCA | 63 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ALGA0031690 | 33946621 | A/G | 27,10 | 0,04 | CHR | CCA | 64 | CCT2, BEST3, MYRFL, CNOT2, KCNMB4, PTPRB |
| LR | HMT HMG MCHC | 5 | ASGA0025416 | 34747588 | T/C | 80,60 | 0,04 | CHR | CCA | 64 | |
| | RBC HMG HMT MCV MCH. HMG | | | | | | -) - | | | | |
| LR | MCHC IL10, HMT HMG MCHC, NEU RBC WBC | 5 | H3GA0016244 | 34769398 | A/G | 70,20 | 0,01 | CHR | CCA | 64 | |
| LR | LYM MON BAS | 5 | ALGA0031717 | 35361757 | C/T | 3,20 | 0,05 | CHR | PCA | 64 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | MARC0021861 | 35776165 | T/C | 37,10 | 0,04 | CHR | CCA | 65 | TMEM19, TBC1D15, TPH2, TRHDE |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ALGA0031731 | 36197319 | A/C | 25,50 | 0,04 | CHR | CCA | 65 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ALGA0031736 | 36314172 | A/C | 27,90 | 0,05 | CHR | CCA | 65 | |
| LR | HMT HMG MCHC | 5 | CASI0009605 | 36346640 | A/G | 27,40 | 0,03 | CHR | CCA | 65 | |
| LR | NEU RBC WBC MON BAS | 5 | ALGA0031740 | 36426114 | C/A | 15,70 | 0,06 | CHR | CCA | 65 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ASGA0025454 | 36903934 | C/T | 35,90 | 0,02 | CHR | CCA | 66 | |
| LR | RBC HMG HMT MCV MCH | 5 | DRGA0005711 | 37397149 | T/C | 29,80 | 0,04 | CHR | CCA | 66 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | INRA0019263 | 38864890 | T/C | 69,80 | 0,04 | CHR | CCA | 67 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | rs334622443 | 38872955 | A/T | NA | 0,04 | CHR | CCA | 67 | |
| | | | | | | | | | | | |

| Breed | Trait | SSC | SNP | Position | m/M | MAF | P-value/ | Type of | Method | ΟΤΙ | Nearest Gene |
|-------|--------------------------------------|-----|-------------|----------|--------|-------|----------|--------------|-----------|-----|--------------|
| Diccu | | 550 | 5111 | 1 USHION | allele | 1,111 | BF | significance | 101001100 | Q11 | within QTL |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | MARC0037200 | 38880761 | T/C | 69,80 | 0,04 | CHR | CCA | 67 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | DRGA0005776 | 43220509 | C/T | 30,50 | 0,04 | CHR | CCA | 68 | U6 |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | DRGA0005773 | 43252599 | A/G | 75,30 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | MARC0113545 | 43293810 | A/G | 0,00 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ALGA0031826 | 43320525 | C/A | 30,50 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ASGA0025493 | 43385239 | G/A | 30,50 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | H3GA0016271 | 43428743 | C/A | 30,50 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ASGA0025490 | 43480338 | T/C | 71,40 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | DRGA0005767 | 43556787 | C/T | 30,50 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | MARC0003440 | 43664480 | T/C | 69,50 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | INRA0019288 | 43688401 | T/C | 73,50 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | MARC0030421 | 43750584 | C/T | 28,60 | 0,04 | CHR | CCA | 68 | |
| LR | RBC HMG HMT MCV MCH, HMT HMG MCHC | 5 | ALGA0031834 | 43879295 | G/A | 30,60 | 0,04 | CHR | CCA | 68 | |
| LR | HMT HMG MCHC | 5 | INRA0019312 | 47324666 | T/C | 71,80 | 0,06 | CHR | CCA | 69 | ITPR2 |

| Breed | Trait | SSC | SNP | Position | m/M | MAF | P-value/ | Type of | Method | QTL | Nearest Gene |
|-------|--------------------------|-----|-------------|----------|--------|-------|----------|--------------|--------|-----|--------------|
| | | | | | allele | | BF | significance | | | within QTL |
| LR | RBC HMG HMT MCV MCH, HMT | 5 | H3GA0016294 | 47424047 | A/G | 38,30 | 0,04 | CHR | CCA | 69 | |
| | HMG MCHC | | | | | , | , , | | | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA, | | |
| LR | MCHC IL10, | 5 | ALGA0031924 | 48896828 | T/G | 57,00 | 0,02 | CHR | TATES | 70 | BCAT1 |
| | HMT HMG MCHC | | | | | | | | | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA. | | |
| LR | MCHC IL10, | 5 | MARC0001027 | 50094492 | G/A | 23,70 | 0,02 | CHR | TATES | 71 | SOX5 |
| | HMT HMG MCHC | | | | | | | | IIIIbb | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | DRGA0005841 | 50243918 | A/G | 76,30 | 0,02 | CHR | TATES | 71 | |
| | HMT HMG MCHC | | | | | | | | INTES | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | ALGA0032074 | 58601394 | A/G | 76,00 | 0,03 | CHR | TATES | 72 | GRIN2B, EMP1 |
| | HMT HMG MCHC | | | | | | | | IAILS | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | H3GA0016359 | 58625915 | C/T | 25,10 | 0,03 | CHR | CCA, | 72 | |
| | HMT HMG MCHC | | | | | | | | IAILS | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | H3GA0016379 | 58840179 | G/A | 23,90 | 0,03 | CHR | CCA, | 72 | |
| | HMT HMG MCHC | | | | | | | | IAILS | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | ALGA0032146 | 59340760 | A/C | 82,80 | 0,03 | CHR | TATES | 72 | |
| | HMT HMG MCHC | | | | | | | | IAILS | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Droad | Trait | SSC SNP Positio | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene | |
|-------|--------------------------|-----------------|-------------|----------|--------|----------|---------|--------------|---------|--------------|----------------|
| breeu | Trait | 350 | 5111 | rosition | allele | MAT | BF | significance | wiethou | Ϋ́́ | within QTL |
| | | | | | | | | | | | TMEM52B, OLR1, |
| | | | | | | | | | | | CLEC7A, |
| | | | | | | | | | | | CLEC1A, |
| | | | | | | | | | | | CLEC12B, |
| | | | | | | | | | | | CLEC1B, |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0025778 | 61783155 | A/G | 23,10 | 0,04 | CHR | CCA | 73 | CLEC12A, |
| | | | | | | | | | | | CLEC2B, CD69, |
| | | | | | | | | | | | KLRB1, A2M, |
| | | | | | | | | | | | KLRG1, M6PR, |
| | | | | | | | | | | | PHC1, A2ML1, |
| | | | | | | | | | | | RIMKLB |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0025791 | 61931507 | A/G | 76,80 | 0,04 | CHR | CCA | 73 | |
| LR | RBC HMG HMT MCV MCH | 5 | DRGA0005951 | 61966384 | G/A | 76,80 | 0,04 | CHR | CCA | 73 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0025794 | 62115185 | T/G | 23,40 | 0,04 | CHR | CCA | 73 | |
| LR | RBC HMG HMT MCV MCH | 5 | DRGA0005956 | 62134657 | T/G | 80,00 | 0,04 | CHR | CCA | 73 | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | MARC0100616 | 62372560 | C/T | 0,00 | 0,04 | CHR | TATES | 73 | |
| | HMT HMG MCHC | | | | | | | | INTES | | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0032322 | 62455175 | G/A | 65,60 | 0,04 | CHR | CCA | 73 | |
| LR | RBC HMG HMT MCV MCH | 5 | DIAS000002 | 62481418 | A/G | 34,90 | 0,04 | CHR | CCA | 73 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0025802 | 62601778 | T/C | 77,10 | 0,04 | CHR | CCA | 73 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0032345 | 62737145 | T/C/G | 39,00 | 0,03 | CHR | CCA | 73 | |
| LR | HMT HMG MCHC | 5 | ASGA0025827 | 63827447 | G/A | 84,70 | 0,02 | CHR | CCA | 74 | ENO2 |
| LR | HMT HMG MCHC | 5 | ASGA0100486 | 66362258 | T/G | 71,70 | 0,05 | CHR | CCA | 75 | |
| LR | NEU RBC WBC MON BAS | 5 | H3GA0055380 | 75848496 | A/G | 94,10 | 0.03 | CHR | CCA | 76 | NELL2, DBX2, |
| | | | | | | , | -, | | | | ANO6 |
| LR | LYM MON BAS | 5 | M1GA0008026 | 76155408 | C/T | 85,20 | 0,02 | CHR | PCA | 76 | |

| Breed Trait | Tweit | SSC | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | ΟΤΙ | Nearest Gene |
|-------------|-------------------------------------|-----|-------------|----------|--------|-------|----------|--------------|----------|-----|--------------------------------------|
| breeu | | 350 | 5111 | rosition | allele | MAF | BF | significance | Wiethou | QIL | within QTL |
| LR | NEU RBC WBC MON BAS, LYM MON BAS | 5 | MARC0004505 | 76180231 | G/A | 94,30 | 0,05 | CHR | CCA, PCA | 76 | |
| LR | NEU RBC WBC MON BAS | 5 | H3GA0016883 | 76215960 | G/A | 94,90 | 0,05 | GEN | CCA | 76 | |
| LR | NEU RBC WBC MON BAS | 5 | MARC0002321 | 76276553 | G/A | 4,90 | 0,05 | GEN | CCA | 76 | |
| | | | | | | | | | | | SLC38A4, |
| LW | HMG MCH, PLT RBC WBC | 5 | ALGA0033064 | 77286779 | T/C | 98,20 | 0,04 | CHR | CCA | 77 | AMIGO2, |
| | | | | | | | | | | | PCED1B, RPAP3 |
| LW | HMG MCH, PLT RBC WBC | 5 | ASGA0093314 | 77402409 | A/G | 8,50 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | ALGA0104452 | 77541676 | A/G | 7,50 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | MARC0090729 | 77680830 | C/T | 0,00 | 0,04 | CHR | CCA | 77 | |
| LR | HMT HMG MCHC | 5 | MARC0012702 | 77884515 | C/A | 35,90 | 0,01 | CHR | CCA | 77 | |
| LR | IL4 EOS IL10 IL1b TNF | 5 | ALGA0105937 | 77892336 | A/G | 89,40 | 0,01 | GEN | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | MARC0098250 | 77948633 | G/A | 0,00 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | ALGA0109048 | 77962305 | T/C | 6,20 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | ALGA0101247 | 77990021 | A/G | 2,90 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | ALGA0104065 | 77997876 | C/T | 97,10 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | MARC0009241 | 78029583 | G/A | 97,10 | 0,04 | CHR | CCA | 77 | |
| LW | HMG MCH, PLT RBC WBC | 5 | ALGA0104516 | 78032160 | G/T | 97,10 | 0,04 | CHR | CCA | 77 | |
| | RBC HMG HMT MCV MCH MCHC, | | | | | | | | | | |
| LW | HMG MCHC, WBC RBC HAP IL1b, | 5 | MARC0013873 | 79815601 | T/C | 79,10 | 3,47 | GEN | M | 78 | CHST11 |
| | PLT RBC WBC | | | | | | | | M | | |
| LR | NEU RBC WBC MON BAS | 5 | ALGA0033413 | 88424483 | T/C | 91,90 | 0,02 | CHR | CCA | 79 | |
| LR | IL12 IL8 | 5 | MARC0080493 | 90118573 | A/G | 79,20 | 0,04 | CHR | PCA | 80 | |
| LW | HMG MCH | 5 | ALGA0105659 | 92864624 | T/C | 40,70 | 0,05 | CHR | CCA | 81 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0100714 | 94149478 | C/T | 17,40 | 0,04 | CHR | CCA | 82 | TMTC3, CEP290, C12orf29, C12orf50 |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0026904 | 94238901 | A/C | 82,60 | 0,04 | CHR | CCA | 82 | |

| Dread | Trait | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------|-----|-------------|----------|--------|-------|----------|--------------|---------|-----|--------------|
| breeu | Trait | 350 | 5141 | rosition | allele | WIAF | BF | significance | wiethou | QIL | within QTL |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033767 | 94367121 | C/T | 8,50 | 0,05 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033764 | 94457579 | T/C | 83,20 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | M1GA0008129 | 94490945 | A/G | 91,40 | 0,03 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033759 | 94518601 | T/G | 91,40 | 0,03 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033757 | 94541296 | T/C | 62,60 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | H3GA0017183 | 94558952 | C/T | 51,30 | 0,05 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033735 | 94705788 | G/A | 36,90 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0026872 | 94785843 | G/T | 41,10 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | INRA0020482 | 94801310 | C/T | 41,70 | 0,05 | CHR | CCA | 82 | |
| LR | WBC BAS | 5 | MARC0101043 | 94860354 | A/G | 0,00 | 0,05 | GEN | PCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0091315 | 95014018 | A/C | 81,70 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | ASGA0026863 | 95042109 | T/C | 81,00 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | DRGA0006240 | 95278246 | A/G | 81,00 | 0,04 | CHR | CCA | 82 | |
| LR | RBC HMG HMT MCV MCH | 5 | H3GA0017164 | 95377091 | G/A | 20,10 | 0,04 | CHR | CCA | 83 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033673 | 95558910 | A/C | 54,40 | 0,04 | CHR | CCA | 83 | |
| LR | RBC HMG HMT MCV MCH | 5 | ALGA0033670 | 95591504 | T/G | 54,30 | 0,04 | CHR | CCA | 83 | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | ASGA0101924 | 97259676 | T/C | 98,90 | 0,00 | GEN | TATES | 84 | |
| | HMT HMG MCHC | | | | | | | | TATES | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | DRGA0006295 | 97412529 | A/C | 98,70 | 0,00 | GEN | TATES | 84 | |
| | HMT HMG MCHC | | | | | | | | TATES | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | 5 | H3GA0017216 | 97477241 | C/T | 1,10 | 0,00 | GEN | TATES | 84 | |
| | HMT HMG MCHC | | | | | | | | IAILS | | |
| LR | RBC HMG HMT MCV MCH | 5 | MARC0030237 | 99102014 | T/G | 23,10 | 0,06 | CHR | CCA | 85 | TMTC2 |
| | | | | | | | | | | | |

| Durad | Troit | SSC | SNP | Position | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|------------------------|-----|-------------|---------------|--------|-------|----------|--------------|--------|-----|-------------------------------------------------------------------------------------------------------------------------|
| вгеец | I rait | 330 | | | allele | MAF | BF | significance | Method | QIL | within QTL |
| LR | HMT HMG MCHC | 5 | ALGA0034135 | 10184641 2 | A/G | 15,00 | 0,05 | CHR | CCA | 86 | |
| LR | IL6 IL10 IL1b | 6 | MARC0041561 | 16171435 | C/T | 80,90 | 0,03 | CHR | CCA | 87 | |
| LR | IL6 IL10 IL1b | 6 | MARC0075761 | 16188799 | G/A | 80,90 | 0,03 | CHR | CCA | 87 | |
| LR | IL4 EOS IL10 IL1b TNF | 6 | ASGA0104222 | 39838897 | C/A | 26,10 | 0,05 | CHR | CCA | 88 | URI1, ZNF536 |
| LR | IL4 EOS IL10 IL1b TNF | 6 | MARC0005196 | 39859759 | C/T | 39,30 | 0,05 | CHR | CCA | 88 | |
| LR | IL4 EOS IL10 IL1b TNF | 6 | MARC0113191 | 39937433 | T/C | 0,00 | 0,05 | CHR | CCA | 88 | |
| LR | IL4 EOS IL10 IL1b TNF | 6 | ASGA0028105 | 40240336 | C/A | 43,50 | 0,05 | CHR | CCA | 88 | |
| LR | IL4 EOS IL10 IL1b TNF | 6 | ASGA0097134 | 41279833 | T/C | 37,50 | 0,06 | CHR | CCA | 88 | |
| | | | | | | | | | | | LYPD5, ZNF283, |
| LR | IL1b WBC EOS IL10 IL12 | 6 | ALGA0100920 | 50604798 | G/A | 54,00 | 0,04 | CHR | CCA | 89 | ZNF404, ZNF45, |
| | | | | | | | | | | | LOC110260999 |
| LR | IL1b WBC EOS IL10 IL12 | 6 | MARC0033200 | 50804198 | C/T | 61,90 | 0,04 | CHR | CCA | 89 | |
| LR | IL6 IL10 IL1b | 6 | ASGA0085935 | 74701117 | C/T | 14,70 | 0,03 | CHR | CCA | 90 | CTRC, CELA2A |
| LR | IL6 IL10 IL1b | 6 | ASGA0100599 | 74701809 | C/T | 14,70 | 0,03 | CHR | CCA | 90 | |
| LR | IL6 IL10 IL1b | 6 | M1GA0025029 | 78113081 | T/C | 11,40 | 0,03 | CHR | CCA | 91 | TMCO4 |
| LR | IL6 IL10 IL1b | 6 | H3GA0053380 | 93420594 | G/T | 47,80 | 0,03 | CHR | ССА | 92 | ZC3H12A, MEAF6, SNIP1, DNALI1, GNL2, RSPO1, C1orf109, CDCA8, EPHA10, MANEAL, YRDC, C1orf122, MTF1, |
| | | | | | | | | | | | INPP5B, SF3A3, FHL3, UTP11, POU3F1 |

| Dread | Troit | SSC | SNP | Position | m/M | MAE | P-value/ | Type of | Mathad | Iethod QTL | Nearest Gene |
|-------|--------------------------------------------------------------------------------------|-----|-------------|----------|--------|-------|----------|--------------|--------|------------|-------------------------------------------------------------------------------------------------------------|
| breeu | 1 ган | | | | allele | MAF | BF | significance | Method | | within QTL |
| LR | IL6 IL10 IL1b | 6 | MARC0082470 | 93442952 | T/C | 47,90 | 0,06 | CHR | CCA | 92 | |
| LR | IL6 IL10 IL1b | 6 | ASGA0028870 | 93958186 | A/G | 55,50 | 0,06 | CHR | CCA | 92 | |
| LR | IL6 IL10 IL1b | 6 | ALGA0035971 | 94051380 | C/T | 62,30 | 0,06 | CHR | CCA | 92 | |
| LR | IL6 IL10 IL1b | 6 | MARC0019060 | 94096694 | T/C | 72,40 | 0,03 | CHR | CCA | 92 | |
| LR | IL6 IL10 IL1b | 6 | M1GA0008815 | 94712287 | C/T | 33,60 | 0,03 | CHR | CCA | 93 | RRAGC, GJA9, RHBDL2, AKIRIN1, NDUFS5, U6, MACF1, PABPC4, SNORA55, HEYL, NT5C1A, HPCAL4 |
| LR | HMG MCHC IL10, IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b | 6 | MARC0033580 | 95566980 | C/T | 45,50 | 0,02 | GEN | CCA | 93 | |
| LR | IL6 IL10 IL1b | 6 | MARC0022542 | 96650040 | T/G | 59,80 | 0,03 | CHR | CCA | 94 | CEP192, PTPN2, PSMG2, CEP76, SPIRE1, PRELID3A, AFG3L2, TUBB6, CIDEA, IMPA2, MPPE1, GNAL |
| LR | IL6 IL10 IL1b | 6 | M1GA0026030 | 96767590 | T/C | 59,80 | 0,03 | CHR | CCA | 94 | |
| LR | IL6 IL10 IL1b | 6 | CASI0006620 | 96926928 | C/T | 31,00 | 0,06 | CHR | CCA | 94 | |
| | | | | | | | | | | | |

| Trait | SSC SNP | SNP | Position | m/M MAF | | P-value/ | Type of Met | Method | thod OTL | Nearest Gene |
|--------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | 550 | | | allele | 1,1,1,1 | BF | significance | | · | within QTL |
| IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b | 6 | ASGA0091444 | 97104675 | G/A | 8,80 | 0,03 | CHR | CCA | 94 | |
| IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b | 6 | MARC0032131 | 97343439 | T/G | 23,50 | 0,03 | CHR | CCA | 94 | |
| HMG MCHC IL10, IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b | 6 | ALGA0036131 | 97620286 | T/C | 32,20 | 0,02 | GEN | CCA | 94 | |
| IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | ALGA0036189 | 99931515 | G/A | 72,60 | 0,03 | CHR | CCA | 95 | PTPRM, U6, LRRC30, LAMA1, ARHGAP28 |
| IL1b WBC EOS IL10 IL12 | 6 | ALGA0036191 | 99956687 | T/C | 94,30 | 0,02 | CHR | CCA | 95 | |
| IL1b WBC EOS IL10 IL12 | 6 | CASI0005798 | 10001831 6 | T/C | 94,30 | 0,02 | CHR | CCA | 95 | |
| IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b, | 6 | MARC0003203 | 10017510 9 | G/A | 27,90 | 0,03 | CHR | CCA | 95 | |
| IL1b WBC EOS IL10 IL12 | 6 | ALGA0115176 | 10020777 0 | C/T | 1,40 | 0,02 | CHR | CCA | 95 | |
| IL1b WBC EOS IL10 IL12 | 6 | ALGA0117017 | 10029206 0 | A/G | 92,70 | 0,02 | CHR | CCA | 95 | |
| IL1b WBC EOS IL10 IL12 | 6 | MARC0021350 | 10031104 0 | C/T | 5,70 | 0,02 | CHR | CCA | 95 | |
| HMG MCHC IL10, IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | H3GA0054139 | 10070916 0 | T/C | 87,00 | 0,05 | GEN | CCA | 95 | |
| | IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b HMG MCHC IL10, IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL15 TNF, IL6 IL10 IL1b IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b IL1b WBC EOS IL10 IL12 IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b, IL1b WBC EOS IL10 IL12 IL1b WBC EOS IL10 IL12 | ITAR 55C IL 16 WBC EOS IL 10 IL 12, IL 4 EOS 6 IL 0 IL 16 TNF, 6 IL 0 IL 10 IL 15 6 IL 10 IL 16 TNF, 6 IL 0 IL 10 IL 15 6 IL 10 IL 12, 1L 4 EOS IL 10 IL 12, 6 IL 10 IL 12, 6 IL 15 WBC EOS IL 10 IL 12, IL 6 IL 10 6 IL 15 WBC EOS IL 10 IL 12, IL 6 IL 10 6 IL 15 WBC EOS IL 10 IL 12, IL 6 IL 10 6 IL 15 WBC EOS IL 10 IL 12, IL 6 IL 10 6 IL 15 WBC EOS IL 10 IL 12, IL 6 IL 10 6 IL 15 WBC EOS IL 10 IL 12, IL 6 IL 10 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 IL 15 WBC EOS IL 10 IL 12 6 <td>ITALSSCSNTIL1b WBC EOS IL10 IL12, IL4 EOS6ASGA0091444IL6 IL10 IL1b6MARC0032131IL1b WBC EOS IL10 IL12, IL4 EOS6MARC0032131IL1b WBC EOS IL10 IL12, IL4 EOS6ALGA0036131IL10 IL156ALGA0036131IL10 IL12,IL4 EOS6IL10 IL12,IL4 EOS IL10 IL12, IL6 IL106IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0036189IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0036191IL1b WBC EOS IL10 IL12, IL6 IL106MARC0003203IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0115176IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0115176IL1b WBC EOS IL10 IL126ALGA0115176IL1b WBC EOS IL10 IL126ALGA0117017IL1b WBC EOS IL10 IL126ALGA0117017IL1b WBC EOS IL10 IL126ALGA0117017IL1b WBC EOS IL10 IL126H3GA0054139</td> <td>ITARSSCSITFORMURIL 16 WBC EOS IL 10 IL 12, IL 4 EOS6ASGA009144497104675IL 6 IL 10 IL 156ASGA009144497104675IL 10 IL 15 TNF,6MARC003213197343439IL 6 IL 10 IL 156MARC003213197620286IL 10 IL 15 TNF,6ALGA003613197620286IL 10 IL 12,110 IL 15 TNF, IL 6 IL 106ALGA003613197620286IL 10 IL 12,IL 6 IL 106ALGA003618999931515IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA003619199956687IL 15 WBC EOS IL 10 IL 12,6ALGA003619199956687IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106MARC00032039IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA011517610020777IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA01151760IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA01151760IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA0115176100202077IL 15 WBC EOS IL 10 IL 126ALGA01151760IL 15 WBC EOS IL 10 IL 126ALGA01170170IL 15 WBC EOS IL 10 IL 126ALGA01170170<td>HatSSCSATPositionalleleIL1b WBC EOS IL10 IL12, IL4 EOS6ASGA009144497104675G/AIL0 IL1b TNF,6MARC003213197343439T/GIL10 IL1b TNF,6MARC003213197343439T/GIL6 IL10 IL1bHMG MCHC IL10, IL1b WBC EOS6ALGA003613197620286T/CIL1b WBC EOS IL10 IL12, IL6 IL106ALGA003618999931515G/AIL1b WBC EOS IL10 IL12, IL6 IL106ALGA003619199956687T/CIL1b WBC EOS IL10 IL126ALGA003619199956687T/CIL1b WBC EOS IL10 IL12, IL6 IL106MARC000320310017510G/AIL1b WBC EOS IL10 IL12, IL6 IL106MARC00032039G/AIL1b WBC EOS IL10 IL12, IL6 IL106ALGA01151760C/TIL1b WBC EOS IL10 IL126ALGA011517610020777C/TIL1b WBC EOS IL10 IL126ALGA01170170A/GIL1b WBC EOS IL10 IL126ALGA01170170C/TIL1b WBC EOS IL10 IL126ALGA01170170C/TIL1b WBC EOS IL10 IL126ALGA011701710029206A/GIL1b WBC EOS IL10 IL126ALGA01170170T/CIL1b WBC EOS IL10 IL126ALGA011701707/CIL1b WBC EOS IL10 IL126ALGA0117017010029206IL1b WBC EOS IL10 IL126ALGA011701707/CIL1b WBC EOS IL10 IL126ALGA0117017</td><td>Ind SSC SVC Position allel PLAP IL Ib WBC EOS IL 10 IL 12, IL 4 EOS 6 ASGA0091444 97104675 G/A 8,80 IL 10 IL 15 TNF, 6 ASGA0091444 97104675 G/A 8,80 IL 10 IL 15 TNF, 6 MARC0032131 97343439 T/G 23,50 IL 6 IL 10 IL 15 6 MARC0032131 97620286 T/C 32,20 IL 10 IL 12, IL 6 IL 10 6 ALGA0036131 97620286 T/C 32,20 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0036189 99931515 G/A 72,60 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0036191 99956687 T/C 94,30 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA015798 10017510 G/A 27,90 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0115176 10020777 0 7 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0115176 10020777 0 7 1,40 IL 16</td><td>Hat SSC SNT Formula allele FAP BF IL1b WBC EOS IL10 IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 IL6 IL10 IL1b 6 ASGA0091444 97104675 G/A 8,80 0,03 IL6 IL10 IL1b 11b WBC EOS IL10 IL12, IL4 EOS 6 MARC0032131 97343439 T/G 23,50 0,03 IL10 IL1b TNF, 6 MARC0032131 97343439 T/G 23,50 0,03 IL10 IL12, IL4 EOS 6 MARC0032131 97620286 T/C 32,20 0,02 IL10 IL12, 6 ALGA0036131 97620286 T/C 94,30 0,02 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 99956687 T/C 94,30 0,02 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA017517 6 72,60 0,03 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 100017510 6/A 27,90 0,03</td><td>International state Sec Sec Sec Sec Formation allele Formation BF significance L1.16 Unite Dess L10 II.12, IL4 EOS ASGA0091444 97104675 G/A 8,80 0.03 CHR L1.6 IL10 II.15 IL10 II.15 TNF, 6 ASGA0091444 97104675 G/A 8,80 0.03 CHR L1.6 IL10 II.15 IL10 II.15 TNF, 6 MARC0032131 97343439 T/G 23,50 0.03 CHR L16 IL10 II.15 B MARC0032131 97343439 T/G 23,50 0.03 CHR L16 L10 II.15 B ALGA0036131 97620286 T/C 32,20 0.02 GEN IL15 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0036191 99931515 G/A 72,60 0.03 CHR IL16 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0036191 99956687 T/C 94,30 0.02 CHR IL16 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0115176 10017510 G/A<td>Thr SSC SV Formula allete INP BF significance Hellow LID WDC EOS LLIO IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 CHR CCA LID WDC EOS LLIO IL12, IL4 EOS 6 MARC0032131 9734349 T/G 23,50 0,03 CHR CCA LIO UL15 TNF, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIO UL15, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIA EOS LIO IL12, IL4 EOS 6 ALGA0036131 9762028 T/C 32,20 0,03 CHR CCA LID WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036180 9993151 G/A 7.60 0,03 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 9995667 T/C 94,30 0,02 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 10001</td><td>InflueSiteSiteSiteFor the set of th</td></td></td> | ITALSSCSNTIL1b WBC EOS IL10 IL12, IL4 EOS6ASGA0091444IL6 IL10 IL1b6MARC0032131IL1b WBC EOS IL10 IL12, IL4 EOS6MARC0032131IL1b WBC EOS IL10 IL12, IL4 EOS6ALGA0036131IL10 IL156ALGA0036131IL10 IL12,IL4 EOS6IL10 IL12,IL4 EOS IL10 IL12, IL6 IL106IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0036189IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0036191IL1b WBC EOS IL10 IL12, IL6 IL106MARC0003203IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0115176IL1b WBC EOS IL10 IL12, IL6 IL106ALGA0115176IL1b WBC EOS IL10 IL126ALGA0115176IL1b WBC EOS IL10 IL126ALGA0117017IL1b WBC EOS IL10 IL126ALGA0117017IL1b WBC EOS IL10 IL126ALGA0117017IL1b WBC EOS IL10 IL126H3GA0054139 | ITARSSCSITFORMURIL 16 WBC EOS IL 10 IL 12, IL 4 EOS6ASGA009144497104675IL 6 IL 10 IL 156ASGA009144497104675IL 10 IL 15 TNF,6MARC003213197343439IL 6 IL 10 IL 156MARC003213197620286IL 10 IL 15 TNF,6ALGA003613197620286IL 10 IL 12,110 IL 15 TNF, IL 6 IL 106ALGA003613197620286IL 10 IL 12,IL 6 IL 106ALGA003618999931515IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA003619199956687IL 15 WBC EOS IL 10 IL 12,6ALGA003619199956687IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106MARC00032039IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA011517610020777IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA01151760IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA01151760IL 15 WBC EOS IL 10 IL 12, IL 6 IL 106ALGA0115176100202077IL 15 WBC EOS IL 10 IL 126ALGA01151760IL 15 WBC EOS IL 10 IL 126ALGA01170170IL 15 WBC EOS IL 10 IL 126ALGA01170170 <td>HatSSCSATPositionalleleIL1b WBC EOS IL10 IL12, IL4 EOS6ASGA009144497104675G/AIL0 IL1b TNF,6MARC003213197343439T/GIL10 IL1b TNF,6MARC003213197343439T/GIL6 IL10 IL1bHMG MCHC IL10, IL1b WBC EOS6ALGA003613197620286T/CIL1b WBC EOS IL10 IL12, IL6 IL106ALGA003618999931515G/AIL1b WBC EOS IL10 IL12, IL6 IL106ALGA003619199956687T/CIL1b WBC EOS IL10 IL126ALGA003619199956687T/CIL1b WBC EOS IL10 IL12, IL6 IL106MARC000320310017510G/AIL1b WBC EOS IL10 IL12, IL6 IL106MARC00032039G/AIL1b WBC EOS IL10 IL12, IL6 IL106ALGA01151760C/TIL1b WBC EOS IL10 IL126ALGA011517610020777C/TIL1b WBC EOS IL10 IL126ALGA01170170A/GIL1b WBC EOS IL10 IL126ALGA01170170C/TIL1b WBC EOS IL10 IL126ALGA01170170C/TIL1b WBC EOS IL10 IL126ALGA011701710029206A/GIL1b WBC EOS IL10 IL126ALGA01170170T/CIL1b WBC EOS IL10 IL126ALGA011701707/CIL1b WBC EOS IL10 IL126ALGA0117017010029206IL1b WBC EOS IL10 IL126ALGA011701707/CIL1b WBC EOS IL10 IL126ALGA0117017</td> <td>Ind SSC SVC Position allel PLAP IL Ib WBC EOS IL 10 IL 12, IL 4 EOS 6 ASGA0091444 97104675 G/A 8,80 IL 10 IL 15 TNF, 6 ASGA0091444 97104675 G/A 8,80 IL 10 IL 15 TNF, 6 MARC0032131 97343439 T/G 23,50 IL 6 IL 10 IL 15 6 MARC0032131 97620286 T/C 32,20 IL 10 IL 12, IL 6 IL 10 6 ALGA0036131 97620286 T/C 32,20 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0036189 99931515 G/A 72,60 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0036191 99956687 T/C 94,30 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA015798 10017510 G/A 27,90 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0115176 10020777 0 7 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0115176 10020777 0 7 1,40 IL 16</td> <td>Hat SSC SNT Formula allele FAP BF IL1b WBC EOS IL10 IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 IL6 IL10 IL1b 6 ASGA0091444 97104675 G/A 8,80 0,03 IL6 IL10 IL1b 11b WBC EOS IL10 IL12, IL4 EOS 6 MARC0032131 97343439 T/G 23,50 0,03 IL10 IL1b TNF, 6 MARC0032131 97343439 T/G 23,50 0,03 IL10 IL12, IL4 EOS 6 MARC0032131 97620286 T/C 32,20 0,02 IL10 IL12, 6 ALGA0036131 97620286 T/C 94,30 0,02 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 99956687 T/C 94,30 0,02 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA017517 6 72,60 0,03 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 100017510 6/A 27,90 0,03</td> <td>International state Sec Sec Sec Sec Formation allele Formation BF significance L1.16 Unite Dess L10 II.12, IL4 EOS ASGA0091444 97104675 G/A 8,80 0.03 CHR L1.6 IL10 II.15 IL10 II.15 TNF, 6 ASGA0091444 97104675 G/A 8,80 0.03 CHR L1.6 IL10 II.15 IL10 II.15 TNF, 6 MARC0032131 97343439 T/G 23,50 0.03 CHR L16 IL10 II.15 B MARC0032131 97343439 T/G 23,50 0.03 CHR L16 L10 II.15 B ALGA0036131 97620286 T/C 32,20 0.02 GEN IL15 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0036191 99931515 G/A 72,60 0.03 CHR IL16 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0036191 99956687 T/C 94,30 0.02 CHR IL16 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0115176 10017510 G/A<td>Thr SSC SV Formula allete INP BF significance Hellow LID WDC EOS LLIO IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 CHR CCA LID WDC EOS LLIO IL12, IL4 EOS 6 MARC0032131 9734349 T/G 23,50 0,03 CHR CCA LIO UL15 TNF, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIO UL15, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIA EOS LIO IL12, IL4 EOS 6 ALGA0036131 9762028 T/C 32,20 0,03 CHR CCA LID WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036180 9993151 G/A 7.60 0,03 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 9995667 T/C 94,30 0,02 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 10001</td><td>InflueSiteSiteSiteFor the set of th</td></td> | HatSSCSATPositionalleleIL1b WBC EOS IL10 IL12, IL4 EOS6ASGA009144497104675G/AIL0 IL1b TNF,6MARC003213197343439T/GIL10 IL1b TNF,6MARC003213197343439T/GIL6 IL10 IL1bHMG MCHC IL10, IL1b WBC EOS6ALGA003613197620286T/CIL1b WBC EOS IL10 IL12, IL6 IL106ALGA003618999931515G/AIL1b WBC EOS IL10 IL12, IL6 IL106ALGA003619199956687T/CIL1b WBC EOS IL10 IL126ALGA003619199956687T/CIL1b WBC EOS IL10 IL12, IL6 IL106MARC000320310017510G/AIL1b WBC EOS IL10 IL12, IL6 IL106MARC00032039G/AIL1b WBC EOS IL10 IL12, IL6 IL106ALGA01151760C/TIL1b WBC EOS IL10 IL126ALGA011517610020777C/TIL1b WBC EOS IL10 IL126ALGA01170170A/GIL1b WBC EOS IL10 IL126ALGA01170170C/TIL1b WBC EOS IL10 IL126ALGA01170170C/TIL1b WBC EOS IL10 IL126ALGA011701710029206A/GIL1b WBC EOS IL10 IL126ALGA01170170T/CIL1b WBC EOS IL10 IL126ALGA011701707/CIL1b WBC EOS IL10 IL126ALGA0117017010029206IL1b WBC EOS IL10 IL126ALGA011701707/CIL1b WBC EOS IL10 IL126ALGA0117017 | Ind SSC SVC Position allel PLAP IL Ib WBC EOS IL 10 IL 12, IL 4 EOS 6 ASGA0091444 97104675 G/A 8,80 IL 10 IL 15 TNF, 6 ASGA0091444 97104675 G/A 8,80 IL 10 IL 15 TNF, 6 MARC0032131 97343439 T/G 23,50 IL 6 IL 10 IL 15 6 MARC0032131 97620286 T/C 32,20 IL 10 IL 12, IL 6 IL 10 6 ALGA0036131 97620286 T/C 32,20 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0036189 99931515 G/A 72,60 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0036191 99956687 T/C 94,30 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA015798 10017510 G/A 27,90 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0115176 10020777 0 7 IL 16 WBC EOS IL 10 IL 12, IL 6 IL 10 6 ALGA0115176 10020777 0 7 1,40 IL 16 | Hat SSC SNT Formula allele FAP BF IL1b WBC EOS IL10 IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 IL6 IL10 IL1b 6 ASGA0091444 97104675 G/A 8,80 0,03 IL6 IL10 IL1b 11b WBC EOS IL10 IL12, IL4 EOS 6 MARC0032131 97343439 T/G 23,50 0,03 IL10 IL1b TNF, 6 MARC0032131 97343439 T/G 23,50 0,03 IL10 IL12, IL4 EOS 6 MARC0032131 97620286 T/C 32,20 0,02 IL10 IL12, 6 ALGA0036131 97620286 T/C 94,30 0,02 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 99956687 T/C 94,30 0,02 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA017517 6 72,60 0,03 IL1b WBC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 100017510 6/A 27,90 0,03 | International state Sec Sec Sec Sec Formation allele Formation BF significance L1.16 Unite Dess L10 II.12, IL4 EOS ASGA0091444 97104675 G/A 8,80 0.03 CHR L1.6 IL10 II.15 IL10 II.15 TNF, 6 ASGA0091444 97104675 G/A 8,80 0.03 CHR L1.6 IL10 II.15 IL10 II.15 TNF, 6 MARC0032131 97343439 T/G 23,50 0.03 CHR L16 IL10 II.15 B MARC0032131 97343439 T/G 23,50 0.03 CHR L16 L10 II.15 B ALGA0036131 97620286 T/C 32,20 0.02 GEN IL15 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0036191 99931515 G/A 72,60 0.03 CHR IL16 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0036191 99956687 T/C 94,30 0.02 CHR IL16 WBC EOS IL10 II.12, IL6 IL10 6 ALGA0115176 10017510 G/A <td>Thr SSC SV Formula allete INP BF significance Hellow LID WDC EOS LLIO IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 CHR CCA LID WDC EOS LLIO IL12, IL4 EOS 6 MARC0032131 9734349 T/G 23,50 0,03 CHR CCA LIO UL15 TNF, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIO UL15, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIA EOS LIO IL12, IL4 EOS 6 ALGA0036131 9762028 T/C 32,20 0,03 CHR CCA LID WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036180 9993151 G/A 7.60 0,03 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 9995667 T/C 94,30 0,02 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 10001</td> <td>InflueSiteSiteSiteFor the set of th</td> | Thr SSC SV Formula allete INP BF significance Hellow LID WDC EOS LLIO IL12, IL4 EOS 6 ASGA0091444 97104675 G/A 8,80 0,03 CHR CCA LID WDC EOS LLIO IL12, IL4 EOS 6 MARC0032131 9734349 T/G 23,50 0,03 CHR CCA LIO UL15 TNF, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIO UL15, 6 MARC0032131 9743439 T/G 23,50 0,03 CHR CCA LIA EOS LIO IL12, IL4 EOS 6 ALGA0036131 9762028 T/C 32,20 0,03 CHR CCA LID WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036180 9993151 G/A 7.60 0,03 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0036191 9995667 T/C 94,30 0,02 CHR CCA IL10 WDC EOS IL10 IL12, IL6 IL10 6 ALGA0115176 10001 | InflueSiteSiteSiteFor the set of th |

| Breed | Trait | SSC | SNP | Position | m/M | MAF | P-value/ | Type of | Method | QTL | Nearest Gene |
|-------|------------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|--------|-----|---------------|
| | | | | | allele | | BF | significance | | | within QTL |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | ASGA0029105 | 10234092 7 | G/A | 9,80 | 0,03 | CHR | CCA | 96 | DLGAP1, TGIF1 |
| LR | IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b | 6 | ALGA0036219 | 10236262 5 | G/A | 9,40 | 0,05 | CHR | CCA | 96 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | ALGA0036233 | 10246473 6 | T/C | 98,60 | 0,03 | CHR | CCA | 96 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | ALGA0036235 | 10249556 1 | A/G | 98,40 | 0,03 | CHR | CCA | 96 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | H3GA0018606 | 10264149 3 | C/T | 10,10 | 0,03 | CHR | CCA | 96 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | DRGA0006658 | 10266493 0 | T/G | 89,90 | 0,03 | CHR | CCA | 96 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | ASGA0029117 | 10270935 2 | T/G | 89,90 | 0,03 | CHR | CCA | 96 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 6 | ALGA0036251 | 10273239 3 | A/G | 10,10 | 0,03 | CHR | CCA | 96 | |
| LR | WBC BAS | 6 | ALGA0115459 | 10333918 4 | A/G | 99,00 | 0,00 | GEN | PCA | 96 | |
| LR | IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b | 6 | ASGA0097110 | 10803346 9 | C/T | 5,90 | 0,05 | CHR | CCA | 97 | |
| LR | IL1b WBC EOS IL10 IL12 | 6 | H3GA0018950 | 14720592 1 | G/A | 25,10 | 0,04 | CHR | CCA | 98 | AK4 |
| LR | IL1b WBC EOS IL10 IL12 | 6 | MARC0091155 | 14988917 1 | C/T | 0,00 | 0,03 | CHR | CCA | 99 | DOCK7 |
| | | | | | | | | | | | |
| Breed | Trait | SSC | SNP | Position | m/M allele | MAF | P-value/ BF | Type of | Method | QTL | Nearest Gene within OTL |
|-------|--------------------------------------------------|-----|-------------|---------------|---------------|-------|----------------|--------------|--------|-----|----------------------------|
| | | | | 15004((7 | ancie | | ы | significance | | | |
| LR | IL4 EOS IL10 IL1b TNF | 6 | ALGA0115609 | 15284667 7 | T/C | 38,20 | 0,05 | CHR | CCA | 100 | FGGY |
| LR | IL1b WBC EOS IL10 IL12, IL4 EOS IL10 IL1b TNF | 6 | ALGA0114316 | 15294454 9 | C/T | 41,10 | 0,04 | CHR | CCA | 100 | |
| | | | | | | | | | | | ssc-mir-7857, |
| | | | | | | | | | | | LOC110261671, |
| LR | HMT HMG MCHC | 7 | H3GA0020313 | 21444076 | C/T | 35,30 | 0,03 | CHR | CCA | 101 | LOC110261673, |
| | | | | | | | | | | | LOC100154071, |
| | | | | | | | | | | | LOC100621915 |
| LR | HMT HMG MCHC | 7 | MARC0114063 | 21610238 | G/A | 0,00 | 0,03 | CHR | CCA | 101 | |
| LR | HMT HMG MCHC | 7 | MARC0055565 | 22727959 | G/A | 41,40 | 0,05 | CHR | CCA | 102 | TRIM10 |
| LR | IL1b WBC EOS IL10 IL12 | 7 | DRGA0008079 | 10534121 3 | T/C | 15,30 | 0,06 | CHR | CCA | 103 | |
| LR | IL1b WBC EOS IL10 IL12 | 7 | ASGA0035841 | 10539350 4 | C/T | 15,70 | 0,06 | CHR | CCA | 103 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 7 | MARC0001297 | 10899630 2 | T/C | 76,60 | 0,06 | CHR | CCA | 104 | |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 7 | MARC0057446 | 10904737 4 | A/C | 76,00 | 0,06 | CHR | CCA | 104 | |
| LR | IL6 IL10 IL1b | 7 | ALGA0044543 | 10906792 1 | T/C | 70,40 | 0,01 | CHR | CCA | 104 | |
| LR | IL6 IL10 IL1b | 7 | CASI0006750 | 10910110 8 | T/C | 82,20 | 0,01 | CHR | CCA | 104 | |
| LR | IL6 IL10 IL1b | 7 | ALGA0044610 | 10973390 1 | C/T | 9,30 | 0,03 | CHR | CCA | 105 | GALC |
| LR | IL1b WBC EOS IL10 IL12, IL6 IL10 IL1b | 7 | MARC0067107 | 11005772 7 | A/G | 75,80 | 0,06 | CHR | CCA | 105 | |

| Durad | Turit | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|---------------|-----|--------------|
| breeu | Iran | 350 | SINE | rosition | allele | MAF | BF | significance | Methou | QIL | within QTL |
| LR | IL6 IL10 IL1b | 7 | ALGA0044644 | 11011387 6 | C/T | 9,70 | 0,01 | CHR | CCA | 105 | |
| LR | HMT HMG MCHC | 7 | rs706107533 | 11517920 7 | C/T | NA | 0,03 | CHR | CCA | 106 | |
| LR | IL4 EOS IL10 IL1b TNF | 8 | ALGA0046044 | 1186987 | C/T | 5,70 | 0,05 | CHR | CCA | 107 | POLN, HAUS3 |
| LW | IL4 IL10 IL1b IL6 | 8 | MARC0111479 | 4598871 | T/G | 0,00 | 0,03 | CHR | CCA | 108 | JAKMIP1 |
| LW | IL4 IL10 IL1b IL6 | 8 | ALGA0107038 | 4605432 | T/C | 36,80 | 0,02 | CHR | CCA | 108 | |
| LW | IL4 IL10 IL1b IL6 | 8 | ASGA0092577 | 4674424 | G/A | 76,30 | 0,02 | CHR | CCA | 108 | |
| LR | TNF IFN IL10 | 8 | M1GA0011804 | 11782932 | A/G | 55,00 | 0,03 | CHR | CCA | 109 | LDB2 |
| LR | IL4 EOS IL10 IL1b TNF | 8 | CASI0003674 | 13589586 | C/A | 7,00 | 0,02 | CHR | CCA | 110 | |
| LR | IL4 EOS IL10 IL1b TNF | 8 | MARC0036889 | 13972046 | A/G | 75,50 | 0,02 | CHR | CCA | 110 | |
| LR | IL4 EOS IL10 IL1b TNF | 8 | MARC0054361 | 14596289 | T/C | 74,10 | 0,02 | CHR | CCA | 110 | |
| | IL4 EOS IL10 IL1b TNF, IL8 TNF, | | | | | | | | | | |
| LR | WBC NEU MON EOS BAS TNF, | 8 | ALGA0046861 | 20647847 | C/T | 1,30 | 0,01 | GEN | CCA | 111 | |
| | TNF IFN IL10 | | | | | | | | | | |
| LW | LYM NEU MON EOS BAS | 8 | ALGA0046885 | 20770188 | G/T | 59,00 | 0,03 | GEN | CCA | 111 | |
| | IL4 EOS IL10 IL1b TNF, IL6 IL10 | | | | | | | | | | |
| LR | IL1b, IL8 TNF, WBC NEU MON EOS BAS TNF, | 8 | ALGA0046899 | 20831553 | G/A | 26,30 | 0,02 | CHR | CCA, TATES | 111 | |
| | TNF IFN IL10 | | | | | | | | | | |
| LR | WBC NEU MON EOS BAS TNF | 8 | ASGA0101895 | 30740074 | T/C | 94,50 | 0,05 | CHR | CCA | 112 | UGDH |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | ASGA0088957 | 35953783 | A/G | 17,70 | 0,03 | CHR | CCA | 113 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Droad | Troit | SSC | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------|-----|---------------|----------|--------|-------|----------|--------------|----------|-----|----------------|
| Dieeu | Trait | 350 | 5111 | rosition | allele | MAF | BF | significance | Ivietnou | QIL | within QTL |
| | | | | | | | | | | | ATP10D, CORIN, |
| | | | | | | | | | | | U6, NFXL1, |
| | | | | | | | | | | | CNGA1, NIPAL1, |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | ALGA0105374 | 37495537 | G/A | 16,50 | 0,03 | CHR | CCA | 114 | TXK, TEC, |
| | | | | | | | | | | | SLAIN2, |
| | | | | | | | | | | | SLC10A4, ZAR1, |
| | | | | | | | | | | | FRYL |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | MARC0045311 | 37967413 | T/C | 15,70 | 0,03 | CHR | CCA | 114 | |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | M1GA0011926 | 38425208 | T/G | 74,30 | 0,03 | CHR | CCA | 114 | |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | MARC0056555 | 39391675 | C/T | 5,00 | 0,03 | CHR | CCA | 115 | |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | ALGA0047813 | 43027473 | A/C | 99,20 | 0,03 | CHR | CCA | 116 | TLL1 |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | MARC0039159 | 44439766 | C/T | 79,00 | 0,03 | CHR | CCA | 117 | |
| | | | | | | | | | | | GPAT3, |
| | | | | | | | | | | | ABRAXAS1, |
| | | | | | | | | | | | MRPS18C, HELQ, |
| | | | | | | | | | | | HPSE, COQ2, |
| LW | LYM NEU MON FOS BAS | 8 | ASGA0040364 | 13491192 | C/T | 17 70 | 0.02 | CHR | CCA | 118 | LOC100524999, |
| 2.0 | | 0 | 1150110010501 | 5 | 0/1 | 17,70 | 0,02 | CIIK | con | 110 | PLAC8, COPS4, |
| | | | | | | | | | | | LIN54, THAP9, |
| | | | | | | | | | | | SEC31A, SCD5, |
| | | | | | | | | | | | ssc-mir-9846, |
| | | | | | | | | | | | TMEM150C |
| LW | LYM NEU MON EOS BAS | 8 | ASGA0040417 | 13524221 | G/A | 23.10 | 0.04 | CHR | CCA | 118 | |
| 2.0 | | 0 | | 5 | 0,11 | 23,10 | 0,01 | cint | CON | 110 | |
| LW | LYM NEU MON EOS BAS | 8 | ASGA0040427 | 13527476 | C/T | 20.60 | 0.02 | CHR | CCA | 118 | |
| | | | | 0 | | 20,00 | -, | | | | |
| | | | | | | | | | | | |

| Breed | Trait | SSC | SNP | Position | m/M | MAF | P-value/ | Type of | Method | QTL | Nearest Gene |
|-------|-------------------------------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|---------------|-----|--------------|
| | | | | | allele | | BF | significance | | | within QTL |
| LW | LYM NEU MON EOS BAS | 8 | ALGA0050145 | 13528553 2 | G/A | 17,80 | 0,02 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | ALGA0115578 | 13555052 3 | A/C | 79,40 | 0,02 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | H3GA0054370 | 13560496 3 | T/C | 77,60 | 0,02 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | DRGA0017418 | 13560734 8 | G/A | 22,40 | 0,02 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | ALGA0109193 | 13562939 9 | A/G | 75,00 | 0,03 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | ASGA0082238 | 13566598 1 | A/C | 79,30 | 0,02 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | ASGA0105760 | 13566871 2 | C/T | 26,10 | 0,02 | CHR | CCA | 118 | |
| LW | LYM NEU MON EOS BAS | 8 | MARC0065298 | 13568915 2 | A/G | 72,20 | 0,02 | CHR | CCA | 118 | |
| LW | RBC HMG HMT MCV MCH MCHC | 9 | MARC0008298 | 71070843 | G/A | 14,10 | 0,05 | GEN | CCA | 119 | CDK14 |
| LW | MON BAS | 9 | H3GA0027937 | 10093959 2 | C/T | 81,70 | 0,03 | CHR | PCA | 120 | MAGI2 |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | ASGA0046986 | 19572163 | G/A | 22,70 | 0,01 | GEN | CCA | 126 | |
| LR | IL8 TNF | 15 | ALGA0087090 | 12013902 4 | T/C | 87,80 | 0,05 | CHR | CCA | 120 | |
| LR | IL8 TNF, WBC HMT EOS HAP IL8 | 15 | ALGA0087116 | 12028616 3 | T/C | 31,90 | 0,01 | GEN | CCA, TATES | 120 | |
| | | | | | | | | | | | |

| Durad | Trait | SSC | SNP Positio | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------|-----|--------------|---------------|--------|--------|----------|--------------|--------|-----|------------------|
| Бгеец | 1 ган | SSC | SINE | rosition | allele | IVIAF | BF | significance | Methou | QIL | within QTL |
| | BAS MON, WBC NEU MON EOS | | | | | | | | | | |
| LR | BAS TNF, | 10 | ALGA0057739 | 20062069 | A/C | 16,30 | 0,01 | GEN | CCA | 127 | |
| | NEU RBC WBC MON BAS | | | | | | | | | | |
| LW | MON BAS | 9 | DRGA0009651 | 10287822 7 | A/C | 15,90 | 0,03 | CHR | PCA | 121 | CCDC146 |
| LR | IL8 TNF | 15 | ALGA0087356 | 12289584 8 | C/A | 43,80 | 0,05 | CHR | CCA | 121 | |
| LR | IL8 TNF | 15 | MARC0114457 | 12305228 6 | G/A | 0,00 | 0,06 | CHR | CCA | 121 | |
| LR | IL8 TNF | 15 | ALGA0087328 | 12324197 1 | T/C | 68,10 | 0,06 | CHR | CCA | 121 | |
| LR | IL8 TNF | 15 | MARC0070811 | 12329314 1 | T/C | 68,10 | 0,06 | CHR | CCA | 121 | |
| LW | TNF MON IFN IL12 IL6 | 9 | ASGA0097568 | 13851785 5 | C/A | 79,30 | 0,01 | GEN | TATES | 122 | |
| LR | IL12 IL8 | 15 | ASGA0070763 | 12427618 7 | G/A | 67,70 | 0,04 | CHR | PCA | 122 | |
| LW | BAS WBC NEU | 10 | M1GA0013576 | 3267437 | G/A | 78,00 | 0,05 | CHR | CCA | 123 | BRINP3 |
| | | | | | | | | | | | ZBTB41, CRB1, |
| ID | WBC NEU MON EOS BAS TNF, | 10 | ASC A0047019 | 20124016 | C/T | (2.20) | 0.02 | CEN | CCA | 107 | DENND1B, |
| LK | NEU RBC WBC MON BAS | 10 | ASGA004/018 | 20134916 | C/1 | 63,30 | 0,02 | GEN | CCA | 127 | C1orf53, LHX9, |
| | | | | | | | | | | | NEK7 |
| TW | DAS WDC NEU | 10 | ALCA0057019 | 10046457 | C/A | 70.60 | 0.05 | CHD | CCA | 124 | MARK1, C1orf115, |
| LW | DAS WDC NEU | 10 | ALGA003/018 | 1004043/ | U/A | /9,00 | 0,05 | UUK | CCA | 124 | MARC2, HLX |
| LW | BAS WBC NEU | 10 | ASGA0046469 | 10399957 | A/C | 6,60 | 0,05 | CHR | CCA | 124 | |
| LW | BAS WBC NEU | 10 | H3GA0029248 | 10680375 | C/T | 15,40 | 0,05 | CHR | CCA | 124 | |
| LW | BAS WBC NEU | 10 | ALGA0057079 | 10721280 | T/C | 15,60 | 0,05 | CHR | CCA | 124 | |

| | Appendix | | | | | | | | | | | | | | |
|----|-------------------------------------------------------------|----|-------------|---------------|-----|-------|------|-----|---------------|-----|------------------------------------------------|--|--|--|--|
| | | | | | | | | | | | | | | | |
| LW | BAS WBC NEU | 10 | MARC0010213 | 10784930 | C/T | 94,60 | 0,05 | CHR | CCA | 124 | | | | | |
| LR | IL8 TNF | 15 | ALGA0088017 | 13132555 7 | T/C | 81,50 | 0,06 | CHR | CCA | 124 | | | | | |
| LW | BAS WBC NEU | 10 | MARC0055782 | 13280955 | G/A | 94,50 | 0,05 | CHR | CCA | 125 | | | | | |
| LR | HMT HMG MCHC | 15 | ASGA0084070 | 13722113 6 | T/G | 23,80 | 0,06 | CHR | CCA | 125 | | | | | |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | MARC0058358 | 20157046 | T/C | 13,70 | 0,00 | CHR | CCA | 127 | | | | | |
| LW | НМБ МСН | 16 | ALGA0089752 | 23580846 | G/A | 74,10 | 0,04 | CHR | CCA | 126 | EGFLAM, LIFR, OSMR, RICTOR, U6, U4, FYB1 | | | | |
| LR | WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | MARC0050841 | 20188434 | A/C | 63,40 | 0,02 | GEN | CCA | 127 | | | | | |
| LW | HMG MCH, PLT RBC WBC | 16 | ALGA0089777 | 24362179 | T/C | 39,40 | 0,04 | CHR | CCA | 126 | | | | | |
| LR | WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | ALGA0106008 | 20444762 | A/C | 75,40 | 0,03 | GEN | CCA | 127 | | | | | |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | H3GA0053667 | 20584936 | C/A | 73,00 | 0,03 | GEN | CCA | 127 | | | | | |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | H3GA0052936 | 20795956 | A/G | 69,90 | 0,01 | GEN | CCA, TATES | 127 | | | | | |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | ASGA0098001 | 20805520 | A/G | 30,10 | 0,01 | GEN | CCA, TATES | 127 | | | | | |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | MARC0108793 | 21031390 | C/T | 0,00 | 0,05 | GEN | CCA | 127 | | | | | |

| Drood | Troit | SSC | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-------------------------------------------------------------|-----|-------------|----------|--------|-------|----------|--------------|---------------|-----|--------------------------------------------------------------------|
| Бгеец | Iran | ssc | SINF | rosition | allele | MAF | BF | significance | Methou | QIL | within QTL |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | MARC0018828 | 21054756 | A/G | 6,20 | 0,05 | GEN | ССА | 127 | |
| LR | BAS MON, WBC NEU MON EOS BAS TNF, NEU RBC WBC MON BAS | 10 | ASGA0083356 | 22817715 | G/A | 91,70 | 0,01 | GEN | CCA, TATES | 129 | NR5A2 |
| LW | IL4 IL10 IL1b IL6, IL6 IFN IL10 IL1b | 11 | ALGA0062985 | 63626204 | C/T | 95,70 | 4,07 | GEN | mvBIMBA M | 143 | DCT |
| LW | EOS MCV PLT WBC IL8, LYM NEU MON EOS BAS | 11 | ALGA0108815 | 70247157 | T/C | 7,30 | 4,35 | GEN | mvBIMBA M | 146 | ITGBL1, FGF14, TPP2, METTL21C, TEX30, POGLUT2 |
| LR | IL4 EOS IL10 IL1b TNF, IFN IL12 IL8 | 12 | ALGA0113815 | 12017916 | T/C | 11,60 | 0,01 | CHR | CCA, PCA | 152 | RGS9 |
| LR | IL4 EOS IL10 IL15 TNF, IFN IL12 IL8 | 12 | H3GA0033531 | 12973397 | C/T | 96,60 | 0,01 | CHR | CCA, PCA | 153 | PRKCA, CACNG5, CACNG4, CACNG1, HELZ, U6, PSMD12, NOL11 |
| LR | WBC NEU MON EOS BAS TNF | 10 | DRGA0010387 | 21726062 | A/G | 63,40 | 0,02 | CHR | CCA | 128 | PTPRC |
| LR | WBC NEU MON EOS BAS TNF | 10 | ALGA0057837 | 22018259 | G/A | 98,60 | 0,02 | CHR | CCA | 128 | |
| LR | WBC NEU MON EOS BAS TNF | 10 | ASGA0047084 | 22210885 | T/C | 1,40 | 0,02 | CHR | CCA | 128 | |
| LR | IL4 EOS IL10 IL1b TNF | 16 | ASGA0073693 | 60020102 | T/G | 2,40 | 0,01 | GEN | CCA | 128 | |
| LR | IL4 EOS IL10 IL1b TNF, IFN IL12 IL8 | 12 | H3GA0055422 | 13531783 | G/T | 4,10 | 0,01 | CHR | CCA, PCA | 153 | |
| LR | IL4 EOS IL10 IL1b TNF | 16 | ALGA0091375 | 66889281 | C/T | 24,20 | 0,01 | GEN | CCA | 129 | |
| LR | WBC BAS | 10 | ASGA0095530 | 33811026 | G/A | 79,50 | 0,05 | GEN | PCA | 130 | NDUFB6 |
| LR | IL4 EOS IL10 IL1b TNF | 16 | MARC0081095 | 68806638 | G/A | 2,60 | 0,01 | GEN | CCA | 130 | |

| Durad | Trait | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|----------------------------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|--------------|-----|--------------------------------------------------------------------------|
| Бгеец | 1 ran | 350 | SINE | rosition | allele | MAF | BF | significance | Method | QIL | within QTL |
| LR | WBC BAS | 10 | MARC0001381 | 36349905 | A/G | 68,50 | 0,05 | GEN | PCA | 131 | |
| LR | IL4 EOS IL10 IL1b TNF, PC3Cyto | 12 | MARC0113018 | 13642774 | T/C | 0,00 | 0,01 | CHR | CCA | 153 | |
| LW | RBC HMG HMT MCV MCH MCHC | 16 | ALGA0091954 | 73703925 | A/C | 61,40 | 0,04 | CHR | CCA | 131 | |
| LR | IL4 EOS IL10 IL1b TNF, IFN IL12 IL8 | 12 | ALGA0105006 | 13982775 | C/T | 3,20 | 0,01 | CHR | CCA, PCA | 153 | |
| LR | NEU RBC WBC MON BAS | 10 | H3GA0030245 | 47362497 | C/T | 67,40 | 0,04 | CHR | CCA | 132 | |
| LR | IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b, IL8 TNF | 12 | ALGA0066702 | 45863925 | A/G | 94,90 | 0,04 | CHR | CCA | 163 | EFCAB5, NSRP1, ssc-mir-423, SLC6A4, BLMH, TMIGD1, CPD, GOSR1 |
| LR | IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b, IL8 TNF | 12 | DRGA0011783 | 45955884 | T/C | 5,10 | 0,04 | CHR | CCA | 163 | |
| LR | IL6 IL10 IL1b | 11 | MARC0043055 | 2474595 | A/G | 90,80 | 0,02 | CHR | CCA | 133 | |
| LR | IL4 EOS IL10 IL1b TNF, IL6 IL10 IL1b, IL8 TNF | 12 | ALGA0114806 | 46640334 | T/G | 9,50 | 0,04 | CHR | CCA | 163 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060404 | 4665665 | G/A | 6,90 | 0,03 | CHR | CCA | 134 | USP12 |
| LR | EOS PLT | 17 | ASGA0076045 | 28192131 | A/G | 8,80 | 0,02 | CHR | CCA | 134 | CFAP61 |
| LR | EOS PLT | 17 | MARC0093077 | 28351838 | G/A | 0,00 | 0,02 | CHR | CCA | 134 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060455 | 5431878 | A/G | 11,50 | 0,02 | CHR | CCA | 135 | FLT3, PAN3, FLT1 |
| LR | IL6 IL10 IL1b | 11 | ASGA0049456 | 5563855 | C/T | 88,50 | 0,02 | CHR | CCA | 135 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060475 | 5591824 | A/G | 8,10 | 0,02 | CHR | CCA | 135 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060479 | 5673798 | C/T | 8,10 | 0,02 | CHR | CCA | 135 | |
| LR | EOS PLT, WBC HMT EOS HAP IL8, WBC NEU MON EOS BAS TNF | 13 | ALGA0072231 | 14124784 2 | A/G | 29,90 | 4,32 | GEN | mvBIMBA M | 166 | IGSF11 |
| LR | IL6 IL10 IL1b | 11 | ALGA0060600 | 7781214 | T/C | 62,90 | 0,02 | CHR | CCA | 136 | B3GLCT, RXFP2, FRY |

| Durad | Tru::4 | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|------------------------|-----|--------------|----------|--------|-------|----------|--------------|---------|-----|--------------|
| Breed | 1 rait | 35C | SINF | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| LR | IL6 IL10 IL1b | 11 | DRGA0010773 | 7803554 | G/A | 62,90 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | DRGA0017521 | 7841215 | T/C | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060603 | 7917555 | A/G | 62,90 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | DRGA0010774 | 7946341 | G/A | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | H3GA0031207 | 7959313 | A/G | 71,90 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | INRA0034855 | 7970578 | G/A | 71,90 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | H3GA0031210 | 8015295 | C/T | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060606 | 8067254 | A/G | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060607 | 8101824 | G/A | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0060610 | 8130087 | A/C | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | MARC0033486 | 8150468 | T/C | 62,90 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | H3GA0031211 | 8164005 | G/A | 67,50 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | DRGA0010776 | 8254699 | G/A | 71,90 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | MARC0032659 | 8298480 | A/C | 28,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | MARC0058476 | 8322594 | T/C | 37,10 | 0,02 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | ASGA0049620 | 8612176 | G/A | 26,70 | 0,02 | CHR | CCA | 136 | |
| LR | EOS PLT | 17 | ASGA0076514 | 33282761 | G/A | 95,70 | 0,02 | CHR | CCA | 136 | STK35, PDYN |
| LR | EOS PLT | 17 | M1GA0021930 | 33651909 | A/C | 72,60 | 0,04 | CHR | CCA | 136 | |
| LR | IL6 IL10 IL1b | 11 | H3GA0031293 | 10367680 | T/C | 69,80 | 0,02 | CHR | CCA | 137 | RFC3 |
| LR | IL6 IL10 IL1b | 11 | MARC0011099 | 10387046 | A/G | 32,30 | 0,02 | CHR | CCA | 137 | |
| LR | IL6 IL10 IL1b | 11 | ASGA0049736 | 10399072 | G/A | 73,70 | 0,02 | CHR | CCA | 137 | |
| LR | IL6 IL10 IL1b | 11 | MARC0089033 | 10420321 | C/A | 87,90 | 0,02 | CHR | CCA | 137 | |
| LR | IL6 IL10 IL1b | 11 | MARC0007430 | 10615611 | T/A | 19,20 | 0,02 | CHR | CCA | 137 | |
| ID | HMG MCHC IL10, HMT HMG | 14 | ALC A0075572 | 12776542 | C/T | 42.10 | 2.60 | CEN | mvBIMBA | 171 | DDCC55 |
| LK | MCHC | 14 | ALUA00/33/2 | 15//0342 | C/ 1 | 42,10 | 3,09 | UEN | М | 1/1 | FK3333 |
| LR | IL6 IL10 IL1b | 11 | INRA0035360 | 13579315 | G/A | 26,30 | 0,02 | CHR | CCA | 138 | |
| | | | | | | | | | | | |

| Breed | Trait | SSC | SNP | Position | m/M | MAF | P-value/ | Type of | Method | ΟΤΙ | Nearest Gene |
|-------|----------------------------------------------------------|-----|-------------|---------------|--------|---------|----------------|--------------|-------------------------------------|------|-------------------------------------------------------------------|
| Diccu | That | 550 | | 1 USHION | allele | 1,1,1,1 | BF | significance | Methou | VII. | within QTL |
| LR | EOS PLT, WBC HMT EOS HAP IL8, WBC NEU MON EOS BAS TNF | 15 | ASGA0070226 | 10059073 3 | T/C | 30,80 | 5,87 | GEN | mvBIMBA M | 183 | CCDC150 |
| LR | IL8 TNF, IL12 IL8 | 15 | MARC0089139 | 10867788 4 | T/A | 65,30 | 0,05 | CHR | CCA, PCA | 185 | PARD3B, NRP2, INO80D |
| LR | IL8 TNF, WBC HMT EOS HAP IL8, IL12 IL8 | 15 | ALGA0086892 | 11613450 8 | C/T | 68,80 | 0.04/3.5 3 | GEN | CCA, TATES, mvBIMBA M. PCA | 188 | SPAG16 |
| LR | IL6 IL10 IL1b | 11 | ALGA0061341 | 21733098 | G/A | 42,60 | 0,05 | CHR | CCA | 139 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0061477 | 23986814 | A/C | 16,30 | 0,02 | CHR | CCA | 140 | |
| LR | IL8 TNF, WBC HMT EOS HAP IL8, IL12 IL8 | 15 | ASGA0070586 | 12010606 6 | G/A | 68,20 | 0.001/4. 77 | GEN | CCA, TATES, mvBIMBA M, PCA | 120 | TNS1, RUFY4, CXCR2, ARPC2, GPBAR1, AAMP, PNKD, TMBIM6 |
| LW | IFN IL10 IL12 IL1b IL4 IL6 | 11 | DRGA0011317 | 52909023 | A/G | 63,20 | 0,00 | CHR | PCA | 141 | |
| LW | IFN IL10 IL12 IL1b IL4 IL6 | 11 | INRA0036664 | 53861212 | C/A | 2,00 | 0,02 | GEN | PCA | 141 | |
| | | | | | | | | | | | |

| Nearest Gene |
|------------------------------------------------------------------------|
| within QTL |
| EPHA1, ZYX, |
| FAM131B, |
| CLCN1, |
| TMEM139, |
| GSTK1, |
| TAS2R40, KEL, |
| TRPV5, TRPV5, |
| TAS2R39, PIP, |
| OR6V1, LLCFC1, |
| EPHB6, PRSS2, |
| TRBV27, U6, |
| TRBV25-1, |
| TRBV19, |
| LOC106508706, |
| LOC100302368, |
| 1KBV3-1, PKSS58, |
| LOC100511166, |
| MGANI2 |
| |
| |
| |
| |
| |
| |
| |
| |
| EPHB6, TRBV2 TRBV2 TRBV1 LOC100 TRBV3 LOC100 MGAM |

| Drood | Troit | SSC | SND | Desition | m/M | мае | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|-----------------------------|-----|---------------|----------|--------|-------|----------|--------------|---------|------|--------------|
| breeu | | ssc | 5111 | rosition | allele | WIAF | BF | significance | wiethou | VIL | within QTL |
| | RBC HMG HMT MCV MCH MCHC, | | | | | | | | | | |
| LW | HMG MCH, | 16 | DRGA0015975 | 24344082 | C/T | 53,10 | 0,03 | GEN | CCA | 126 | |
| | PLT RBC WBC | | | | | | | | | | |
| | RBC HMG HMT MCV MCH MCHC, | | | | | | | | | | |
| LW | HMG MCH, | 16 | ASGA0072751 | 25032947 | C/T | 82,10 | 0,03 | GEN | CCA | 127 | |
| | PLT RBC WBC | | | | | | | | | | |
| LW | HMG MCHC, WBC RBC HAP IL1b, | 16 | MARC0030066 | 72841711 | C/T | 38.20 | 3.35 | GEN | mvBIMBA | 131 | SEMA5A, U6 |
| 2 | PLT RBC WBC | 10 | | , | 0,1 | 00,20 | 0,00 | 0LIV | М | 101 | |
| | RBC HMG HMT MCV MCH MCHC. | | | | | | 0.05/3.0 | | CCA, | | |
| LW | HMG MCH, HMG MCHC | 16 | ALGA0091962 | 73764474 | G/A | 42,10 | 5 | GEN | mvBIMBA | 131 | |
| | | | | | | | | | М | | |
| LR | MCV MCHC HAP | 18 | ASGA0105592 | 7734440 | C/A | 24,30 | 0,06 | CHR | PCA | 141 | |
| | RBC HMG HMT MCV MCH MCHC, | | | | | | | | | | |
| LW | HMG MCH, | 16 | ASGA0074790 | 78019054 | G/A | 99,10 | 0,01 | GEN | CCA, | 132 | |
| | IL8 HMT WBC, WBC RBC HAP | | | | | | | | TATES | | |
| | IL1b, PLT RBC WBC | | | | | | | | | | |
| | RBC HMG HMT MCV MCH MCHC, | | | | | | | | | | |
| * *** | HMG MCH, | 16 | | 20022202 | | 7.00 | 0.04 | CEN | GGA | 100 | |
| LW | HMT HMG MCHC, IL8 HMT WBC, | 16 | MIGA0021462 | 78037702 | A/G | 7,90 | 0,04 | GEN | CCA | 132 | |
| | WBC RBC HAP IL16, PL1 RBC | | | | | | | | | | |
| T 337 | | 11 | AL C A00(2457 | 52077700 | A./C | 00.00 | 0.02 | CEN | DCA | 1.42 | |
| | | 11 | ALGA0062457 | 539///90 | A/G | 98,00 | 0,02 | GEN | PCA | 142 | |
| LW | IFN IL10 IL12 IL16 IL4 IL6 | 11 | SIR10000315 | 54315287 | G/1 | 0,00 | 0,02 | GEN | PCA | 142 | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | 1 | | | | |

| Drood | Troit | 88C | SND | Desition | m/M | мар | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|------------------------------------|-----|---------------|----------|------------|-------|----------|--------------|----------|-----|-----------------|
| breeu | Iran | 330 | SINF | rosition | allele | WIAF | BF | significance | Methou | QIL | within QTL |
| | | | | | | | | | | | CLEC5A, PRSS37, |
| | | | | | | | | | | | TAS2R4, TAS2R3, |
| LR | MCV MCHC HAP | 18 | MARC0112998 | 8006092 | T/C | 0,00 | 0,06 | CHR | PCA | 142 | SSBP1, WEE2, |
| | | | | | | | | | | | DENND11, AGK, |
| | | | | | | | | | | | MEM178B |
| LW | BAS WBC NEU, LYM NEU EOS | 17 | ALGA0112929 | 106110 | A/G | 55.50 | 0.04 | GEN | CCA, | 133 | |
| | BAS | | | | | , | , | | TATES | | |
| LR | WBC NEU MON EOS BAS TNF, | 17 | ALGA0094419 | 31515709 | T/C | 4,80 | 0,01 | GEN | CCA, PCA | 135 | |
| | WBC BAS | | | | | · | | | | | |
| LR | MCV MCHC HAP | 18 | ASGA0078747 | 8204406 | C/T | 24,10 | 0,06 | CHR | PCA | 142 | |
| LW | IL16 IL10 IL12, IL4 IL10 IL16 IL6, | 17 | MARC0045544 | 38811036 | A/C | 19,30 | 4,48 | GEN | mvBIMBA | 137 | CEP250 |
| | IL6 IFN IL10 IL16 | | | | | | | | М | | |
| LW | RBC HMG HMT MCV MCH MCHC, | 17 | ASGA0077178 | 45775572 | G/A | 59,50 | 0,05 | CHR | CCA | 138 | PTPRT, U6 |
| ID | HMT HMG MCHC | 10 | AT C A0006880 | 8221100 | T/C | 72.50 | 0.02 | CUD | DCA | 142 | |
| | | 10 | ALGA0090880 | 8321190 | | 72,30 | 0,02 | | PCA | 142 | |
| | | 18 | ASGA0078760 | 8442517 | U/A T/C | 75.00 | 0,00 | CHR | PCA | 142 | |
| LK | RBC HMG HMT MCV MCH MCHC | 10 | ASGA0078700 | 0442317 | 1/C | 75,90 | 0,00 | CHIK | ICA | 142 | |
| LW | HMT HMG MCHC | 17 | ALGA0123186 | 45833341 | A/C | 44,70 | 0,05 | CHR | CCA | 138 | |
| | RBC HMG HMT MCV MCH MCHC | | | | | | | | | | |
| LW | HMT HMG MCHC | 17 | ALGA0109744 | 45890603 | C/A | 53,70 | 0,05 | GEN | CCA | 138 | |
| | RBC HMG HMT MCV MCH MCHC. | | | | | | | | CCA. | | |
| LW | HMT HMG MCHC, MCV MCHC | 18 | H3GA0050210 | 2540065 | G/A | 76,30 | 0.02/9.4 | GEN | mvBIMBA | 140 | |
| | НАР | | | | | | 4 | | M, PCA | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Dread | Tueit | SSC | CNID | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|---------------|-----|-------------|----------|--------|-------|----------|--------------|--------|-----|----------------------------------------------------------------------|
| breeu | Trait | ssc | SINF | rosition | allele | MAF | BF | significance | Methou | QIL | within QTL |
| | | | | | | | | | | | BRAF, NDUFB2, |
| | | | | | | | | | | | ADCK2, U6, |
| | | | | | | | | | | | DENND2A, |
| LR | MCV MCHC HAP | 18 | H3GA0050329 | 9041613 | G/A | 76,90 | 0,06 | CHR | PCA | 143 | MKRN1, RAB19, |
| | | | | | | | | | | | SLC37A3, |
| | | | | | | | | | | | KDM7A, PARP12, |
| | | | | | | | | | | | TBXAS1, HIPK2 |
| LR | MCV MCHC HAP | 18 | ALGA0096968 | 9386834 | C/T | 61,30 | 0,02 | CHR | PCA | 143 | |
| LR | MCV MCHC HAP | 18 | H3GA0056352 | 9871442 | A/C | 54,30 | 0,01 | CHR | PCA | 143 | |
| LW | EOS BAS | 11 | ASGA0051613 | 67683899 | G/A | 88,40 | 0,02 | CHR | PCA | 144 | SLC15A1 |
| LW | EOS BAS | 11 | rs342919012 | 67687842 | G/A | NA | 0,02 | CHR | PCA | 144 | |
| LW | EOS BAS | 11 | rs326593788 | 67687850 | T/C | NA | 0,02 | CHR | PCA | 144 | |
| LW | EOS BAS | 11 | ALGA0063379 | 67697289 | G/A | 11,60 | 0,02 | CHR | PCA | 144 | |
| LW | EOS BAS | 11 | ASGA0051621 | 67714628 | T/C | 11,60 | 0,02 | CHR | PCA | 144 | |
| LR | МСУ МСНС НАР | 18 | ASGA0078874 | 10641854 | T/C | 60,00 | 0,01 | CHR | РСА | 144 | ZC3HAV1L, KIAA1549, TMEM213, ATP6V0A4, U6, Y RNA, SVOPL, |
| | | | | | | | | | | | TRIM24 |
| LR | MCV MCHC HAP | 18 | ALGA0097012 | 11264864 | C/T | 89,10 | 0,02 | CHR | PCA | 144 | |
| | | | | | | | | | | | CLYBL, ZIC5, |
| LW | EOS BAS | 11 | ASGA0051648 | 68510765 | C/T | 19,90 | 0,02 | CHR | PCA | 145 | ZIC2, PCCA, U6, |
| | | | | | | | | | | | GGACT |
| LR | IL6 IL10 IL1b | 11 | ALGA0063462 | 69323838 | G/A | 98,10 | 0,02 | CHR | CCA | 145 | |
| LR | МСУ МСНС НАР | 18 | INRA0055202 | 12429018 | C/T | 82,60 | 0,04 | CHR | PCA | 145 | CHRM2, ssc-mir- 490-1 |

| Durad | Trait | SSC SNP Positio | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene | |
|-------|--------------------------------------|-----------------|-------------|----------|--------|----------|---------|--------------|----------|--------------|--------------|
| вгееа | Iran | 350 | SINF | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| LR | MCV MCHC HAP | 18 | MARC0030508 | 13279854 | T/G | 67,70 | 0,02 | CHR | PCA | 145 | |
| LR | RBC HMG HMT MCV MCH, PC3RBCs | 18 | MARC0072034 | 6968918 | A/G | 41,00 | 0,04 | CHR | CCA | 141 | |
| LR | IL6 IL10 IL1b | 11 | M1GA0015299 | 70370312 | C/T | 98,50 | 0,06 | CHR | CCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0063574 | 70392258 | A/G | 97,20 | 0,06 | CHR | CCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0063603 | 70518157 | C/T | 3,20 | 0,06 | CHR | CCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | H3GA0032472 | 70572911 | G/A | 3,70 | 0,02 | CHR | CCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | MARC0051848 | 71048614 | C/T | 92,30 | 0,02 | CHR | CCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | MARC0085875 | 71100401 | A/G | 92,30 | 0,02 | CHR | CCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | DIAS0003373 | 71110085 | C/T | 6,20 | 0,02 | CHR | CCA | 146 | |
| LR | MCV MCHC HAP | 18 | H3GA0050418 | 14855749 | C/T | 18,60 | 0,05 | CHR | PCA | 146 | |
| LR | MCV MCHC HAP | 18 | INRA0055273 | 15706111 | A/G | 18,00 | 0,03 | CHR | PCA | 146 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0102712 | 71257051 | G/A | 3,80 | 0,02 | CHR | CCA | 147 | |
| LR | IL6 IL10 IL1b | 11 | ALGA0102815 | 71280437 | T/C | 92,20 | 0,02 | CHR | CCA | 147 | |
| LR | RBC HMG HMT MCV MCH | 18 | MARC0063061 | 24962723 | C/T | 37,60 | 0,03 | CHR | CCA | 147 | AASS, PTPRZ1 |
| LR | RBC HMG HMT MCV MCH | 18 | ASGA0092854 | 24990743 | C/T | 26,80 | 0,03 | CHR | CCA | 147 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | MARC0068323 | 7391549 | G/A | 69,20 | 0,03 | CHR | CCA, PCA | 141 | |
| LW | BAS WBC NEU, LYM NEU MON EOS BAS | 18 | ALGA0097582 | 25200554 | C/T | 83,40 | 0,03 | CHR | CCA | 147 | |
| LW | BAS WBC NEU, LYM NEU MON EOS BAS | 18 | ASGA0079343 | 25373224 | C/T | 17,00 | 0,05 | CHR | CCA | 147 | |
| LR | IL6 IL10 IL1b | 11 | ASGA0051917 | 73150897 | G/A/T | 93,70 | 0,06 | CHR | CCA | 148 | |
| LR | MCV MCHC HAP | 18 | H3GA0051025 | 46713612 | A/G | 22,00 | 0,06 | CHR | PCA | 148 | |
| LR | IL6 IL10 IL1b | 11 | INRA0037562 | 76483089 | A/G | 98,10 | 0,02 | CHR | CCA | 149 | |
| LR | RBC HMG HMT MCV MCH | 18 | MARC0025541 | 50663391 | A/G | 44,90 | 0,03 | CHR | CCA | 149 | POLM |
| LR | WBC HMT EOS HAP IL8 | 18 | H3GA0051155 | 50710948 | T/C | 7,20 | 0,02 | GEN | CCA | 149 | |

| Ducad | Troit | SSC | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------------------|-----|-------------|----------|--------|-------|----------|--------------|--------------|-----|--------------|
| breeu | 1 rait | 55C | SINF | rosition | allele | MAF | BF | significance | Methou | QIL | within QTL |
| LR | NEU RBC WBC MON BAS | 18 | ASGA0080341 | 51353492 | G/A | 9,50 | 0,04 | CHR | CCA | 149 | |
| LW | LYM NEU MON EOS BAS | 12 | M1GA0026919 | 7396035 | C/A | 18,80 | 4,80 | GEN | mvBIMBA M | 150 | |
| LR | IFN IL12 IL8 | 12 | ALGA0064792 | 9141861 | T/C | 8,60 | 0,05 | CHR | PCA | 151 | |
| LW | IL4 IL10 IL1b IL6 | 12 | ASGA0105686 | 9540202 | G/A | 39,30 | 3,07 | GEN | mvBIMBA M | 151 | |
| LR | IL4 EOS IL10 IL1b TNF | 12 | M1GA0027137 | 11878926 | A/G | 4,70 | 0,04 | CHR | CCA | 152 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ASGA0092914 | 7397094 | A/C | 30,80 | 0,03 | CHR | CCA, PCA | 141 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ASGA0078726 | 7404576 | A/G | 69,20 | 0,03 | CHR | CCA, PCA | 141 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ALGA0096832 | 7541311 | G/C | 26,40 | 0,03 | CHR | CCA, PCA | 141 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ALGA0105511 | 7717391 | C/T | 55,70 | 0,06 | GEN | CCA, PCA | 141 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ALGA0121880 | 7775625 | G/A | 73,20 | 0,04 | CHR | CCA, PCA | 141 | |
| LR | IL4 EOS IL10 IL1b TNF, PC3Cyto | 12 | MARC0070276 | 14204868 | G/A | 92,10 | 0,01 | CHR | CCA | 154 | BPTF |
| LR | IL4 EOS IL10 IL1b TNF | 12 | ALGA0065378 | 17196251 | G/A | 2,60 | 0,01 | CHR | CCA | 155 | MAPT |
| LR | NEU RBC WBC MON BAS | 12 | DIAS0003753 | 21492055 | G/A | 77,80 | 0,06 | CHR | CCA | 156 | |
| LW | IL4 IL10 IL1b IL6 | 12 | ALGA0065672 | 24650734 | T/C | 0,60 | 4,71 | GEN | mvBIMBA M | 157 | SKAP1 |
| LW | IFN IL10 IL12 IL1b IL4 IL6 | 12 | ASGA0082570 | 38304022 | G/T | 3,00 | 0,01 | CHR | PCA | 158 | |
| LW | IFN IL10 IL12 IL1b IL4 IL6 | 12 | MARC0092718 | 40705609 | T/C | 0,00 | 0,06 | CHR | PCA | 159 | |
| LW | IFN IL8 TNF | 12 | MARC0087562 | 42225466 | T/C | 80,60 | 0,02 | CHR | PCA | 160 | MYO1D |
| LW | IFN IL10 IL12 IL1b IL4 IL6 | 12 | ALGA0108238 | 42366158 | T/C | 13,30 | 0,01 | CHR | PCA | 161 | MYO1D |
| LW | IFN IL8 TNF | 12 | ALGA0066551 | 42419728 | T/C | 30,60 | 0,02 | CHR | PCA | 161 | |

| Droad | Twoit | SSC SNP Pos | Desition | m/M MAF | n/M MAF P-value/ Ty | / Type of Method | | OTI | Nearest Gene | | |
|-------|-------------|-------------|-------------|----------|---------------------|------------------|------|--------------|--------------|-----------------|-------------------|
| breeu | Trait | 350 | 5111 | rosition | allele | MAF | BF | significance | Methou | QIL | within QTL |
| | | | | | | | | | | | KSR1, NOS2, |
| | | | | | | | | | | | NLK, TMEM97, |
| | | | | | | | | | | | IFT20, TNFAIP1, |
| | | | | | | | | | | | VTN, |
| | | | | | | | | | | | POLDIP2, |
| | | | | | | | | | | | ТМЕМ199, |
| | | | | | | | | | | | SEBOX, SARM1, |
| | | | | | | | | | | | SLC46A1, |
| | | | | | | | | | | | SLC13A2, FOXN1, |
| | | | | | | | | | | | UNC119, PIGS, |
| | | | | | | | | | | | ALDOC, SPAG5, |
| | | | | | | | | | | | KIAA0100, |
| | | | | | | | | | | KIAA0100, SDF2, | |
| LW | IFN IL8 TNF | 12 | MARC0072172 | 43987384 | G/A | 80,60 | 0,02 | CHR | CHR PCA | 162 | SUPT6H, |
| | | | | | | | | | | | PROCA1, RAB34, |
| | | | | | | | | | | | RPL23A, |
| | | | | | | | | | | | SNORD42, |
| | | | | | | | | | | | TLCD1, |
| | | | | | | | | | | | SNORD4A, |
| | | | | | | | | | | | SNORD4B, NEK8, |
| | | | | | | | | | | | TRAF4, U6, |
| | | | | | | | | | | | FAM222B, ERAL1, |
| | | | | | | | | | | | ssc-mir-451, ssc- |
| | | | | | | | | | | | mir-144, FLOT2, |
| | | | | | | | | | | | DHRS13, PHF12, |
| | | | | | | | | | | | SEZ6, PIPOX, |
| | | | | | | | | | | | CRYBA1 |

| Duri | 70 1 4 | 660 | CND | Desition | m/M | MAE | P-value/ | Type of | Madaad | OTI | Nearest Gene |
|-------|--------------------------------------|-----|-------------|---------------|--------|-------|----------|--------------|----------|-----|---------------------------------------------------------------------------|
| вгееа | | 350 | SINP | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| LR | IL6 IL10 IL1b | 12 | ALGA0066685 | 45415984 | T/C | 77,80 | 0,06 | CHR | CCA | 162 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ALGA0118449 | 7777685 | C/A | 35,50 | 0,04 | CHR | CCA, PCA | 141 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | DIAS0001617 | 8165185 | T/C | 57,50 | 0,03 | CHR | CCA, PCA | 142 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ALGA0096869 | 8190336 | A/G | 57,50 | 0,03 | CHR | CCA, PCA | 142 | |
| LR | NEU RBC WBC MON BAS | 12 | ASGA0101646 | 60019204 | T/C | 46,00 | 0,06 | CHR | CCA | 164 | |
| LR | NEU RBC WBC MON BAS | 12 | ALGA0107813 | 62837875 | A/G/T | 66,50 | 0,03 | CHR | CCA | 165 | |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | M1GA0023025 | 8250254 | C/T | 73,90 | 0,03 | CHR | CCA, PCA | 142 | |
| LR | HMT HMG MCHC | 13 | MARC0065723 | 16709645 9 | T/C | 19,80 | 0,05 | CHR | CCA | 167 | |
| LR | HMT HMG MCHC | 13 | ALGA0072888 | 17463699 6 | C/T | 6,40 | 0,05 | CHR | CCA | 168 | |
| LR | НМТ НМБ МСНС | 13 | DRGA0013179 | 17743920 7 | T/G | 1,70 | 0,05 | CHR | CCA | 169 | ROBO2 |
| LR | WBC NEU MON EOS BAS TNF | 13 | ASGA0059913 | 19839422 0 | T/C | 91,00 | 0,04 | GEN | CCA | 170 | RUNX1 |
| LR | RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | rs339209283 | 8264050 | T/C | NA | 0,03 | CHR | CCA, PCA | 142 | |
| LR | LYM MON BAS | 14 | ASGA0063055 | 42631536 | C/T | 39,70 | 0,03 | CHR | РСА | 172 | SGSM1, PIWIL3, TMEM211, KIAA1671, CRYBB3, CRYBB2, GRK3, U6 |

| David | TD 14 | 660 | CNID | Destites | m/M | MAE | P-value/ | Type of | Madaad | OTI | Nearest Gene |
|-------|-------------|-----|-------------|----------|--------|-------|----------|--------------|--------|-----|-----------------------|
| Breed | Irait | 55C | SINP | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| LR | LYM MON BAS | 14 | DIAS0001091 | 42951477 | C/T | 72,10 | 0,03 | CHR | PCA | 172 | |
| LR | LYM MON BAS | 14 | H3GA0040005 | 43387115 | G/A | 72,30 | 0,03 | CHR | PCA | 172 | |
| LR | LYM MON BAS | 14 | ALGA0077324 | 44752740 | C/T | 75,00 | 0,05 | CHR | PCA | 173 | MN1, PITPNB, TTC28 |
| LR | LYM MON BAS | 14 | ALGA0077342 | 45036066 | T/C | 75,60 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063176 | 45080096 | A/C | 76,10 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | MARC0061666 | 45126379 | G/A | 22,30 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ALGA0077352 | 45167309 | C/T | 22,30 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063186 | 45182965 | T/C | 77,70 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063188 | 45211762 | A/C | 77,80 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ALGA0077360 | 45237972 | C/T | 77,70 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | MARC0021603 | 45277886 | G/A | 22,30 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063192 | 45329416 | T/C | 22,30 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063198 | 45347247 | A/G | 76,70 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063199 | 45359541 | A/C | 23,90 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | MARC0006658 | 45412495 | G/T | 76,70 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | MARC0081626 | 45577136 | T/G | 18,60 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ASGA0063205 | 45602780 | C/T | 75,40 | 0,03 | CHR | PCA | 173 | |
| LR | LYM MON BAS | 14 | ALGA0077379 | 45795115 | G/A | 23,30 | 0,03 | CHR | PCA | 174 | TTC28 |
| | | | | | | | | | | | |

| Breed Trait | Tueit | SSC | SND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------------|--------------|-----|-----------------|----------|--------|-------|----------|--------------|---------|-----|------------------|
| Dieeu | ITAIL | 350 | 5111 | rosition | allele | WIAF | BF | significance | wiethou | QIL | within QTL |
| | | | | | | | | | | | TTC28, U1, |
| | | | | | | | | | | | CHEK2, HSCB, |
| | | | | | | | | | | | CCDC117, XBP1, |
| | | | | | | | | | | | ZNRF3, |
| IR | I YM MON BAS | 14 | MARC0047822 | 45827810 | T/C | 23 30 | 0.03 | CHR | РСА | 175 | C22orf31, |
| LIC | | 17 | WI/ IICC0047022 | 45027010 | 1/0 | 25,50 | 0,05 | CIIK | 10/1 | 175 | KREMEN1, |
| | | | | | | | | | | | EMID1, RHBDD3, |
| | | | | | | | | | | | EWSR1, GAS2L1, |
| | | | | | | | | | | | RASL10A, AP1B1, |
| | | | | | | | | | | | SNORD125 |
| LR | LYM MON BAS | 14 | ALGA0077382 | 46031357 | A/C | 76,70 | 0,03 | CHR | PCA | 175 | |
| LR | LYM MON BAS | 14 | INRA0043964 | 46418356 | G/A | 23,30 | 0,03 | CHR | PCA | 175 | |
| LR | LYM MON BAS | 14 | DBNP0002145 | 46436960 | C/T | 76,70 | 0,03 | CHR | PCA | 175 | |
| LR | LYM MON BAS | 14 | ALGA0077394 | 46473900 | G/A | 76,70 | 0,03 | CHR | PCA | 175 | |
| LR | LYM MON BAS | 14 | MARC0048650 | 46520497 | A/G | 40,40 | 0,03 | CHR | PCA | 175 | |
| LR | LYM MON BAS | 14 | ASGA0063175 | 47751439 | G/A | 24,90 | 0,04 | CHR | PCA | 176 | |
| LR | HMT HMG MCHC | 14 | H3GA0040407 | 57739629 | C/T | 26,80 | 0,02 | CHR | CCA | 177 | |
| LR | HMT HMG MCHC | 14 | ALGA0077929 | 57765084 | C/T | 26,60 | 0,02 | CHR | CCA | 177 | |
| | | | | | | | | | | | TRIM67, FAM89A, |
| IR | HMT HMG MCHC | 14 | MARC0013023 | 59263540 | C/A | 12.60 | 0.01 | GEN | CCA | 178 | ARV1, TTC13, |
| LIC | | 17 | WI IICC0015025 | 57205540 | CIT | 12,00 | 0,01 | GLIV | CON | 170 | Clorf198, CAPN9, |
| | | | | | | | | | | | AGT, COG2 |
| LR | HMT HMG MCHC | 14 | ASGA0063815 | 59277912 | T/C | 30,40 | 0,01 | GEN | CCA | 178 | |
| LR | HMT HMG MCHC | 14 | ALGA0078088 | 59646142 | C/T | 30,80 | 0,00 | CHR | CCA | 178 | |
| LR | HMT HMG MCHC | 14 | ALGA0078075 | 59656180 | T/C | 30,90 | 0,00 | CHR | CCA | 178 | |
| LR | HMT HMG MCHC | 14 | ALGA0106769 | 59712299 | T/C | 11,30 | 0,02 | CHR | CCA | 178 | |
| LR | HMT HMG MCHC | 14 | MARC0004519 | 59803997 | A/C | 65,30 | 0,00 | CHR | CCA | 179 | |

| | CCC | CND | Destition | 111/171 | MAR | I -value/ | 1 ype of | M. 41 J | OTI | ivearest Gene |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| าาสน | 55C | SINP | Position | allele | MAF | BF | significance | Method | QIL | within QTL |
| HMT HMG MCHC | 14 | ALGA0078091 | 59831072 | G/A | 71,40 | 0,00 | CHR | CCA | 179 | |
| HMT HMG MCHC | 14 | ALGA0079175 | 79949671 | G/A/T | 9,50 | 0,03 | CHR | CCA | 180 | KCNMA1 |
| HMT HMG MCHC | 14 | ALGA0079177 | 79982953 | C/T | 9,50 | 0,03 | CHR | CCA | 180 | |
| LYM MON BAS | 14 | ALGA0083196 | 13765463 2 | C/T | 89,30 | 0,04 | CHR | PCA | 181 | |
| HMT HMG MCHC | 15 | MARC0113166 | 22554502 | G/T | 0,00 | 0,06 | CHR | CCA | 182 | |
| HMT HMG MCHC | 15 | ASGA0068971 | 22571234 | A/C | 30,00 | 0,06 | CHR | CCA | 182 | |
| HMT HMG MCHC | 15 | ALGA0102752 | 23400874 | G/A | 75,60 | 0,06 | CHR | CCA | 182 | |
| RBC HMG HMT MCV MCH, PC3RBCs | 18 | MARC0007516 | 8567714 | A/G | 34,40 | 0,04 | CHR | CCA | 142 | |
| IL8 TNF | 15 | ALGA0086618 | 10760456 8 | A/G | 14,50 | 0,05 | CHR | CCA | 184 | PARD3B, U6 |
| IL8 TNF | 15 | DRGA0015341 | 10775384 7 | C/A | 83,50 | 0,05 | CHR | CCA | 184 | |
| IL8 TNF | 15 | MARC0089453 | 10788749 3 | T/G | 34,30 | 0,06 | CHR | CCA | 184 | |
| IL8 TNF | 15 | ALGA0086631 | 10802461 6 | T/G | 46,70 | 0,01 | CHR | CCA | 184 | |
| IL8 TNF | 15 | ALGA0108737 | 10833535 3 | G/A | 48,80 | 0,04 | GEN | CCA | 184 | |
| IL12 IL8 | 15 | H3GA0044814 | 10847242 7 | A/G | 53,70 | 0,04 | CHR | PCA | 184 | |
| IL12 IL8 | 15 | DRGA0015357 | 10850520 9 | C/A | 53,00 | 0,04 | CHR | РСА | 184 | |
| RBC HMG HMT MCV MCH, MCV MCHC HAP | 18 | ALGA0096931 | 8587608 | T/G | 23,60 | 0,03 | CHR | CCA, PCA | 142 | |
| | HMT HMG MCHC HMT HMG MCHC HMT HMG MCHC LYM MON BAS HMT HMG MCHC HMT HMG MCHC HMT HMG MCHC RBC HMG HMT MCV MCH, PC3RBCs IL8 TNF IL8 TNF IL8 TNF IL8 TNF IL8 TNF IL12 IL8 IL12 IL8 RBC HMG HMT MCV MCH, MCV MCHC HAP | HMT HMG MCHC 14 HMT HMG MCHC 14 HMT HMG MCHC 14 LYM MON BAS 14 HMT HMG MCHC 15 HMT HMG MCHC 15 HMT HMG MCHC 15 HMT HMG MCHC 15 RBC HMG HMT MCV MCH, 18 PC3RBCs 15 IL8 TNF 15 IL12 IL8 15 IL12 IL8 15 RBC HMG HMT MCV MCH, MCV 18 MCHC HAP 18 | HMT HMG MCHC 14 ALGA0078091 HMT HMG MCHC 14 ALGA0079175 HMT HMG MCHC 14 ALGA0079177 LYM MON BAS 14 ALGA0083196 HMT HMG MCHC 15 MARC0113166 HMT HMG MCHC 15 ASGA0068971 HMT HMG MCHC 15 ALGA0102752 RBC HMG HMT MCV MCH, 15 ALGA0086618 IL8 TNF 15 ALGA0086618 IL8 TNF 15 MARC0007516 IL8 TNF 15 MARC0089453 IL8 TNF 15 ALGA0108737 IL8 TNF 15 ALGA0108737 IL8 TNF 15 ALGA0108737 IL12 IL8 15 BGA0015357 RBC HMG HMT MCV MCH, MCV MCHC HAP 18 ALGA0096931 | Image: Harring methods in the system of the syste | Image: Harring and the system of th | Image: biologic | Image: biologic | Image: birth of the second | Image: the second se | Image in the second |

| Breed | Trait | SSC | SNP | Position | m/M | MAF | P-value/ | Type of | Method | QTL | Nearest Gene |
|--------|-------------------------------------|-----|--------------|---------------|--------|-------|----------|--------------|---------|-----|--------------|
| | | | | | allele | | BF | significance | | | within QTL |
| LR | IL8 TNF, PC2Cyto | 15 | ASGA0070317 | 10879492 6 | G/C | 32,30 | 0,05 | CHR | CCA | 185 | |
| LR | IL8 TNF | 15 | H3GA0044820 | 10884811 4 | C/T | 39,60 | 0,04 | CHR | CCA | 185 | |
| LR | IL8 TNF | 15 | ASGA0093834 | 10921502 7 | T/C | 14,30 | 0,05 | CHR | CCA | 185 | |
| LR | IL8 TNF | 15 | ALGA0086678 | 10939496 5 | G/A | 50,70 | 0,05 | GEN | CCA | 185 | |
| LR | IL8 TNF | 15 | ALGA0086703 | 10997146 9 | C/T | 60,00 | 0,01 | CHR | CCA | 186 | DYTN |
| LR | BAS MON | 15 | ALGA0086800 | 11262497 7 | C/T | 90,10 | 0,01 | GEN | CCA | 187 | UNC80 |
| LW | BAS WBC NEU, LYM NEU MON EOS BAS | 18 | DRGA0016945 | 25162286 | C/T | 16,60 | 0,03 | CHR | CCA | 147 | |
| LW | LYM NEU MON EOS BAS | 15 | ALGA0086932 | 11719653 5 | G/A | 47,70 | 0,01 | CHR | CCA | 189 | |
| LR | IL8 TNF | 15 | H3GA0044951 | 11998403 6 | T/C | 59,10 | 0,06 | CHR | CCA | 190 | TNS1 |
| LR | IL8 TNF | 15 | ASGA0070560 | 11999520 3 | A/G | 40,00 | 0,06 | CHR | CCA | 190 | |
| LW | RBC HMG HMT MCV MCH MCHC | NA | ALGA0014284 | NA | T/C | 57,50 | 0,03 | CHR | CCA | | |
| | | | | | | | | | CCA, | | |
| | BAS MON, IL4 IL10 IL1b IL6, NEU | | ALC A0072570 | | O/T | 10.50 | 0.01/3.2 | CEN | TATES, | | |
| LK, LW | RBC WBC MON BAS | NA | ALGA00/35/9 | NA | C/1 | 10,50 | 2 | GEN | mvBIMBA | | |
| | | | | | | | | | М | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| Dread | Tueit | 550 | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|-------|--------------------------|------|---------------|----------|--------|-------|----------|--------------|--------|-----|--------------|
| Dreeu | Trait | ssc | 5111 | rosition | allele | MAF | BF | significance | Methou | Q1L | within QTL |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | NA | DRGA0006288 | NA | NA | 1,10 | 0,00 | GEN | TATES | | |
| | HMT HMG MCHC | | | | | | | | INILS | | |
| LR | IL4 EOS IL10 IL1b TNF | NA | ALGA0046492 | NA | C/T | 84,90 | 0,02 | CHR | CCA | | |
| LR | HMT HMG MCHC | NA | ALGA0072783 | NA | G/A | 19,80 | 0,05 | CHR | CCA | | |
| | RBC HMG HMT MCV MCH, HMG | | | | | | | | CCA | | |
| LR | MCHC IL10, | NA | INRA0020540 | NA | NA | 98,90 | 0,00 | GEN | TATES | | |
| | HMT HMG MCHC | | | | | | | | IAILS | | |
| LW | RBC HMG HMT MCV MCH MCHC | NA | ALGA0102592 | NA | G/A | 33,00 | 0,05 | CHR | CCA | | |
| IR | RBC HMG HMT MCV MCH, HMT | NΔ | AI GA0031749 | NΔ | C/T | 32 50 | 0.03 | CHR | CCA | | |
| LIC | HMG MCHC | 1112 | 71LO/10051747 | 1177 | 0/1 | 52,50 | 0,05 | CIIK | cen | | |
| LW | LYM NEU MON EOS BAS | NA | ALGA0105830 | NA | G/A | 59,40 | 0,02 | CHR | CCA | | |
| LR | RBC HMG HMT MCV MCH, HMT | NA | AI GA0031838 | NA | G/T | 30.50 | 0.04 | CHR | CCA | | |
| LIC | HMG MCHC | 1112 | ALC/10051050 | 1171 | 0/1 | 50,50 | 0,04 | CIIK | cen | | |
| LW | RBC HMG HMT MCV MCH MCHC | NA | ALGA0120738 | NA | G/A | 92,80 | 0,02 | CHR | CCA | | |
| LR | WBC BAS | NA | ALGA0122704 | NA | A/G | 1,40 | 0,01 | GEN | PCA | | |
| LR | BAS MON | NA | ASGA0011563 | NA | C/T | 31,40 | 0,05 | GEN | CCA | | |
| LR | WBC NEU MON EOS BAS TNF | NA | ASGA0046381 | NA | T/G | 14,20 | 0,03 | CHR | CCA | | |
| LR | WBC NEU MON EOS BAS TNF | NA | ASGA0096826 | NA | T/C | 79,80 | 0,05 | GEN | CCA | | |
| LR | IL8 TNF | NA | ASGA0102483 | NA | C/T | 48,80 | 0,04 | GEN | CCA | | |
| LW | RBC HMG HMT MCV MCH MCHC | NA | ASGA0102908 | NA | T/C | 44,10 | 0,05 | CHR | CCA | | |
| LW | IFN IL8 TNF | NA | CASI0003808 | NA | NA | 1,00 | 0,03 | GEN | PCA | | |
| LR | RBC HMG HMT MCV MCH | NA | DBWU0000913 | NA | G/A | 49,70 | 0,01 | CHR | CCA | | |
| LR | IL6 IL10 IL1b | NA | DIAS0000434 | NA | G/A | 22,70 | 0,03 | CHR | CCA | | |
| LR | RBC HMG HMT MCV MCH | NA | DIAS0000994 | NA | NA | 98,00 | 0,04 | CHR | CCA | | |
| LR | IL4 EOS IL10 IL1b TNF | NA | DRGA0006061 | NA | NA | 1,60 | 0,01 | GEN | CCA | | |
| | | | | | | | | | | | |

| Drood | Tunit | SSC | CND | Desition | m/M | MAE | P-value/ | Type of | Mathad | OTI | Nearest Gene |
|---------|---------------------------|-----|----------------|----------|--------|-------|----------|--------------|----------|-----|--------------|
| breeu | Trait | ssc | SINF | rosition | allele | IVIAF | BF | significance | Methou | QIL | within QTL |
| | HMG MCH, WBC BAS, PLT RBC | NΛ | H3GA0016800 | NA | T/C | 90.30 | 0.04 | СНЪ | | | |
| L W, LK | WBC | INA | 1150A0010077 | | 1/C | 70,50 | 0,04 | CIIK | CCA, ICA | | |
| LR | NEU RBC WBC MON BAS | NA | FBF0127SLC47A1 | NA | NA | NA | 0,06 | CHR | CCA | | |
| LW | RBC HMG HMT MCV MCH MCHC | NA | H3GA0000686 | NA | G/A | 24,20 | 0,05 | CHR | CCA | | |
| LW | RBC HMG HMT MCV MCH MCHC | NA | H3GA0000711 | NA | G/A | 25,90 | 0,05 | CHR | CCA | | |
| LR | WBC HMT EOS HAP IL8 | NA | H3GA0009907 | NA | A/G | 9,40 | 0,02 | CHR | CCA | | |
| LW | HMG MCH, PLT RBC WBC | NA | ALGA0103880 | NA | T/C | 94,10 | 0,04 | CHR | CCA | | |
| LR | HMT HMG MCHC | NA | INRA0019232 | NA | T/C | 28,30 | 0,03 | CHR | CCA | | |
| LR | RBC HMG HMT MCV MCH | NA | INRA0020434 | NA | T/C | 50,90 | 0,06 | CHR | CCA | | |
| LW | HMG MCH, PLT RBC WBC | NA | ALGA0115368 | NA | T/C | 6,20 | 0,04 | CHR | CCA | | |
| LR | MCV MCHC HAP | NA | M1GA0023051 | NA | T/C | 39,40 | 0,01 | CHR | PCA | | |
| LR | IL4 EOS IL10 IL1b TNF | NA | MARC0001707 | NA | T/C | 25,90 | 0,02 | CHR | CCA | | |
| LR | WBC NEU MON EOS BAS TNF | NA | MARC0010639 | NA | C/T | 79,80 | 0,05 | GEN | CCA | | |
| LR | WBC HMT EOS HAP IL8 | NA | MARC0013233 | NA | C/T | 90,70 | 0,02 | CHR | CCA | | |
| LR | LYM MON BAS | NA | MARC0030251 | NA | T/C | 76,70 | 0,03 | CHR | PCA | | |
| LW | RBC HMG HMT MCV MCH MCHC | 8 | rs323551662 | 41838395 | C/G | NA | 0,03 | CHR | CCA | | |
| LR | IFN IL12 IL8 | NA | SIRI0000276 | NA | NA | 0,00 | 0,03 | CHR | PCA | | |
| LW | IFN IL8 TNF | NA | SIRI0001107 | NA | NA | 0,00 | 0,03 | GEN | PCA | | |

SSC=*Sus scrofa* chromosome, SNP=single nucleotide polymorphism, m/M allele=minor/major allele, MAF=minor allele frequency, QTL nr.=Quantitative trait loci progressive number based on ± 1 Mbp distance from a significant SNP, LR=Landrace, LW=Large White, RBC=red blood cells, HMG=hemoglobin, HMT=hematocrit, MCV= mean corpuscular volume, MCH=mean corpuscular hemoglobin, MCHC=mean corpuscular hemoglobin concentration, PLT=platelets, WBC=white blood cells, NEU=neutrophils, LYM=lymphocytes, MON=monocytes, EOS=eosinophils, BAS=basophils, HAP=haptoglobin, IFN- γ = interferon- γ , IL=interleukin, TNF- α = tumor necrosis factor- α , PC=principal component, CCA=canonical correlation analysis, PCA=principal component analysis.

Funding and Acknowledgements

Funding

Katharina Roth was financially supported during her doctoral study by funds of the Federal Ministry of Food and Agriculture (BMEL) based on a decision of the Parliament of the Federal Republic of Germany via the Federal Office for Agriculture and Food (BLE) under the innovation support programme within the G-I-FER - Genomic indicators for boar taint, reproduction, and robustness in Landrace and Large White populations projects (FKZ2817904115).

Funding – chapter 3 and 4

The studies were performed within the "pigFit" project which was supported by funds of the German Government's Special Purpose Fund held at Landwirtschaftliche Rentenbank (FKZ28-RZ-3-72.038).

Acknowledgments -chapter 3 and 4

The authors want to thank Dr. Hubert Henne and Dr. Anne Kathrin Appel at Bundeshybridzuchtprogramm (BHZP GmbH) for providing data sets and their everlasting support. We wish to thank the staff at the farms belonging to the breeding company as well as to the Institute of Animal Science at University Bonn who provided care for animals, collected on-farm data, and helped to analyze immune measurements. The authors thank the German Government's Special Purpose Fund held at Landwirtschaftliche Rentenbank for the financial support of the "pigFit" project, where this study was performed.

Acknowledgement - Danksagung

Ich möchte mich herzlich bei allen bedanken, die auf unterschiedlichste Art und Weise zur Erstellung dieser Arbeit beigetragen haben.

Mein herzlicher Dank gilt Prof. Dr. Karl Schellander für die Überlassung des Themas der vorliegenden Dissertation, für Ihr Vertrauen und die Möglichkeit die Dissertation autonom sowie gleichzeitig von Ihnen geführt zu gestalten.

Mein ganz besonderer Dank gilt Dr. Ernst Tholen, meinem Doktorvater, der mich in diesem Vorhaben bestärkt und motiviert hat. Vielen Dank für die Möglichkeit am Institut für Tierwissenschaften zu promovieren und in Projekten wie pigFit und G-I-FER mitarbeiten zu dürfen. Danke für Dein Verständnis und das stetige Vertrauen die mitunter herausfordernden Aufgaben zu bewältigen. Es war ein Privileg für mich an Deiner Seite in den Projekten zu arbeiten Ich möchte mich bei Dir für die Chancen zur Weitebildung und beruflichen Qualifikation im In- und Ausland bedanken. Danke für alle statistischen, fachlichen, beruflichen und privaten Ratschläge. Ich habe von Dir persönlich jede Menge für mein weiteres Leben gelernt und bedanke mich nochmals herzlich.

Außerdem möchte ich mich bei Dr. Christine Große-Brinkhaus bedanken. Du hast mich von Anfang an begleitet, mir den Rücken immer freigehalten und mich während der Dissertation gefestigt. Für fachliche und kollegiale Probleme hattest Du unaufhörlich ein Ohr offen und hast mich aufgebaut. Von Deinem Fachwissen, Deinen kreativen Ideen konnte ich stetig schöpfen. Deine positive Aussicht als "Alles wird gut" hat mir stets geholfen und mich angespornt.

Mein Dank geht auch an Dr. Maren Pröll-Cornelissen. Du hast Dich fortwährend für mich eingesetzt, mich gestärkt und all die zahlreichen Manuskripte korrigiert. Deine unerschöpfliche positive Art und Dein Zuspruch motivierten mich in jedem Vorhaben. Danke für Deine Unterstützung, Dr. Christiane Neuhof. Deine Tür war immer offen für alle meine Beklagnisse. Dein Glaube an mich hat mich durchgehend inspiriert. Es ist wunderbar bei der BLE wieder an deiner und Esthers Seite zu arbeiten. Danke an Dr. Esther Heuß, Dr. Julia Welzenbach, Dr. Ines Brinke, Christina Dauben und Beatrix Bonhof für Eure motivierenden Worte, viele schöne Gespräche und die tolle Zeit als Teil der Arbeitsgruppe Haustiergenetik.

Ich möchte mich bei allen Projektpartnern und Beteiligten der Projekte pigFit und G-I-FER bedanken. Ohne Sie und Ihren Einsatz wäre diese Arbeit und die Durchführung der Projekte nicht möglich gewesen.

Ich möchte mich bei allen Kollegen des Instituts für Tierwissenschaften für das heimische Gefühl auf der Arbeit bedanken. Danke Peter und Ivan, dass Ihr in technischen Fragen stets zur

Stelle wart. Vielen Dank Bianca für Deinen Einsatz und Deine Hilfe in allen bürokratischen Fragen. Dankeschön an die Technischen Assistentinnen - Helga, Birgit, Nadine, Julia und Michel - der Abteilung Tierzucht für Eure tatkräftige Unterstützung in den Projekten pigFit und G-I-FER. Ohne den Einsatz zahlreicher Kollegen wäre die Durchführung der Studien undenkbar.

Ich möchte mich bei allen Doktoranden der Abteilungen Tierzucht und Tierernährung, speziell bei Haiko, Helge, Bernd, Thomas, Bea, Valerié und Klara, für die Schöne Zeit im und außerhalb des Instituts bedanken. Haiko, Helge, Bernd und Thomas danke ich für Eure Hilfe, den Zuspruch, die Unterstützung, die Ratschläge, das Feiern und Lachen. Mein Durchhaltevermögen und meine Billardfähigkeiten haben sich dank Euch signifikant verbessert!

Dankeschön an all meine Freunde, insbesondere Jasmin und Familie Schneider, die mich auf allen meinen Wegen unterstützten. Ich möchte von ganzem Herzen meiner Familie -Eltern, Schwester, Schwager, Neffen und Nichte- danken. Vielen Dank für Eure liebevolle Unterstützung und den Glauben an mich.

Es macht mich dankbar, meinen Sohn Theodor um mich zu haben, der in mich vertraut und für mich alles ins Verhältnis setzt. Am meisten möchte ich mich bei meinem Ehemann, Dima, bedanken. Danke für all Deine unermessliche Geduld, Dein Verständnis und Deine Unterstützung meiner wissenschaftlichen Karriere. Mit liebevollem, gegenseitigem Beistand meistern wir gemeinsam alle Herausforderungen des Lebens. Auf das was da noch kommt!

Publications and presentations

Roth K.; Pröll-Cornelissen M, J.; Heuß E. M.; Dauben C. M.; Henne H.; Appel A. K.; Schellander K., Tholen E.; Große-Brinkhaus C. (2022): Genetic parameters of immune traits for Landrace and Large White pig breeds. PLOS One.

Roth K.; Pröll-Cornelissen M, J.; Heuß E. M.; M.; Henne H.; Appel A. K.; Schellander K., Tholen E.; Große-Brinkhaus C. (2022): Multivariate genome-wide associations for immune traits in two maternal pig lines. PLOS One.

Brinke, I.; Große-Brinkhaus, C.; Roth, K.; Pröll-Cornelissen, M.J.; Klein, S.; Schellander, K.; Tholen, E. (2021): Endocrine Fertility Parameters—Genomic Background and Their Genetic Relationship to Boar Taint in German Landrace and Large White. Animals 11, 231.

Dauben, C.M.; Pröll-Cornelissen, M.J.; Heuß, E.M.; Appel A. K.; Henne H.; Roth, K.; Schellander K., Tholen E.; Große-Brinkhaus C. (2021): Genome-wide associations for immune traits in two maternal pig lines. BMC Genomics 22, 717.

Brinke, I.; Große-Brinkhaus, C.; Roth, K.; Pröll-Cornelissen, M. J.; Henne, H.; Schellander, K.; Tholen, E. (2020): Genomic background and genetic relationships between boar taint and fertility traits in German Landrace and Large White. BMC Genetics 21 (1), p. 2170.

Roth K.; Pröll-Cornelissen M, J.; Heuß E. M.; Dauben C. M.; Appel A. K.; Henne H.; Schellander K., Tholen E.; Große-Brinkhaus C. (2019): Multivariate genetische Assoziationsstudien von Immunmerkmalen bei Schweinen aus Reinzuchtlinien. Vortragstagung der Deutschen Gesellschaft für Züchtungskunde e.V. (DGfZ) und der Gesellschaft für Tierzuchtwissenschaften e.V. (GfT), 11.09-12.09.2019, Gießen, Deutschland.

Brinke I.; Große-Brinkhaus C.; Roth K.; Pröll-Cornelissen M.J.; Schiefler I.; Klein S.; Schellander K.; Tholen E. (2019): Genomische Selektion für Ebergeruchsmerkmale unter Berücksichtigung von Fruchtbarkeit in Landrasse und Large White. Vortragstagung der Deutschen Gesellschaft für Züchtungskunde e.V. (DGfZ) und der Gesellschaft für Tierzuchtwissenschaften e.V. (GfT), 11.09-12.09.2019, Gießen, Deutschland.

Brinke I.; Roth K.; Pröll-Cornelissen M.J.; Große-Brinkhaus C.; Schiefler I.; Tholen E. (2019): Genetic analyses of boar taint and reproduction traits in Landrace and Large White. 70th Annual Meeting of the European Federation of Animal Science (EAAP), 26.08.-30.08.2019, Ghent, Belgium.

Dauben C.M.; Heuß E.M.; Pröll-Cornelissen M.J.; Roth K.; Henne H.; Appel A.K.; Schellander K.; Tholen E.; Große-Brinkhaus C. (2019): Genome-wide association analyses and fine

mapping of immune traits in dam lines using sequence data. 70th Annual Meeting of the European Federation of Animal Science (EAAP), 26.08.-30.08.2019, Ghent, Belgium.

Dauben C.M.; Heuß E.M.; Pröll-Cornelissen M.J.; Roth K.; Henne H.; Appel A.K.; Schellander K., Tholen E., Große-Brinkhaus C. (2019): Genome-wide associations and fine mapping of immune traits in dam lines using sequence data. Animal Genetics and Diseases, 8.05-10.05.2019, Hinxton, Cambridge, United Kingdom.

Brinke I.; Roth K.; Pröll-Cornelissen M.J.; Große-Brinkhaus C.; Schiefler I.; Schellander K.; Tholen E. (2018): Genetische Analysen von Ebergeruch und Fruchtbarkeit in den Mutterlinien beim Schwein. Vortragstagung der Deutschen Gesellschaft für Züchtungskunde e.V. (DGfZ) und der Gesellschaft für Tierzuchtwissenschaften e.V. (GfT), 12.09-13.09.2018, Bonn, Deutschland.

Roth K.; Dauben C. M.; Pröll-Cornelissen M, J.; Appel A. K.; Henne H.; Schellander K., Tholen E.; Große-Brinkhaus C. (2018): Genetische Analysen von Immunmerkmalen bei Schweinen aus Reinzuchtlinien. Vortragstagung der Deutschen Gesellschaft für Züchtungskunde e.V. (DGfZ) und der Gesellschaft für Tierzuchtwissenschaften e.V. (GfT), 12.09-13.09.2018, Bonn, Deutschland.

Brinke I.; Roth K.; Pröll-Cornelissen M.J.; Große-Brinkhaus C.; Schiefler I.; Tholen E. (2018): G-I-FER: Genetische Analysen von Ebergeruch und Fruchtbarkeit in Mutterlinien beim Schwein. Innovationstage der Bundesanstalt für Landwirtschaft und Ernährung 2018, 23.10-24.10.2018, Bonn, Deutschland.

Brinke I.; Roth K.; Pröll-Cornelissen M.J.; Große-Brinkhaus C.; Schiefler I.; Schellander K.; Tholen E. (2018): Genetic analysis of boar taint and fertility traits including hormone profiles in dam lines. 69th Annual Meeting of the European Federation of Animal Science (EAAP), 27.08.-31.08.2018, Dubrovnik, Croatia.

Roth K.; Dauben C. M.; Heuß. E.M.; Pröll-Cornelissen M, J.; Henne H.; Appel A. K.; Schellander K., Tholen E.; Große-Brinkhaus C. (2018): Genetic analysis of immune traits of two maternal pig lines. 69th Annual Meeting of the European Federation of Animal Science (EAAP), 27.08.-31.08.2018, Dubrovnik, Croatia.

Brinke I.; Roth K.; Pröll-Cornelissen M.J.; Große-Brinkhaus C.; Tholen E. (2017, 2018, 2019):G-I-FER: Genetische Analysen von Ebergeruch und Fruchtbarkeit in Mutterlinien beim Schwein. Jahrestagung des Fördervereins für Bioökonomieforschung e.V. (2017, 2018, 2019), Deutschland.